<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:tcas="http:///uima/tcas.ecore" xmlns:types="http:///edu/cmu/lti/qalab/types.ecore" xmlns:type="http:///edu/cmu/lti/qa4mre/type.ecore" xmlns:examples="http:///org/apache/uima/examples.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><cas:Sofa xmi:id="12" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="PLoS ONE: Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesOpen AccessResearch ArticleAlzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesMatthias Cacquevel, Lor��ne Aeschbach, Jemila Houacine, Patrick C. Fraering*��cole Polytechnique F��d��rale de Lausanne, Brain Mind Institute, Laboratory of Molecular and Cellular Biology of Alzheimer's Disease, Lausanne, SwitzerlandAbstract Top BackgroundMutations linked to early onset, familial forms of Alzheimer's disease (FAD) are found most frequently in PSEN1, the gene encoding presenilin-1 (PS1). Together with nicastrin (NCT), anterior pharynx-defective protein 1 (APH1), and presenilin enhancer 2 (PEN2), the catalytic subunit PS1 constitutes the core of the ��-secretase complex and contributes to the proteolysis of the amyloid precursor protein (APP) into amyloid-beta (A��) peptides. Although there is a growing consensus that FAD-linked PS1 mutations affect A�� production by enhancing the A��1���42/A��1���40 ratio, it remains unclear whether and how they affect the generation of APP intracellular domain (AICD). Moreover, controversy exists as to how PS1 mutations exert their effects in different experimental systems, by either increasing A��1���42 production, decreasing A��1���40 production, or both. Because it could be explained by the heterogeneity in the composition of ��-secretase, we purified to homogeneity complexes made of human NCT, APH1aL, PEN2, and the pathogenic PS1 mutants L166P, ��E9, or P436Q.Methodology/Principal FindingsWe took advantage of a mouse embryonic fibroblast cell line lacking PS1 and PS2 to generate different stable cell lines overexpressing human ��-secretase complexes with different FAD-linked PS1 mutations. A multi-step affinity purification procedure was used to isolate semi-purified or highly purified ��-secretase complexes. The functional characterization of these complexes revealed that all PS1 FAD-linked mutations caused a loss of ��-secretase activity phenotype, in terms of A��1���40, A��1���42 and APP intracellular domain productions in vitro.Conclusion/SignificanceOur data support the view that PS1 mutations lead to a strong ��-secretase loss-of-function phenotype and an increased A��1���42/A��1���40 ratio, two mechanisms that are potentially involved in the pathogenesis of Alzheimer's disease.Citation: Cacquevel M, Aeschbach L, Houacine J, Fraering PC (2012) Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase Complexes. PLoS ONE 7(4): e35133. doi:10.1371/journal.pone.0035133Editor: Stefano L. Sensi, University G. D'Annunzio, ItalyReceived: February 20, 2012; Accepted: March 13, 2012; Published: April 18, 2012Copyright: �� 2012 Cacquevel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Funding: This work was supported by the Swiss National Foundation (to and LA and PCF; grant 31003A_134938/1) and the National Centre for Competence in Research (���Neuronal Plasticity and Repair��� (to JH and PCF)), and the Strauss foundation (to PCF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Competing interests: The authors have declared that no competing interests exist.* E-mail: patrick.fraering@epfl.chIntroduction Top Since their discovery in 1995 and their association with early onset familial Alzheimer's disease (FAD) [1], [2], the presenilin genes PSEN1 and PSEN2 have been widely studied, and the complexity of their biological role is becoming increasingly evident. PSEN1 and PSEN2 encode transmembrane proteins PS1 and PS2, respectively, that constitute the catalytic core of ��-secretase, the founding member of an emerging class of unconventional, Intramembrane-Cleaving Proteases (I-CLiPs) [3]. Active ��-secretase is a multiprotein complex composed of PS1 or PS2 together with nicastrin (NCT), the anterior pharynx-defective protein 1 (APH1), and the presenilin enhancer 2 (PEN2). Experimental evidence such as the binding of transition-state analogue ��-secretase inhibitors to PS1 [4], as well as the abolishment of ��-secretase activity when PS1 lacks the aspartate residues critical for proteolysis [4], [5], [6], have confirmed that presenilins harbour the active site of the enzymatic complex.PS1 and PS2 play fundamental roles in cell signalling as part of the ��-secretase complex. The latter cleaves numerous type-I membrane proteins in their transmembrane domain [7], releasing their corresponding intracellular domains, which are capable of influencing gene expression. For some substrates like NOTCH1 or ERBB4, the ��-secretase cleavage is essential for their biological function, whereas for other substrates like DCC or NEUREXIN-3�� [8], the possible role of the cleavage in signalling events has not been formally established (see [9] for a review). The amyloid precursor protein (APP) is processed by the successive actions of ��-secretase (BACE1) and ��-secretase, generating amyloid-beta peptides (A��) of different lengths, ranging from 37 to 46 amino acids [10]. Cleavage of the APP C-terminal fragments (APP-CTFs) by ��-secretase also releases the APP intracellular domain (AICD), which has been recently involved in the regulation of brain ApoE expression, a major genetic determinant of AD, and in cholesterol metabolism [11]. In addition, PS1 has been shown to interact with a growing list of proteins that modulate ��-secretase activity [9], [12], [13], [14].In a pathological context, 185 missense mutations in PSEN1 and 13 mutations in PSEN2 have been identified and found to be associated with FAD (www.molgen.ua.ac.be/ADMutations). It was initially suggested that such mutations lead to a toxic gain of function because they are associated with a relative increased production of longer and more hydrophobic A�� species, mainly A��1���42, that accumulate and aggregate early in the course of thedisease [15], [16]. Similar phenotypes have been observed by independent groups in cell-based studies performed with different mammalian cell lines [17], [18], [19], [20], [21], [22]. Despite this growing consensus, the above-mentioned studies provided conflicting results regarding the relative proportions of A��42, A��40, and AICD resulting from the PSEN mutations. On one hand, a gain-of-function phenotype was suggested due to the observed increase in A��42 production, accompanied or not with reduced A��40 production, thereby leading to an increased A��42/A��40 ratio. On the other hand, reduced AICD production suggested a loss-of-function phenotype [20]. Differences in the methodologies and cell types used to assess the effects of PSEN mutations on A�� and AICD productions can explain this controversy as to how PS mutations exert their effects. For example, endogenous PS has been suggested to affect such analysis, as the FAD-linked PSEN1 mutations led to a decrease in the total amount of A�� generated in PS1 and PS2 double knockout cells [23]. Next, it has been reported that ��-secretase complexes are heterogeneous in composition (with two PS genes and three APH1 isoforms, six combinations of ��-secretase are possible), with distinct functional properties influencing the relative amount of A�� species generated [24]. In order to investigate the biochemical and functional properties of ��-secretase in cell-free systems, we and others have recently purified this enzymatic complex to homogeneity [25], [26], [27]. In particular, protocols for the high-grade purification of proteolytically active ��-secretase constituted of NCT, APH1aL, PEN2 and wild-type PS1 [26], [27] allowed the reconstitution of 3D structures at 15 �� and 12 �� resolution by EM and cryo-EM and gave new insights on the structure and activity of the enzyme [28], [29]. However, these studies were exclusively focused on the wild-type PS1. Here, we report for the first time the functional characterization of highly purified and homogenous human ��-secretase particles carrying different FAD-linked PS1 mutants. Our biochemical and functional findings strongly suggest that pathogenic mutations in PSEN1 cause a loss of ��-secretase activity.Results Top Generation, selection and characterization of stable cell lines overexpressing ��-secretase complexes with FAD-linked PS1 mutantsIn order to facilitate high-grade purification of homogenous human ��-secretase complexes containing different PS1 variants, we took advantage of a previously generated mouse embryonic fibroblast (MEF) cell line that lacks the two presenilins (PS1/2���/���) [30], [31]. Our global strategy consisted in producing stable cell lines, on a PS1/2���/��� background, that overexpress tagged versions of the three human ��-secretase subunits NCT, APH1 and PEN2 together with different variants of human PS1, and to purify the different human ��-secretase complexes by three sequential affinity purification steps. This strategy allowed us to exclude a possible co-purification of mouse ��-secretase components. First, a parental cell line was generated by co-transducing lentiviral vectors of human NCT-V5 (hNCT-V5), human APH1aL-HA (hAPH1aL-HA) and human Flag-PEN2 (Flag-hPEN2) into MEF PS1/2���/���. Lentivectors are stably integrated into the cell genome and allow the generation of cell lines overexpressing multiple genes in a short period of time. Next, the clone expressing the highest levels of all three recombinant proteins was selected (designated �� - PS1/2) and used as the parental cell line that was further transduced with lentivectors carrying the following different human PS1 variants: PS1-WT, three dominant-negative forms of PS1 that lack the crucial, catalytic site aspartate residues (D257A, D385A, and both D257A/D385A referred to as DDAA later in the article), and three FAD-linked PS1 mutants (L166P, ��E9 and P436Q, with mean disease onset at 24 years, 45.5 years and 28.3 years, respectively).For each PS1 variant, two individual clones were selected based on the expression levels of the recombinant proteins, and extensively characterized (Figure 1). To distinguish those cell lines overexpressing all ��-sectease components from wild-type MEFs, they are collectively designated ��-MEFs. As shown in Figure 1A, the analysis of total protein extracts confirmed that PS is required for the maturation of NCT and the stability of PEN2 [23], [32]. As expected, and when compared to the parental ��- PS1/2 cell line, higher levels of the mature form of NCT were observed in all PS1-overexpressing clones. In contrast to PEN2, APH1aL levels were relatively similar in all PS1 clones and the parental cell line. Indeed, and as previously reported [23], [32], PEN2 levels were higher in the clones overexpressing WT PS1 and FAD-linked PS1 mutants, and to a lesser extent in the clones overexpressing the dominant negative forms of PS1. Interestingly, PEN2 migrated on the gel as an apparent double band, possibly reflecting a post-translational modification. Different patterns of PS1 expression and autoproteolysis were observed in the different clones. First, and in sharp contrast to the other clones, those expressing PS1-WT or PS1-L166P displayed higher levels of PS1-NTF and PS1-CTF fragments compared with full-length PS1 (PS1-FL; Figure 1A). As estimated by densitometry, the NTF fragments of PS1-WT and PS1-L166P account for 87��2% and 79��7% of total PS1 (PS1-NTF+PS1-FL), respectively. Next, the PS1-��E9 clones did not show any detectable NTF or CTF fragments, as previously described [33], while P436Q and the three dominant negative variants of PS1 were characterized by low levels of PS1-NTF and PS1-CTF fragments, suggesting that these variants were less prone to endoproteolysis.thumbnailFigure 1. Generation of stable cell lines overexpressing all human ��-secretase components with FAD-linked PS1 variants.MEF PS1/2���/��� were stably co-transduced with lentiviral vectors carrying genes encoding hNCT-V5, Flag-hPEN2, hAPH1aL-HA and clones were isolated by limiting dilution to generate a cell line, designated as ��- PS1/2, that overexpresses high amount of the three subunits. ��- PS1/2 MEFs were further transduced with hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned. Each clone, derived form the ��- PS1/2, was conveniently named according to the mutation present in PS1 preceded by the symbol �� and followed by the number of the clone (��-MEF) in order to distinguish them from wild-type MEF (WT MEF) and MEF PS1/2���/���. Two clones per ��-secretase variant were selected for characterization. (A���B) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 4���12% Bis-Tris or 12% Tris-Glycine gels and analysed by immunostaining to detect the ��-secretase core components NCT (NCT164), PS1 (NTF, MAB1563; CTF; MAB5232), APH1aL-HA (3F10), and Flag-PEN2 (M2) (A), and endogenous APP (A8717) (B). ��-Actin was used as a loading control. Each lane represents one selected clone. CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated.doi:10.1371/journal.pone.0035133.g001 We next investigated the effects of PSEN1 mutations on the processing of endogenous APP. As expected, and as indicated by increased levels of intracellular APP-CTFs (a common characteristic among known substrates in response to ��-secretase pharmacological inhibition), the activity of ��-secretase was significantly altered in the PS deficient parental �� - PS1/2 cell line as well as in all clones expressing dominant negative forms of PS1 (Figure 1B). In the clones expressing PS1-WT, APP-CTFs were almost undetectable due to high ��-secretase activity, while clones expressing PS1-L166P or PS1-P436Q displayed APP-CTF accumulation. In PS1-��E9 clones, a mild APP-CTF accumulation was observed (Figure 1B). Although a poor recovery of ��-secretase activity for the PS1-L166P and a comparatively better performance of PS1-��E9 have been reported by others under similar experimental conditions [23], the potential of PS1-P436Q mutation to restore the processing of endogenous APP-CTFs has never been assessed [34], [35]. Importantly, all observations described above for the cells overexpressing simultaneously hNCT-V5, hAPH1aL-HA, Flag-hPEN2 and the different PS1 variants are very consistent with those made in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other ��-secretase components (cf. Figure S1A). These data suggest that the effect of FAD mutations in PS1 on APP-CTFs accumulation was similar in presence or absence of other human components of the ��-secretase.Next, we further investigated the effect of PS1 variants on the cellular production/secretion of A�� species. For this purpose, and as described elsewhere [36], we used an APP-based ��-secretase substrate with a Flag tag at its C-terminus (SPA4CT-Flag). This substrate was transduced in the above-described ��-secretase overexpressing stable cell lines (��-MEFs) as well as in wild-type MEFs, and APP-CTFs and A�� levels were measured in cell lysate and cell media, respectively (Figure 2). Under these conditions, the overexpression of SPA4CT-Flag led to an accumulation of two bands corresponding to the exogenous substrate, associated with a concomitant decrease of endogenous APP-CTFs levels (Figure 2A and Figure S2). As estimated by ELISA, a three-fold increase in A��1���40 and A��1���42 levels was observed in the cell culture media of cell lines overexpressing human ��-secretase (��-MEF WT), in comparison to untransduced WT MEFs (Figure 2B). Also, the average A��1���42/A��1���40 ratios were not significantly different in those cell lines (Mean �� SD: ��-MEF WT#5: 0.30��0.01; ��-MEF WT#8: 0.29��0.01; WT MEF: 0.19��0.06). Next, overexpression of SPA4CT-Flag in ��-MEFs led to the pronounced intracellular accumulation of APP-CTFs in cells overexpressing the PS1 aspartate mutants (Figure 2C), and to the secretion in the cell culture media of different A�� levels as measured by ELISA (Figure 2D). First, only traces of both A��1���40 and A��1���42 were detected in ��-MEFs overexpressing PS1 with aspartate mutants. Next, ��-MEFs overexpressing PS1 with FAD-linked mutations displayed a pronounced variability in A�� levels when compared to the wild-type clones. Overall, the average A��1���40 levels were decreased in these cell lines (Mean of two clones in pg/mL �� SD: WT: 224.6��0.1, L166P: 84.3��34.2, ��E9: 167.2��40.7, P436Q: 82.8��74.7), while the A��1���42 levels were increased (Mean of two clones in pg/mL �� SD: WT: 69.9��7.9, L166P: 310.7��81.0, ��E9: 94.4��18.5, P436Q: 141.1��98.5). Consistent with previously reported data, the A��1���42/A��1���40 ratios were increased in all ��-MEF clones overexpressing PS1 with FAD-linked mutations (Figure 2D) (Mean of two clones pg/mL �� SD: WT: 0.31��0.03, L166P: 3.8��0.58, ��E9: 0.6��0.03, P436Q: 2.0��0.59).thumbnailFigure 2. A�� production in cell lines overexpressing human ��-secretase components with FAD-linked PS1 variants.WT MEF, ��-MEF and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]) and a Flag Tag in C-terminus. Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717) (A, C). A��1���40 and A��1���42 levels were also measured in the corresponding cell culture media (B, D). Data corresponds to three independent experiments (Mean �� SEM).doi:10.1371/journal.pone.0035133.g002 FAD-linked PS1 mutations alter the activity of semi-purified ��-secretase complexesWe next assessed the activity of ��-secretase with FAD-linked PS1 mutations in microsomal extracts of ��-MEFs. Membrane protein extracts were prepared and ��-secretase activity was assayed on an exogenous recombinant APP-based substrate consisting of the C-terminal 99 amino acid residues of APP, and referred to as C100-Flag (Figure 3A). The generation of the cleavage product AICD-Flag was detected by Western blot analysis and measured by densitometry. As shown in Figure 3A, the levels of AICD-Flag generated from the PS1-L166P and PS1-��E9 clones accounted for 42��1% and 13��6% of that in the PS1-WT clones, respectively. AICD-Flag was undetectable in the clones expressing PS1-P436Q as well as in the three dominant negative aspartate PS1 variants. Similar results were observed in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other human ��-secretase components (Figure S1B).thumbnailFigure 3. Enzymatic activity of partially purified ��-secretase complexes with FAD-linked PS1 mutants.(A) ��-Secretase activity assays performed with ��-MEF and �� - PS1/2 microsomal extracts prepared in 1% CHAPSO-HEPES buffer. Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag). Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563). The relative amounts of AICD-Flag generated in the reactions, reflecting ��-secretase activity, were estimated by densitometry. PS1 immunostaining was used to assess the amount of input material. (B) Equal amounts of microsomal proteins were immunoprecipitated overnight at 4��C with either anti-Flag M2 or anti-HA affinity resins, and submitted to a C100-His assay according to the same protocol as in (A). Protein samples were separated by SDS-PAGE and analysed by immunostaining for ��-secretase subunits ((NCT164 (NCT), MAB1563 (PS1-NTF), or UD1 (PEN2)). AICD-His cleavage products were immunostained with an anti-APP-CTF antibody (A8717). *Indicates a non-specific band corresponding to the IgG light chains. (C) A��1���40 and A��1���42 were quantified by sandwich ELISA and represented in pg/mL (left Y-axis) or in percentage (right Y-axis) of the mean of A��1���40 levels generated by the two wild-type clones. A��1���42/A��1���40 ratios are indicated on the top of the bars. The results were confirmed in three independent experiments and a representative dataset is shown.doi:10.1371/journal.pone.0035133.g003 We next performed activity assays under semi-purified conditions. To do so, ��-secretase complexes from the different clones were co-immunoprecipitated from microsomal extracts and their activities were assayed in vitro with the C100-His substrate. Two immunoprecipitation protocols using two affinity resins (anti-Flag M2 and anti-HA 3F10, targeting respectively Flag-PEN2 and APH1aL-HA) were compared to exclude a possible heterogeneity of ��-secretase complexes potentially generated under such conditions. As shown in Figure 3B, the anti-Flag and anti-HA resins immunoprecipitated similar levels of NCT, PS1 and PEN2 and the activity of the ��-secretase complexes was similar regardless of the affinity resins used (Figures 3B). In agreement with the assays performed using microsomal extracts (Figure 3A), those performed with semi-purified complexes revealed that FAD-linked mutants drastically reduced AICD generation, when compared to PS1-WT (Figure 3B). Furthermore, levels of A��1���40 produced from PS1-L166P, PS1-��E9 and P436Q variants fell respectively to ~6%, ~1.5% and ~0.5%, when compared to these produced from PS1-WT ��-secretase. Following the same tendency, A��1���42 levels generated from PS1-L166P, PS1-��E9 and PS1-P436Q ��-secretase variants were respectively estimated to ~20%, ~5% and ~3% of these produced with PS1-WT-containing complexes. The A��1-42/A��1���40 ratio measured for WT ��-MEFs was consistent with our cell-based data (compare Figures 2D and 3C), validating our in vitro experimental conditions. Interestingly, an overall A��1���42/A��1���40 ratio of ~1 was estimated for all PS1 mutants, with the exception of P436Q#4 (~2). However, in the latter, the ratio may have been overestimated because the A��1���40 levels measured were at the detection limit. This similarity in the A��1���42/A��1���40 ratios generated by the different mutantshas, to the best of our knowledge, never been observed in previous studies.Highly purified ��-secretase complexes with FAD-linked PS1 mutants display a loss-of-function phenotypeIn order to further investigate how PS1 variants affect APP-CTF cleavage and to validate our observations performed in semi-purified conditions, we purified to homogeneity ��-secretase complexes from the selected clones described in Figure 1. The purification process (described in details under Materials &amp; Methods and depicted in Figure 4A) involved three sequential affinity purifications starting from microsomal extracts. Since all cell lines were generated on a PS knockout background, this strategy allowed us to purify exclusively and selectively ��-secretase complexes made of human components. As highlighted in Figure 4B, our protocol led to the production of stable, high molecular weight ��-secretase complexes (HMWCs) with an apparent molecular mass on Blue Native (BN)-PAGE of ~350 kDa, which is consistent with previous reports [26], [27], [37]. The silver stained particles on the BN gel confirmed the high purity of these complexes (Figure 4B, upper panel), for which the identity was established by cross-reactivity with antibodies specific to NCT and PS1 (Figure 4B, lower panels). As the main goal of this experiment was to compare the efficacy of the different ��-secretase complexes to process APP-based substrates, it is important to note that the final yields of the complexes purified from the different clones were very similar (Figure 4B), thus facilitating further comparative analyses. The immunoblot analysis of the purified complexes (Figure 4C) confirmed the presence of all core components (NCT-V5, APH1aL-HA, Flag-PEN2 and PS1) and globally recapitulates the maturation processes observed in the Figure 1. Interestingly, the relative PS1-NTF/CTF to PS1-FL ratios in the purified ��-secretase complexes containing the three PS1 dominant-negative or the PS1-P436Q variants were higher than those estimated in the whole cell extracts before purification (Figure 1A), indicating that endoproteolysis of PS1 was not completely abolished by these mutations. To assess how FAD-linked mutations in PS1 affect ��-secretase activity in these purified complexes, we performed in vitro assays by using C100-Flag substrate (Figure 3A) and equal amounts of the different purified complexes, immediately after the purification to avoid freezing/thawing cycles that might affect enzymatic activity. As shown in Figure 5A, ��-secretase activity based on AICD-Flag production was easily detected in complexes purified from the two PS1-WT clones. This is in sharp contrast to the other purified complexes that did not generate detectable AICD under our experimental conditions (Figure 5A). Next, sandwich ELISAs directed against A��1���40 and A��1���42 were performed in order to further characterize the specific activity of the purified complexes. Reflecting the levels of AICD and considering the detection limits of our sandwich ELISA, the production of both A�� species by ��-secretase complexes containing PS1-WT was at least 10-fold higher than in complexes with the FAD-linked or dominant-negative PS1 variants (Figure 5B). The A��1���42/A��1���40 ratio measured in PS1-WT ��-secretase complexes (~0.22) was similar to that previously reported [26], [27], thus excluding a possible qualitative alteration of ��-secretase activity with this protocol. Together, our results strongly support the hypothesis that the pathogenic L166P, ��E9, and P436Q mutations in PSEN1 cause a drastic loss (at least 90% as estimated by ELISA) of ��-secretase activity.thumbnailFigure 4. High-grade purification of human ��-secretase complexes with FAD-linked PS1 mutants.(A) Schematic representation of the ��-secretase purification process. Briefly, Presenilin double-knockout MEFs were used to first generate cell lines that stably overexpress human ��-secretase complexes containing different PS1 variants. Next, these cell lines were used for a multi-step purification procedure as described in the material and methods. (B) Blue-Native PAGE analysis of purified ��-secretase complexes made of different PS1 variants. Equal volumes of the different purified ��-secretase preparations were separated by native-PAGE on a 4���16% Bis-Tris gel, and stained with silver nitrate (top panel), or immunostained for NCT (NCT164, middle panel) or PS1-NTF (ab10281, bottom panel) as indicated. ��-Secretase complexes appeared on the gel as high molecular weight complexes (HMWCs) of ~350 kDa. Note that the levels of HMWCs were similar for all clones. (C) Equal volumes of purified ��-secretase complexes with FAD-linked PS1 mutants were separated under denaturing conditions (SDS-PAGE) and immunostained with anti-NCT (NCT164), anti-PS1-NTF (MAB1563), anti-PS1-CTF (MAB5232), anti-HA (3F10), or anti-Flag (M2) antibodies. Two independent purifications were performed on each clone with similar results. A representative dataset is shown.doi:10.1371/journal.pone.0035133.g004 thumbnailFigure 5. Enzymatic activity of highly purified ��-secretase complexes with FAD-linked or aspartate PS1 mutants.Equal amounts of the different purified ��-secretase preparations characterized in Figure 4 were tested for activity on C100-Flag, as described in Figure 3. The resulting cleavage products were separated by SDS-PAGE and detected by immunostaining with an anti-Flag antibody (M2) for C100-Flag or AICD-Flag (A), and by sandwich ELISA for A��1���40 or A��1���42 (B). Note that the levels of A�� produced from FAD-linked ��-secretase complexes were all in the non-linear range of the ELISA standards, close to the detection limit. Whenever possible, A��1���42/A��1���40 ratios were quantified and indicated on the top of the bars. Two independent purifications were performed on each clone and similar results were obtained. A representative dataset is shown.doi:10.1371/journal.pone.0035133.g005 Discussion Top Several conflicting results as to how Alzheimer's disease-linked mutations in PSEN1 affect the processing of APP by ��-secretase have been reported. First, it has been previously reported that transgenic animals with FAD-linked PS1 mutations show increasing brain levels of A��1���42 [15], [38]. Since A��1���42, the first A�� specie deposited in the brain of AD patients [16], [39], is more prone to aggregation when compared to shorter A�� species [40], [41], [42], it has been implicated in the seeding of amyloid plaques in AD patients with PSEN1 mutations [43]. This was further validated in vivo as the overexpression of PS1 mutants in APP transgenic mice accelerated the rate of A�� accumulation and deposition in the brain [44], [45]. However, Bentahir and colleagues challenged this view by showing that several PSEN1 mutations were also capable to decrease total A�� production in PS1/PS2 knockout cells [23]. These findings suggested that endogenous PS1 and PS2 may influence the mutant phenotype in cells or in vivo. By extension, we hypothesized that the other components of ��-secretase, namely APH1, NCT and PEN2, may influence the mutant phenotype as well. Indeed, ��-secretase complexes are heterogeneous in composition due to the existence of two human APH1 genes, APH1a and APH1b, and two splicing isoforms of APH1a (S and L), as well as two presenilin genes, PSEN1 and PSEN2. Therefore, it is plausible that a single mutation in PSEN1 confers different catalytic properties to distinct ��-secretase subtypes. This hypothesis is supported by recent investigations showing that APH1 variants can modulate A�� profiles. When compared to APH1aS or L, overexpression of APH1b in MEF knockout for all APH1 genes led to increased production of longer A�� species [24]. With this regard, it is important to note that all four mouse variants of APH1 are expressed in the MEF cell line used in previous studies [23] and employed here (cf. Figure S3). Since the phenotype of PS1 mutations have mainly been assessed in vivo or in cell-based systems, we investigated the effects of FAD-linked PS1 mutants on the processing of APP-CTFs in cell-free systems, by using semi-purified and purified enzymatic complexes isolated from MEF PS1/PS2 double knockout cells stably overexpressing differentially tagged human ��-secretase components. Under these conditions, the biochemical and functional properties of ��-secretase complexes bearing either FAD-linked PS1 mutants (L166P, ��E9, and P436Q), dominant-negative forms of PS1 or wild-type PS1 were characterized. The activity of ��-secretase with PS1-WT was similar to that reported for ��-secretase purified from our CHO cells overexpressing NCT-V5, APH1aL, Flag-PEN2 and PS1-WT [26], [27], that resulted in A��1���42/A��1���40 ratios between 0.1 and 0.3. In contrast, we found a major loss in the activity of ��-secretase complexes containing either the dominant-negative PS1 variants or the FAD-linked PS1 mutants. Although a total loss of activity was expected for the dominant negative forms of ��-secretase [5], [6], [32], the drastic loss of activity seen here with the FAD-linked PS1 mutants was unexpected. Indeed, the PS1-L166P variant has previously been reported to increase A��1���42 levels both in vivo [46] and in vitro [20], in the presence of endogenous PS1, PS2 and APH1 components. In contrast, Bentahir and colleagues found that PS1-L166P decreased both A��1���40 and A��1���42 production in a PS knockout background. These results are consistent with our in vitro data, although the reduction in A��1���42 and A��1���40 production was more pronounced in our system. However, they differ from our cell-based data in which we observed an increase in A��1���42 associated with a decrease in A��1���40. Taken together, these data suggest that the overexpression of the other human components of ��-secretase can influence the phenotype of FAD-linked mutations. Another possible explanation for these discrepancies comes from the use, in previously described cellular systems, of APP carrying the Swedish mutation (K670M/N671L) [20], [23], [46]. Initially, this APP variant was shown to enhance the production of all A�� species by favouring its ��-secretase cleavage [47], [48]. However, Munter and colleagues recently demonstrated that the APP Swedish mutation can also affect the specificity of the ��-secretase cleavage [49]. In particular, these authors showed that over-expression of APP Swedish in a neuronal cell line led to a 4-fold increase in secreted A��42, associated with only a 2-fold increase of total A��, compared with the wild-type APP. Therefore, one cannot exclude the possibility of differential interactions between PS1-WT or PS1 variants and different APP variants, as suggested earlier [50].As far as the PS1-��E9 mutant is concerned, previous cell-based studies have reported a decrease in A��40 levels associated with an increase in A��42 levels [51], [52], or no changes in A��40 levels despite increased A��42 levels [53], or a decrease in both A�� species [23]. In the present study, A��1���40, A��1���42, as well as AICD levels generated from purified ��-secretase complexes with PS1-��E9 were close to the limit of detection, resulting in a loss of at least 95% of the ��-secretase activity compared to wild-type PS1. Similarly, we found a near to complete loss of ��-secretase activity for complexes with the aggressive PS1-P436Q mutant (mean onset: 28.3 years) [54]. Consistent with a recent study [35], and in contrast to PS1-L166P, the maturation of the full-length PS1-P436Q protein into PS1-NTF and PS1-CTF was impaired. Interestingly, the same study also reported that P436Q variant showed a decreased ��-secretase activity and A��40 and A��42 secretion in PS1/PS2 double knockout cells (~75% or ~50% of the control for A��40 or A��42, respectively), but to a lesser extent than what we measured in this study (more than 97% for both A�� species).Overall, our data show that, under our experimental conditions, the FAD-linked PS1 mutants cause a drastic loss of activity (at least 90%) in the highly purified and homogeneous as well as semi-purified ��-secretase complexes. This loss-of-function is asymmetrical as A��1���42 levels were relatively less affected than A��1���40 levels. Interestingly, the ratio between the two A�� species was similar for the variants tested here (~1), suggesting a common modulatory mechanism. Our findings further support a model in which the subtype of ��-secretase containing APH1aL and FAD-linked PS1 mutants generates a higher A��42/A��40 ratio compared to PS1-WT, as previously observed in vivo [15], [38]. Taken together, the overall reduction in A�� levels strongly suggest that other regulatory mechanisms or cellular components may exist and account for the strong amyloid pathology observed in AD patients carrying these FAD-linked PSEN1 mutations. In agreement with this hypothesis, we report that the phenotype of FAD-linked PSEN1 mutations is different whether we consider the cell-based or the cell-free conditions. Indeed, even if A��42/A��40 ratios were globally increased in both experimental conditions, A�� production was strikingly different.One possible explanation would be that specific subtypes of ��-secretase complexes are less affected than others by PSEN1 mutations. For instance, it remains unknown whether ��-secretase complexes carrying APH1b or APH1aS are similarly affected by PSEN1 mutations. In support to that regard, Winkler and colleagues recently purified human ��-secretase with PS1-L166P and observed that such complexes, containing both APH1a and AHP1b, led to increased A��1���42 production associated with decreased A��1���40 production, as compared to the PS1-WT complexes. Another possible explanation would be that purified ��-secretase complexes lack binding partners modulating the processing of APP-based substrates, due to purification conditions affecting physical interactions of proteins. These include TMP21 or the recently reported ��-secretase activating protein (GSAP) [12], [13]. Further biochemical analyses are needed to test this hypothesis.The loss of activity in ��-secretase containing PS1 variants also leads to decreased generation of AICD. As AICD is involved in the transcriptional regulation of several genes, including the neprilysin [55], and the lipoprotein receptor, LRP1 [11], it is likely that mutations in PSEN1 impair the regulation of these genes in vivo. For instance, it is possible that unknown genes transcriptionally regulated in vivo by the AICD might influence A�� metabolism in return. In support to these views, Veeraraghavalu and colleagues recently demonstrated that Notch signalling was impaired in transgenic mice overexpressing PS1 mutants, albeit in the presence of endogenous PS1-WT and all APH1 isoforms [56]. They found decreased self-renewal and differentiation of neuronal precursor cells in the subventricular zone, suggesting that the loss-of-function phenotype of PSEN1 mutations can also be observed in heterogeneous conditions. These results are reminiscent of the previous report from Saura and colleagues showing that conditional inactivation of both presenilins in vivo induces age-dependent neurodegeneration associated with memory impairment [57]. Altogether, the above-described data suggest that alternative pathways of neurodegeneration related to loss of ��-secretase functions are possible and relevant to AD. They further support the concept that modulating rather than inhibiting ��-secretase activity would be a more appropriate therapeutic strategy for AD [58]. Supporting this view, the ��-secretase inhibitor Semagacestat tested in phase III clinical trials not only failed to slow cognitive decline in patients with mild-to-moderate AD, but actually made it worse [59].Collectively, our findings support a model in which FAD-linked mutations in PSEN1 likely induce A�� pathology by perturbing the relative ratio between A�� species and by impairing developmental and cellular signalling pathways controlled by ��-secretase substrates. This deleterious dual effect might explain why FAD-linked PSEN1 mutations cause early onset Alzheimer's disease. Since it has been established that A�� and AICD are generated following the processing by ��-secretase at two distinct gamma- and epsilon-cleavage sites in APP [60], further investigation is now required to better understand whether and how FAD mutations in PS1 differentially affect the epsilon versus gamma-cleavage sites in APP, as well as in other known ��-secretase substrates.Materials and Methods Top DNA Constructs and mutagenesisNCT-V5, Flag-PEN2, APH1aL-HA, wild-type PS1 human cDNAs (PS1-WT) were obtained from D. Selkoe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA). PS1 ��E9 cDNA was obtained from C. Saura (Universitat Aut��noma de Barcelona, Spain). PS1 D257A and PS1 D385A cDNAs were obtained from M. Wolfe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA). Mutations in PSEN1, namely, L166P and P436Q, were generated by PCR-based mutagenesis on the plasmid pcDNA3.1/Zeo(+)-PS1-WT using T7 or BGH primers (specific to the plasmid DNA sequence) together with the corresponding primers: L166P Rv: 5��� CAG CAA CAA Taa gct tGA TAT AAT AGG 3���; L166P Fw: 5��� CTT ATT ATA TCa agc ttA TTG TTG CTG 3���; P436Q Rv: 5��� TCG AGT TTA Gaa gct tTC TTG AAA ATG GCA AGG AG 3���; P436Q Fw: 5��� TCG AGT TTA Gaa gct tTG CCA GCT CTT CAA ATC TCC 3���. The sequences corresponding to enzyme restriction sites are given in small letters. The PCR fragments were next digested with BamHI/HindIII and HindIII/XhoI respectively, and were subcloned into pcDNA3. PS1 D257A/D385A (DDAA) was obtained by subcloning the DraI/XhoI digested fragment of PS1 D385A into pcDNA3.1-PS1 D257A. The APP based substrate SPA4CT-Flag, corresponding to the signal peptide of APP fused to the APP-C99-Flag with a small linker region (DA) [36], was obtained by removing the HindIII/EcoRI fragment of pcDNA3-APP695-Flag and inserting the following annealed primers: 5��� AGC TTA TGC TGC CCG GTT TG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT CGG GCG GAT GCA GAT GCA G 3��� and 5��� AAT TCT GCA TCT GCA TCC GCC CGA GCC GTC CAG GCG GCC AGC AGG AGC AGT GCC AAA CCG GGC AGC ATA 3���. All constructs were next subcloned into the self-inactivated vector pSIN-PGK-WHV cassette (a kind gift from R. Zufferey, Brain Mind Institute, EPFL, Lausanne, Switzerland). Inserts for plasmids pET21-C100-Flag, and pET21-C100-His were generated by PCR as previously described [27]. Plasmids pMD2G and psPAX2 were obtained from D. Trono (Global Health Institute, EPFL, Lausanne, Switzerland).Lentivector productionReplication-defective lentiviral particles were produced by a three-plasmid transient transfection of cells from the human embryonic kidney HEK 293T cell line [61]. Briefly, cells were incubated in 10 cm dishes until they reached 70% confluence and were transiently co-transfected by the calcium phosphate method, with 5 ��g of envelope plasmid (pMD2G), 15 ��g of packaging plasmid (psPAX2), and 20 ��g of vector plasmids (pSIN-PGK-WHV). Cells were incubated overnight with DNA-calcium precipitates, washed twice with Dulbecco's modified Eagle's medium (DMEM, Invitrogen) and incubated with 7 mL of DMEM. After 24 h, the conditioned medium was harvested and cells were incubated a second time with 7 mL of DMEM for 24 h. Media were then pooled, passed through 0.45 ��m filter, and stored at ���80��C as 2 mL aliquots until use. A p24 ELISA (Zeptometrix corporation) was performed on each batch of media in order to evaluate the number of viral particles generated.Generation of stable cell lines through multiple gene transductionsMouse Embryonic Fibroblasts (MEFs, obtained from B. De Strooper, Flanders University Institute of Biotechnology, Belgium) defective in PSEN1 and PSEN2 [30], [31] were cultivated in 10 cm dishes in DMEM, supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin (P/S) (Invitrogen). A first set of stable cell lines was generated by co-transducing NCT-V5, APH1aL-HA, and Flag-PEN2 containing lentiviral vectors (LV) repeatedly for two weeks at each passage (1/20). Ten clones were isolated by the limiting dilution method and were further screened for NCT-V5, Flag-PEN2 and APH1aL-HA expression by immunodetection. The clone that showed the highest expression of the three proteins (designated �� - PS1/2) was used as the parental cell line to generate the stable cell lines expressing different PS1 variants, by the same method and by using lentiviral vectors carrying human PS1-WT, PS1-L166P, PS1-��E9, PS1-P436Q, PS1-D257A, PS1-D385A, and PS1-DDAA. For each PS1 variant, five clones were selected for a full characterization and two of them were further used for ��-secretase purification. For SPA4CT overexpression experiments, 500,000 cells of each clone were exposed to the same arbitrary dose of lentiviral vectors carrying human SPA4CT-Flag in 2 mL of DMEM, 1% FBS, P/S and were plated in 6-wells plates for 72 h. The medium was next replaced by fresh DMEM, 2% FBS, P/S for 24 h. Finally, cell culture medium was harvested, supplemented with protease inhibitor cocktail (Roche), centrifuged for 3 min at 1,000�� rpm and frozen at ���80��C until further processing. Cells were washed in PBS and submitted to protein extraction.Protein extractionTotal protein extracts were prepared in 1% NP40 - HEPES buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche), and were clarified by centrifugation for 1 h at 16,000�� g, 4��C. Cell membranes were obtained as described below and solubilised in 1% CHAPSO - HEPES buffer and centrifuged at 16,000�� g for 1 h. Supernatants corresponding to the microsomal protein extracts were harvested and stored at ���80��C. Protein content of the extracts was estimated by the BCA protein assay reagent kit (Pierce).Multi-step purification of human ��-secretase complexes with FAD-linked PS1 variants1) Cell membrane preparation. MEF PS1/PS2 DKO cells (1.0��109 cells) expressing NCT-V5, Flag-PEN2, APH1aL-HA and different forms of PS1: wild type (WT), or with FAD-linked variants or lacking the critical aspartate residues, were collected from 15 cm dishes and fully resuspended in 40 mL of MES buffer (50 mM MES, pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche). Next, cells were passed four times through a high-pressure homogenizer (Emulsiflex-C5, Avestin Inc, ON Canada) at a pressure greater than 1,000 psi. Nuclei and unbroken cells were removed by centrifugation at 3,000�� g for 20 min at 4��C in a Beckman Coulter Allegra X-15R centrifuge. The supernatant was collected and centrifuged at 100,000�� g for 1 h at 4��C in a SW32Ti rotor using a Beckman Coulter Optima L-80 ultracentrifuge to recover the membrane preparation in the pellet. 2) Bicarbonate wash. The membrane pellet was fully resuspended in 1.6 mL of ice cold sodium bicarbonate buffer (0.1 M NaHCO3, pH 11.3) by pipetting up and down at least 30 times, and incubated at 4��C for 20 min. The washed membranes were then centrifuged at 100,000�� g for 1 h at 4��C and stored at ���80��C until use. 3) Solubilisation of ��-secretase complexes. The bicarbonate-washed membranes were fully resuspended in 1.7 mL of 1% CHAPSO - HEPES buffer by pipetting up and down at least 30 times. The membranes were then incubated at 4��C for 1 h. To pellet the insoluble material, the solution was centrifuged at 16,000�� g at 4��C for 1 h, the pellet was discarded, and the supernatant saved. This lysate is defined as ���solubilised ��-secretase preparation���. Next, these freshly prepared solubilised preparations were used for affinity purification of ��-secretase complexes as described below. 4) Anti-Flag M2 affinity purification. The solubilised ��-secretase preparations were first diluted 1:2 with HEPES buffer, and further diluted 1:6 with 0.1% digitonin - TBS buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) (final detergent concentration: 0.08% CHAPSO, 0.08% digitonin) and incubated overnight at 4��C with agitation after adding 200 ��L of anti-Flag M2 affinity resin beads (Sigma-Aldrich) that had been pre-equilibrated in 0.1% Digitonin - TBS buffer. The beads were washed 3 times in the same buffer, and the bound proteins were eluted over 4 h at 4��C with 0.4 mL of this buffer containing 200 ��g/mL of Flag peptides (Sigma-Aldrich). This elution step was repeated once for 1 h at 4��C and the eluted fractions were pooled and designated ���M2 pooled 800 ��L fractions���. 5) Anti-V5 affinity purification. The M2 pooled fractions (volume made up to 1 mL with 0.1% Digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-V5 affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin-TBS buffer. The beads were washed 3 times in the same buffer, and the bound proteins were eluted for 1 h at 4��C with 0.4 mL of this buffer containing 500 ��g/mL of V5 peptides (Sigma-Aldrich). This elution step was repeated 4 times, and the eluted fractions were pooled and designated ���V5 pooled 1.6 mL fractions���. 6) Anti-HA affinity purification. As a final purification step, the V5 pooled fractions (volume made up to 1.8 mL with 0.1% digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-HA affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin - TBS buffer. The beads were washed 3 times in the same buffer, and the bound proteins were eluted overnight at 4��C with 0.2 mL of this buffer containing 200 ��g/mL of HA peptides (Sigma-Aldrich). This elution step was repeated once, for 1 h at 4��C, and the two eluted fractions were kept separately, designated ���HA fraction E1��� and ���HA fraction E2���.Co-immunoprecipitationCo-IPs were performed on microsomal protein extracts. Briefly, 100 ��g of proteins were diluted in a final volume of 1 mL of 1% CHAPSO - HEPES extraction buffer containing protease inhibitors (Roche), and 50 ��L of pre-equilibrated anti-Flag or anti-HA affinity beads (Sigma-Aldrich) were added. Samples were next incubated overnight at 4��C on a rotator wheel and were washed three times in 0.2% CHAPSO - HEPES buffer. Finally, beads were resuspended in 50 ��L of 0.2% CHAPSO - HEPES buffer and were used for in vitro ��-secretase assays.In vitro ��-secretase activity assaysIn vitro ��-secretase activity assays were performed as previously described [27]. ��-Secretase APP-based substrates were expressed in E. coli transfected with plasmids pET21-C100-Flag or pET21-C100-His as a fusion protein consisting of a Met for translation initiation, and either the Flag tag sequence (C100-Flag) or the His tag sequence (C100-His), and were affinity purified using an anti-Flag resin (M2, Sigma-Aldrich) or an Ni-NTA agarose resin (Invitrogen), respectively. In vitro assays were performed at 37��C for 4 h, with 1 ��M of recombinant substrate, 0.025% phosphatidylethanolamine (PE) and 0.1% phosphatidylcholine (PC). ��-Secretase activity was quantified by measuring the amount of AICD and A�� generated during the reaction, by immunoblot or sandwich ELISA respectively, as described below.SDS-PAGE, Native PAGE, Western blotting and antibodiesTotal or microsomal protein extracts were resolved by electrophoresis on NuPAGE�� Novex�� 4���12% Bis-Tris Gels (Invitrogen) or on standard 12% acrylamide/bisacrylamide Tris Glycine gels for SDS-PAGE analysis. Purified ��-secretase was resolved by electrophoresis on NativePAGE��� Novex�� Bis-Tris 4���16% Gels for Blue Native (BN)-PAGE analysis (Invitrogen). Silver staining was performed directly on gel according to manufacturer instructions (Biorad). For immunoblot analysis, gels were transferred to nitrocellulose or PVDF membranes (Whatman), and probed with the following antibodies: anti-Nicastrin NCT164 (BD Bioscience), anti-V5-tag for NCT-V5 (Covance), MAB1563 (Millipore) or ab10281 (Abcam) for PS1 NTF, MAB5232 for PS1 CTF (Millipore), 3F10 for APH1aL-HA (Roche), anti-Flag M2 for Flag-PEN-2 or C100-Flag (Sigma-Aldrich), A8717 for APP CTF (Sigma-Aldrich), and A2066 for ��-actin (Sigma-Aldrich). Anti-mouse/rabbit/rat IgG conjugated to Alexa 680 were purchased from Invitrogen. The Odyssey infrared imaging system (LICOR) was used to detect the fluorescent signal.Quantification of A�� peptidesA�� peptides from the ��-secretase assays described above were quantified by sandwich ELISA according to the protocol provided by the manufacturer. Three kits were used to detect human A��1���40(Invitrogen KHB3481) and A��1���42 (Invitrogen KHB3544 and Wako 269-64401).Supporting Information Top Figure S1. Characterization of stable cell lines overexpressing human FAD-linked PS1 variants in MEF PS1/2���/���. Presenilin double-knockout mouse embryonic fibroblasts were stably transduced with lentiviral vectors carrying genes encoding hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned. Two clones per PS1 variant were selected for characterization. (A) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with various antibodies to detect the endogenous ��-secretase core components: NCT (NCT164), hPS1 (NTF, MAB1563), and PEN2 (UD1), and with an antibody for APP (A8717). ��-Actin was used as a loading control. Each lane represents one selected clone. (B) ��-Secretase activity assays were performed with microsomal extracts prepared in 1% CHAPSO-HEPES buffer. Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag). Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563). PS1 immunostaining was used to assess the amount of input material. * Indicates a non-specific band, which was not detected in microsomal protein extracts of the same cell lines using the same antibody (MAB1563) (B). CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated.(TIF)Figure S2. APP-CTF profiles in WT MEF, MEF PS1/2���/��� and �� - PS1/2 transduced with the SPA4CT construct. WT MEF, MEF PS1/2���/��� and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]). Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717).(TIF)Figure S3. APH1 isoforms expressed in MEF PS1/2���/���. Total RNAs were extracted from presenilin double-knockout MEFs, using standard procedures (Qiagen RNAeasy kit) and were quantified by spectrophotometry. One microgram of total RNAs was reverse transcribed for 1 h at 42��C by using the ImProm-II reverse transcription system (Promega) and oligo-dT primer in a final volume of 20 ��L. PCR was next performed for each APH1 isoform on 1 ��L of RT reaction by using the Roche PCR kit under standard conditions and the primers described in Table S1. The following cycling conditions were applied for all reactions: 94��C, 3 min; 30 cycles of [94��C, 30 s; 58��C, 30 s; 70��C, 40 s]; 70��C, 10 min. PCR products were separated on a 2% agarose gel and visualized using Alpha Innotech UV imager.(TIF)Table S1. Primers used to detect APH1 isoforms in MEF PS1/2���/���. F: Forward, R: Reverse.(DOC)Acknowledgments Top We are grateful to B. De Strooper for the WT and PS1���/��� PS2���/��� KO mouse embryonic fibroblasts, to C. Saura for the PS1 ��E9, to M. Wolfe for the PS1 D257A and PS1 D385A cDNAs, and to D. Selkoe for the APH1aL-HA, NCT-V5, and Flag-PEN2 cDNAs. We also thank J.R. Alattia, C. Schweizer, and A. Alahari for critical readings of the manuscript.Author Contributions Top Conceived and designed the experiments: MC PCF. Performed the experiments: MC LA JH. Analyzed the data: MC LA JH PCF. Wrote the paper: MC PCF. Edited the manuscript: MC LA JH PCF. Supervised the project: PCF.References Top Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775���778. Find this article online Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754���760. Find this article online Weihofen A, Martoglio B (2003) Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol 13: 71���78. Find this article online Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2: 428���434. Find this article online Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398: 513���517. Find this article online Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ (2000) The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J Biol Chem 275: 3173���3178. Find this article online Beel AJ, Sanders CR (2008) Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 65: 1311���1334. Find this article online Bot N, Schweizer C, Ben Halima S, Fraering PC (2010) Processing of the synaptic cell-adhesion molecule neurexin-3{beta} by Alzheimer's disease {alpha}- and {gamma}-secretases. J Biol Chem. Find this article online Parks AL, Curtis D (2007) Presenilin diversifies its portfolio. Trends Genet 23: 140���150. Find this article online Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25: 436���445. Find this article online Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, et al. (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56: 66���78. Find this article online Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, et al. (2006) TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440: 1208���1212. Find this article online He G, Luo W, Li P, Remmers C, Netzer WJ, et al. (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467: 95���98. Find this article online Wakabayashi T, De Strooper B (2008) Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 23: 194���204. Find this article online Citron M, Westaway D, Xia W, Carlson G, Diehl T, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67���72. Find this article online Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, et al. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59: 398���407. Find this article online Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, et al. (1998) Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43: 256���258. Find this article online Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, et al. (1999) Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett 265: 61���63. Find this article online Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, et al. (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 20: 8717���8726. Find this article online Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A 99: 8025���8030. Find this article online Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y (2003) Distinct mechanisms by mutant presenilin 1 and 2 leading toincreased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells. Biochemistry 42: 1042���1052. Find this article online Dowjat WK, Kuchna I, Wisniewski T, Wegiel J (2004) A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. J Alzheimers Dis 6: 31���43. Find this article online Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, et al. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96: 732���742. Find this article online Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, et al. (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324: 639���642. Find this article online Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, et al. (2003) Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem 278: 24277���24284. Find this article online Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, et al. (2004) Purification and characterization of the human gamma-secretase complex. Biochemistry 43: 9774���9789. Find this article online Cacquevel M, Aeschbach L, Osenkowski P, Li D, Ye W, et al. (2008) Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J Neurochem 104: 210���220. Find this article online Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, et al. (2006) Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A 103: 6889���6894. Find this article online Osenkowski P, Li H, Ye W, Li D, Aeschbach L, et al. (2009) Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol 385: 642���652. Find this article online Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, et al. (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 96: 11872���11877. Find this article online Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, et al. (2003) gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci 116: 1127���1136. Find this article online Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, et al. (2003) Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin. J Biol Chem 278: 43430���43436. Find this article online Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17: 181���190. Find this article online Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, et al. (2007) Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest 117: 1230���1239. Find this article online Heilig EA, Xia W, Shen J, Kelleher RJ (2010) A presenilin-1 mutation identified in familial Alzheimer's disease with cotton wool plaques causes nearly complete loss of {gamma}-secretase activity. J Biol Chem. Find this article online Lichtenthaler SF, Multhaup G, Masters CL, Beyreuther K (1999) A novel substrate for analyzing Alzheimer's disease gamma-secretase. FEBS letters 453: 288���292. Find this article online Fraering PC, LaVoie MJ, Ye W, Ostaszewski BL, Kimberly WT, et al. (2004) Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry 43: 323���333. Find this article online Duff K, Eckman C, Zehr C, Yu X, Prada CM, et al. (1996) Increased amyloid-beta42(43) in brainsof mice expressing mutant presenilin 1. Nature 383: 710���713. Find this article online Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45���53. Find this article online Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, et al. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267: 546���554. Find this article online Jan A, Gokce O, Luthi-Carter R, Lashuel HA (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem 283: 28176���28189. Find this article online Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693���4697. Find this article online Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864���870. Find this article online Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97���100. Find this article online Borchelt DR, Lee MK, Gonzales V, Slunt HH, Ratovitski T, et al. (2002)&#10;Q: What effect can be observed when when ��-secretase is blocked? &#10;&#10;A: APP-CTF accumulation&#10;A: PSEN1 mutations&#10;A: cell-based data&#10;A: APH1 variants&#10;A: transition-state analogue&#10;&#10;Q: When APH1 genes are overexpressed in MEF KO what happens with the A��?&#10;&#10;A: They are purified&#10;A: They are anterior&#10;A: They are shorter&#10;A: They are longer&#10;A: They are supported&#10;&#10;Q: In which gene are mutations associated to many cases of early-onset familial forms of Alzheimer's disease?G&#10;&#10;A: FAD&#10;A: I-CLiPs&#10;A: NCT&#10;A: PSEN1&#10;A: D257A&#10;&#10;Q: What experimental technique was used specifically to purify the ��-secretase complex?&#10;&#10;A: plasmids&#10;A: affinity chromatography&#10;A: lysate&#10;A: cell lines&#10;A: knockout experiments&#10;&#10;Q: What peptide is able to control the expression of the ApoE gene?&#10;&#10;A: AD&#10;A: APP-CTFs&#10;A: c-secretase&#10;A: cholesterol&#10;A: AICD&#10;&#10;Q: Which amino acid is critical for the activity of the PS1 protein?&#10;&#10;A: aspartate&#10;A: C-terminal&#10;A: 42-residue&#10;A: 99&#10;A: DDAA&#10;&#10;Q: What experimental technique was used to determine the structure of ��-secretase?&#10;&#10;A: densitometry&#10;A: EM&#10;A: ELISA&#10;A: immunostaining&#10;A: purification&#10;&#10;Q: What candidate drug that blocks the ��-secretase is now tested in clinical trials?&#10;&#10;A: LRP1&#10;A: biochemical&#10;A: PSEN1&#10;A: AD&#10;A: Semagacestat&#10;&#10;Q: What mutation of the PS1 protein causes ��-secretase activity almost to disappear?&#10;&#10;A: P436Q&#10;A: L166P&#10;A: wild-type&#10;A: AICD&#10;A: C100-His&#10;&#10;Q: How many mutations relevant for familial forms of Alzheimer's disease have been detected for the PSEN1 gene?&#10;&#10;A: 13&#10;A: 42&#10;A: P436Q&#10;A: 185&#10;A: PSEN2&#10;&#10;"/><types:TestDocument xmi:id="1" sofa="12" begin="0" end="65298" text="PLoS ONE: Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesOpen AccessResearch ArticleAlzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesMatthias Cacquevel, Lor��ne Aeschbach, Jemila Houacine, Patrick C. Fraering*��cole Polytechnique F��d��rale de Lausanne, Brain Mind Institute, Laboratory of Molecular and Cellular Biology of Alzheimer's Disease, Lausanne, SwitzerlandAbstract Top BackgroundMutations linked to early onset, familial forms of Alzheimer's disease (FAD) are found most frequently in PSEN1, the gene encoding presenilin-1 (PS1). Together with nicastrin (NCT), anterior pharynx-defective protein 1 (APH1), and presenilin enhancer 2 (PEN2), the catalytic subunit PS1 constitutes the core of the ��-secretase complex and contributes to the proteolysis of the amyloid precursor protein (APP) into amyloid-beta (A��) peptides. Although there is a growing consensus that FAD-linked PS1 mutations affect A�� production by enhancing the A��1���42/A��1���40 ratio, it remains unclear whether and how they affect the generation of APP intracellular domain (AICD). Moreover, controversy exists as to how PS1 mutations exert their effects in different experimental systems, by either increasing A��1���42 production, decreasing A��1���40 production, or both. Because it could be explained by the heterogeneity in the composition of ��-secretase, we purified to homogeneity complexes made of human NCT, APH1aL, PEN2, and the pathogenic PS1 mutants L166P, ��E9, or P436Q.Methodology/Principal FindingsWe took advantage of a mouse embryonic fibroblast cell line lacking PS1 and PS2 to generate different stable cell lines overexpressing human ��-secretase complexes with different FAD-linked PS1 mutations. A multi-step affinity purification procedure was used to isolate semi-purified or highly purified ��-secretase complexes. The functional characterization of these complexes revealed that all PS1 FAD-linked mutations caused a loss of ��-secretase activity phenotype, in terms of A��1���40, A��1���42 and APP intracellular domain productions in vitro.Conclusion/SignificanceOur data support the view that PS1 mutations lead to a strong ��-secretase loss-of-function phenotype and an increased A��1���42/A��1���40 ratio, two mechanisms that are potentially involved in the pathogenesis of Alzheimer's disease.Citation: Cacquevel M, Aeschbach L, Houacine J, Fraering PC (2012) Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase Complexes. PLoS ONE 7(4): e35133. doi:10.1371/journal.pone.0035133Editor: Stefano L. Sensi, University G. D'Annunzio, ItalyReceived: February 20, 2012; Accepted: March 13, 2012; Published: April 18, 2012Copyright: �� 2012 Cacquevel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Funding: This work was supported by the Swiss National Foundation (to and LA and PCF; grant 31003A_134938/1) and the National Centre for Competence in Research (���Neuronal Plasticity and Repair��� (to JH and PCF)), and the Strauss foundation (to PCF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Competing interests: The authors have declared that no competing interests exist.* E-mail: patrick.fraering@epfl.chIntroduction Top Since their discovery in 1995 and their association with early onset familial Alzheimer's disease (FAD) [1], [2], the presenilin genes PSEN1 and PSEN2 have been widely studied, and the complexity of their biological role is becoming increasingly evident. PSEN1 and PSEN2 encode transmembrane proteins PS1 and PS2, respectively, that constitute the catalytic core of ��-secretase, the founding member of an emerging class of unconventional, Intramembrane-Cleaving Proteases (I-CLiPs) [3]. Active ��-secretase is a multiprotein complex composed of PS1 or PS2 together with nicastrin (NCT), the anterior pharynx-defective protein 1 (APH1), and the presenilin enhancer 2 (PEN2). Experimental evidence such as the binding of transition-state analogue ��-secretase inhibitors to PS1 [4], as well as the abolishment of ��-secretase activity when PS1 lacks the aspartate residues critical for proteolysis [4], [5], [6], have confirmed that presenilins harbour the active site of the enzymatic complex.PS1 and PS2 play fundamental roles in cell signalling as part of the ��-secretase complex. The latter cleaves numerous type-I membrane proteins in their transmembrane domain [7], releasing their corresponding intracellular domains, which are capable of influencing gene expression. For some substrates like NOTCH1 or ERBB4, the ��-secretase cleavage is essential for their biological function, whereas for other substrates like DCC or NEUREXIN-3�� [8], the possible role of the cleavage in signalling events has not been formally established (see [9] for a review). The amyloid precursor protein (APP) is processed by the successive actions of ��-secretase (BACE1) and ��-secretase, generating amyloid-beta peptides (A��) of different lengths, ranging from 37 to 46 amino acids [10]. Cleavage of the APP C-terminal fragments (APP-CTFs) by ��-secretase also releases the APP intracellular domain (AICD), which has been recently involved in the regulation of brain ApoE expression, a major genetic determinant of AD, and in cholesterol metabolism [11]. In addition, PS1 has been shown to interact with a growing list of proteins that modulate ��-secretase activity [9], [12], [13], [14].In a pathological context, 185 missense mutations in PSEN1 and 13 mutations in PSEN2 have been identified and found to be associated with FAD (www.molgen.ua.ac.be/ADMutations). It was initially suggested that such mutations lead to a toxic gain of function because they are associated with a relative increased production of longer and more hydrophobic A�� species, mainly A��1���42, that accumulate and aggregate early in the course of thedisease [15], [16]. Similar phenotypes have been observed by independent groups in cell-based studies performed with different mammalian cell lines [17], [18], [19], [20], [21], [22]. Despite this growing consensus, the above-mentioned studies provided conflicting results regarding the relative proportions of A��42, A��40, and AICD resulting from the PSEN mutations. On one hand, a gain-of-function phenotype was suggested due to the observed increase in A��42 production, accompanied or not with reduced A��40 production, thereby leading to an increased A��42/A��40 ratio. On the other hand, reduced AICD production suggested a loss-of-function phenotype [20]. Differences in the methodologies and cell types used to assess the effects of PSEN mutations on A�� and AICD productions can explain this controversy as to how PS mutations exert their effects. For example, endogenous PS has been suggested to affect such analysis, as the FAD-linked PSEN1 mutations led to a decrease in the total amount of A�� generated in PS1 and PS2 double knockout cells [23]. Next, it has been reported that ��-secretase complexes are heterogeneous in composition (with two PS genes and three APH1 isoforms, six combinations of ��-secretase are possible), with distinct functional properties influencing the relative amount of A�� species generated [24]. In order to investigate the biochemical and functional properties of ��-secretase in cell-free systems, we and others have recently purified this enzymatic complex to homogeneity [25], [26], [27]. In particular, protocols for the high-grade purification of proteolytically active ��-secretase constituted of NCT, APH1aL, PEN2 and wild-type PS1 [26], [27] allowed the reconstitution of 3D structures at 15 �� and 12 �� resolution by EM and cryo-EM and gave new insights on the structure and activity of the enzyme [28], [29]. However, these studies were exclusively focused on the wild-type PS1. Here, we report for the first time the functional characterization of highly purified and homogenous human ��-secretase particles carrying different FAD-linked PS1 mutants. Our biochemical and functional findings strongly suggest that pathogenic mutations in PSEN1 cause a loss of ��-secretase activity.Results Top Generation, selection and characterization of stable cell lines overexpressing ��-secretase complexes with FAD-linked PS1 mutantsIn order to facilitate high-grade purification of homogenous human ��-secretase complexes containing different PS1 variants, we took advantage of a previously generated mouse embryonic fibroblast (MEF) cell line that lacks the two presenilins (PS1/2���/���) [30], [31]. Our global strategy consisted in producing stable cell lines, on a PS1/2���/��� background, that overexpress tagged versions of the three human ��-secretase subunits NCT, APH1 and PEN2 together with different variants of human PS1, and to purify the different human ��-secretase complexes by three sequential affinity purification steps. This strategy allowed us to exclude a possible co-purification of mouse ��-secretase components. First, a parental cell line was generated by co-transducing lentiviral vectors of human NCT-V5 (hNCT-V5), human APH1aL-HA (hAPH1aL-HA) and human Flag-PEN2 (Flag-hPEN2) into MEF PS1/2���/���. Lentivectors are stably integrated into the cell genome and allow the generation of cell lines overexpressing multiple genes in a short period of time. Next, the clone expressing the highest levels of all three recombinant proteins was selected (designated �� - PS1/2) and used as the parental cell line that was further transduced with lentivectors carrying the following different human PS1 variants: PS1-WT, three dominant-negative forms of PS1 that lack the crucial, catalytic site aspartate residues (D257A, D385A, and both D257A/D385A referred to as DDAA later in the article), and three FAD-linked PS1 mutants (L166P, ��E9 and P436Q, with mean disease onset at 24 years, 45.5 years and 28.3 years, respectively).For each PS1 variant, two individual clones were selected based on the expression levels of the recombinant proteins, and extensively characterized (Figure 1). To distinguish those cell lines overexpressing all ��-sectease components from wild-type MEFs, they are collectively designated ��-MEFs. As shown in Figure 1A, the analysis of total protein extracts confirmed that PS is required for the maturation of NCT and the stability of PEN2 [23], [32]. As expected, and when compared to the parental ��- PS1/2 cell line, higher levels of the mature form of NCT were observed in all PS1-overexpressing clones. In contrast to PEN2, APH1aL levels were relatively similar in all PS1 clones and the parental cell line. Indeed, and as previously reported [23], [32], PEN2 levels were higher in the clones overexpressing WT PS1 and FAD-linked PS1 mutants, and to a lesser extent in the clones overexpressing the dominant negative forms of PS1. Interestingly, PEN2 migrated on the gel as an apparent double band, possibly reflecting a post-translational modification. Different patterns of PS1 expression and autoproteolysis were observed in the different clones. First, and in sharp contrast to the other clones, those expressing PS1-WT or PS1-L166P displayed higher levels of PS1-NTF and PS1-CTF fragments compared with full-length PS1 (PS1-FL; Figure 1A). As estimated by densitometry, the NTF fragments of PS1-WT and PS1-L166P account for 87��2% and 79��7% of total PS1 (PS1-NTF+PS1-FL), respectively. Next, the PS1-��E9 clones did not show any detectable NTF or CTF fragments, as previously described [33], while P436Q and the three dominant negative variants of PS1 were characterized by low levels of PS1-NTF and PS1-CTF fragments, suggesting that these variants were less prone to endoproteolysis.thumbnailFigure 1. Generation of stable cell lines overexpressing all human ��-secretase components with FAD-linked PS1 variants.MEF PS1/2���/��� were stably co-transduced with lentiviral vectors carrying genes encoding hNCT-V5, Flag-hPEN2, hAPH1aL-HA and clones were isolated by limiting dilution to generate a cell line, designated as ��- PS1/2, that overexpresses high amount of the three subunits. ��- PS1/2 MEFs were further transduced with hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned. Each clone, derived form the ��- PS1/2, was conveniently named according to the mutation present in PS1 preceded by the symbol �� and followed by the number of the clone (��-MEF) in order to distinguish them from wild-type MEF (WT MEF) and MEF PS1/2���/���. Two clones per ��-secretase variant were selected for characterization. (A���B) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 4���12% Bis-Tris or 12% Tris-Glycine gels and analysed by immunostaining to detect the ��-secretase core components NCT (NCT164), PS1 (NTF, MAB1563; CTF; MAB5232), APH1aL-HA (3F10), and Flag-PEN2 (M2) (A), and endogenous APP (A8717) (B). ��-Actin was used as a loading control. Each lane represents one selected clone. CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated.doi:10.1371/journal.pone.0035133.g001 We next investigated the effects of PSEN1 mutations on the processing of endogenous APP. As expected, and as indicated by increased levels of intracellular APP-CTFs (a common characteristic among known substrates in response to ��-secretase pharmacological inhibition), the activity of ��-secretase was significantly altered in the PS deficient parental �� - PS1/2 cell line as well as in all clones expressing dominant negative forms of PS1 (Figure 1B). In the clones expressing PS1-WT, APP-CTFs were almost undetectable due to high ��-secretase activity, while clones expressing PS1-L166P or PS1-P436Q displayed APP-CTF accumulation. In PS1-��E9 clones, a mild APP-CTF accumulation was observed (Figure 1B). Although a poor recovery of ��-secretase activity for the PS1-L166P and a comparatively better performance of PS1-��E9 have been reported by others under similar experimental conditions [23], the potential of PS1-P436Q mutation to restore the processing of endogenous APP-CTFs has never been assessed [34], [35]. Importantly, all observations described above for the cells overexpressing simultaneously hNCT-V5, hAPH1aL-HA, Flag-hPEN2 and the different PS1 variants are very consistent with those made in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other ��-secretase components (cf. Figure S1A). These data suggest that the effect of FAD mutations in PS1 on APP-CTFs accumulation was similar in presence or absence of other human components of the ��-secretase.Next, we further investigated the effect of PS1 variants on the cellular production/secretion of A�� species. For this purpose, and as described elsewhere [36], we used an APP-based ��-secretase substrate with a Flag tag at its C-terminus (SPA4CT-Flag). This substrate was transduced in the above-described ��-secretase overexpressing stable cell lines (��-MEFs) as well as in wild-type MEFs, and APP-CTFs and A�� levels were measured in cell lysate and cell media, respectively (Figure 2). Under these conditions, the overexpression of SPA4CT-Flag led to an accumulation of two bands corresponding to the exogenous substrate, associated with a concomitant decrease of endogenous APP-CTFs levels (Figure 2A and Figure S2). As estimated by ELISA, a three-fold increase in A��1���40 and A��1���42 levels was observed in the cell culture media of cell lines overexpressing human ��-secretase (��-MEF WT), in comparison to untransduced WT MEFs (Figure 2B). Also, the average A��1���42/A��1���40 ratios were not significantly different in those cell lines (Mean �� SD: ��-MEF WT#5: 0.30��0.01; ��-MEF WT#8: 0.29��0.01; WT MEF: 0.19��0.06). Next, overexpression of SPA4CT-Flag in ��-MEFs led to the pronounced intracellular accumulation of APP-CTFs in cells overexpressing the PS1 aspartate mutants (Figure 2C), and to the secretion in the cell culture media of different A�� levels as measured by ELISA (Figure 2D). First, only traces of both A��1���40 and A��1���42 were detected in ��-MEFs overexpressing PS1 with aspartate mutants. Next, ��-MEFs overexpressing PS1 with FAD-linked mutations displayed a pronounced variability in A�� levels when compared to the wild-type clones. Overall, the average A��1���40 levels were decreased in these cell lines (Mean of two clones in pg/mL �� SD: WT: 224.6��0.1, L166P: 84.3��34.2, ��E9: 167.2��40.7, P436Q: 82.8��74.7), while the A��1���42 levels were increased (Mean of two clones in pg/mL �� SD: WT: 69.9��7.9, L166P: 310.7��81.0, ��E9: 94.4��18.5, P436Q: 141.1��98.5). Consistent with previously reported data, the A��1���42/A��1���40 ratios were increased in all ��-MEF clones overexpressing PS1 with FAD-linked mutations (Figure 2D) (Mean of two clones pg/mL �� SD: WT: 0.31��0.03, L166P: 3.8��0.58, ��E9: 0.6��0.03, P436Q: 2.0��0.59).thumbnailFigure 2. A�� production in cell lines overexpressing human ��-secretase components with FAD-linked PS1 variants.WT MEF, ��-MEF and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]) and a Flag Tag in C-terminus. Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717) (A, C). A��1���40 and A��1���42 levels were also measured in the corresponding cell culture media (B, D). Data corresponds to three independent experiments (Mean �� SEM).doi:10.1371/journal.pone.0035133.g002 FAD-linked PS1 mutations alter the activity of semi-purified ��-secretase complexesWe next assessed the activity of ��-secretase with FAD-linked PS1 mutations in microsomal extracts of ��-MEFs. Membrane protein extracts were prepared and ��-secretase activity was assayed on an exogenous recombinant APP-based substrate consisting of the C-terminal 99 amino acid residues of APP, and referred to as C100-Flag (Figure 3A). The generation of the cleavage product AICD-Flag was detected by Western blot analysis and measured by densitometry. As shown in Figure 3A, the levels of AICD-Flag generated from the PS1-L166P and PS1-��E9 clones accounted for 42��1% and 13��6% of that in the PS1-WT clones, respectively. AICD-Flag was undetectable in the clones expressing PS1-P436Q as well as in the three dominant negative aspartate PS1 variants. Similar results were observed in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other human ��-secretase components (Figure S1B).thumbnailFigure 3. Enzymatic activity of partially purified ��-secretase complexes with FAD-linked PS1 mutants.(A) ��-Secretase activity assays performed with ��-MEF and �� - PS1/2 microsomal extracts prepared in 1% CHAPSO-HEPES buffer. Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag). Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563). The relative amounts of AICD-Flag generated in the reactions, reflecting ��-secretase activity, were estimated by densitometry. PS1 immunostaining was used to assess the amount of input material. (B) Equal amounts of microsomal proteins were immunoprecipitated overnight at 4��C with either anti-Flag M2 or anti-HA affinity resins, and submitted to a C100-His assay according to the same protocol as in (A). Protein samples were separated by SDS-PAGE and analysed by immunostaining for ��-secretase subunits ((NCT164 (NCT), MAB1563 (PS1-NTF), or UD1 (PEN2)). AICD-His cleavage products were immunostained with an anti-APP-CTF antibody (A8717). *Indicates a non-specific band corresponding to the IgG light chains. (C) A��1���40 and A��1���42 were quantified by sandwich ELISA and represented in pg/mL (left Y-axis) or in percentage (right Y-axis) of the mean of A��1���40 levels generated by the two wild-type clones. A��1���42/A��1���40 ratios are indicated on the top of the bars. The results were confirmed in three independent experiments and a representative dataset is shown.doi:10.1371/journal.pone.0035133.g003 We next performed activity assays under semi-purified conditions. To do so, ��-secretase complexes from the different clones were co-immunoprecipitated from microsomal extracts and their activities were assayed in vitro with the C100-His substrate. Two immunoprecipitation protocols using two affinity resins (anti-Flag M2 and anti-HA 3F10, targeting respectively Flag-PEN2 and APH1aL-HA) were compared to exclude a possible heterogeneity of ��-secretase complexes potentially generated under such conditions. As shown in Figure 3B, the anti-Flag and anti-HA resins immunoprecipitated similar levels of NCT, PS1 and PEN2 and the activity of the ��-secretase complexes was similar regardless of the affinity resins used (Figures 3B). In agreement with the assays performed using microsomal extracts (Figure 3A), those performed with semi-purified complexes revealed that FAD-linked mutants drastically reduced AICD generation, when compared to PS1-WT (Figure 3B). Furthermore, levels of A��1���40 produced from PS1-L166P, PS1-��E9 and P436Q variants fell respectively to ~6%, ~1.5% and ~0.5%, when compared to these produced from PS1-WT ��-secretase. Following the same tendency, A��1���42 levels generated from PS1-L166P, PS1-��E9 and PS1-P436Q ��-secretase variants were respectively estimated to ~20%, ~5% and ~3% of these produced with PS1-WT-containing complexes. The A��1-42/A��1���40 ratio measured for WT ��-MEFs was consistent with our cell-based data (compare Figures 2D and 3C), validating our in vitro experimental conditions. Interestingly, an overall A��1���42/A��1���40 ratio of ~1 was estimated for all PS1 mutants, with the exception of P436Q#4 (~2). However, in the latter, the ratio may have been overestimated because the A��1���40 levels measured were at the detection limit. This similarity in the A��1���42/A��1���40 ratios generated by the different mutantshas, to the best of our knowledge, never been observed in previous studies.Highly purified ��-secretase complexes with FAD-linked PS1 mutants display a loss-of-function phenotypeIn order to further investigate how PS1 variants affect APP-CTF cleavage and to validate our observations performed in semi-purified conditions, we purified to homogeneity ��-secretase complexes from the selected clones described in Figure 1. The purification process (described in details under Materials &amp; Methods and depicted in Figure 4A) involved three sequential affinity purifications starting from microsomal extracts. Since all cell lines were generated on a PS knockout background, this strategy allowed us to purify exclusively and selectively ��-secretase complexes made of human components. As highlighted in Figure 4B, our protocol led to the production of stable, high molecular weight ��-secretase complexes (HMWCs) with an apparent molecular mass on Blue Native (BN)-PAGE of ~350 kDa, which is consistent with previous reports [26], [27], [37]. The silver stained particles on the BN gel confirmed the high purity of these complexes (Figure 4B, upper panel), for which the identity was established by cross-reactivity with antibodies specific to NCT and PS1 (Figure 4B, lower panels). As the main goal of this experiment was to compare the efficacy of the different ��-secretase complexes to process APP-based substrates, it is important to note that the final yields of the complexes purified from the different clones were very similar (Figure 4B), thus facilitating further comparative analyses. The immunoblot analysis of the purified complexes (Figure 4C) confirmed the presence of all core components (NCT-V5, APH1aL-HA, Flag-PEN2 and PS1) and globally recapitulates the maturation processes observed in the Figure 1. Interestingly, the relative PS1-NTF/CTF to PS1-FL ratios in the purified ��-secretase complexes containing the three PS1 dominant-negative or the PS1-P436Q variants were higher than those estimated in the whole cell extracts before purification (Figure 1A), indicating that endoproteolysis of PS1 was not completely abolished by these mutations. To assess how FAD-linked mutations in PS1 affect ��-secretase activity in these purified complexes, we performed in vitro assays by using C100-Flag substrate (Figure 3A) and equal amounts of the different purified complexes, immediately after the purification to avoid freezing/thawing cycles that might affect enzymatic activity. As shown in Figure 5A, ��-secretase activity based on AICD-Flag production was easily detected in complexes purified from the two PS1-WT clones. This is in sharp contrast to the other purified complexes that did not generate detectable AICD under our experimental conditions (Figure 5A). Next, sandwich ELISAs directed against A��1���40 and A��1���42 were performed in order to further characterize the specific activity of the purified complexes. Reflecting the levels of AICD and considering the detection limits of our sandwich ELISA, the production of both A�� species by ��-secretase complexes containing PS1-WT was at least 10-fold higher than in complexes with the FAD-linked or dominant-negative PS1 variants (Figure 5B). The A��1���42/A��1���40 ratio measured in PS1-WT ��-secretase complexes (~0.22) was similar to that previously reported [26], [27], thus excluding a possible qualitative alteration of ��-secretase activity with this protocol. Together, our results strongly support the hypothesis that the pathogenic L166P, ��E9, and P436Q mutations in PSEN1 cause a drastic loss (at least 90% as estimated by ELISA) of ��-secretase activity.thumbnailFigure 4. High-grade purification of human ��-secretase complexes with FAD-linked PS1 mutants.(A) Schematic representation of the ��-secretase purification process. Briefly, Presenilin double-knockout MEFs were used to first generate cell lines that stably overexpress human ��-secretase complexes containing different PS1 variants. Next, these cell lines were used for a multi-step purification procedure as described in the material and methods. (B) Blue-Native PAGE analysis of purified ��-secretase complexes made of different PS1 variants. Equal volumes of the different purified ��-secretase preparations were separated by native-PAGE on a 4���16% Bis-Tris gel, and stained with silver nitrate (top panel), or immunostained for NCT (NCT164, middle panel) or PS1-NTF (ab10281, bottom panel) as indicated. ��-Secretase complexes appeared on the gel as high molecular weight complexes (HMWCs) of ~350 kDa. Note that the levels of HMWCs were similar for all clones. (C) Equal volumes of purified ��-secretase complexes with FAD-linked PS1 mutants were separated under denaturing conditions (SDS-PAGE) and immunostained with anti-NCT (NCT164), anti-PS1-NTF (MAB1563), anti-PS1-CTF (MAB5232), anti-HA (3F10), or anti-Flag (M2) antibodies. Two independent purifications were performed on each clone with similar results. A representative dataset is shown.doi:10.1371/journal.pone.0035133.g004 thumbnailFigure 5. Enzymatic activity of highly purified ��-secretase complexes with FAD-linked or aspartate PS1 mutants.Equal amounts of the different purified ��-secretase preparations characterized in Figure 4 were tested for activity on C100-Flag, as described in Figure 3. The resulting cleavage products were separated by SDS-PAGE and detected by immunostaining with an anti-Flag antibody (M2) for C100-Flag or AICD-Flag (A), and by sandwich ELISA for A��1���40 or A��1���42 (B). Note that the levels of A�� produced from FAD-linked ��-secretase complexes were all in the non-linear range of the ELISA standards, close to the detection limit. Whenever possible, A��1���42/A��1���40 ratios were quantified and indicated on the top of the bars. Two independent purifications were performed on each clone and similar results were obtained. A representative dataset is shown.doi:10.1371/journal.pone.0035133.g005 Discussion Top Several conflicting results as to how Alzheimer's disease-linked mutations in PSEN1 affect the processing of APP by ��-secretase have been reported. First, it has been previously reported that transgenic animals with FAD-linked PS1 mutations show increasing brain levels of A��1���42 [15], [38]. Since A��1���42, the first A�� specie deposited in the brain of AD patients [16], [39], is more prone to aggregation when compared to shorter A�� species [40], [41], [42], it has been implicated in the seeding of amyloid plaques in AD patients with PSEN1 mutations [43]. This was further validated in vivo as the overexpression of PS1 mutants in APP transgenic mice accelerated the rate of A�� accumulation and deposition in the brain [44], [45]. However, Bentahir and colleagues challenged this view by showing that several PSEN1 mutations were also capable to decrease total A�� production in PS1/PS2 knockout cells [23]. These findings suggested that endogenous PS1 and PS2 may influence the mutant phenotype in cells or in vivo. By extension, we hypothesized that the other components of ��-secretase, namely APH1, NCT and PEN2, may influence the mutant phenotype as well. Indeed, ��-secretase complexes are heterogeneous in composition due to the existence of two human APH1 genes, APH1a and APH1b, and two splicing isoforms of APH1a (S and L), as well as two presenilin genes, PSEN1 and PSEN2. Therefore, it is plausible that a single mutation in PSEN1 confers different catalytic properties to distinct ��-secretase subtypes. This hypothesis is supported by recent investigations showing that APH1 variants can modulate A�� profiles. When compared to APH1aS or L, overexpression of APH1b in MEF knockout for all APH1 genes led to increased production of longer A�� species [24]. With this regard, it is important to note that all four mouse variants of APH1 are expressed in the MEF cell line used in previous studies [23] and employed here (cf. Figure S3). Since the phenotype of PS1 mutations have mainly been assessed in vivo or in cell-based systems, we investigated the effects of FAD-linked PS1 mutants on the processing of APP-CTFs in cell-free systems, by using semi-purified and purified enzymatic complexes isolated from MEF PS1/PS2 double knockout cells stably overexpressing differentially tagged human ��-secretase components. Under these conditions, the biochemical and functional properties of ��-secretase complexes bearing either FAD-linked PS1 mutants (L166P, ��E9, and P436Q), dominant-negative forms of PS1 or wild-type PS1 were characterized. The activity of ��-secretase with PS1-WT was similar to that reported for ��-secretase purified from our CHO cells overexpressing NCT-V5, APH1aL, Flag-PEN2 and PS1-WT [26], [27], that resulted in A��1���42/A��1���40 ratios between 0.1 and 0.3. In contrast, we found a major loss in the activity of ��-secretase complexes containing either the dominant-negative PS1 variants or the FAD-linked PS1 mutants. Although a total loss of activity was expected for the dominant negative forms of ��-secretase [5], [6], [32], the drastic loss of activity seen here with the FAD-linked PS1 mutants was unexpected. Indeed, the PS1-L166P variant has previously been reported to increase A��1���42 levels both in vivo [46] and in vitro [20], in the presence of endogenous PS1, PS2 and APH1 components. In contrast, Bentahir and colleagues found that PS1-L166P decreased both A��1���40 and A��1���42 production in a PS knockout background. These results are consistent with our in vitro data, although the reduction in A��1���42 and A��1���40 production was more pronounced in our system. However, they differ from our cell-based data in which we observed an increase in A��1���42 associated with a decrease in A��1���40. Taken together, these data suggest that the overexpression of the other human components of ��-secretase can influence the phenotype of FAD-linked mutations. Another possible explanation for these discrepancies comes from the use, in previously described cellular systems, of APP carrying the Swedish mutation (K670M/N671L) [20], [23], [46]. Initially, this APP variant was shown to enhance the production of all A�� species by favouring its ��-secretase cleavage [47], [48]. However, Munter and colleagues recently demonstrated that the APP Swedish mutation can also affect the specificity of the ��-secretase cleavage [49]. In particular, these authors showed that over-expression of APP Swedish in a neuronal cell line led to a 4-fold increase in secreted A��42, associated with only a 2-fold increase of total A��, compared with the wild-type APP. Therefore, one cannot exclude the possibility of differential interactions between PS1-WT or PS1 variants and different APP variants, as suggested earlier [50].As far as the PS1-��E9 mutant is concerned, previous cell-based studies have reported a decrease in A��40 levels associated with an increase in A��42 levels [51], [52], or no changes in A��40 levels despite increased A��42 levels [53], or a decrease in both A�� species [23]. In the present study, A��1���40, A��1���42, as well as AICD levels generated from purified ��-secretase complexes with PS1-��E9 were close to the limit of detection, resulting in a loss of at least 95% of the ��-secretase activity compared to wild-type PS1. Similarly, we found a near to complete loss of ��-secretase activity for complexes with the aggressive PS1-P436Q mutant (mean onset: 28.3 years) [54]. Consistent with a recent study [35], and in contrast to PS1-L166P, the maturation of the full-length PS1-P436Q protein into PS1-NTF and PS1-CTF was impaired. Interestingly, the same study also reported that P436Q variant showed a decreased ��-secretase activity and A��40 and A��42 secretion in PS1/PS2 double knockout cells (~75% or ~50% of the control for A��40 or A��42, respectively), but to a lesser extent than what we measured in this study (more than 97% for both A�� species).Overall, our data show that, under our experimental conditions, the FAD-linked PS1 mutants cause a drastic loss of activity (at least 90%) in the highly purified and homogeneous as well as semi-purified ��-secretase complexes. This loss-of-function is asymmetrical as A��1���42 levels were relatively less affected than A��1���40 levels. Interestingly, the ratio between the two A�� species was similar for the variants tested here (~1), suggesting a common modulatory mechanism. Our findings further support a model in which the subtype of ��-secretase containing APH1aL and FAD-linked PS1 mutants generates a higher A��42/A��40 ratio compared to PS1-WT, as previously observed in vivo [15], [38]. Taken together, the overall reduction in A�� levels strongly suggest that other regulatory mechanisms or cellular components may exist and account for the strong amyloid pathology observed in AD patients carrying these FAD-linked PSEN1 mutations. In agreement with this hypothesis, we report that the phenotype of FAD-linked PSEN1 mutations is different whether we consider the cell-based or the cell-free conditions. Indeed, even if A��42/A��40 ratios were globally increased in both experimental conditions, A�� production was strikingly different.One possible explanation would be that specific subtypes of ��-secretase complexes are less affected than others by PSEN1 mutations. For instance, it remains unknown whether ��-secretase complexes carrying APH1b or APH1aS are similarly affected by PSEN1 mutations. In support to that regard, Winkler and colleagues recently purified human ��-secretase with PS1-L166P and observed that such complexes, containing both APH1a and AHP1b, led to increased A��1���42 production associated with decreased A��1���40 production, as compared to the PS1-WT complexes. Another possible explanation would be that purified ��-secretase complexes lack binding partners modulating the processing of APP-based substrates, due to purification conditions affecting physical interactions of proteins. These include TMP21 or the recently reported ��-secretase activating protein (GSAP) [12], [13]. Further biochemical analyses are needed to test this hypothesis.The loss of activity in ��-secretase containing PS1 variants also leads to decreased generation of AICD. As AICD is involved in the transcriptional regulation of several genes, including the neprilysin [55], and the lipoprotein receptor, LRP1 [11], it is likely that mutations in PSEN1 impair the regulation of these genes in vivo. For instance, it is possible that unknown genes transcriptionally regulated in vivo by the AICD might influence A�� metabolism in return. In support to these views, Veeraraghavalu and colleagues recently demonstrated that Notch signalling was impaired in transgenic mice overexpressing PS1 mutants, albeit in the presence of endogenous PS1-WT and all APH1 isoforms [56]. They found decreased self-renewal and differentiation of neuronal precursor cells in the subventricular zone, suggesting that the loss-of-function phenotype of PSEN1 mutations can also be observed in heterogeneous conditions. These results are reminiscent of the previous report from Saura and colleagues showing that conditional inactivation of both presenilins in vivo induces age-dependent neurodegeneration associated with memory impairment [57]. Altogether, the above-described data suggest that alternative pathways of neurodegeneration related to loss of ��-secretase functions are possible and relevant to AD. They further support the concept that modulating rather than inhibiting ��-secretase activity would be a more appropriate therapeutic strategy for AD [58]. Supporting this view, the ��-secretase inhibitor Semagacestat tested in phase III clinical trials not only failed to slow cognitive decline in patients with mild-to-moderate AD, but actually made it worse [59].Collectively, our findings support a model in which FAD-linked mutations in PSEN1 likely induce A�� pathology by perturbing the relative ratio between A�� species and by impairing developmental and cellular signalling pathways controlled by ��-secretase substrates. This deleterious dual effect might explain why FAD-linked PSEN1 mutations cause early onset Alzheimer's disease. Since it has been established that A�� and AICD are generated following the processing by ��-secretase at two distinct gamma- and epsilon-cleavage sites in APP [60], further investigation is now required to better understand whether and how FAD mutations in PS1 differentially affect the epsilon versus gamma-cleavage sites in APP, as well as in other known ��-secretase substrates.Materials and Methods Top DNA Constructs and mutagenesisNCT-V5, Flag-PEN2, APH1aL-HA, wild-type PS1 human cDNAs (PS1-WT) were obtained from D. Selkoe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA). PS1 ��E9 cDNA was obtained from C. Saura (Universitat Aut��noma de Barcelona, Spain). PS1 D257A and PS1 D385A cDNAs were obtained from M. Wolfe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA). Mutations in PSEN1, namely, L166P and P436Q, were generated by PCR-based mutagenesis on the plasmid pcDNA3.1/Zeo(+)-PS1-WT using T7 or BGH primers (specific to the plasmid DNA sequence) together with the corresponding primers: L166P Rv: 5��� CAG CAA CAA Taa gct tGA TAT AAT AGG 3���; L166P Fw: 5��� CTT ATT ATA TCa agc ttA TTG TTG CTG 3���; P436Q Rv: 5��� TCG AGT TTA Gaa gct tTC TTG AAA ATG GCA AGG AG 3���; P436Q Fw: 5��� TCG AGT TTA Gaa gct tTG CCA GCT CTT CAA ATC TCC 3���. The sequences corresponding to enzyme restriction sites are given in small letters. The PCR fragments were next digested with BamHI/HindIII and HindIII/XhoI respectively, and were subcloned into pcDNA3. PS1 D257A/D385A (DDAA) was obtained by subcloning the DraI/XhoI digested fragment of PS1 D385A into pcDNA3.1-PS1 D257A. The APP based substrate SPA4CT-Flag, corresponding to the signal peptide of APP fused to the APP-C99-Flag with a small linker region (DA) [36], was obtained by removing the HindIII/EcoRI fragment of pcDNA3-APP695-Flag and inserting the following annealed primers: 5��� AGC TTA TGC TGC CCG GTT TG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT CGG GCG GAT GCA GAT GCA G 3��� and 5��� AAT TCT GCA TCT GCA TCC GCC CGA GCC GTC CAG GCG GCC AGC AGG AGC AGT GCC AAA CCG GGC AGC ATA 3���. All constructs were next subcloned into the self-inactivated vector pSIN-PGK-WHV cassette (a kind gift from R. Zufferey, Brain Mind Institute, EPFL, Lausanne, Switzerland). Inserts for plasmids pET21-C100-Flag, and pET21-C100-His were generated by PCR as previously described [27]. Plasmids pMD2G and psPAX2 were obtained from D. Trono (Global Health Institute, EPFL, Lausanne, Switzerland).Lentivector productionReplication-defective lentiviral particles were produced by a three-plasmid transient transfection of cells from the human embryonic kidney HEK 293T cell line [61]. Briefly, cells were incubated in 10 cm dishes until they reached 70% confluence and were transiently co-transfected by the calcium phosphate method, with 5 ��g of envelope plasmid (pMD2G), 15 ��g of packaging plasmid (psPAX2), and 20 ��g of vector plasmids (pSIN-PGK-WHV). Cells were incubated overnight with DNA-calcium precipitates, washed twice with Dulbecco's modified Eagle's medium (DMEM, Invitrogen) and incubated with 7 mL of DMEM. After 24 h, the conditioned medium was harvested and cells were incubated a second time with 7 mL of DMEM for 24 h. Media were then pooled, passed through 0.45 ��m filter, and stored at ���80��C as 2 mL aliquots until use. A p24 ELISA (Zeptometrix corporation) was performed on each batch of media in order to evaluate the number of viral particles generated.Generation of stable cell lines through multiple gene transductionsMouse Embryonic Fibroblasts (MEFs, obtained from B. De Strooper, Flanders University Institute of Biotechnology, Belgium) defective in PSEN1 and PSEN2 [30], [31] were cultivated in 10 cm dishes in DMEM, supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin (P/S) (Invitrogen). A first set of stable cell lines was generated by co-transducing NCT-V5, APH1aL-HA, and Flag-PEN2 containing lentiviral vectors (LV) repeatedly for two weeks at each passage (1/20). Ten clones were isolated by the limiting dilution method and were further screened for NCT-V5, Flag-PEN2 and APH1aL-HA expression by immunodetection. The clone that showed the highest expression of the three proteins (designated �� - PS1/2) was used as the parental cell line to generate the stable cell lines expressing different PS1 variants, by the same method and by using lentiviral vectors carrying human PS1-WT, PS1-L166P, PS1-��E9, PS1-P436Q, PS1-D257A, PS1-D385A, and PS1-DDAA. For each PS1 variant, five clones were selected for a full characterization and two of them were further used for ��-secretase purification. For SPA4CT overexpression experiments, 500,000 cells of each clone were exposed to the same arbitrary dose of lentiviral vectors carrying human SPA4CT-Flag in 2 mL of DMEM, 1% FBS, P/S and were plated in 6-wells plates for 72 h. The medium was next replaced by fresh DMEM, 2% FBS, P/S for 24 h. Finally, cell culture medium was harvested, supplemented with protease inhibitor cocktail (Roche), centrifuged for 3 min at 1,000�� rpm and frozen at ���80��C until further processing. Cells were washed in PBS and submitted to protein extraction.Protein extractionTotal protein extracts were prepared in 1% NP40 - HEPES buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche), and were clarified by centrifugation for 1 h at 16,000�� g, 4��C. Cell membranes were obtained as described below and solubilised in 1% CHAPSO - HEPES buffer and centrifuged at 16,000�� g for 1 h. Supernatants corresponding to the microsomal protein extracts were harvested and stored at ���80��C. Protein content of the extracts was estimated by the BCA protein assay reagent kit (Pierce).Multi-step purification of human ��-secretase complexes with FAD-linked PS1 variants1) Cell membrane preparation. MEF PS1/PS2 DKO cells (1.0��109 cells) expressing NCT-V5, Flag-PEN2, APH1aL-HA and different forms of PS1: wild type (WT), or with FAD-linked variants or lacking the critical aspartate residues, were collected from 15 cm dishes and fully resuspended in 40 mL of MES buffer (50 mM MES, pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche). Next, cells were passed four times through a high-pressure homogenizer (Emulsiflex-C5, Avestin Inc, ON Canada) at a pressure greater than 1,000 psi. Nuclei and unbroken cells were removed by centrifugation at 3,000�� g for 20 min at 4��C in a Beckman Coulter Allegra X-15R centrifuge. The supernatant was collected and centrifuged at 100,000�� g for 1 h at 4��C in a SW32Ti rotor using a Beckman Coulter Optima L-80 ultracentrifuge to recover the membrane preparation in the pellet. 2) Bicarbonate wash. The membrane pellet was fully resuspended in 1.6 mL of ice cold sodium bicarbonate buffer (0.1 M NaHCO3, pH 11.3) by pipetting up and down at least 30 times, and incubated at 4��C for 20 min. The washed membranes were then centrifuged at 100,000�� g for 1 h at 4��C and stored at ���80��C until use. 3) Solubilisation of ��-secretase complexes. The bicarbonate-washed membranes were fully resuspended in 1.7 mL of 1% CHAPSO - HEPES buffer by pipetting up and down at least 30 times. The membranes were then incubated at 4��C for 1 h. To pellet the insoluble material, the solution was centrifuged at 16,000�� g at 4��C for 1 h, the pellet was discarded, and the supernatant saved. This lysate is defined as ���solubilised ��-secretase preparation���. Next, these freshly prepared solubilised preparations were used for affinity purification of ��-secretase complexes as described below. 4) Anti-Flag M2 affinity purification. The solubilised ��-secretase preparations were first diluted 1:2 with HEPES buffer, and further diluted 1:6 with 0.1% digitonin - TBS buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) (final detergent concentration: 0.08% CHAPSO, 0.08% digitonin) and incubated overnight at 4��C with agitation after adding 200 ��L of anti-Flag M2 affinity resin beads (Sigma-Aldrich) that had been pre-equilibrated in 0.1% Digitonin - TBS buffer. The beads were washed 3 times in the same buffer, and the bound proteins were eluted over 4 h at 4��C with 0.4 mL of this buffer containing 200 ��g/mL of Flag peptides (Sigma-Aldrich). This elution step was repeated once for 1 h at 4��C and the eluted fractions were pooled and designated ���M2 pooled 800 ��L fractions���. 5) Anti-V5 affinity purification. The M2 pooled fractions (volume made up to 1 mL with 0.1% Digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-V5 affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin-TBS buffer. The beads were washed 3 times in the same buffer, and the bound proteins were eluted for 1 h at 4��C with 0.4 mL of this buffer containing 500 ��g/mL of V5 peptides (Sigma-Aldrich). This elution step was repeated 4 times, and the eluted fractions were pooled and designated ���V5 pooled 1.6 mL fractions���. 6) Anti-HA affinity purification. As a final purification step, the V5 pooled fractions (volume made up to 1.8 mL with 0.1% digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-HA affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin - TBS buffer. The beads were washed 3 times in the same buffer, and the bound proteins were eluted overnight at 4��C with 0.2 mL of this buffer containing 200 ��g/mL of HA peptides (Sigma-Aldrich). This elution step was repeated once, for 1 h at 4��C, and the two eluted fractions were kept separately, designated ���HA fraction E1��� and ���HA fraction E2���.Co-immunoprecipitationCo-IPs were performed on microsomal protein extracts. Briefly, 100 ��g of proteins were diluted in a final volume of 1 mL of 1% CHAPSO - HEPES extraction buffer containing protease inhibitors (Roche), and 50 ��L of pre-equilibrated anti-Flag or anti-HA affinity beads (Sigma-Aldrich) were added. Samples were next incubated overnight at 4��C on a rotator wheel and were washed three times in 0.2% CHAPSO - HEPES buffer. Finally, beads were resuspended in 50 ��L of 0.2% CHAPSO - HEPES buffer and were used for in vitro ��-secretase assays.In vitro ��-secretase activity assaysIn vitro ��-secretase activity assays were performed as previously described [27]. ��-Secretase APP-based substrates were expressed in E. coli transfected with plasmids pET21-C100-Flag or pET21-C100-His as a fusion protein consisting of a Met for translation initiation, and either the Flag tag sequence (C100-Flag) or the His tag sequence (C100-His), and were affinity purified using an anti-Flag resin (M2, Sigma-Aldrich) or an Ni-NTA agarose resin (Invitrogen), respectively. In vitro assays were performed at 37��C for 4 h, with 1 ��M of recombinant substrate, 0.025% phosphatidylethanolamine (PE) and 0.1% phosphatidylcholine (PC). ��-Secretase activity was quantified by measuring the amount of AICD and A�� generated during the reaction, by immunoblot or sandwich ELISA respectively, as described below.SDS-PAGE, Native PAGE, Western blotting and antibodiesTotal or microsomal protein extracts were resolved by electrophoresis on NuPAGE�� Novex�� 4���12% Bis-Tris Gels (Invitrogen) or on standard 12% acrylamide/bisacrylamide Tris Glycine gels for SDS-PAGE analysis. Purified ��-secretase was resolved by electrophoresis on NativePAGE��� Novex�� Bis-Tris 4���16% Gels for Blue Native (BN)-PAGE analysis (Invitrogen). Silver staining was performed directly on gel according to manufacturer instructions (Biorad). For immunoblot analysis, gels were transferred to nitrocellulose or PVDF membranes (Whatman), and probed with the following antibodies: anti-Nicastrin NCT164 (BD Bioscience), anti-V5-tag for NCT-V5 (Covance), MAB1563 (Millipore) or ab10281 (Abcam) for PS1 NTF, MAB5232 for PS1 CTF (Millipore), 3F10 for APH1aL-HA (Roche), anti-Flag M2 for Flag-PEN-2 or C100-Flag (Sigma-Aldrich), A8717 for APP CTF (Sigma-Aldrich), and A2066 for ��-actin (Sigma-Aldrich). Anti-mouse/rabbit/rat IgG conjugated to Alexa 680 were purchased from Invitrogen. The Odyssey infrared imaging system (LICOR) was used to detect the fluorescent signal.Quantification of A�� peptidesA�� peptides from the ��-secretase assays described above were quantified by sandwich ELISA according to the protocol provided by the manufacturer. Three kits were used to detect human A��1���40(Invitrogen KHB3481) and A��1���42 (Invitrogen KHB3544 and Wako 269-64401).Supporting Information Top Figure S1. Characterization of stable cell lines overexpressing human FAD-linked PS1 variants in MEF PS1/2���/���. Presenilin double-knockout mouse embryonic fibroblasts were stably transduced with lentiviral vectors carrying genes encoding hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned. Two clones per PS1 variant were selected for characterization. (A) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with various antibodies to detect the endogenous ��-secretase core components: NCT (NCT164), hPS1 (NTF, MAB1563), and PEN2 (UD1), and with an antibody for APP (A8717). ��-Actin was used as a loading control. Each lane represents one selected clone. (B) ��-Secretase activity assays were performed with microsomal extracts prepared in 1% CHAPSO-HEPES buffer. Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag). Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563). PS1 immunostaining was used to assess the amount of input material. * Indicates a non-specific band, which was not detected in microsomal protein extracts of the same cell lines using the same antibody (MAB1563) (B). CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated.(TIF)Figure S2. APP-CTF profiles in WT MEF, MEF PS1/2���/��� and �� - PS1/2 transduced with the SPA4CT construct. WT MEF, MEF PS1/2���/��� and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]). Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717).(TIF)Figure S3. APH1 isoforms expressed in MEF PS1/2���/���. Total RNAs were extracted from presenilin double-knockout MEFs, using standard procedures (Qiagen RNAeasy kit) and were quantified by spectrophotometry. One microgram of total RNAs was reverse transcribed for 1 h at 42��C by using the ImProm-II reverse transcription system (Promega) and oligo-dT primer in a final volume of 20 ��L. PCR was next performed for each APH1 isoform on 1 ��L of RT reaction by using the Roche PCR kit under standard conditions and the primers described in Table S1. The following cycling conditions were applied for all reactions: 94��C, 3 min; 30 cycles of [94��C, 30 s; 58��C, 30 s; 70��C, 40 s]; 70��C, 10 min. PCR products were separated on a 2% agarose gel and visualized using Alpha Innotech UV imager.(TIF)Table S1. Primers used to detect APH1 isoforms in MEF PS1/2���/���. F: Forward, R: Reverse.(DOC)Acknowledgments Top We are grateful to B. De Strooper for the WT and PS1���/��� PS2���/��� KO mouse embryonic fibroblasts, to C. Saura for the PS1 ��E9, to M. Wolfe for the PS1 D257A and PS1 D385A cDNAs, and to D. Selkoe for the APH1aL-HA, NCT-V5, and Flag-PEN2 cDNAs. We also thank J.R. Alattia, C. Schweizer, and A. Alahari for critical readings of the manuscript.Author Contributions Top Conceived and designed the experiments: MC PCF. Performed the experiments: MC LA JH. Analyzed the data: MC LA JH PCF. Wrote the paper: MC PCF. Edited the manuscript: MC LA JH PCF. Supervised the project: PCF.References Top Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775���778. Find this article online Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754���760. Find this article online Weihofen A, Martoglio B (2003) Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol 13: 71���78. Find this article online Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2: 428���434. Find this article online Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398: 513���517. Find this article online Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ (2000) The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J Biol Chem 275: 3173���3178. Find this article online Beel AJ, Sanders CR (2008) Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 65: 1311���1334. Find this article online Bot N, Schweizer C, Ben Halima S, Fraering PC (2010) Processing of the synaptic cell-adhesion molecule neurexin-3{beta} by Alzheimer's disease {alpha}- and {gamma}-secretases. J Biol Chem. Find this article online Parks AL, Curtis D (2007) Presenilin diversifies its portfolio. Trends Genet 23: 140���150. Find this article online Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25: 436���445. Find this article online Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, et al. (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56: 66���78. Find this article online Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, et al. (2006) TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440: 1208���1212. Find this article online He G, Luo W, Li P, Remmers C, Netzer WJ, et al. (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467: 95���98. Find this article online Wakabayashi T, De Strooper B (2008) Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 23: 194���204. Find this article online Citron M, Westaway D, Xia W, Carlson G, Diehl T, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67���72. Find this article online Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, et al. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59: 398���407. Find this article online Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, et al. (1998) Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43: 256���258. Find this article online Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, et al. (1999) Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett 265: 61���63. Find this article online Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, et al. (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 20: 8717���8726. Find this article online Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A 99: 8025���8030. Find this article online Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y (2003) Distinct mechanisms by mutant presenilin 1 and 2 leading toincreased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells. Biochemistry 42: 1042���1052. Find this article online Dowjat WK, Kuchna I, Wisniewski T, Wegiel J (2004) A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. J Alzheimers Dis 6: 31���43. Find this article online Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, et al. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96: 732���742. Find this article online Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, et al. (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324: 639���642. Find this article online Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, et al. (2003) Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem 278: 24277���24284. Find this article online Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, et al. (2004) Purification and characterization of the human gamma-secretase complex. Biochemistry 43: 9774���9789. Find this article online Cacquevel M, Aeschbach L, Osenkowski P, Li D, Ye W, et al. (2008) Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J Neurochem 104: 210���220. Find this article online Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, et al. (2006) Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A 103: 6889���6894. Find this article online Osenkowski P, Li H, Ye W, Li D, Aeschbach L, et al. (2009) Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol 385: 642���652. Find this article online Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, et al. (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 96: 11872���11877. Find this article online Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, et al. (2003) gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci 116: 1127���1136. Find this article online Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, et al. (2003) Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin. J Biol Chem 278: 43430���43436. Find this article online Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17: 181���190. Find this article online Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, et al. (2007) Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest 117: 1230���1239. Find this article online Heilig EA, Xia W, Shen J, Kelleher RJ (2010) A presenilin-1 mutation identified in familial Alzheimer's disease with cotton wool plaques causes nearly complete loss of {gamma}-secretase activity. J Biol Chem. Find this article online Lichtenthaler SF, Multhaup G, Masters CL, Beyreuther K (1999) A novel substrate for analyzing Alzheimer's disease gamma-secretase. FEBS letters 453: 288���292. Find this article online Fraering PC, LaVoie MJ, Ye W, Ostaszewski BL, Kimberly WT, et al. (2004) Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry 43: 323���333. Find this article online Duff K, Eckman C, Zehr C, Yu X, Prada CM, et al. (1996) Increased amyloid-beta42(43) in brainsof mice expressing mutant presenilin 1. Nature 383: 710���713. Find this article online Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45���53. Find this article online Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, et al. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267: 546���554. Find this article online Jan A, Gokce O, Luthi-Carter R, Lashuel HA (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem 283: 28176���28189. Find this article online Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693���4697. Find this article online Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864���870. Find this article online Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97���100. Find this article online Borchelt DR, Lee MK, Gonzales V, Slunt HH, Ratovitski T, et al. (2002)" id="QA4MRE-2012_BIOMEDICAL_GS.xml_4" filteredText="Together with nicastrin (NCT), anterior pharynx-defective protein 1 (APH1), and presenilin enhancer 2 (PEN2), the catalytic subunit PS1 constitutes the core of the ��-secretase complex and contributes to the proteolysis of the amyloid precursor protein (APP) into amyloid-beta (A��) peptides.&#10;Although there is a growing consensus that FAD-linked PS1 mutations affect A�� production by enhancing the A��1���42/A��1���40 ratio, it remains unclear whether and how they affect the generation of APP intracellular domain (AICD).&#10;Moreover, controversy exists as to how PS1 mutations exert their effects in different experimental systems, by either increasing A��1���42 production, decreasing A��1���40 production, or both.&#10;Because it could be explained by the heterogeneity in the composition of ��-secretase, we purified to homogeneity complexes made of human NCT, APH1aL, PEN2, and the pathogenic PS1 mutants L166P, ��E9, or P436Q.&#10;Methodology/Principal FindingsWe took advantage of a mouse embryonic fibroblast cell line lacking PS1 and PS2 to generate different stable cell lines overexpressing human ��-secretase complexes with different FAD-linked PS1 mutations.&#10;A multi-step affinity purification procedure was used to isolate semi-purified or highly purified ��-secretase complexes.&#10;The functional characterization of these complexes revealed that all PS1 FAD-linked mutations caused a loss of ��-secretase activity phenotype, in terms of A��1���40, A��1���42 and APP intracellular domain productions in vitro.&#10;Conclusion/SignificanceOur data support the view that PS1 mutations lead to a strong ��-secretase loss-of-function phenotype and an increased A��1���42/A��1���40 ratio, two mechanisms that are potentially involved in the pathogenesis of Alzheimer's disease.&#10;pone.0035133Editor: Stefano L. Sensi, University G. D'Annunzio, ItalyReceived: February 20, 2012; Accepted: March 13, 2012; Published: April 18, 2012Copyright: �� 2012 Cacquevel et al.&#10;This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&#10;Funding: This work was supported by the Swiss National Foundation (to and LA and PCF; grant 31003A_134938/1) and the National Centre for Competence in Research (���Neuronal Plasticity and Repair��� (to JH and PCF)), and the Strauss foundation (to PCF).&#10;The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Competing interests: The authors have declared that no competing interests exist.&#10;* E-mail: patrick.fraering@epfl.chIntroduction Top Since their discovery in 1995 and their association with early onset familial Alzheimer's disease (FAD) [1], [2], the presenilin genes PSEN1 and PSEN2 have been widely studied, and the complexity of their biological role is becoming increasingly evident.&#10;PSEN1 and PSEN2 encode transmembrane proteins PS1 and PS2, respectively, that constitute the catalytic core of ��-secretase, the founding member of an emerging class of unconventional, Intramembrane-Cleaving Proteases (I-CLiPs) [3].&#10;Active ��-secretase is a multiprotein complex composed of PS1 or PS2 together with nicastrin (NCT), the anterior pharynx-defective protein 1 (APH1), and the presenilin enhancer 2 (PEN2).&#10;Experimental evidence such as the binding of transition-state analogue ��-secretase inhibitors to PS1 [4], as well as the abolishment of ��-secretase activity when PS1 lacks the aspartate residues critical for proteolysis [4], [5], [6], have confirmed that presenilins harbour the active site of the enzymatic complex.&#10;PS1 and PS2 play fundamental roles in cell signalling as part of the ��-secretase complex.&#10;The latter cleaves numerous type-I membrane proteins in their transmembrane domain [7], releasing their corresponding intracellular domains, which are capable of influencing gene expression.&#10;For some substrates like NOTCH1 or ERBB4, the ��-secretase cleavage is essential for their biological function, whereas for other substrates like DCC or NEUREXIN-3�� [8], the possible role of the cleavage in signalling events has not been formally established (see [9] for a review).&#10;The amyloid precursor protein (APP) is processed by the successive actions of ��-secretase (BACE1) and ��-secretase, generating amyloid-beta peptides (A��) of different lengths, ranging from 37 to 46 amino acids [10].&#10;Cleavage of the APP C-terminal fragments (APP-CTFs) by ��-secretase also releases the APP intracellular domain (AICD), which has been recently involved in the regulation of brain ApoE expression, a major genetic determinant of AD, and in cholesterol metabolism [11].&#10;In addition, PS1 has been shown to interact with a growing list of proteins that modulate ��-secretase activity [9], [12], [13], [14].&#10;In a pathological context, 185 missense mutations in PSEN1 and 13 mutations in PSEN2 have been identified and found to be associated with FAD (www.molgen.ua.ac.be/ADMutations).&#10;It was initially suggested that such mutations lead to a toxic gain of function because they are associated with a relative increased production of longer and more hydrophobic A�� species, mainly A��1���42, that accumulate and aggregate early in the course of thedisease [15], [16].&#10;Similar phenotypes have been observed by independent groups in cell-based studies performed with different mammalian cell lines [17], [18], [19], [20], [21], [22].&#10;Despite this growing consensus, the above-mentioned studies provided conflicting results regarding the relative proportions of A��42, A��40, and AICD resulting from the PSEN mutations.&#10;On one hand, a gain-of-function phenotype was suggested due to the observed increase in A��42 production, accompanied or not with reduced A��40 production, thereby leading to an increased A��42/A��40 ratio.&#10;On the other hand, reduced AICD production suggested a loss-of-function phenotype [20].&#10;Differences in the methodologies and cell types used to assess the effects of PSEN mutations on A�� and AICD productions can explain this controversy as to how PS mutations exert their effects.&#10;For example, endogenous PS has been suggested to affect such analysis, as the FAD-linked PSEN1 mutations led to a decrease in the total amount of A�� generated in PS1 and PS2 double knockout cells [23].&#10;Next, it has been reported that ��-secretase complexes are heterogeneous in composition (with two PS genes and three APH1 isoforms, six combinations of ��-secretase are possible), with distinct functional properties influencing the relative amount of A�� species generated [24].&#10;In order to investigate the biochemical and functional properties of ��-secretase in cell-free systems, we and others have recently purified this enzymatic complex to homogeneity [25], [26], [27].&#10;In particular, protocols for the high-grade purification of proteolytically active ��-secretase constituted of NCT, APH1aL, PEN2 and wild-type PS1 [26], [27] allowed the reconstitution of 3D structures at 15 �� and 12 �� resolution by EM and cryo-EM and gave new insights on the structure and activity of the enzyme [28], [29].&#10;However, these studies were exclusively focused on the wild-type PS1.&#10;Here, we report for the first time the functional characterization of highly purified and homogenous human ��-secretase particles carrying different FAD-linked PS1 mutants.&#10;Our biochemical and functional findings strongly suggest that pathogenic mutations in PSEN1 cause a loss of ��-secretase activity.&#10;Results Top Generation, selection and characterization of stable cell lines overexpressing ��-secretase complexes with FAD-linked PS1 mutantsIn order to facilitate high-grade purification of homogenous human ��-secretase complexes containing different PS1 variants, we took advantage of a previously generated mouse embryonic fibroblast (MEF) cell line that lacks the two presenilins (PS1/2���/���) [30], [31].&#10;Our global strategy consisted in producing stable cell lines, on a PS1/2���/��� background, that overexpress tagged versions of the three human ��-secretase subunits NCT, APH1 and PEN2 together with different variants of human PS1, and to purify the different human ��-secretase complexes by three sequential affinity purification steps.&#10;This strategy allowed us to exclude a possible co-purification of mouse ��-secretase components.&#10;First, a parental cell line was generated by co-transducing lentiviral vectors of human NCT-V5 (hNCT-V5), human APH1aL-HA (hAPH1aL-HA) and human Flag-PEN2 (Flag-hPEN2) into MEF PS1/2���/���.&#10;Lentivectors are stably integrated into the cell genome and allow the generation of cell lines overexpressing multiple genes in a short period of time.&#10;Next, the clone expressing the highest levels of all three recombinant proteins was selected (designated �� - PS1/2) and used as the parental cell line that was further transduced with lentivectors carrying the following different human PS1 variants: PS1-WT, three dominant-negative forms of PS1 that lack the crucial, catalytic site aspartate residues (D257A, D385A, and both D257A/D385A referred to as DDAA later in the article), and three FAD-linked PS1 mutants (L166P, ��E9 and P436Q, with mean disease onset at 24 years, 45.5 years and 28.3 years, respectively).&#10;For each PS1 variant, two individual clones were selected based on the expression levels of the recombinant proteins, and extensively characterized (Figure 1).&#10;To distinguish those cell lines overexpressing all ��-sectease components from wild-type MEFs, they are collectively designated ��-MEFs.&#10;As shown in Figure 1A, the analysis of total protein extracts confirmed that PS is required for the maturation of NCT and the stability of PEN2 [23], [32].&#10;As expected, and when compared to the parental ��- PS1/2 cell line, higher levels of the mature form of NCT were observed in all PS1-overexpressing clones.&#10;In contrast to PEN2, APH1aL levels were relatively similar in all PS1 clones and the parental cell line.&#10;Indeed, and as previously reported [23], [32], PEN2 levels were higher in the clones overexpressing WT PS1 and FAD-linked PS1 mutants, and to a lesser extent in the clones overexpressing the dominant negative forms of PS1.&#10;Interestingly, PEN2 migrated on the gel as an apparent double band, possibly reflecting a post-translational modification.&#10;Different patterns of PS1 expression and autoproteolysis were observed in the different clones.&#10;First, and in sharp contrast to the other clones, those expressing PS1-WT or PS1-L166P displayed higher levels of PS1-NTF and PS1-CTF fragments compared with full-length PS1 (PS1-FL; Figure 1A).&#10;As estimated by densitometry, the NTF fragments of PS1-WT and PS1-L166P account for 87��2% and 79��7% of total PS1 (PS1-NTF+PS1-FL), respectively.&#10;Next, the PS1-��E9 clones did not show any detectable NTF or CTF fragments, as previously described [33], while P436Q and the three dominant negative variants of PS1 were characterized by low levels of PS1-NTF and PS1-CTF fragments, suggesting that these variants were less prone to endoproteolysis.&#10;Generation of stable cell lines overexpressing all human ��-secretase components with FAD-linked PS1 variants.&#10;MEF PS1/2���/��� were stably co-transduced with lentiviral vectors carrying genes encoding hNCT-V5, Flag-hPEN2, hAPH1aL-HA and clones were isolated by limiting dilution to generate a cell line, designated as ��- PS1/2, that overexpresses high amount of the three subunits.&#10;- PS1/2 MEFs were further transduced with hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned.&#10;Each clone, derived form the ��- PS1/2, was conveniently named according to the mutation present in PS1 preceded by the symbol �� and followed by the number of the clone (��-MEF) in order to distinguish them from wild-type MEF (WT MEF) and MEF PS1/2���/���.&#10;Two clones per ��-secretase variant were selected for characterization.&#10;(A���B) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 4���12% Bis-Tris or 12% Tris-Glycine gels and analysed by immunostaining to detect the ��-secretase core components NCT (NCT164), PS1 (NTF, MAB1563; CTF; MAB5232), APH1aL-HA (3F10), and Flag-PEN2 (M2) (A), and endogenous APP (A8717) (B).&#10;-Actin was used as a loading control.&#10;Each lane represents one selected clone.&#10;g001 We next investigated the effects of PSEN1 mutations on the processing of endogenous APP.&#10;As expected, and as indicated by increased levels of intracellular APP-CTFs (a common characteristic among known substrates in response to ��-secretase pharmacological inhibition), the activity of ��-secretase was significantly altered in the PS deficient parental �� - PS1/2 cell line as well as in all clones expressing dominant negative forms of PS1 (Figure 1B).&#10;In the clones expressing PS1-WT, APP-CTFs were almost undetectable due to high ��-secretase activity, while clones expressing PS1-L166P or PS1-P436Q displayed APP-CTF accumulation.&#10;In PS1-��E9 clones, a mild APP-CTF accumulation was observed (Figure 1B).&#10;Although a poor recovery of ��-secretase activity for the PS1-L166P and a comparatively better performance of PS1-��E9 have been reported by others under similar experimental conditions [23], the potential of PS1-P436Q mutation to restore the processing of endogenous APP-CTFs has never been assessed [34], [35].&#10;Importantly, all observations described above for the cells overexpressing simultaneously hNCT-V5, hAPH1aL-HA, Flag-hPEN2 and the different PS1 variants are very consistent with those made in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other ��-secretase components (cf. Figure S1A).&#10;These data suggest that the effect of FAD mutations in PS1 on APP-CTFs accumulation was similar in presence or absence of other human components of the ��-secretase.&#10;Next, we further investigated the effect of PS1 variants on the cellular production/secretion of A�� species.&#10;For this purpose, and as described elsewhere [36], we used an APP-based ��-secretase substrate with a Flag tag at its C-terminus (SPA4CT-Flag).&#10;This substrate was transduced in the above-described ��-secretase overexpressing stable cell lines (��-MEFs) as well as in wild-type MEFs, and APP-CTFs and A�� levels were measured in cell lysate and cell media, respectively (Figure 2).&#10;Under these conditions, the overexpression of SPA4CT-Flag led to an accumulation of two bands corresponding to the exogenous substrate, associated with a concomitant decrease of endogenous APP-CTFs levels (Figure 2A and Figure S2).&#10;As estimated by ELISA, a three-fold increase in A��1���40 and A��1���42 levels was observed in the cell culture media of cell lines overexpressing human ��-secretase (��-MEF WT), in comparison to untransduced WT MEFs (Figure 2B).&#10;Next, overexpression of SPA4CT-Flag in ��-MEFs led to the pronounced intracellular accumulation of APP-CTFs in cells overexpressing the PS1 aspartate mutants (Figure 2C), and to the secretion in the cell culture media of different A�� levels as measured by ELISA (Figure 2D).&#10;First, only traces of both A��1���40 and A��1���42 were detected in ��-MEFs overexpressing PS1 with aspartate mutants.&#10;Next, ��-MEFs overexpressing PS1 with FAD-linked mutations displayed a pronounced variability in A�� levels when compared to the wild-type clones.&#10;A�� production in cell lines overexpressing human ��-secretase components with FAD-linked PS1 variants.&#10;WT MEF, ��-MEF and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]) and a Flag Tag in C-terminus.&#10;Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717) (A, C).&#10;Data corresponds to three independent experiments (Mean �� SEM).&#10;g002 FAD-linked PS1 mutations alter the activity of semi-purified ��-secretase complexesWe next assessed the activity of ��-secretase with FAD-linked PS1 mutations in microsomal extracts of ��-MEFs.&#10;Membrane protein extracts were prepared and ��-secretase activity was assayed on an exogenous recombinant APP-based substrate consisting of the C-terminal 99 amino acid residues of APP, and referred to as C100-Flag (Figure 3A).&#10;The generation of the cleavage product AICD-Flag was detected by Western blot analysis and measured by densitometry.&#10;As shown in Figure 3A, the levels of AICD-Flag generated from the PS1-L166P and PS1-��E9 clones accounted for 42��1% and 13��6% of that in the PS1-WT clones, respectively.&#10;AICD-Flag was undetectable in the clones expressing PS1-P436Q as well as in the three dominant negative aspartate PS1 variants.&#10;Similar results were observed in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other human ��-secretase components (Figure S1B).&#10;Enzymatic activity of partially purified ��-secretase complexes with FAD-linked PS1 mutants. (A) ��-Secretase activity assays performed with ��-MEF and �� - PS1/2 microsomal extracts prepared in 1% CHAPSO-HEPES buffer.&#10;Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag).&#10;Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563).&#10;The relative amounts of AICD-Flag generated in the reactions, reflecting ��-secretase activity, were estimated by densitometry.&#10;PS1 immunostaining was used to assess the amount of input material.&#10;(B) Equal amounts of microsomal proteins were immunoprecipitated overnight at 4��C with either anti-Flag M2 or anti-HA affinity resins, and submitted to a C100-His assay according to the same protocol as in (A).&#10;Protein samples were separated by SDS-PAGE and analysed by immunostaining for ��-secretase subunits ((NCT164 (NCT), MAB1563 (PS1-NTF), or UD1 (PEN2)).&#10;AICD-His cleavage products were immunostained with an anti-APP-CTF antibody (A8717).&#10;*Indicates a non-specific band corresponding to the IgG light chains.&#10;(C) A��1���40 and A��1���42 were quantified by sandwich ELISA and represented in pg/mL (left Y-axis) or in percentage (right Y-axis) of the mean of A��1���40 levels generated by the two wild-type clones.&#10;The results were confirmed in three independent experiments and a representative dataset is shown.&#10;g003 We next performed activity assays under semi-purified conditions.&#10;To do so, ��-secretase complexes from the different clones were co-immunoprecipitated from microsomal extracts and their activities were assayed in vitro with the C100-His substrate.&#10;Two immunoprecipitation protocols using two affinity resins (anti-Flag M2 and anti-HA 3F10, targeting respectively Flag-PEN2 and APH1aL-HA) were compared to exclude a possible heterogeneity of ��-secretase complexes potentially generated under such conditions.&#10;As shown in Figure 3B, the anti-Flag and anti-HA resins immunoprecipitated similar levels of NCT, PS1 and PEN2 and the activity of the ��-secretase complexes was similar regardless of the affinity resins used (Figures 3B).&#10;In agreement with the assays performed using microsomal extracts (Figure 3A), those performed with semi-purified complexes revealed that FAD-linked mutants drastically reduced AICD generation, when compared to PS1-WT (Figure 3B).&#10;Furthermore, levels of A��1���40 produced from PS1-L166P, PS1-��E9 and P436Q variants fell respectively to ~6%, ~1.5% and ~0.5%, when compared to these produced from PS1-WT ��-secretase.&#10;Following the same tendency, A��1���42 levels generated from PS1-L166P, PS1-��E9 and PS1-P436Q ��-secretase variants were respectively estimated to ~20%, ~5% and ~3% of these produced with PS1-WT-containing complexes.&#10;The A��1-42/A��1���40 ratio measured for WT ��-MEFs was consistent with our cell-based data (compare Figures 2D and 3C), validating our in vitro experimental conditions.&#10;Interestingly, an overall A��1���42/A��1���40 ratio of ~1 was estimated for all PS1 mutants, with the exception of P436Q#4 (~2).&#10;However, in the latter, the ratio may have been overestimated because the A��1���40 levels measured were at the detection limit.&#10;This similarity in the A��1���42/A��1���40 ratios generated by the different mutantshas, to the best of our knowledge, never been observed in previous studies.&#10;Highly purified ��-secretase complexes with FAD-linked PS1 mutants display a loss-of-function phenotypeIn order to further investigate how PS1 variants affect APP-CTF cleavage and to validate our observations performed in semi-purified conditions, we purified to homogeneity ��-secretase complexes from the selected clones described in Figure 1.&#10;The purification process (described in details under Materials &amp; Methods and depicted in Figure 4A) involved three sequential affinity purifications starting from microsomal extracts.&#10;Since all cell lines were generated on a PS knockout background, this strategy allowed us to purify exclusively and selectively ��-secretase complexes made of human components.&#10;As highlighted in Figure 4B, our protocol led to the production of stable, high molecular weight ��-secretase complexes (HMWCs) with an apparent molecular mass on Blue Native (BN)-PAGE of ~350 kDa, which is consistent with previous reports [26], [27], [37].&#10;The silver stained particles on the BN gel confirmed the high purity of these complexes (Figure 4B, upper panel), for which the identity was established by cross-reactivity with antibodies specific to NCT and PS1 (Figure 4B, lower panels).&#10;As the main goal of this experiment was to compare the efficacy of the different ��-secretase complexes to process APP-based substrates, it is important to note that the final yields of the complexes purified from the different clones were very similar (Figure 4B), thus facilitating further comparative analyses.&#10;The immunoblot analysis of the purified complexes (Figure 4C) confirmed the presence of all core components (NCT-V5, APH1aL-HA, Flag-PEN2 and PS1) and globally recapitulates the maturation processes observed in the Figure 1.&#10;Interestingly, the relative PS1-NTF/CTF to PS1-FL ratios in the purified ��-secretase complexes containing the three PS1 dominant-negative or the PS1-P436Q variants were higher than those estimated in the whole cell extracts before purification (Figure 1A), indicating that endoproteolysis of PS1 was not completely abolished by these mutations.&#10;To assess how FAD-linked mutations in PS1 affect ��-secretase activity in these purified complexes, we performed in vitro assays by using C100-Flag substrate (Figure 3A) and equal amounts of the different purified complexes, immediately after the purification to avoid freezing/thawing cycles that might affect enzymatic activity.&#10;As shown in Figure 5A, ��-secretase activity based on AICD-Flag production was easily detected in complexes purified from the two PS1-WT clones.&#10;This is in sharp contrast to the other purified complexes that did not generate detectable AICD under our experimental conditions (Figure 5A).&#10;Next, sandwich ELISAs directed against A��1���40 and A��1���42 were performed in order to further characterize the specific activity of the purified complexes.&#10;Reflecting the levels of AICD and considering the detection limits of our sandwich ELISA, the production of both A�� species by ��-secretase complexes containing PS1-WT was at least 10-fold higher than in complexes with the FAD-linked or dominant-negative PS1 variants (Figure 5B).&#10;The A��1���42/A��1���40 ratio measured in PS1-WT ��-secretase complexes (~0.22) was similar to that previously reported [26], [27], thus excluding a possible qualitative alteration of ��-secretase activity with this protocol.&#10;Together, our results strongly support the hypothesis that the pathogenic L166P, ��E9, and P436Q mutations in PSEN1 cause a drastic loss (at least 90% as estimated by ELISA) of ��-secretase activity.&#10;High-grade purification of human ��-secretase complexes with FAD-linked PS1 mutants. (A) Schematic representation of the ��-secretase purification process.&#10;Briefly, Presenilin double-knockout MEFs were used to first generate cell lines that stably overexpress human ��-secretase complexes containing different PS1 variants.&#10;Next, these cell lines were used for a multi-step purification procedure as described in the material and methods.&#10;(B) Blue-Native PAGE analysis of purified ��-secretase complexes made of different PS1 variants.&#10;Equal volumes of the different purified ��-secretase preparations were separated by native-PAGE on a 4���16% Bis-Tris gel, and stained with silver nitrate (top panel), or immunostained for NCT (NCT164, middle panel) or PS1-NTF (ab10281, bottom panel) as indicated.&#10;-Secretase complexes appeared on the gel as high molecular weight complexes (HMWCs) of ~350 kDa.&#10;Note that the levels of HMWCs were similar for all clones.&#10;(C) Equal volumes of purified ��-secretase complexes with FAD-linked PS1 mutants were separated under denaturing conditions (SDS-PAGE) and immunostained with anti-NCT (NCT164), anti-PS1-NTF (MAB1563), anti-PS1-CTF (MAB5232), anti-HA (3F10), or anti-Flag (M2) antibodies.&#10;Two independent purifications were performed on each clone with similar results.&#10;A representative dataset is shown.&#10;Enzymatic activity of highly purified ��-secretase complexes with FAD-linked or aspartate PS1 mutants.&#10;Equal amounts of the different purified ��-secretase preparations characterized in Figure 4 were tested for activity on C100-Flag, as described in Figure 3.&#10;The resulting cleavage products were separated by SDS-PAGE and detected by immunostaining with an anti-Flag antibody (M2) for C100-Flag or AICD-Flag (A), and by sandwich ELISA for A��1���40 or A��1���42 (B).&#10;Note that the levels of A�� produced from FAD-linked ��-secretase complexes were all in the non-linear range of the ELISA standards, close to the detection limit.&#10;Whenever possible, A��1���42/A��1���40 ratios were quantified and indicated on the top of the bars.&#10;Two independent purifications were performed on each clone and similar results were obtained.&#10;A representative dataset is shown.&#10;g005 Discussion Top Several conflicting results as to how Alzheimer's disease-linked mutations in PSEN1 affect the processing of APP by ��-secretase have been reported.&#10;First, it has been previously reported that transgenic animals with FAD-linked PS1 mutations show increasing brain levels of A��1���42 [15], [38].&#10;Since A��1���42, the first A�� specie deposited in the brain of AD patients [16], [39], is more prone to aggregation when compared to shorter A�� species [40], [41], [42], it has been implicated in the seeding of amyloid plaques in AD patients with PSEN1 mutations [43].&#10;This was further validated in vivo as the overexpression of PS1 mutants in APP transgenic mice accelerated the rate of A�� accumulation and deposition in the brain [44], [45].&#10;However, Bentahir and colleagues challenged this view by showing that several PSEN1 mutations were also capable to decrease total A�� production in PS1/PS2 knockout cells [23].&#10;These findings suggested that endogenous PS1 and PS2 may influence the mutant phenotype in cells or in vivo.&#10;By extension, we hypothesized that the other components of ��-secretase, namely APH1, NCT and PEN2, may influence the mutant phenotype as well.&#10;Indeed, ��-secretase complexes are heterogeneous in composition due to the existence of two human APH1 genes, APH1a and APH1b, and two splicing isoforms of APH1a (S and L), as well as two presenilin genes, PSEN1 and PSEN2.&#10;Therefore, it is plausible that a single mutation in PSEN1 confers different catalytic properties to distinct ��-secretase subtypes.&#10;This hypothesis is supported by recent investigations showing that APH1 variants can modulate A�� profiles.&#10;When compared to APH1aS or L, overexpression of APH1b in MEF knockout for all APH1 genes led to increased production of longer A�� species [24].&#10;With this regard, it is important to note that all four mouse variants of APH1 are expressed in the MEF cell line used in previous studies [23] and employed here (cf. Figure S3).&#10;Since the phenotype of PS1 mutations have mainly been assessed in vivo or in cell-based systems, we investigated the effects of FAD-linked PS1 mutants on the processing of APP-CTFs in cell-free systems, by using semi-purified and purified enzymatic complexes isolated from MEF PS1/PS2 double knockout cells stably overexpressing differentially tagged human ��-secretase components.&#10;Under these conditions, the biochemical and functional properties of ��-secretase complexes bearing either FAD-linked PS1 mutants (L166P, ��E9, and P436Q), dominant-negative forms of PS1 or wild-type PS1 were characterized.&#10;The activity of ��-secretase with PS1-WT was similar to that reported for ��-secretase purified from our CHO cells overexpressing NCT-V5, APH1aL, Flag-PEN2 and PS1-WT [26], [27], that resulted in A��1���42/A��1���40 ratios between 0.1 and 0.3.&#10;In contrast, we found a major loss in the activity of ��-secretase complexes containing either the dominant-negative PS1 variants or the FAD-linked PS1 mutants.&#10;Although a total loss of activity was expected for the dominant negative forms of ��-secretase [5], [6], [32], the drastic loss of activity seen here with the FAD-linked PS1 mutants was unexpected.&#10;Indeed, the PS1-L166P variant has previously been reported to increase A��1���42 levels both in vivo [46] and in vitro [20], in the presence of endogenous PS1, PS2 and APH1 components.&#10;In contrast, Bentahir and colleagues found that PS1-L166P decreased both A��1���40 and A��1���42 production in a PS knockout background.&#10;These results are consistent with our in vitro data, although the reduction in A��1���42 and A��1���40 production was more pronounced in our system.&#10;However, they differ from our cell-based data in which we observed an increase in A��1���42 associated with a decrease in A��1���40.&#10;Taken together, these data suggest that the overexpression of the other human components of ��-secretase can influence the phenotype of FAD-linked mutations.&#10;Another possible explanation for these discrepancies comes from the use, in previously described cellular systems, of APP carrying the Swedish mutation (K670M/N671L) [20], [23], [46].&#10;Initially, this APP variant was shown to enhance the production of all A�� species by favouring its ��-secretase cleavage [47], [48].&#10;However, Munter and colleagues recently demonstrated that the APP Swedish mutation can also affect the specificity of the ��-secretase cleavage [49].&#10;In particular, these authors showed that over-expression of APP Swedish in a neuronal cell line led to a 4-fold increase in secreted A��42, associated with only a 2-fold increase of total A��, compared with the wild-type APP.&#10;Therefore, one cannot exclude the possibility of differential interactions between PS1-WT or PS1 variants and different APP variants, as suggested earlier [50].&#10;As far as the PS1-��E9 mutant is concerned, previous cell-based studies have reported a decrease in A��40 levels associated with an increase in A��42 levels [51], [52], or no changes in A��40 levels despite increased A��42 levels [53], or a decrease in both A�� species [23].&#10;In the present study, A��1���40, A��1���42, as well as AICD levels generated from purified ��-secretase complexes with PS1-��E9 were close to the limit of detection, resulting in a loss of at least 95% of the ��-secretase activity compared to wild-type PS1.&#10;Similarly, we found a near to complete loss of ��-secretase activity for complexes with the aggressive PS1-P436Q mutant (mean onset: 28.3 years) [54].&#10;Consistent with a recent study [35], and in contrast to PS1-L166P, the maturation of the full-length PS1-P436Q protein into PS1-NTF and PS1-CTF was impaired.&#10;Interestingly, the same study also reported that P436Q variant showed a decreased ��-secretase activity and A��40 and A��42 secretion in PS1/PS2 double knockout cells (~75% or ~50% of the control for A��40 or A��42, respectively), but to a lesser extent than what we measured in this study (more than 97% for both A�� species).&#10;Overall, our data show that, under our experimental conditions, the FAD-linked PS1 mutants cause a drastic loss of activity (at least 90%) in the highly purified and homogeneous as well as semi-purified ��-secretase complexes.&#10;This loss-of-function is asymmetrical as A��1���42 levels were relatively less affected than A��1���40 levels.&#10;Interestingly, the ratio between the two A�� species was similar for the variants tested here (~1), suggesting a common modulatory mechanism.&#10;Our findings further support a model in which the subtype of ��-secretase containing APH1aL and FAD-linked PS1 mutants generates a higher A��42/A��40 ratio compared to PS1-WT, as previously observed in vivo [15], [38].&#10;Taken together, the overall reduction in A�� levels strongly suggest that other regulatory mechanisms or cellular components may exist and account for the strong amyloid pathology observed in AD patients carrying these FAD-linked PSEN1 mutations.&#10;In agreement with this hypothesis, we report that the phenotype of FAD-linked PSEN1 mutations is different whether we consider the cell-based or the cell-free conditions.&#10;Indeed, even if A��42/A��40 ratios were globally increased in both experimental conditions, A�� production was strikingly different.&#10;One possible explanation would be that specific subtypes of ��-secretase complexes are less affected than others by PSEN1 mutations.&#10;For instance, it remains unknown whether ��-secretase complexes carrying APH1b or APH1aS are similarly affected by PSEN1 mutations.&#10;In support to that regard, Winkler and colleagues recently purified human ��-secretase with PS1-L166P and observed that such complexes, containing both APH1a and AHP1b, led to increased A��1���42 production associated with decreased A��1���40 production, as compared to the PS1-WT complexes.&#10;Another possible explanation would be that purified ��-secretase complexes lack binding partners modulating the processing of APP-based substrates, due to purification conditions affecting physical interactions of proteins.&#10;These include TMP21 or the recently reported ��-secretase activating protein (GSAP) [12], [13].&#10;Further biochemical analyses are needed to test this hypothesis.&#10;The loss of activity in ��-secretase containing PS1 variants also leads to decreased generation of AICD.&#10;As AICD is involved in the transcriptional regulation of several genes, including the neprilysin [55], and the lipoprotein receptor, LRP1 [11], it is likely that mutations in PSEN1 impair the regulation of these genes in vivo.&#10;For instance, it is possible that unknown genes transcriptionally regulated in vivo by the AICD might influence A�� metabolism in return.&#10;In support to these views, Veeraraghavalu and colleagues recently demonstrated that Notch signalling was impaired in transgenic mice overexpressing PS1 mutants, albeit in the presence of endogenous PS1-WT and all APH1 isoforms [56].&#10;They found decreased self-renewal and differentiation of neuronal precursor cells in the subventricular zone, suggesting that the loss-of-function phenotype of PSEN1 mutations can also be observed in heterogeneous conditions.&#10;These results are reminiscent of the previous report from Saura and colleagues showing that conditional inactivation of both presenilins in vivo induces age-dependent neurodegeneration associated with memory impairment [57].&#10;Altogether, the above-described data suggest that alternative pathways of neurodegeneration related to loss of ��-secretase functions are possible and relevant to AD.&#10;They further support the concept that modulating rather than inhibiting ��-secretase activity would be a more appropriate therapeutic strategy for AD [58].&#10;Supporting this view, the ��-secretase inhibitor Semagacestat tested in phase III clinical trials not only failed to slow cognitive decline in patients with mild-to-moderate AD, but actually made it worse [59].&#10;Collectively, our findings support a model in which FAD-linked mutations in PSEN1 likely induce A�� pathology by perturbing the relative ratio between A�� species and by impairing developmental and cellular signalling pathways controlled by ��-secretase substrates.&#10;This deleterious dual effect might explain why FAD-linked PSEN1 mutations cause early onset Alzheimer's disease.&#10;Since it has been established that A�� and AICD are generated following the processing by ��-secretase at two distinct gamma- and epsilon-cleavage sites in APP [60], further investigation is now required to better understand whether and how FAD mutations in PS1 differentially affect the epsilon versus gamma-cleavage sites in APP, as well as in other known ��-secretase substrates.&#10;Materials and Methods Top DNA Constructs and mutagenesisNCT-V5, Flag-PEN2, APH1aL-HA, wild-type PS1 human cDNAs (PS1-WT) were obtained from D. Selkoe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA).&#10;PS1 ��E9 cDNA was obtained from C. Saura (Universitat Aut��noma de Barcelona, Spain).&#10;PS1 D257A and PS1 D385A cDNAs were obtained from M. Wolfe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA).&#10;The sequences corresponding to enzyme restriction sites are given in small letters.&#10;The PCR fragments were next digested with BamHI/HindIII and HindIII/XhoI respectively, and were subcloned into pcDNA3.&#10;PS1 D257A/D385A (DDAA) was obtained by subcloning the DraI/XhoI digested fragment of PS1 D385A into pcDNA3.1-PS1 D257A.&#10;All constructs were next subcloned into the self-inactivated vector pSIN-PGK-WHV cassette (a kind gift from R. Zufferey, Brain Mind Institute, EPFL, Lausanne, Switzerland).&#10;Inserts for plasmids pET21-C100-Flag, and pET21-C100-His were generated by PCR as previously described [27].&#10;Plasmids pMD2G and psPAX2 were obtained from D. Trono (Global Health Institute, EPFL, Lausanne, Switzerland).&#10;Lentivector productionReplication-defective lentiviral particles were produced by a three-plasmid transient transfection of cells from the human embryonic kidney HEK 293T cell line [61].&#10;Briefly, cells were incubated in 10 cm dishes until they reached 70% confluence and were transiently co-transfected by the calcium phosphate method, with 5 ��g of envelope plasmid (pMD2G), 15 ��g of packaging plasmid (psPAX2), and 20 ��g of vector plasmids (pSIN-PGK-WHV).&#10;Cells were incubated overnight with DNA-calcium precipitates, washed twice with Dulbecco's modified Eagle's medium (DMEM, Invitrogen) and incubated with 7 mL of DMEM.&#10;After 24 h, the conditioned medium was harvested and cells were incubated a second time with 7 mL of DMEM for 24 h. Media were then pooled, passed through 0.45 ��m filter, and stored at ���80��C as 2 mL aliquots until use.&#10;A p24 ELISA (Zeptometrix corporation) was performed on each batch of media in order to evaluate the number of viral particles generated.&#10;Generation of stable cell lines through multiple gene transductionsMouse Embryonic Fibroblasts (MEFs, obtained from B. De Strooper, Flanders University Institute of Biotechnology, Belgium) defective in PSEN1 and PSEN2 [30], [31] were cultivated in 10 cm dishes in DMEM, supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin (P/S) (Invitrogen).&#10;A first set of stable cell lines was generated by co-transducing NCT-V5, APH1aL-HA, and Flag-PEN2 containing lentiviral vectors (LV) repeatedly for two weeks at each passage (1/20).&#10;Ten clones were isolated by the limiting dilution method and were further screened for NCT-V5, Flag-PEN2 and APH1aL-HA expression by immunodetection.&#10;The clone that showed the highest expression of the three proteins (designated �� - PS1/2) was used as the parental cell line to generate the stable cell lines expressing different PS1 variants, by the same method and by using lentiviral vectors carrying human PS1-WT, PS1-L166P, PS1-��E9, PS1-P436Q, PS1-D257A, PS1-D385A, and PS1-DDAA.&#10;For each PS1 variant, five clones were selected for a full characterization and two of them were further used for ��-secretase purification.&#10;For SPA4CT overexpression experiments, 500,000 cells of each clone were exposed to the same arbitrary dose of lentiviral vectors carrying human SPA4CT-Flag in 2 mL of DMEM, 1% FBS, P/S and were plated in 6-wells plates for 72 h. The medium was next replaced by fresh DMEM, 2% FBS, P/S for 24 h. Finally, cell culture medium was harvested, supplemented with protease inhibitor cocktail (Roche), centrifuged for 3 min at 1,000�� rpm and frozen at ���80��C until further processing.&#10;Cells were washed in PBS and submitted to protein extraction.&#10;Protein extractionTotal protein extracts were prepared in 1% NP40 - HEPES buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche), and were clarified by centrifugation for 1 h at 16,000�� g, 4��C. Cell membranes were obtained as described below and solubilised in 1% CHAPSO - HEPES buffer and centrifuged at 16,000�� g for 1 h. Supernatants corresponding to the microsomal protein extracts were harvested and stored at ���80��C. Protein content of the extracts was estimated by the BCA protein assay reagent kit (Pierce).&#10;Multi-step purification of human ��-secretase complexes with FAD-linked PS1 variants1) Cell membrane preparation.&#10;MEF PS1/PS2 DKO cells (1.0��109 cells) expressing NCT-V5, Flag-PEN2, APH1aL-HA and different forms of PS1: wild type (WT), or with FAD-linked variants or lacking the critical aspartate residues, were collected from 15 cm dishes and fully resuspended in 40 mL of MES buffer (50 mM MES, pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche).&#10;Next, cells were passed four times through a high-pressure homogenizer (Emulsiflex-C5, Avestin Inc, ON Canada) at a pressure greater than 1,000 psi.&#10;Nuclei and unbroken cells were removed by centrifugation at 3,000�� g for 20 min at 4��C in a Beckman Coulter Allegra X-15R centrifuge.&#10;The supernatant was collected and centrifuged at 100,000�� g for 1 h at 4��C in a SW32Ti rotor using a Beckman Coulter Optima L-80 ultracentrifuge to recover the membrane preparation in the pellet.&#10;The membrane pellet was fully resuspended in 1.6 mL of ice cold sodium bicarbonate buffer (0.1 M NaHCO3, pH 11.3) by pipetting up and down at least 30 times, and incubated at 4��C for 20 min.&#10;The washed membranes were then centrifuged at 100,000�� g for 1 h at 4��C and stored at ���80��C until use.&#10;3) Solubilisation of ��-secretase complexes.&#10;The bicarbonate-washed membranes were fully resuspended in 1.7 mL of 1% CHAPSO - HEPES buffer by pipetting up and down at least 30 times.&#10;The membranes were then incubated at 4��C for 1 h. To pellet the insoluble material, the solution was centrifuged at 16,000�� g at 4��C for 1 h, the pellet was discarded, and the supernatant saved.&#10;This lysate is defined as ���solubilised ��-secretase preparation���.&#10;Next, these freshly prepared solubilised preparations were used for affinity purification of ��-secretase complexes as described below.&#10;4) Anti-Flag M2 affinity purification.&#10;The solubilised ��-secretase preparations were first diluted 1:2 with HEPES buffer, and further diluted 1:6 with 0.1% digitonin - TBS buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) (final detergent concentration: 0.08% CHAPSO, 0.08% digitonin) and incubated overnight at 4��C with agitation after adding 200 ��L of anti-Flag M2 affinity resin beads (Sigma-Aldrich) that had been pre-equilibrated in 0.1% Digitonin - TBS buffer.&#10;The beads were washed 3 times in the same buffer, and the bound proteins were eluted over 4 h at 4��C with 0.4 mL of this buffer containing 200 ��g/mL of Flag peptides (Sigma-Aldrich).&#10;This elution step was repeated once for 1 h at 4��C and the eluted fractions were pooled and designated ���M2 pooled 800 ��L fractions���.&#10;5) Anti-V5 affinity purification.&#10;The M2 pooled fractions (volume made up to 1 mL with 0.1% Digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-V5 affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin-TBS buffer.&#10;The beads were washed 3 times in the same buffer, and the bound proteins were eluted for 1 h at 4��C with 0.4 mL of this buffer containing 500 ��g/mL of V5 peptides (Sigma-Aldrich).&#10;This elution step was repeated 4 times, and the eluted fractions were pooled and designated ���V5 pooled 1.6 mL fractions���.&#10;As a final purification step, the V5 pooled fractions (volume made up to 1.8 mL with 0.1% digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-HA affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin - TBS buffer.&#10;The beads were washed 3 times in the same buffer, and the bound proteins were eluted overnight at 4��C with 0.2 mL of this buffer containing 200 ��g/mL of HA peptides (Sigma-Aldrich).&#10;This elution step was repeated once, for 1 h at 4��C, and the two eluted fractions were kept separately, designated ���HA fraction E1��� and ���HA fraction E2���.&#10;Co-immunoprecipitationCo-IPs were performed on microsomal protein extracts.&#10;Briefly, 100 ��g of proteins were diluted in a final volume of 1 mL of 1% CHAPSO - HEPES extraction buffer containing protease inhibitors (Roche), and 50 ��L of pre-equilibrated anti-Flag or anti-HA affinity beads (Sigma-Aldrich) were added.&#10;Samples were next incubated overnight at 4��C on a rotator wheel and were washed three times in 0.2% CHAPSO - HEPES buffer.&#10;Finally, beads were resuspended in 50 ��L of 0.2% CHAPSO - HEPES buffer and were used for in vitro ��-secretase assays.&#10;In vitro ��-secretase activity assaysIn vitro ��-secretase activity assays were performed as previously described [27].&#10;-Secretase APP-based substrates were expressed in E. coli transfected with plasmids pET21-C100-Flag or pET21-C100-His as a fusion protein consisting of a Met for translation initiation, and either the Flag tag sequence (C100-Flag) or the His tag sequence (C100-His), and were affinity purified using an anti-Flag resin (M2, Sigma-Aldrich) or an Ni-NTA agarose resin (Invitrogen), respectively.&#10;-Secretase activity was quantified by measuring the amount of AICD and A�� generated during the reaction, by immunoblot or sandwich ELISA respectively, as described below.SDS-PAGE, Native PAGE, Western blotting and antibodiesTotal or microsomal protein extracts were resolved by electrophoresis on NuPAGE�� Novex�� 4���12% Bis-Tris Gels (Invitrogen) or on standard 12% acrylamide/bisacrylamide Tris Glycine gels for SDS-PAGE analysis.&#10;Purified ��-secretase was resolved by electrophoresis on NativePAGE��� Novex�� Bis-Tris 4���16% Gels for Blue Native (BN)-PAGE analysis (Invitrogen).&#10;Silver staining was performed directly on gel according to manufacturer instructions (Biorad).&#10;For immunoblot analysis, gels were transferred to nitrocellulose or PVDF membranes (Whatman), and probed with the following antibodies: anti-Nicastrin NCT164 (BD Bioscience), anti-V5-tag for NCT-V5 (Covance), MAB1563 (Millipore) or ab10281 (Abcam) for PS1 NTF, MAB5232 for PS1 CTF (Millipore), 3F10 for APH1aL-HA (Roche), anti-Flag M2 for Flag-PEN-2 or C100-Flag (Sigma-Aldrich), A8717 for APP CTF (Sigma-Aldrich), and A2066 for ��-actin (Sigma-Aldrich).&#10;Anti-mouse/rabbit/rat IgG conjugated to Alexa 680 were purchased from Invitrogen.&#10;The Odyssey infrared imaging system (LICOR) was used to detect the fluorescent signal.&#10;Quantification of A�� peptidesA�� peptides from the ��-secretase assays described above were quantified by sandwich ELISA according to the protocol provided by the manufacturer.&#10;Supporting Information Top Figure S1.&#10;Characterization of stable cell lines overexpressing human FAD-linked PS1 variants in MEF PS1/2���/���.&#10;Presenilin double-knockout mouse embryonic fibroblasts were stably transduced with lentiviral vectors carrying genes encoding hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned.&#10;Two clones per PS1 variant were selected for characterization.&#10;(A) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with various antibodies to detect the endogenous ��-secretase core components: NCT (NCT164), hPS1 (NTF, MAB1563), and PEN2 (UD1), and with an antibody for APP (A8717).&#10;-Actin was used as a loading control.&#10;Each lane represents one selected clone.&#10;(B) ��-Secretase activity assays were performed with microsomal extracts prepared in 1% CHAPSO-HEPES buffer.&#10;Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag).&#10;Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563).&#10;PS1 immunostaining was used to assess the amount of input material.&#10;* Indicates a non-specific band, which was not detected in microsomal protein extracts of the same cell lines using the same antibody (MAB1563) (B).&#10;APP-CTF profiles in WT MEF, MEF PS1/2���/��� and �� - PS1/2 transduced with the SPA4CT construct.&#10;WT MEF, MEF PS1/2���/��� and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]).&#10;Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717). (TIF)Figure S3.&#10;Total RNAs were extracted from presenilin double-knockout MEFs, using standard procedures (Qiagen RNAeasy kit) and were quantified by spectrophotometry.&#10;One microgram of total RNAs was reverse transcribed for 1 h at 42��C by using the ImProm-II reverse transcription system (Promega) and oligo-dT primer in a final volume of 20 ��L. PCR was next performed for each APH1 isoform on 1 ��L of RT reaction by using the Roche PCR kit under standard conditions and the primers described in Table S1.&#10;PCR products were separated on a 2% agarose gel and visualized using Alpha Innotech UV imager. (TIF)Table S1.&#10;Primers used to detect APH1 isoforms in MEF PS1/2���/���.&#10;F: Forward, R: Reverse. (DOC)Acknowledgments Top We are grateful to B. De Strooper for the WT and PS1���/��� PS2���/��� KO mouse embryonic fibroblasts, to C. Saura for the PS1 ��E9, to M. Wolfe for the PS1 D257A and PS1 D385A cDNAs, and to D. Selkoe for the APH1aL-HA, NCT-V5, and Flag-PEN2 cDNAs.&#10;We also thank J.R. Alattia, C. Schweizer, and A. Alahari for critical readings of the manuscript.&#10;Author Contributions Top Conceived and designed the experiments: MC PCF.&#10;Supervised the project: PCF.&#10;Find this article online Wakabayashi T, De Strooper B (2008) Presenilins: members of the gamma-secretase quartets, but part-time soloists too.&#10;Find this article online Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease.&#10;" sentenceList="15261 15273 15285 15297 15309 15321 15333 15345 15357 15369 15381 15393 15405 15417 15429 15441 15453 15465 15477 15489 15501 15513 15525 15537 15549 15561 15573 15585 15597 15609 15621 15633 15645 15657 15669 15681 15693 15705 15717 15729 15741 15753 15765 15777 15789 15801 15813 15825 15837 15849 15861 15873 15885 15897 15909 15921 15933 15945 15957 15969 15981 15993 16005 16017 16029 16041 16053 16065 16077 16089 16101 16113 16125 16137 16149 16161 16173 16185 16197 16209 16221 16233 16245 16257 16269 16281 16293 16305 16317 16329 16341 16353 16365 16377 16389 16401 16413 16425 16437 16449 16461 16473 16497 16509 16521 16533 16545 16557 16569 16581 16593 16605 16617 16629 16641 16653 16665 16677 16689 16701 16713 16725 16737 16749 16761 16773 16785 16797 16809 16821 16833 16845 16857 16869 16881 16893 16905 16917 16929 16941 16953 16965 16977 17001 17013 17025 17037 17049 17061 17073 17085 17097 17109 17121 17133 17145 17157 17169 17181 17193 17205 17217 17229 17241 17253 17265 17277 17289 17301 17313 17325 17337 17349 17361 17373 17385 17397 17409 17421 17433 17445 17457 17469 17481 17493 17505 17517 17529 17541 17553 17565 17577 17589 17601 17613 17625 17637 17649 17661 17673 17685 17697 17709 17721 17733 17745 17757 17769 17781 17793 17805 17817 17829 17841 17853 17865 17877 17889 17901 17913 17925 17937 17949 17961 17973 17985 17997 18009 18021 18033 18045 18057 18069 18081 18093 18105 18117 18129 18141 18153 18165 18177 18189 18201 18213 18225 18237 18249 18261 18273 18285 18297 18309 18321 18333 18345 18357 18369 18381 18393 18405 18417 18429 18441 18453 18465 18477 18489 18501 18513 18525 18537 18549 18561 18573 18585 18597 18609 18621 18633 18645 18657 18669 18681 18693 18705 18717 18729 18741 18753 18765 18777 18789 18801 18813 18825 18837 18849 18873 18885 18897 18921 18933 18945 18957 18969 18993 19005 19029 19041 19053 19065 19077 19089 19101 19113 19125 19137 19149 19161 19173 19185 19197 19209 19221 19233 19245 19257 19269 19281 19293 19305 19317 19329 19341 19353 19365 19377 19389 19401 19413 19425 19437 19449 19461 19473 19485 19497 19509 19521 19533 19545 19557 19569 19581 19593 19605 19617 19629 19641 19653 19665 19677 19689 19701 19713 19725 19737 19749 19761 19773 19785 19797 19809 19821 19833 19845 19857 19869 19881 19893 19905 19917 19929 19941 19953 19965 19977 19989 20001 20013 20025 20037 20049 20061 20073 20085 20097 20109 20121 20133 20145 20157 20169" qaList="120 228 336 444 552 660 768 876 984 1092"/><types:Question xmi:id="19" sofa="12" begin="65302" end="65365" text="What effect can be observed when when ��-secretase is blocked? " nerList="15021"/><types:Question xmi:id="127" sofa="12" begin="65479" end="65549" text="When APH1 genes are overexpressed in MEF KO what happens with the A��?" nerList="15034 15043"/><types:Question xmi:id="235" sofa="12" begin="65658" end="65765" text="In which gene are mutations associated to many cases of early-onset familial forms of Alzheimer's disease?G" nerList=""/><types:Question xmi:id="343" sofa="12" begin="65814" end="65899" text="What experimental technique was used specifically to purify the ��-secretase complex?" nerList="15060"/><types:Question xmi:id="451" sofa="12" begin="65992" end="66056" text="What peptide is able to control the expression of the ApoE gene?" nerList="15073"/><types:Question xmi:id="559" sofa="12" begin="66118" end="66183" text="Which amino acid is critical for the activity of the PS1 protein?" nerList="15086"/><types:Question xmi:id="667" sofa="12" begin="66244" end="66324" text="What experimental technique was used to determine the structure of ��-secretase?" nerList="15099"/><types:Question xmi:id="775" sofa="12" begin="66395" end="66477" text="What candidate drug that blocks the ��-secretase is now tested in clinical trials?" nerList="15112"/><types:Question xmi:id="883" sofa="12" begin="66537" end="66619" text="What mutation of the PS1 protein causes ��-secretase activity almost to disappear?" nerList="15125 15134"/><types:Question xmi:id="991" sofa="12" begin="66676" end="66784" text="How many mutations relevant for familial forms of Alzheimer's disease have been detected for the PSEN1 gene?" nerList="15150"/><types:Answer xmi:id="29" sofa="12" begin="65370" end="65390" text="APP-CTF accumulation" id="0" isCorrect="true" isSelected="false" nerList="15163"/><types:Answer xmi:id="44" sofa="12" begin="65394" end="65409" text="PSEN1 mutations" id="1" isCorrect="false" isSelected="false" nerList="15176"/><types:Answer xmi:id="59" sofa="12" begin="65413" end="65428" text="cell-based data" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="74" sofa="12" begin="65432" end="65445" text="APH1 variants" id="3" isCorrect="false" isSelected="false" nerList="15190"/><types:Answer xmi:id="89" sofa="12" begin="65449" end="65474" text="transition-state analogue" id="4" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="137" sofa="12" begin="65554" end="65571" text="They are purified" id="0" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="152" sofa="12" begin="65575" end="65592" text="They are anterior" id="1" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="167" sofa="12" begin="65596" end="65612" text="They are shorter" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="182" sofa="12" begin="65616" end="65631" text="They are longer" id="3" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="197" sofa="12" begin="65635" end="65653" text="They are supported" id="4" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="245" sofa="12" begin="65770" end="65773" text="FAD" id="0" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="260" sofa="12" begin="65777" end="65784" text="I-CLiPs" id="1" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="275" sofa="12" begin="65788" end="65791" text="NCT" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="290" sofa="12" begin="65795" end="65800" text="PSEN1" id="3" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="305" sofa="12" begin="65804" end="65809" text="D257A" id="4" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="353" sofa="12" begin="65904" end="65912" text="plasmids" id="0" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="368" sofa="12" begin="65916" end="65939" text="affinity chromatography" id="1" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="383" sofa="12" begin="65943" end="65949" text="lysate" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="398" sofa="12" begin="65953" end="65963" text="cell lines" id="3" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="413" sofa="12" begin="65967" end="65987" text="knockout experiments" id="4" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="461" sofa="12" begin="66061" end="66063" text="AD" id="0" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="476" sofa="12" begin="66067" end="66075" text="APP-CTFs" id="1" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="491" sofa="12" begin="66079" end="66090" text="c-secretase" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="506" sofa="12" begin="66094" end="66105" text="cholesterol" id="3" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="521" sofa="12" begin="66109" end="66113" text="AICD" id="4" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="569" sofa="12" begin="66188" end="66197" text="aspartate" id="0" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="584" sofa="12" begin="66201" end="66211" text="C-terminal" id="1" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="599" sofa="12" begin="66215" end="66225" text="42-residue" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="614" sofa="12" begin="66229" end="66231" text="99" id="3" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="629" sofa="12" begin="66235" end="66239" text="DDAA" id="4" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="677" sofa="12" begin="66329" end="66341" text="densitometry" id="0" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="692" sofa="12" begin="66345" end="66347" text="EM" id="1" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="707" sofa="12" begin="66351" end="66356" text="ELISA" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="722" sofa="12" begin="66360" end="66374" text="immunostaining" id="3" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="737" sofa="12" begin="66378" end="66390" text="purification" id="4" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="785" sofa="12" begin="66482" end="66486" text="LRP1" id="0" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="800" sofa="12" begin="66490" end="66501" text="biochemical" id="1" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="815" sofa="12" begin="66505" end="66510" text="PSEN1" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="830" sofa="12" begin="66514" end="66516" text="AD" id="3" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="845" sofa="12" begin="66520" end="66532" text="Semagacestat" id="4" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="893" sofa="12" begin="66624" end="66629" text="P436Q" id="0" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="908" sofa="12" begin="66633" end="66638" text="L166P" id="1" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="923" sofa="12" begin="66642" end="66651" text="wild-type" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="938" sofa="12" begin="66655" end="66659" text="AICD" id="3" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="953" sofa="12" begin="66663" end="66671" text="C100-His" id="4" isCorrect="false" isSelected="false" nerList="15243"/><types:Answer xmi:id="1001" sofa="12" begin="66789" end="66791" text="13" id="0" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="1016" sofa="12" begin="66795" end="66797" text="42" id="1" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="1031" sofa="12" begin="66801" end="66806" text="P436Q" id="2" isCorrect="false" isSelected="false" nerList=""/><types:Answer xmi:id="1046" sofa="12" begin="66810" end="66813" text="185" id="3" isCorrect="true" isSelected="false" nerList=""/><types:Answer xmi:id="1061" sofa="12" begin="66817" end="66822" text="PSEN2" id="4" isCorrect="false" isSelected="false" nerList=""/><types:QuestionAnswerSet xmi:id="120" sofa="12" begin="0" end="0" question="19" answerList="29 44 59 74 89"/><types:QuestionAnswerSet xmi:id="228" sofa="12" begin="0" end="0" question="127" answerList="137 152 167 182 197"/><types:QuestionAnswerSet xmi:id="336" sofa="12" begin="0" end="0" question="235" answerList="245 260 275 290 305"/><types:QuestionAnswerSet xmi:id="444" sofa="12" begin="0" end="0" question="343" answerList="353 368 383 398 413"/><types:QuestionAnswerSet xmi:id="552" sofa="12" begin="0" end="0" question="451" answerList="461 476 491 506 521"/><types:QuestionAnswerSet xmi:id="660" sofa="12" begin="0" end="0" question="559" answerList="569 584 599 614 629"/><types:QuestionAnswerSet xmi:id="768" sofa="12" begin="0" end="0" question="667" answerList="677 692 707 722 737"/><types:QuestionAnswerSet xmi:id="876" sofa="12" begin="0" end="0" question="775" answerList="785 800 815 830 845"/><types:QuestionAnswerSet xmi:id="984" sofa="12" begin="0" end="0" question="883" answerList="893 908 923 938 953"/><types:QuestionAnswerSet xmi:id="1092" sofa="12" begin="0" end="0" question="991" answerList="1001 1016 1031 1046 1061"/><tcas:DocumentAnnotation xmi:id="1130" sofa="12" begin="0" end="66824" language="en"/><examples:SourceDocumentInformation xmi:id="1135" sofa="12" begin="0" end="0" uri="file:/home/zhenggq/Courses/SoftwareEngineeringI/Workspace/hw5-team03/qa4mre-alzheimer-task/data/12-test-alzheimer/QA4MRE-2012_BIOMEDICAL_GS.xml" offsetInSource="3" documentSize="177345" lastSegment="true"/><types:Sentence xmi:id="1143" sofa="12" begin="0" end="691" id="0" text="PLoS ONE: Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesOpen AccessResearch ArticleAlzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesMatthias Cacquevel, Lor��ne Aeschbach, Jemila Houacine, Patrick C. Fraering*��cole Polytechnique F��d��rale de Lausanne, Brain Mind Institute, Laboratory of Molecular and Cellular Biology of Alzheimer's Disease, Lausanne, SwitzerlandAbstract Top BackgroundMutations linked to early onset, familial forms of Alzheimer's disease (FAD) are found most frequently in PSEN1, the gene encoding presenilin-1 (PS1)." qualityScore="0.0" bFilter="false"/><types:Sentence xmi:id="1155" sofa="12" begin="692" end="984" id="1" text="Together with nicastrin (NCT), anterior pharynx-defective protein 1 (APH1), and presenilin enhancer 2 (PEN2), the catalytic subunit PS1 constitutes the core of the ��-secretase complex and contributes to the proteolysis of the amyloid precursor protein (APP) into amyloid-beta (A��) peptides." qualityScore="0.9166666666666666" bFilter="false" nerList="8129 8138 8147 8156 8165 8174 8183"/><types:Sentence xmi:id="1167" sofa="12" begin="985" end="1216" id="2" text="Although there is a growing consensus that FAD-linked PS1 mutations affect A�� production by enhancing the A��1���42/A��1���40 ratio, it remains unclear whether and how they affect the generation of APP intracellular domain (AICD)." qualityScore="0.7959183673469388" bFilter="false" nerList="8214 8223 8232"/><types:Sentence xmi:id="1179" sofa="12" begin="1217" end="1409" id="3" text="Moreover, controversy exists as to how PS1 mutations exert their effects in different experimental systems, by either increasing A��1���42 production, decreasing A��1���40 production, or both." qualityScore="0.8461538461538461" bFilter="false" nerList="8251"/><types:Sentence xmi:id="1191" sofa="12" begin="1410" end="1620" id="4" text="Because it could be explained by the heterogeneity in the composition of ��-secretase, we purified to homogeneity complexes made of human NCT, APH1aL, PEN2, and the pathogenic PS1 mutants L166P, ��E9, or P436Q." qualityScore="0.9772727272727273" bFilter="false" nerList="8264 8273 8282 8291"/><types:Sentence xmi:id="1203" sofa="12" begin="1620" end="1854" id="5" text="Methodology/Principal FindingsWe took advantage of a mouse embryonic fibroblast cell line lacking PS1 and PS2 to generate different stable cell lines overexpressing human ��-secretase complexes with different FAD-linked PS1 mutations." qualityScore="0.9714285714285714" bFilter="false" nerList="8313 8322 8331 8340"/><types:Sentence xmi:id="1215" sofa="12" begin="1855" end="1976" id="6" text="A multi-step affinity purification procedure was used to isolate semi-purified or highly purified ��-secretase complexes." qualityScore="0.95" bFilter="false" nerList="8362"/><types:Sentence xmi:id="1227" sofa="12" begin="1977" end="2204" id="7" text="The functional characterization of these complexes revealed that all PS1 FAD-linked mutations caused a loss of ��-secretase activity phenotype, in terms of A��1���40, A��1���42 and APP intracellular domain productions in vitro." qualityScore="0.8297872340425532" bFilter="false" nerList="8375 8384 8393 8402"/><types:Sentence xmi:id="1239" sofa="12" begin="2204" end="2461" id="8" text="Conclusion/SignificanceOur data support the view that PS1 mutations lead to a strong ��-secretase loss-of-function phenotype and an increased A��1���42/A��1���40 ratio, two mechanisms that are potentially involved in the pathogenesis of Alzheimer's disease." qualityScore="0.8823529411764706" bFilter="false" nerList="8424 8433"/><types:Sentence xmi:id="1251" sofa="12" begin="2461" end="2653" id="9" text="Citation: Cacquevel M, Aeschbach L, Houacine J, Fraering PC (2012) Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase Complexes." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="1263" sofa="12" begin="2654" end="2676" id="10" text="PLoS ONE 7(4): e35133." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="1275" sofa="12" begin="2677" end="2697" id="11" text="doi:10.1371/journal." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="1287" sofa="12" begin="2697" end="2881" id="12" text="pone.0035133Editor: Stefano L. Sensi, University G. D'Annunzio, ItalyReceived: February 20, 2012; Accepted: March 13, 2012; Published: April 18, 2012Copyright: �� 2012 Cacquevel et al." qualityScore="0.7857142857142857" bFilter="false" nerList=""/><types:Sentence xmi:id="1299" sofa="12" begin="2882" end="3117" id="13" text="This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="1311" sofa="12" begin="3117" end="3369" id="14" text="Funding: This work was supported by the Swiss National Foundation (to and LA and PCF; grant 31003A_134938/1) and the National Centre for Competence in Research (���Neuronal Plasticity and Repair��� (to JH and PCF)), and the Strauss foundation (to PCF)." qualityScore="0.8928571428571429" bFilter="false" nerList=""/><types:Sentence xmi:id="1323" sofa="12" begin="3370" end="3576" id="15" text="The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Competing interests: The authors have declared that no competing interests exist." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="1335" sofa="12" begin="3576" end="3881" id="16" text="* E-mail: patrick.fraering@epfl.chIntroduction Top Since their discovery in 1995 and their association with early onset familial Alzheimer's disease (FAD) [1], [2], the presenilin genes PSEN1 and PSEN2 have been widely studied, and the complexity of their biological role is becoming increasingly evident." qualityScore="0.9137931034482758" bFilter="false" nerList="8453 8462"/><types:Sentence xmi:id="1347" sofa="12" begin="3882" end="4114" id="17" text="PSEN1 and PSEN2 encode transmembrane proteins PS1 and PS2, respectively, that constitute the catalytic core of ��-secretase, the founding member of an emerging class of unconventional, Intramembrane-Cleaving Proteases (I-CLiPs) [3]." qualityScore="0.9523809523809523" bFilter="false" nerList="8478 8487 8496 8505 8514"/><types:Sentence xmi:id="1359" sofa="12" begin="4115" end="4301" id="18" text="Active ��-secretase is a multiprotein complex composed of PS1 or PS2 together with nicastrin (NCT), the anterior pharynx-defective protein 1 (APH1), and the presenilin enhancer 2 (PEN2)." qualityScore="0.9210526315789473" bFilter="false" nerList="8539 8548 8557 8566 8575 8584"/><types:Sentence xmi:id="1371" sofa="12" begin="4302" end="4620" id="19" text="Experimental evidence such as the binding of transition-state analogue ��-secretase inhibitors to PS1 [4], as well as the abolishment of ��-secretase activity when PS1 lacks the aspartate residues critical for proteolysis [4], [5], [6], have confirmed that presenilins harbour the active site of the enzymatic complex." qualityScore="0.9384615384615385" bFilter="false" nerList="8612 8621"/><types:Sentence xmi:id="1383" sofa="12" begin="4620" end="4710" id="20" text="PS1 and PS2 play fundamental roles in cell signalling as part of the ��-secretase complex." qualityScore="1.0" bFilter="false" nerList="8637 8646 8655"/><types:Sentence xmi:id="1395" sofa="12" begin="4711" end="4901" id="21" text="The latter cleaves numerous type-I membrane proteins in their transmembrane domain [7], releasing their corresponding intracellular domains, which are capable of influencing gene expression." qualityScore="0.9310344827586207" bFilter="false" nerList="8674"/><types:Sentence xmi:id="1407" sofa="12" begin="4902" end="5185" id="22" text="For some substrates like NOTCH1 or ERBB4, the ��-secretase cleavage is essential for their biological function, whereas for other substrates like DCC or NEUREXIN-3�� [8], the possible role of the cleavage in signalling events has not been formally established (see [9] for a review)." qualityScore="0.9137931034482758" bFilter="false" nerList="8687 8696 8705"/><types:Sentence xmi:id="1419" sofa="12" begin="5186" end="5403" id="23" text="The amyloid precursor protein (APP) is processed by the successive actions of ��-secretase (BACE1) and ��-secretase, generating amyloid-beta peptides (A��) of different lengths, ranging from 37 to 46 amino acids [10]." qualityScore="0.8979591836734694" bFilter="false" nerList="8724 8733 8742 8751 8760 8769"/><types:Sentence xmi:id="1431" sofa="12" begin="5404" end="5670" id="24" text="Cleavage of the APP C-terminal fragments (APP-CTFs) by ��-secretase also releases the APP intracellular domain (AICD), which has been recently involved in the regulation of brain ApoE expression, a major genetic determinant of AD, and in cholesterol metabolism [11]." qualityScore="0.8653846153846154" bFilter="false" nerList="8797 8806 8815 8824"/><types:Sentence xmi:id="1443" sofa="12" begin="5671" end="5805" id="25" text="In addition, PS1 has been shown to interact with a growing list of proteins that modulate ��-secretase activity [9], [12], [13], [14]." qualityScore="0.8888888888888888" bFilter="false" nerList="8846 8855"/><types:Sentence xmi:id="1455" sofa="12" begin="5805" end="5981" id="26" text="In a pathological context, 185 missense mutations in PSEN1 and 13 mutations in PSEN2 have been identified and found to be associated with FAD (www.molgen.ua.ac.be/ADMutations)." qualityScore="0.90625" bFilter="false" nerList=""/><types:Sentence xmi:id="1467" sofa="12" begin="5982" end="6264" id="27" text="It was initially suggested that such mutations lead to a toxic gain of function because they are associated with a relative increased production of longer and more hydrophobic A�� species, mainly A��1���42, that accumulate and aggregate early in the course of thedisease [15], [16]." qualityScore="0.8947368421052632" bFilter="false" nerList=""/><types:Sentence xmi:id="1479" sofa="12" begin="6265" end="6428" id="28" text="Similar phenotypes have been observed by independent groups in cell-based studies performed with different mammalian cell lines [17], [18], [19], [20], [21], [22]." qualityScore="0.85" bFilter="false" nerList=""/><types:Sentence xmi:id="1491" sofa="12" begin="6429" end="6613" id="29" text="Despite this growing consensus, the above-mentioned studies provided conflicting results regarding the relative proportions of A��42, A��40, and AICD resulting from the PSEN mutations." qualityScore="0.8125" bFilter="false" nerList="8874 8883"/><types:Sentence xmi:id="1503" sofa="12" begin="6614" end="6820" id="30" text="On one hand, a gain-of-function phenotype was suggested due to the observed increase in A��42 production, accompanied or not with reduced A��40 production, thereby leading to an increased A��42/A��40 ratio." qualityScore="0.8181818181818181" bFilter="false" nerList=""/><types:Sentence xmi:id="1515" sofa="12" begin="6821" end="6908" id="31" text="On the other hand, reduced AICD production suggested a loss-of-function phenotype [20]." qualityScore="0.875" bFilter="false" nerList=""/><types:Sentence xmi:id="1527" sofa="12" begin="6909" end="7102" id="32" text="Differences in the methodologies and cell types used to assess the effects of PSEN mutations on A�� and AICD productions can explain this controversy as to how PS mutations exert their effects." qualityScore="0.8823529411764706" bFilter="false" nerList=""/><types:Sentence xmi:id="1539" sofa="12" begin="7103" end="7305" id="33" text="For example, endogenous PS has been suggested to affect such analysis, as the FAD-linked PSEN1 mutations led to a decrease in the total amount of A�� generated in PS1 and PS2 double knockout cells [23]." qualityScore="0.9024390243902439" bFilter="false" nerList="8902 8911 8920"/><types:Sentence xmi:id="1551" sofa="12" begin="7306" end="7584" id="34" text="Next, it has been reported that ��-secretase complexes are heterogeneous in composition (with two PS genes and three APH1 isoforms, six combinations of ��-secretase are possible), with distinct functional properties influencing the relative amount of A�� species generated [24]." qualityScore="0.9433962264150944" bFilter="false" nerList="8939 8948 8957 8966"/><types:Sentence xmi:id="1563" sofa="12" begin="7585" end="7781" id="35" text="In order to investigate the biochemical and functional properties of ��-secretase in cell-free systems, we and others have recently purified this enzymatic complex to homogeneity [25], [26], [27]." qualityScore="0.925" bFilter="false" nerList="8988"/><types:Sentence xmi:id="1575" sofa="12" begin="7782" end="8109" id="36" text="In particular, protocols for the high-grade purification of proteolytically active ��-secretase constituted of NCT, APH1aL, PEN2 and wild-type PS1 [26], [27] allowed the reconstitution of 3D structures at 15 �� and 12 �� resolution by EM and cryo-EM and gave new insights on the structure and activity of the enzyme [28], [29]." qualityScore="0.8783783783783784" bFilter="false" nerList="9001 9010 9019 9028"/><types:Sentence xmi:id="1587" sofa="12" begin="8110" end="8179" id="37" text="However, these studies were exclusively focused on the wild-type PS1." qualityScore="1.0" bFilter="false" nerList="9050"/><types:Sentence xmi:id="1599" sofa="12" begin="8180" end="8352" id="38" text="Here, we report for the first time the functional characterization of highly purified and homogenous human ��-secretase particles carrying different FAD-linked PS1 mutants." qualityScore="0.9642857142857143" bFilter="false" nerList="9063 9072"/><types:Sentence xmi:id="1611" sofa="12" begin="8353" end="8483" id="39" text="Our biochemical and functional findings strongly suggest that pathogenic mutations in PSEN1 cause a loss of ��-secretase activity." qualityScore="1.0" bFilter="false" nerList="9088 9097"/><types:Sentence xmi:id="1623" sofa="12" begin="8483" end="8893" id="40" text="Results Top Generation, selection and characterization of stable cell lines overexpressing ��-secretase complexes with FAD-linked PS1 mutantsIn order to facilitate high-grade purification of homogenous human ��-secretase complexes containing different PS1 variants, we took advantage of a previously generated mouse embryonic fibroblast (MEF) cell line that lacks the two presenilins (PS1/2���/���) [30], [31]." qualityScore="0.9358974358974359" bFilter="false" nerList="9113 9122 9131 9140"/><types:Sentence xmi:id="1635" sofa="12" begin="8894" end="9231" id="41" text="Our global strategy consisted in producing stable cell lines, on a PS1/2���/��� background, that overexpress tagged versions of the three human ��-secretase subunits NCT, APH1 and PEN2 together with different variants of human PS1, and to purify the different human ��-secretase complexes by three sequential affinity purification steps." qualityScore="0.9696969696969697" bFilter="false" nerList="9162 9171 9180 9189 9198"/><types:Sentence xmi:id="1647" sofa="12" begin="9232" end="9328" id="42" text="This strategy allowed us to exclude a possible co-purification of mouse ��-secretase components." qualityScore="1.0" bFilter="false" nerList="9223"/><types:Sentence xmi:id="1659" sofa="12" begin="9329" end="9519" id="43" text="First, a parental cell line was generated by co-transducing lentiviral vectors of human NCT-V5 (hNCT-V5), human APH1aL-HA (hAPH1aL-HA) and human Flag-PEN2 (Flag-hPEN2) into MEF PS1/2���/���." qualityScore="0.8780487804878049" bFilter="false" nerList="9236 9245 9254 9263"/><types:Sentence xmi:id="1671" sofa="12" begin="9520" end="9671" id="44" text="Lentivectors are stably integrated into the cell genome and allow the generation of cell lines overexpressing multiple genes in a short period of time." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="1683" sofa="12" begin="9672" end="10239" id="45" text="Next, the clone expressing the highest levels of all three recombinant proteins was selected (designated �� - PS1/2) and used as the parental cell line that was further transduced with lentivectors carrying the following different human PS1 variants: PS1-WT, three dominant-negative forms of PS1 that lack the crucial, catalytic site aspartate residues (D257A, D385A, and both D257A/D385A referred to as DDAA later in the article), and three FAD-linked PS1 mutants (L166P, ��E9 and P436Q, with mean disease onset at 24 years, 45.5 years and 28.3 years, respectively)." qualityScore="0.9217391304347826" bFilter="false" nerList="9286 9295 9304 9313 9322 9331"/><types:Sentence xmi:id="1695" sofa="12" begin="10239" end="10398" id="46" text="For each PS1 variant, two individual clones were selected based on the expression levels of the recombinant proteins, and extensively characterized (Figure 1)." qualityScore="0.9615384615384616" bFilter="false" nerList="9359 9368"/><types:Sentence xmi:id="1707" sofa="12" begin="10399" end="10535" id="47" text="To distinguish those cell lines overexpressing all ��-sectease components from wild-type MEFs, they are collectively designated ��-MEFs." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="1719" sofa="12" begin="10536" end="10691" id="48" text="As shown in Figure 1A, the analysis of total protein extracts confirmed that PS is required for the maturation of NCT and the stability of PEN2 [23], [32]." qualityScore="0.8787878787878788" bFilter="false" nerList="9385 9394 9403"/><types:Sentence xmi:id="1731" sofa="12" begin="10692" end="10847" id="49" text="As expected, and when compared to the parental ��- PS1/2 cell line, higher levels of the mature form of NCT were observed in all PS1-overexpressing clones." qualityScore="0.9393939393939394" bFilter="false" nerList="9422"/><types:Sentence xmi:id="1743" sofa="12" begin="10848" end="10952" id="50" text="In contrast to PEN2, APH1aL levels were relatively similar in all PS1 clones and the parental cell line." qualityScore="1.0" bFilter="false" nerList="9435 9444 9453"/><types:Sentence xmi:id="1755" sofa="12" begin="10953" end="11175" id="51" text="Indeed, and as previously reported [23], [32], PEN2 levels were higher in the clones overexpressing WT PS1 and FAD-linked PS1 mutants, and to a lesser extent in the clones overexpressing the dominant negative forms of PS1." qualityScore="0.9111111111111111" bFilter="false" nerList="9472 9481 9490 9499"/><types:Sentence xmi:id="1767" sofa="12" begin="11176" end="11298" id="52" text="Interestingly, PEN2 migrated on the gel as an apparent double band, possibly reflecting a post-translational modification." qualityScore="1.0" bFilter="false" nerList="9521"/><types:Sentence xmi:id="1779" sofa="12" begin="11299" end="11394" id="53" text="Different patterns of PS1 expression and autoproteolysis were observed in the different clones." qualityScore="1.0" bFilter="false" nerList="9534"/><types:Sentence xmi:id="1791" sofa="12" begin="11395" end="11589" id="54" text="First, and in sharp contrast to the other clones, those expressing PS1-WT or PS1-L166P displayed higher levels of PS1-NTF and PS1-CTF fragments compared with full-length PS1 (PS1-FL; Figure 1A)." qualityScore="0.8974358974358975" bFilter="false" nerList="9547 9556 9565 9574 9583 9592"/><types:Sentence xmi:id="1803" sofa="12" begin="11590" end="11736" id="55" text="As estimated by densitometry, the NTF fragments of PS1-WT and PS1-L166P account for 87��2% and 79��7% of total PS1 (PS1-NTF+PS1-FL), respectively." qualityScore="0.7777777777777778" bFilter="false" nerList="9620 9629 9638 9647 9656"/><types:Sentence xmi:id="1815" sofa="12" begin="11737" end="12036" id="56" text="Next, the PS1-��E9 clones did not show any detectable NTF or CTF fragments, as previously described [33], while P436Q and the three dominant negative variants of PS1 were characterized by low levels of PS1-NTF and PS1-CTF fragments, suggesting that these variants were less prone to endoproteolysis." qualityScore="0.9122807017543859" bFilter="false" nerList="9681 9690 9699 9708 9717"/><types:Sentence xmi:id="1827" sofa="12" begin="12036" end="12054" id="57" text="thumbnailFigure 1." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="1839" sofa="12" begin="12055" end="12165" id="58" text="Generation of stable cell lines overexpressing all human ��-secretase components with FAD-linked PS1 variants." qualityScore="0.9444444444444444" bFilter="false" nerList="9742"/><types:Sentence xmi:id="1851" sofa="12" begin="12165" end="12437" id="59" text="MEF PS1/2���/��� were stably co-transduced with lentiviral vectors carrying genes encoding hNCT-V5, Flag-hPEN2, hAPH1aL-HA and clones were isolated by limiting dilution to generate a cell line, designated as ��- PS1/2, that overexpresses high amount of the three subunits." qualityScore="0.9310344827586207" bFilter="false" nerList="9755"/><types:Sentence xmi:id="1863" sofa="12" begin="12440" end="12602" id="60" text="- PS1/2 MEFs were further transduced with hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned." qualityScore="0.9032258064516129" bFilter="false" nerList="9768"/><types:Sentence xmi:id="1875" sofa="12" begin="12603" end="12860" id="61" text="Each clone, derived form the ��- PS1/2, was conveniently named according to the mutation present in PS1 preceded by the symbol �� and followed by the number of the clone (��-MEF) in order to distinguish them from wild-type MEF (WT MEF) and MEF PS1/2���/���." qualityScore="0.8852459016393442" bFilter="false" nerList="9781 9790"/><types:Sentence xmi:id="1887" sofa="12" begin="12861" end="12932" id="62" text="Two clones per ��-secretase variant were selected for characterization." qualityScore="1.0" bFilter="false" nerList="9806"/><types:Sentence xmi:id="1899" sofa="12" begin="12933" end="13298" id="63" text="(A���B) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 4���12% Bis-Tris or 12% Tris-Glycine gels and analysed by immunostaining to detect the ��-secretase core components NCT (NCT164), PS1 (NTF, MAB1563; CTF; MAB5232), APH1aL-HA (3F10), and Flag-PEN2 (M2) (A), and endogenous APP (A8717) (B)." qualityScore="0.8315789473684211" bFilter="false" nerList="9819 9828 9837 9846 9855"/><types:Sentence xmi:id="1911" sofa="12" begin="13301" end="13338" id="64" text="-Actin was used as a loading control." qualityScore="1.0" bFilter="false" nerList="9880"/><types:Sentence xmi:id="1923" sofa="12" begin="13339" end="13379" id="65" text="Each lane represents one selected clone." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="1935" sofa="12" begin="13380" end="13521" id="66" text="CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="1947" sofa="12" begin="13521" end="13541" id="67" text="doi:10.1371/journal." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="1959" sofa="12" begin="13541" end="13554" id="68" text="pone.0035133." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="1971" sofa="12" begin="13554" end="13647" id="69" text="g001 We next investigated the effects of PSEN1 mutations on the processing of endogenous APP." qualityScore="0.9333333333333333" bFilter="false" nerList="9894 9903"/><types:Sentence xmi:id="1983" sofa="12" begin="13648" end="14013" id="70" text="As expected, and as indicated by increased levels of intracellular APP-CTFs (a common characteristic among known substrates in response to ��-secretase pharmacological inhibition), the activity of ��-secretase was significantly altered in the PS deficient parental �� - PS1/2 cell line as well as in all clones expressing dominant negative forms of PS1 (Figure 1B)." qualityScore="0.9571428571428572" bFilter="false" nerList="9919 9928 9937"/><types:Sentence xmi:id="1995" sofa="12" begin="14014" end="14194" id="71" text="In the clones expressing PS1-WT, APP-CTFs were almost undetectable due to high ��-secretase activity, while clones expressing PS1-L166P or PS1-P436Q displayed APP-CTF accumulation." qualityScore="0.8787878787878788" bFilter="false" nerList="9956 9965 9974 9983"/><types:Sentence xmi:id="2007" sofa="12" begin="14195" end="14268" id="72" text="In PS1-��E9 clones, a mild APP-CTF accumulation was observed (Figure 1B)." qualityScore="0.8823529411764706" bFilter="false" nerList="10005"/><types:Sentence xmi:id="2019" sofa="12" begin="14269" end="14581" id="73" text="Although a poor recovery of ��-secretase activity for the PS1-L166P and a comparatively better performance of PS1-��E9 have been reported by others under similar experimental conditions [23], the potential of PS1-P436Q mutation to restore the processing of endogenous APP-CTFs has never been assessed [34], [35]." qualityScore="0.9344262295081968" bFilter="false" nerList="10018 10027 10036 10045"/><types:Sentence xmi:id="2031" sofa="12" begin="14582" end="14904" id="74" text="Importantly, all observations described above for the cells overexpressing simultaneously hNCT-V5, hAPH1aL-HA, Flag-hPEN2 and the different PS1 variants are very consistent with those made in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other ��-secretase components (cf. Figure S1A)." qualityScore="0.953125" bFilter="false" nerList="10067 10076 10085 10094"/><types:Sentence xmi:id="2043" sofa="12" begin="14905" end="15070" id="75" text="These data suggest that the effect of FAD mutations in PS1 on APP-CTFs accumulation was similar in presence or absence of other human components of the ��-secretase." qualityScore="0.935483870967742" bFilter="false" nerList="10116 10125 10134 10143"/><types:Sentence xmi:id="2055" sofa="12" begin="15070" end="15179" id="76" text="Next, we further investigated the effect of PS1 variants on the cellular production/secretion of A�� species." qualityScore="0.95" bFilter="false" nerList="10165"/><types:Sentence xmi:id="2067" sofa="12" begin="15180" end="15323" id="77" text="For this purpose, and as described elsewhere [36], we used an APP-based ��-secretase substrate with a Flag tag at its C-terminus (SPA4CT-Flag)." qualityScore="0.9090909090909091" bFilter="false" nerList="10178"/><types:Sentence xmi:id="2079" sofa="12" begin="15324" end="15560" id="78" text="This substrate was transduced in the above-described ��-secretase overexpressing stable cell lines (��-MEFs) as well as in wild-type MEFs, and APP-CTFs and A�� levels were measured in cell lysate and cell media, respectively (Figure 2)." qualityScore="0.9411764705882353" bFilter="false" nerList="10191 10200 10209"/><types:Sentence xmi:id="2091" sofa="12" begin="15561" end="15792" id="79" text="Under these conditions, the overexpression of SPA4CT-Flag led to an accumulation of two bands corresponding to the exogenous substrate, associated with a concomitant decrease of endogenous APP-CTFs levels (Figure 2A and Figure S2)." qualityScore="0.9736842105263158" bFilter="false" nerList="10228"/><types:Sentence xmi:id="2103" sofa="12" begin="15793" end="16022" id="80" text="As estimated by ELISA, a three-fold increase in A��1���40 and A��1���42 levels was observed in the cell culture media of cell lines overexpressing human ��-secretase (��-MEF WT), in comparison to untransduced WT MEFs (Figure 2B)." qualityScore="0.8245614035087719" bFilter="false" nerList="10241 10250 10259"/><types:Sentence xmi:id="2115" sofa="12" begin="16023" end="16204" id="81" text="Also, the average A��1���42/A��1���40 ratios were not significantly different in those cell lines (Mean �� SD: ��-MEF WT#5: 0.30��0.01; ��-MEF WT#8: 0.29��0.01; WT MEF: 0.19��0.06)." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2127" sofa="12" begin="16205" end="16480" id="82" text="Next, overexpression of SPA4CT-Flag in ��-MEFs led to the pronounced intracellular accumulation of APP-CTFs in cells overexpressing the PS1 aspartate mutants (Figure 2C), and to the secretion in the cell culture media of different A�� levels as measured by ELISA (Figure 2D)." qualityScore="0.9444444444444444" bFilter="false" nerList="10278 10287 10296"/><types:Sentence xmi:id="2139" sofa="12" begin="16481" end="16599" id="83" text="First, only traces of both A��1���40 and A��1���42 were detected in ��-MEFs overexpressing PS1 with aspartate mutants." qualityScore="0.8064516129032258" bFilter="false" nerList="10315 10324 10333"/><types:Sentence xmi:id="2151" sofa="12" begin="16600" end="16746" id="84" text="Next, ��-MEFs overexpressing PS1 with FAD-linked mutations displayed a pronounced variability in A�� levels when compared to the wild-type clones." qualityScore="0.9285714285714286" bFilter="false" nerList="10352"/><types:Sentence xmi:id="2163" sofa="12" begin="16747" end="17081" id="85" text="Overall, the average A��1���40 levels were decreased in these cell lines (Mean of two clones in pg/mL �� SD: WT: 224.6��0.1, L166P: 84.3��34.2, ��E9: 167.2��40.7, P436Q: 82.8��74.7), while the A��1���42 levels were increased (Mean of two clones in pg/mL �� SD: WT: 69.9��7.9, L166P: 310.7��81.0, ��E9: 94.4��18.5, P436Q: 141.1��98.5)." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2175" sofa="12" begin="17082" end="17350" id="86" text="Consistent with previously reported data, the A��1���42/A��1���40 ratios were increased in all ��-MEF clones overexpressing PS1 with FAD-linked mutations (Figure 2D) (Mean of two clones pg/mL �� SD: WT: 0.31��0.03, L166P: 3.8��0.58, ��E9: 0.6��0.03, P436Q: 2.0��0.59)." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2187" sofa="12" begin="17350" end="17368" id="87" text="thumbnailFigure 2." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2199" sofa="12" begin="17369" end="17472" id="88" text="A�� production in cell lines overexpressing human ��-secretase components with FAD-linked PS1 variants." qualityScore="0.8947368421052632" bFilter="false" nerList="10365"/><types:Sentence xmi:id="2211" sofa="12" begin="17472" end="17692" id="89" text="WT MEF, ��-MEF and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]) and a Flag Tag in C-terminus." qualityScore="0.7777777777777778" bFilter="false" nerList="10378 10387 10396"/><types:Sentence xmi:id="2223" sofa="12" begin="17693" end="17894" id="90" text="Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717) (A, C)." qualityScore="0.7857142857142857" bFilter="false" nerList="10415"/><types:Sentence xmi:id="2235" sofa="12" begin="17895" end="17992" id="91" text="A��1���40 and A��1���42 levels were also measured in the corresponding cell culture media (B, D)." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2247" sofa="12" begin="17993" end="18057" id="92" text="Data corresponds to three independent experiments (Mean �� SEM)." qualityScore="0.9166666666666666" bFilter="false" nerList=""/><types:Sentence xmi:id="2259" sofa="12" begin="18057" end="18077" id="93" text="doi:10.1371/journal." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2271" sofa="12" begin="18077" end="18090" id="94" text="pone.0035133." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2283" sofa="12" begin="18090" end="18288" id="95" text="g002 FAD-linked PS1 mutations alter the activity of semi-purified ��-secretase complexesWe next assessed the activity of ��-secretase with FAD-linked PS1 mutations in microsomal extracts of ��-MEFs." qualityScore="0.9473684210526316" bFilter="false" nerList="10429 10438 10447 10456"/><types:Sentence xmi:id="2295" sofa="12" begin="18289" end="18516" id="96" text="Membrane protein extracts were prepared and ��-secretase activity was assayed on an exogenous recombinant APP-based substrate consisting of the C-terminal 99 amino acid residues of APP, and referred to as C100-Flag (Figure 3A)." qualityScore="0.9024390243902439" bFilter="false" nerList="10478 10487 10496"/><types:Sentence xmi:id="2307" sofa="12" begin="18517" end="18633" id="97" text="The generation of the cleavage product AICD-Flag was detected by Western blot analysis and measured by densitometry." qualityScore="0.9444444444444444" bFilter="false" nerList="10515"/><types:Sentence xmi:id="2319" sofa="12" begin="18634" end="18805" id="98" text="As shown in Figure 3A, the levels of AICD-Flag generated from the PS1-L166P and PS1-��E9 clones accounted for 42��1% and 13��6% of that in the PS1-WT clones, respectively." qualityScore="0.8571428571428572" bFilter="false" nerList="10528 10537 10546"/><types:Sentence xmi:id="2331" sofa="12" begin="18806" end="18933" id="99" text="AICD-Flag was undetectable in the clones expressing PS1-P436Q as well as in the three dominant negative aspartate PS1 variants." qualityScore="0.9523809523809523" bFilter="false" nerList="10565"/><types:Sentence xmi:id="2343" sofa="12" begin="18934" end="19099" id="100" text="Similar results were observed in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other human ��-secretase components (Figure S1B)." qualityScore="0.9459459459459459" bFilter="false" nerList="10578 10587"/><types:Sentence xmi:id="2355" sofa="12" begin="19099" end="19117" id="101" text="thumbnailFigure 3." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2379" sofa="12" begin="19210" end="19335" id="102" text="Enzymatic activity of partially purified ��-secretase complexes with FAD-linked PS1 mutants. (A) ��-Secretase activity assays performed with ��-MEF and �� - PS1/2 microsomal extracts prepared in 1% CHAPSO-HEPES buffer." qualityScore="0.8541666666666666" bFilter="false" nerList="10603 10612 10621"/><types:Sentence xmi:id="2391" sofa="12" begin="19336" end="19533" id="103" text="Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag)." qualityScore="0.7560975609756098" bFilter="false" nerList=""/><types:Sentence xmi:id="2403" sofa="12" begin="19534" end="19628" id="104" text="Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563)." qualityScore="0.8947368421052632" bFilter="false" nerList="10641"/><types:Sentence xmi:id="2415" sofa="12" begin="19629" end="19756" id="105" text="The relative amounts of AICD-Flag generated in the reactions, reflecting ��-secretase activity, were estimated by densitometry." qualityScore="0.9545454545454546" bFilter="false" nerList="10654"/><types:Sentence xmi:id="2427" sofa="12" begin="19757" end="19824" id="106" text="PS1 immunostaining was used to assess the amount of input material." qualityScore="1.0" bFilter="false" nerList="10667"/><types:Sentence xmi:id="2439" sofa="12" begin="19825" end="20036" id="107" text="(B) Equal amounts of microsomal proteins were immunoprecipitated overnight at 4��C with either anti-Flag M2 or anti-HA affinity resins, and submitted to a C100-His assay according to the same protocol as in (A)." qualityScore="0.8809523809523809" bFilter="false" nerList="10680 10689 10698"/><types:Sentence xmi:id="2451" sofa="12" begin="20037" end="20187" id="108" text="Protein samples were separated by SDS-PAGE and analysed by immunostaining for ��-secretase subunits ((NCT164 (NCT), MAB1563 (PS1-NTF), or UD1 (PEN2))." qualityScore="0.8823529411764706" bFilter="false" nerList="10717 10726 10735 10744 10753 10762"/><types:Sentence xmi:id="2463" sofa="12" begin="20188" end="20272" id="109" text="AICD-His cleavage products were immunostained with an anti-APP-CTF antibody (A8717)." qualityScore="0.7857142857142857" bFilter="false" nerList="10790 10799"/><types:Sentence xmi:id="2475" sofa="12" begin="20273" end="20342" id="110" text="*Indicates a non-specific band corresponding to the IgG light chains." qualityScore="1.0" bFilter="false" nerList="10815"/><types:Sentence xmi:id="2487" sofa="12" begin="20343" end="20546" id="111" text="(C) A��1���40 and A��1���42 were quantified by sandwich ELISA and represented in pg/mL (left Y-axis) or in percentage (right Y-axis) of the mean of A��1���40 levels generated by the two wild-type clones." qualityScore="0.7719298245614035" bFilter="false" nerList="10828"/><types:Sentence xmi:id="2499" sofa="12" begin="20547" end="20611" id="112" text="A��1���42/A��1���40 ratios are indicated on the top of the bars." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2511" sofa="12" begin="20612" end="20710" id="113" text="The results were confirmed in three independent experiments and a representative dataset is shown." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="2523" sofa="12" begin="20710" end="20730" id="114" text="doi:10.1371/journal." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2535" sofa="12" begin="20730" end="20743" id="115" text="pone.0035133." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2547" sofa="12" begin="20743" end="20813" id="116" text="g003 We next performed activity assays under semi-purified conditions." qualityScore="1.0" bFilter="false" nerList="10842"/><types:Sentence xmi:id="2559" sofa="12" begin="20814" end="20996" id="117" text="To do so, ��-secretase complexes from the different clones were co-immunoprecipitated from microsomal extracts and their activities were assayed in vitro with the C100-His substrate." qualityScore="1.0" bFilter="false" nerList="10855 10864"/><types:Sentence xmi:id="2571" sofa="12" begin="20997" end="21257" id="118" text="Two immunoprecipitation protocols using two affinity resins (anti-Flag M2 and anti-HA 3F10, targeting respectively Flag-PEN2 and APH1aL-HA) were compared to exclude a possible heterogeneity of ��-secretase complexes potentially generated under such conditions." qualityScore="0.9523809523809523" bFilter="false" nerList="10880 10889 10898 10907"/><types:Sentence xmi:id="2583" sofa="12" begin="21258" end="21480" id="119" text="As shown in Figure 3B, the anti-Flag and anti-HA resins immunoprecipitated similar levels of NCT, PS1 and PEN2 and the activity of the ��-secretase complexes was similar regardless of the affinity resins used (Figures 3B)." qualityScore="0.9534883720930233" bFilter="false" nerList="10929 10938 10947 10956 10965 10974"/><types:Sentence xmi:id="2595" sofa="12" begin="21481" end="21710" id="120" text="In agreement with the assays performed using microsomal extracts (Figure 3A), those performed with semi-purified complexes revealed that FAD-linked mutants drastically reduced AICD generation, when compared to PS1-WT (Figure 3B)." qualityScore="0.9210526315789473" bFilter="false" nerList="11002 11011"/><types:Sentence xmi:id="2607" sofa="12" begin="21711" end="21897" id="121" text="Furthermore, levels of A��1���40 produced from PS1-L166P, PS1-��E9 and P436Q variants fell respectively to ~6%, ~1.5% and ~0.5%, when compared to these produced from PS1-WT ��-secretase." qualityScore="0.8235294117647058" bFilter="false" nerList="11027 11036 11045 11054"/><types:Sentence xmi:id="2619" sofa="12" begin="21898" end="22115" id="122" text="Following the same tendency, A��1���42 levels generated from PS1-L166P, PS1-��E9 and PS1-P436Q ��-secretase variants were respectively estimated to ~20%, ~5% and ~3% of these produced with PS1-WT-containing complexes." qualityScore="0.8653846153846154" bFilter="false" nerList="11076 11085 11094 11103 11112"/><types:Sentence xmi:id="2631" sofa="12" begin="22116" end="22285" id="123" text="The A��1-42/A��1���40 ratio measured for WT ��-MEFs was consistent with our cell-based data (compare Figures 2D and 3C), validating our in vitro experimental conditions." qualityScore="0.825" bFilter="false" nerList="11137"/><types:Sentence xmi:id="2643" sofa="12" begin="22286" end="22414" id="124" text="Interestingly, an overall A��1���42/A��1���40 ratio of ~1 was estimated for all PS1 mutants, with the exception of P436Q#4 (~2)." qualityScore="0.75" bFilter="false" nerList="11150"/><types:Sentence xmi:id="2655" sofa="12" begin="22415" end="22543" id="125" text="However, in the latter, the ratio may have been overestimated because the A��1���40 levels measured were at the detection limit." qualityScore="0.8888888888888888" bFilter="false" nerList="11163"/><types:Sentence xmi:id="2667" sofa="12" begin="22544" end="22703" id="126" text="This similarity in the A��1���42/A��1���40 ratios generated by the different mutantshas, to the best of our knowledge, never been observed in previous studies." qualityScore="0.8333333333333334" bFilter="false" nerList=""/><types:Sentence xmi:id="2679" sofa="12" begin="22703" end="23048" id="127" text="Highly purified ��-secretase complexes with FAD-linked PS1 mutants display a loss-of-function phenotypeIn order to further investigate how PS1 variants affect APP-CTF cleavage and to validate our observations performed in semi-purified conditions, we purified to homogeneity ��-secretase complexes from the selected clones described in Figure 1." qualityScore="0.9298245614035088" bFilter="false" nerList="11177 11186 11195 11204"/><types:Sentence xmi:id="2691" sofa="12" begin="23049" end="23232" id="128" text="The purification process (described in details under Materials &amp; Methods and depicted in Figure 4A) involved three sequential affinity purifications starting from microsomal extracts." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="2703" sofa="12" begin="23233" end="23409" id="129" text="Since all cell lines were generated on a PS knockout background, this strategy allowed us to purify exclusively and selectively ��-secretase complexes made of human components." qualityScore="0.9666666666666667" bFilter="false" nerList=""/><types:Sentence xmi:id="2715" sofa="12" begin="23410" end="23667" id="130" text="As highlighted in Figure 4B, our protocol led to the production of stable, high molecular weight ��-secretase complexes (HMWCs) with an apparent molecular mass on Blue Native (BN)-PAGE of ~350 kDa, which is consistent with previous reports [26], [27], [37]." qualityScore="0.8983050847457628" bFilter="false" nerList="11228"/><types:Sentence xmi:id="2727" sofa="12" begin="23668" end="23907" id="131" text="The silver stained particles on the BN gel confirmed the high purity of these complexes (Figure 4B, upper panel), for which the identity was established by cross-reactivity with antibodies specific to NCT and PS1 (Figure 4B, lower panels)." qualityScore="0.9555555555555556" bFilter="false" nerList="11241 11250"/><types:Sentence xmi:id="2739" sofa="12" begin="23908" end="24221" id="132" text="As the main goal of this experiment was to compare the efficacy of the different ��-secretase complexes to process APP-based substrates, it is important to note that the final yields of the complexes purified from the different clones were very similar (Figure 4B), thus facilitating further comparative analyses." qualityScore="0.9821428571428571" bFilter="false" nerList="11266"/><types:Sentence xmi:id="2751" sofa="12" begin="24222" end="24446" id="133" text="The immunoblot analysis of the purified complexes (Figure 4C) confirmed the presence of all core components (NCT-V5, APH1aL-HA, Flag-PEN2 and PS1) and globally recapitulates the maturation processes observed in the Figure 1." qualityScore="0.926829268292683" bFilter="false" nerList="11279 11288 11297 11306"/><types:Sentence xmi:id="2763" sofa="12" begin="24447" end="24792" id="134" text="Interestingly, the relative PS1-NTF/CTF to PS1-FL ratios in the purified ��-secretase complexes containing the three PS1 dominant-negative or the PS1-P436Q variants were higher than those estimated in the whole cell extracts before purification (Figure 1A), indicating that endoproteolysis of PS1 was not completely abolished by these mutations." qualityScore="0.9491525423728814" bFilter="false" nerList="11328 11337 11346 11355 11364 11373"/><types:Sentence xmi:id="2775" sofa="12" begin="24793" end="25123" id="135" text="To assess how FAD-linked mutations in PS1 affect ��-secretase activity in these purified complexes, we performed in vitro assays by using C100-Flag substrate (Figure 3A) and equal amounts of the different purified complexes, immediately after the purification to avoid freezing/thawing cycles that might affect enzymatic activity." qualityScore="0.9821428571428571" bFilter="false" nerList="11401"/><types:Sentence xmi:id="2787" sofa="12" begin="25124" end="25268" id="136" text="As shown in Figure 5A, ��-secretase activity based on AICD-Flag production was easily detected in complexes purified from the two PS1-WT clones." qualityScore="0.9285714285714286" bFilter="false" nerList="11414 11423"/><types:Sentence xmi:id="2799" sofa="12" begin="25269" end="25411" id="137" text="This is in sharp contrast to the other purified complexes that did not generate detectable AICD under our experimental conditions (Figure 5A)." qualityScore="0.9565217391304348" bFilter="false" nerList=""/><types:Sentence xmi:id="2811" sofa="12" begin="25412" end="25571" id="138" text="Next, sandwich ELISAs directed against A��1���40 and A��1���42 were performed in order to further characterize the specific activity of the purified complexes." qualityScore="0.8181818181818181" bFilter="false" nerList="11440 11449"/><types:Sentence xmi:id="2823" sofa="12" begin="25572" end="25853" id="139" text="Reflecting the levels of AICD and considering the detection limits of our sandwich ELISA, the production of both A�� species by ��-secretase complexes containing PS1-WT was at least 10-fold higher than in complexes with the FAD-linked or dominant-negative PS1 variants (Figure 5B)." qualityScore="0.8867924528301887" bFilter="false" nerList="11465 11474"/><types:Sentence xmi:id="2835" sofa="12" begin="25854" end="26079" id="140" text="The A��1���42/A��1���40 ratio measured in PS1-WT ��-secretase complexes (~0.22) was similar to that previously reported [26], [27], thus excluding a possible qualitative alteration of ��-secretase activity with this protocol." qualityScore="0.8070175438596492" bFilter="false" nerList="11490 11499"/><types:Sentence xmi:id="2847" sofa="12" begin="26080" end="26279" id="141" text="Together, our results strongly support the hypothesis that the pathogenic L166P, ��E9, and P436Q mutations in PSEN1 cause a drastic loss (at least 90% as estimated by ELISA) of ��-secretase activity." qualityScore="0.9523809523809523" bFilter="false" nerList="11515 11524"/><types:Sentence xmi:id="2859" sofa="12" begin="26279" end="26297" id="142" text="thumbnailFigure 4." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="2883" sofa="12" begin="26382" end="26452" id="143" text="High-grade purification of human ��-secretase complexes with FAD-linked PS1 mutants. (A) Schematic representation of the ��-secretase purification process." qualityScore="0.9310344827586207" bFilter="false" nerList="11540 11549 11558"/><types:Sentence xmi:id="2895" sofa="12" begin="26453" end="26620" id="144" text="Briefly, Presenilin double-knockout MEFs were used to first generate cell lines that stably overexpress human ��-secretase complexes containing different PS1 variants." qualityScore="1.0" bFilter="false" nerList="11577 11586"/><types:Sentence xmi:id="2907" sofa="12" begin="26621" end="26735" id="145" text="Next, these cell lines were used for a multi-step purification procedure as described in the material and methods." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="2919" sofa="12" begin="26736" end="26832" id="146" text="(B) Blue-Native PAGE analysis of purified ��-secretase complexes made of different PS1 variants." qualityScore="0.8947368421052632" bFilter="false" nerList=""/><types:Sentence xmi:id="2931" sofa="12" begin="26833" end="27097" id="147" text="Equal volumes of the different purified ��-secretase preparations were separated by native-PAGE on a 4���16% Bis-Tris gel, and stained with silver nitrate (top panel), or immunostained for NCT (NCT164, middle panel) or PS1-NTF (ab10281, bottom panel) as indicated." qualityScore="0.9137931034482758" bFilter="false" nerList="11604 11613 11622 11631"/><types:Sentence xmi:id="2943" sofa="12" begin="27100" end="27196" id="148" text="-Secretase complexes appeared on the gel as high molecular weight complexes (HMWCs) of ~350 kDa." qualityScore="0.9473684210526316" bFilter="false" nerList=""/><types:Sentence xmi:id="2955" sofa="12" begin="27197" end="27255" id="149" text="Note that the levels of HMWCs were similar for all clones." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="2967" sofa="12" begin="27256" end="27526" id="150" text="(C) Equal volumes of purified ��-secretase complexes with FAD-linked PS1 mutants were separated under denaturing conditions (SDS-PAGE) and immunostained with anti-NCT (NCT164), anti-PS1-NTF (MAB1563), anti-PS1-CTF (MAB5232), anti-HA (3F10), or anti-Flag (M2) antibodies." qualityScore="0.8709677419354839" bFilter="false" nerList="11655 11664 11673 11682 11691"/><types:Sentence xmi:id="2979" sofa="12" begin="27527" end="27607" id="151" text="Two independent purifications were performed on each clone with similar results." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="2991" sofa="12" begin="27608" end="27642" id="152" text="A representative dataset is shown." qualityScore="0.8" bFilter="false" nerList=""/><types:Sentence xmi:id="3003" sofa="12" begin="27642" end="27662" id="153" text="doi:10.1371/journal." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="3015" sofa="12" begin="27662" end="27675" id="154" text="pone.0035133." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="3027" sofa="12" begin="27675" end="27698" id="155" text="g004 thumbnailFigure 5." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="3039" sofa="12" begin="27699" end="27801" id="156" text="Enzymatic activity of highly purified ��-secretase complexes with FAD-linked or aspartate PS1 mutants." qualityScore="0.9411764705882353" bFilter="false" nerList="11718 11727"/><types:Sentence xmi:id="3051" sofa="12" begin="27801" end="27957" id="157" text="Equal amounts of the different purified ��-secretase preparations characterized in Figure 4 were tested for activity on C100-Flag, as described in Figure 3." qualityScore="0.9285714285714286" bFilter="false" nerList="11743"/><types:Sentence xmi:id="3063" sofa="12" begin="27958" end="28165" id="158" text="The resulting cleavage products were separated by SDS-PAGE and detected by immunostaining with an anti-Flag antibody (M2) for C100-Flag or AICD-Flag (A), and by sandwich ELISA for A��1���40 or A��1���42 (B)." qualityScore="0.7647058823529411" bFilter="false" nerList="11756 11765 11774"/><types:Sentence xmi:id="3075" sofa="12" begin="28166" end="28328" id="159" text="Note that the levels of A�� produced from FAD-linked ��-secretase complexes were all in the non-linear range of the ELISA standards, close to the detection limit." qualityScore="0.9117647058823529" bFilter="false" nerList="11793"/><types:Sentence xmi:id="3087" sofa="12" begin="28329" end="28428" id="160" text="Whenever possible, A��1���42/A��1���40 ratios were quantified and indicated on the top of the bars." qualityScore="0.7692307692307692" bFilter="false" nerList=""/><types:Sentence xmi:id="3099" sofa="12" begin="28429" end="28522" id="161" text="Two independent purifications were performed on each clone and similar results were obtained." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="3111" sofa="12" begin="28523" end="28557" id="162" text="A representative dataset is shown." qualityScore="0.8" bFilter="false" nerList=""/><types:Sentence xmi:id="3123" sofa="12" begin="28557" end="28577" id="163" text="doi:10.1371/journal." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="3135" sofa="12" begin="28577" end="28590" id="164" text="pone.0035133." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="3147" sofa="12" begin="28590" end="28758" id="165" text="g005 Discussion Top Several conflicting results as to how Alzheimer's disease-linked mutations in PSEN1 affect the processing of APP by ��-secretase have been reported." qualityScore="0.9655172413793104" bFilter="false" nerList="11809 11818 11827 11836"/><types:Sentence xmi:id="3159" sofa="12" begin="28759" end="28905" id="166" text="First, it has been previously reported that transgenic animals with FAD-linked PS1 mutations show increasing brain levels of A��1���42 [15], [38]." qualityScore="0.8125" bFilter="false" nerList="11858"/><types:Sentence xmi:id="3171" sofa="12" begin="28906" end="29176" id="167" text="Since A��1���42, the first A�� specie deposited in the brain of AD patients [16], [39], is more prone to aggregation when compared to shorter A�� species [40], [41], [42], it has been implicated in the seeding of amyloid plaques in AD patients with PSEN1 mutations [43]." qualityScore="0.8194444444444444" bFilter="false" nerList="11871"/><types:Sentence xmi:id="3183" sofa="12" begin="29177" end="29352" id="168" text="This was further validated in vivo as the overexpression of PS1 mutants in APP transgenic mice accelerated the rate of A�� accumulation and deposition in the brain [44], [45]." qualityScore="0.8857142857142857" bFilter="false" nerList="11884 11893"/><types:Sentence xmi:id="3195" sofa="12" begin="29353" end="29529" id="169" text="However, Bentahir and colleagues challenged this view by showing that several PSEN1 mutations were also capable to decrease total A�� production in PS1/PS2 knockout cells [23]." qualityScore="0.935483870967742" bFilter="false" nerList="11909"/><types:Sentence xmi:id="3207" sofa="12" begin="29530" end="29638" id="170" text="These findings suggested that endogenous PS1 and PS2 may influence the mutant phenotype in cells or in vivo." qualityScore="1.0" bFilter="false" nerList="11922 11931"/><types:Sentence xmi:id="3219" sofa="12" begin="29639" end="29782" id="171" text="By extension, we hypothesized that the other components of ��-secretase, namely APH1, NCT and PEN2, may influence the mutant phenotype as well." qualityScore="0.9655172413793104" bFilter="false" nerList="11947 11956 11965 11974"/><types:Sentence xmi:id="3231" sofa="12" begin="29783" end="30005" id="172" text="Indeed, ��-secretase complexes are heterogeneous in composition due to the existence of two human APH1 genes, APH1a and APH1b, and two splicing isoforms of APH1a (S and L), as well as two presenilin genes, PSEN1 and PSEN2." qualityScore="0.9574468085106383" bFilter="false" nerList="11996 12005 12014 12023 12032 12041 12050 12059"/><types:Sentence xmi:id="3243" sofa="12" begin="30006" end="30138" id="173" text="Therefore, it is plausible that a single mutation in PSEN1 confers different catalytic properties to distinct ��-secretase subtypes." qualityScore="1.0" bFilter="false" nerList="12093"/><types:Sentence xmi:id="3255" sofa="12" begin="30139" end="30246" id="174" text="This hypothesis is supported by recent investigations showing that APH1 variants can modulate A�� profiles." qualityScore="0.9411764705882353" bFilter="false" nerList="12106"/><types:Sentence xmi:id="3267" sofa="12" begin="30247" end="30391" id="175" text="When compared to APH1aS or L, overexpression of APH1b in MEF knockout for all APH1 genes led to increased production of longer A�� species [24]." qualityScore="0.8620689655172413" bFilter="false" nerList="12119 12128 12137"/><types:Sentence xmi:id="3279" sofa="12" begin="30392" end="30570" id="176" text="With this regard, it is important to note that all four mouse variants of APH1 are expressed in the MEF cell line used in previous studies [23] and employed here (cf. Figure S3)." qualityScore="0.9473684210526316" bFilter="false" nerList="12156"/><types:Sentence xmi:id="3291" sofa="12" begin="30571" end="30952" id="177" text="Since the phenotype of PS1 mutations have mainly been assessed in vivo or in cell-based systems, we investigated the effects of FAD-linked PS1 mutants on the processing of APP-CTFs in cell-free systems, by using semi-purified and purified enzymatic complexes isolated from MEF PS1/PS2 double knockout cells stably overexpressing differentially tagged human ��-secretase components." qualityScore="0.953125" bFilter="false" nerList="12169 12178 12187 12196 12205"/><types:Sentence xmi:id="3303" sofa="12" begin="30953" end="31176" id="178" text="Under these conditions, the biochemical and functional properties of ��-secretase complexes bearing either FAD-linked PS1 mutants (L166P, ��E9, and P436Q), dominant-negative forms of PS1 or wild-type PS1 were characterized." qualityScore="0.9767441860465116" bFilter="false" nerList="12230 12239 12248 12257"/><types:Sentence xmi:id="3315" sofa="12" begin="31177" end="31420" id="179" text="The activity of ��-secretase with PS1-WT was similar to that reported for ��-secretase purified from our CHO cells overexpressing NCT-V5, APH1aL, Flag-PEN2 and PS1-WT [26], [27], that resulted in A��1���42/A��1���40 ratios between 0.1 and 0.3." qualityScore="0.7575757575757576" bFilter="false" nerList="12279 12288 12297 12306 12315 12324 12333"/><types:Sentence xmi:id="3327" sofa="12" begin="31421" end="31581" id="180" text="In contrast, we found a major loss in the activity of ��-secretase complexes containing either the dominant-negative PS1 variants or the FAD-linked PS1 mutants." qualityScore="0.9666666666666667" bFilter="false" nerList="12364 12373 12382"/><types:Sentence xmi:id="3339" sofa="12" begin="31582" end="31779" id="181" text="Although a total loss of activity was expected for the dominant negative forms of ��-secretase [5], [6], [32], the drastic loss of activity seen here with the FAD-linked PS1 mutants was unexpected." qualityScore="0.9111111111111111" bFilter="false" nerList="12401"/><types:Sentence xmi:id="3351" sofa="12" begin="31780" end="31964" id="182" text="Indeed, the PS1-L166P variant has previously been reported to increase A��1���42 levels both in vivo [46] and in vitro [20], in the presence of endogenous PS1, PS2 and APH1 components." qualityScore="0.8837209302325582" bFilter="false" nerList="12414 12423 12432 12441 12450"/><types:Sentence xmi:id="3363" sofa="12" begin="31965" end="32101" id="183" text="In contrast, Bentahir and colleagues found that PS1-L166P decreased both A��1���40 and A��1���42 production in a PS knockout background." qualityScore="0.7741935483870968" bFilter="false" nerList="12475 12484"/><types:Sentence xmi:id="3375" sofa="12" begin="32102" end="32250" id="184" text="These results are consistent with our in vitro data, although the reduction in A��1���42 and A��1���40 production was more pronounced in our system." qualityScore="0.8235294117647058" bFilter="false" nerList="12500 12509"/><types:Sentence xmi:id="3387" sofa="12" begin="32251" end="32383" id="185" text="However, they differ from our cell-based data in which we observed an increase in A��1���42 associated with a decrease in A��1���40." qualityScore="0.8181818181818181" bFilter="false" nerList=""/><types:Sentence xmi:id="3399" sofa="12" begin="32384" end="32541" id="186" text="Taken together, these data suggest that the overexpression of the other human components of ��-secretase can influence the phenotype of FAD-linked mutations." qualityScore="0.962962962962963" bFilter="false" nerList="12526"/><types:Sentence xmi:id="3411" sofa="12" begin="32542" end="32725" id="187" text="Another possible explanation for these discrepancies comes from the use, in previously described cellular systems, of APP carrying the Swedish mutation (K670M/N671L) [20], [23], [46]." qualityScore="0.8918918918918919" bFilter="false" nerList="12539"/><types:Sentence xmi:id="3423" sofa="12" begin="32726" end="32859" id="188" text="Initially, this APP variant was shown to enhance the production of all A�� species by favouring its ��-secretase cleavage [47], [48]." qualityScore="0.8709677419354839" bFilter="false" nerList=""/><types:Sentence xmi:id="3435" sofa="12" begin="32860" end="33009" id="189" text="However, Munter and colleagues recently demonstrated that the APP Swedish mutation can also affect the specificity of the ��-secretase cleavage [49]." qualityScore="0.9230769230769231" bFilter="false" nerList="12553"/><types:Sentence xmi:id="3447" sofa="12" begin="33010" end="33235" id="190" text="In particular, these authors showed that over-expression of APP Swedish in a neuronal cell line led to a 4-fold increase in secreted A��42, associated with only a 2-fold increase of total A��, compared with the wild-type APP." qualityScore="0.8541666666666666" bFilter="false" nerList=""/><types:Sentence xmi:id="3459" sofa="12" begin="33236" end="33396" id="191" text="Therefore, one cannot exclude the possibility of differential interactions between PS1-WT or PS1 variants and different APP variants, as suggested earlier [50]." qualityScore="0.8846153846153846" bFilter="false" nerList="12567"/><types:Sentence xmi:id="3471" sofa="12" begin="33396" end="33671" id="192" text="As far as the PS1-��E9 mutant is concerned, previous cell-based studies have reported a decrease in A��40 levels associated with an increase in A��42 levels [51], [52], or no changes in A��40 levels despite increased A��42 levels [53], or a decrease in both A�� species [23]." qualityScore="0.8169014084507042" bFilter="false" nerList="12580 12589 12598 12607"/><types:Sentence xmi:id="3483" sofa="12" begin="33672" end="33929" id="193" text="In the present study, A��1���40, A��1���42, as well as AICD levels generated from purified ��-secretase complexes with PS1-��E9 were close to the limit of detection, resulting in a loss of at least 95% of the ��-secretase activity compared to wild-type PS1." qualityScore="0.8787878787878788" bFilter="false" nerList="12629 12638 12647 12656 12665 12674 12683"/><types:Sentence xmi:id="3495" sofa="12" begin="33930" end="34080" id="194" text="Similarly, we found a near to complete loss of ��-secretase activity for complexes with the aggressive PS1-P436Q mutant (mean onset: 28.3 years) [54]." qualityScore="0.9090909090909091" bFilter="false" nerList="12714 12723"/><types:Sentence xmi:id="3507" sofa="12" begin="34081" end="34238" id="195" text="Consistent with a recent study [35], and in contrast to PS1-L166P, the maturation of the full-length PS1-P436Q protein into PS1-NTF and PS1-CTF was impaired." qualityScore="0.9090909090909091" bFilter="false" nerList="12739 12748 12757 12766"/><types:Sentence xmi:id="3519" sofa="12" begin="34239" end="34566" id="196" text="Interestingly, the same study also reported that P436Q variant showed a decreased ��-secretase activity and A��40 and A��42 secretion in PS1/PS2 double knockout cells (~75% or ~50% of the control for A��40 or A��42, respectively), but to a lesser extent than what we measured in this study (more than 97% for both A�� species)." qualityScore="0.8481012658227848" bFilter="false" nerList="12788 12797 12806 12815 12824"/><types:Sentence xmi:id="3531" sofa="12" begin="34566" end="34792" id="197" text="Overall, our data show that, under our experimental conditions, the FAD-linked PS1 mutants cause a drastic loss of activity (at least 90%) in the highly purified and homogeneous as well as semi-purified ��-secretase complexes." qualityScore="0.9555555555555556" bFilter="false" nerList="12849 12858"/><types:Sentence xmi:id="3543" sofa="12" begin="34793" end="34903" id="198" text="This loss-of-function is asymmetrical as A��1���42 levels were relatively less affected than A��1���40 levels." qualityScore="0.7692307692307692" bFilter="false" nerList="12874 12883"/><types:Sentence xmi:id="3555" sofa="12" begin="34904" end="35045" id="199" text="Interestingly, the ratio between the two A�� species was similar for the variants tested here (~1), suggesting a common modulatory mechanism." qualityScore="0.9285714285714286" bFilter="false" nerList=""/><types:Sentence xmi:id="3567" sofa="12" begin="35046" end="35264" id="200" text="Our findings further support a model in which the subtype of ��-secretase containing APH1aL and FAD-linked PS1 mutants generates a higher A��42/A��40 ratio compared to PS1-WT, as previously observed in vivo [15], [38]." qualityScore="0.8333333333333334" bFilter="false" nerList="12900 12909 12918 12927"/><types:Sentence xmi:id="3579" sofa="12" begin="35265" end="35511" id="201" text="Taken together, the overall reduction in A�� levels strongly suggest that other regulatory mechanisms or cellular components may exist and account for the strong amyloid pathology observed in AD patients carrying these FAD-linked PSEN1 mutations." qualityScore="0.9230769230769231" bFilter="false" nerList="12949 12958"/><types:Sentence xmi:id="3591" sofa="12" begin="35512" end="35682" id="202" text="In agreement with this hypothesis, we report that the phenotype of FAD-linked PSEN1 mutations is different whether we consider the cell-based or the cell-free conditions." qualityScore="0.9655172413793104" bFilter="false" nerList="12974"/><types:Sentence xmi:id="3603" sofa="12" begin="35683" end="35815" id="203" text="Indeed, even if A��42/A��40 ratios were globally increased in both experimental conditions, A�� production was strikingly different." qualityScore="0.8076923076923077" bFilter="false" nerList=""/><types:Sentence xmi:id="3615" sofa="12" begin="35815" end="35947" id="204" text="One possible explanation would be that specific subtypes of ��-secretase complexes are less affected than others by PSEN1 mutations." qualityScore="1.0" bFilter="false" nerList="12988 12997"/><types:Sentence xmi:id="3627" sofa="12" begin="35948" end="36079" id="205" text="For instance, it remains unknown whether ��-secretase complexes carrying APH1b or APH1aS are similarly affected by PSEN1 mutations." qualityScore="1.0" bFilter="false" nerList="13013 13022 13031"/><types:Sentence xmi:id="3639" sofa="12" begin="36080" end="36371" id="206" text="In support to that regard, Winkler and colleagues recently purified human ��-secretase with PS1-L166P and observed that such complexes, containing both APH1a and AHP1b, led to increased A��1���42 production associated with decreased A��1���40 production, as compared to the PS1-WT complexes." qualityScore="0.8813559322033898" bFilter="false" nerList="13050 13059 13068 13077 13086 13095"/><types:Sentence xmi:id="3651" sofa="12" begin="36372" end="36595" id="207" text="Another possible explanation would be that purified ��-secretase complexes lack binding partners modulating the processing of APP-based substrates, due to purification conditions affecting physical interactions of proteins." qualityScore="0.96875" bFilter="false" nerList="13123"/><types:Sentence xmi:id="3663" sofa="12" begin="36596" end="36691" id="208" text="These include TMP21 or the recently reported ��-secretase activating protein (GSAP) [12], [13]." qualityScore="0.8636363636363636" bFilter="false" nerList="13136 13145"/><types:Sentence xmi:id="3675" sofa="12" begin="36692" end="36756" id="209" text="Further biochemical analyses are needed to test this hypothesis." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="3687" sofa="12" begin="36756" end="36860" id="210" text="The loss of activity in ��-secretase containing PS1 variants also leads to decreased generation of AICD." qualityScore="0.9473684210526316" bFilter="false" nerList="13162 13171"/><types:Sentence xmi:id="3699" sofa="12" begin="36861" end="37087" id="211" text="As AICD is involved in the transcriptional regulation of several genes, including the neprilysin [55], and the lipoprotein receptor, LRP1 [11], it is likely that mutations in PSEN1 impair the regulation of these genes in vivo." qualityScore="0.9318181818181819" bFilter="false" nerList="13187 13196"/><types:Sentence xmi:id="3711" sofa="12" begin="37088" end="37225" id="212" text="For instance, it is possible that unknown genes transcriptionally regulated in vivo by the AICD might influence A�� metabolism in return." qualityScore="0.9166666666666666" bFilter="false" nerList="13212"/><types:Sentence xmi:id="3723" sofa="12" begin="37226" end="37458" id="213" text="In support to these views, Veeraraghavalu and colleagues recently demonstrated that Notch signalling was impaired in transgenic mice overexpressing PS1 mutants, albeit in the presence of endogenous PS1-WT and all APH1 isoforms [56]." qualityScore="0.9459459459459459" bFilter="false" nerList="13225 13234 13243 13252"/><types:Sentence xmi:id="3735" sofa="12" begin="37459" end="37684" id="214" text="They found decreased self-renewal and differentiation of neuronal precursor cells in the subventricular zone, suggesting that the loss-of-function phenotype of PSEN1 mutations can also be observed in heterogeneous conditions." qualityScore="1.0" bFilter="false" nerList="13274"/><types:Sentence xmi:id="3747" sofa="12" begin="37685" end="37909" id="215" text="These results are reminiscent of the previous report from Saura and colleagues showing that conditional inactivation of both presenilins in vivo induces age-dependent neurodegeneration associated with memory impairment [57]." qualityScore="0.967741935483871" bFilter="false" nerList=""/><types:Sentence xmi:id="3759" sofa="12" begin="37910" end="38076" id="216" text="Altogether, the above-described data suggest that alternative pathways of neurodegeneration related to loss of ��-secretase functions are possible and relevant to AD." qualityScore="0.962962962962963" bFilter="false" nerList="13288"/><types:Sentence xmi:id="3771" sofa="12" begin="38077" end="38232" id="217" text="They further support the concept that modulating rather than inhibiting ��-secretase activity would be a more appropriate therapeutic strategy for AD [58]." qualityScore="0.9230769230769231" bFilter="false" nerList="13301"/><types:Sentence xmi:id="3783" sofa="12" begin="38233" end="38443" id="218" text="Supporting this view, the ��-secretase inhibitor Semagacestat tested in phase III clinical trials not only failed to slow cognitive decline in patients with mild-to-moderate AD, but actually made it worse [59]." qualityScore="0.9230769230769231" bFilter="false" nerList="13314"/><types:Sentence xmi:id="3795" sofa="12" begin="38443" end="38708" id="219" text="Collectively, our findings support a model in which FAD-linked mutations in PSEN1 likely induce A�� pathology by perturbing the relative ratio between A�� species and by impairing developmental and cellular signalling pathways controlled by ��-secretase substrates." qualityScore="0.9333333333333333" bFilter="false" nerList="13327 13336"/><types:Sentence xmi:id="3807" sofa="12" begin="38709" end="38821" id="220" text="This deleterious dual effect might explain why FAD-linked PSEN1 mutations cause early onset Alzheimer's disease." qualityScore="0.9411764705882353" bFilter="false" nerList="13352"/><types:Sentence xmi:id="3819" sofa="12" begin="38822" end="39204" id="221" text="Since it has been established that A�� and AICD are generated following the processing by ��-secretase at two distinct gamma- and epsilon-cleavage sites in APP [60], further investigation is now required to better understand whether and how FAD mutations in PS1 differentially affect the epsilon versus gamma-cleavage sites in APP, as well as in other known ��-secretase substrates." qualityScore="0.9178082191780822" bFilter="false" nerList="13365 13374 13383 13392 13401 13410 13419 13428"/><types:Sentence xmi:id="3831" sofa="12" begin="39204" end="39429" id="222" text="Materials and Methods Top DNA Constructs and mutagenesisNCT-V5, Flag-PEN2, APH1aL-HA, wild-type PS1 human cDNAs (PS1-WT) were obtained from D. Selkoe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA)." qualityScore="0.8468085106382979" bFilter="false" nerList="13462 13471 13480 13489 13498"/><types:Sentence xmi:id="3843" sofa="12" begin="39430" end="39515" id="223" text="PS1 ��E9 cDNA was obtained from C. Saura (Universitat Aut��noma de Barcelona, Spain)." qualityScore="0.95" bFilter="false" nerList="13523"/><types:Sentence xmi:id="3855" sofa="12" begin="39516" end="39649" id="224" text="PS1 D257A and PS1 D385A cDNAs were obtained from M. Wolfe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA)." qualityScore="0.8928571428571429" bFilter="false" nerList="13536 13545"/><types:Sentence xmi:id="3867" sofa="12" begin="39650" end="40127" id="225" text="Mutations in PSEN1, namely, L166P and P436Q, were generated by PCR-based mutagenesis on the plasmid pcDNA3.1/Zeo(+)-PS1-WT using T7 or BGH primers (specific to the plasmid DNA sequence) together with the corresponding primers: L166P Rv: 5��� CAG CAA CAA Taa gct tGA TAT AAT AGG 3���; L166P Fw: 5��� CTT ATT ATA TCa agc ttA TTG TTG CTG 3���; P436Q Rv: 5��� TCG AGT TTA Gaa gct tTC TTG AAA ATG GCA AGG AG 3���; P436Q Fw: 5��� TCG AGT TTA Gaa gct tTG CCA GCT CTT CAA ATC TCC 3���." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="3879" sofa="12" begin="40128" end="40211" id="226" text="The sequences corresponding to enzyme restriction sites are given in small letters." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="3891" sofa="12" begin="40212" end="40330" id="227" text="The PCR fragments were next digested with BamHI/HindIII and HindIII/XhoI respectively, and were subcloned into pcDNA3." qualityScore="0.8842105263157894" bFilter="false" nerList="13562 13571"/><types:Sentence xmi:id="3903" sofa="12" begin="40331" end="40450" id="228" text="PS1 D257A/D385A (DDAA) was obtained by subcloning the DraI/XhoI digested fragment of PS1 D385A into pcDNA3.1-PS1 D257A." qualityScore="0.9130434782608696" bFilter="false" nerList="13587 13596 13605"/><types:Sentence xmi:id="3915" sofa="12" begin="40451" end="40924" id="229" text="The APP based substrate SPA4CT-Flag, corresponding to the signal peptide of APP fused to the APP-C99-Flag with a small linker region (DA) [36], was obtained by removing the HindIII/EcoRI fragment of pcDNA3-APP695-Flag and inserting the following annealed primers: 5��� AGC TTA TGC TGC CCG GTT TG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT CGG GCG GAT GCA GAT GCA G 3��� and 5��� AAT TCT GCA TCT GCA TCC GCC CGA GCC GTC CAG GCG GCC AGC AGG AGC AGT GCC AAA CCG GGC AGC ATA 3���." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="3927" sofa="12" begin="40925" end="41097" id="230" text="All constructs were next subcloned into the self-inactivated vector pSIN-PGK-WHV cassette (a kind gift from R. Zufferey, Brain Mind Institute, EPFL, Lausanne, Switzerland)." qualityScore="0.875" bFilter="false" nerList=""/><types:Sentence xmi:id="3939" sofa="12" begin="41098" end="41206" id="231" text="Inserts for plasmids pET21-C100-Flag, and pET21-C100-His were generated by PCR as previously described [27]." qualityScore="0.9" bFilter="false" nerList="13625 13634"/><types:Sentence xmi:id="3951" sofa="12" begin="41207" end="41316" id="232" text="Plasmids pMD2G and psPAX2 were obtained from D. Trono (Global Health Institute, EPFL, Lausanne, Switzerland)." qualityScore="0.9" bFilter="false" nerList=""/><types:Sentence xmi:id="3963" sofa="12" begin="41316" end="41502" id="233" text="Lentivector productionReplication-defective lentiviral particles were produced by a three-plasmid transient transfection of cells from the human embryonic kidney HEK 293T cell line [61]." qualityScore="0.9230769230769231" bFilter="false" nerList=""/><types:Sentence xmi:id="3975" sofa="12" begin="41503" end="41775" id="234" text="Briefly, cells were incubated in 10 cm dishes until they reached 70% confluence and were transiently co-transfected by the calcium phosphate method, with 5 ��g of envelope plasmid (pMD2G), 15 ��g of packaging plasmid (psPAX2), and 20 ��g of vector plasmids (pSIN-PGK-WHV)." qualityScore="0.8852459016393442" bFilter="false" nerList="13652"/><types:Sentence xmi:id="3987" sofa="12" begin="41776" end="41942" id="235" text="Cells were incubated overnight with DNA-calcium precipitates, washed twice with Dulbecco's modified Eagle's medium (DMEM, Invitrogen) and incubated with 7 mL of DMEM." qualityScore="0.8666666666666667" bFilter="false" nerList=""/><types:Sentence xmi:id="3999" sofa="12" begin="41943" end="42165" id="236" text="After 24 h, the conditioned medium was harvested and cells were incubated a second time with 7 mL of DMEM for 24 h. Media were then pooled, passed through 0.45 ��m filter, and stored at ���80��C as 2 mL aliquots until use." qualityScore="0.8333333333333334" bFilter="false" nerList=""/><types:Sentence xmi:id="4011" sofa="12" begin="42166" end="42302" id="237" text="A p24 ELISA (Zeptometrix corporation) was performed on each batch of media in order to evaluate the number of viral particles generated." qualityScore="0.9166666666666666" bFilter="false" nerList="13667"/><types:Sentence xmi:id="4023" sofa="12" begin="42302" end="42667" id="238" text="Generation of stable cell lines through multiple gene transductionsMouse Embryonic Fibroblasts (MEFs, obtained from B. De Strooper, Flanders University Institute of Biotechnology, Belgium) defective in PSEN1 and PSEN2 [30], [31] were cultivated in 10 cm dishes in DMEM, supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin (P/S) (Invitrogen)." qualityScore="0.8695652173913043" bFilter="false" nerList="13680 13689"/><types:Sentence xmi:id="4035" sofa="12" begin="42668" end="42849" id="239" text="A first set of stable cell lines was generated by co-transducing NCT-V5, APH1aL-HA, and Flag-PEN2 containing lentiviral vectors (LV) repeatedly for two weeks at each passage (1/20)." qualityScore="0.8378378378378378" bFilter="false" nerList="13705 13714"/><types:Sentence xmi:id="4047" sofa="12" begin="42850" end="42999" id="240" text="Ten clones were isolated by the limiting dilution method and were further screened for NCT-V5, Flag-PEN2 and APH1aL-HA expression by immunodetection." qualityScore="0.92" bFilter="false" nerList="13730 13739 13748"/><types:Sentence xmi:id="4059" sofa="12" begin="43000" end="43336" id="241" text="The clone that showed the highest expression of the three proteins (designated �� - PS1/2) was used as the parental cell line to generate the stable cell lines expressing different PS1 variants, by the same method and by using lentiviral vectors carrying human PS1-WT, PS1-L166P, PS1-��E9, PS1-P436Q, PS1-D257A, PS1-D385A, and PS1-DDAA." qualityScore="0.9589041095890412" bFilter="false" nerList="13767 13776 13785 13794 13803 13812 13821 13830"/><types:Sentence xmi:id="4071" sofa="12" begin="43337" end="43477" id="242" text="For each PS1 variant, five clones were selected for a full characterization and two of them were further used for ��-secretase purification." qualityScore="1.0" bFilter="false" nerList="13864"/><types:Sentence xmi:id="4083" sofa="12" begin="43478" end="43957" id="243" text="For SPA4CT overexpression experiments, 500,000 cells of each clone were exposed to the same arbitrary dose of lentiviral vectors carrying human SPA4CT-Flag in 2 mL of DMEM, 1% FBS, P/S and were plated in 6-wells plates for 72 h. The medium was next replaced by fresh DMEM, 2% FBS, P/S for 24 h. Finally, cell culture medium was harvested, supplemented with protease inhibitor cocktail (Roche), centrifuged for 3 min at 1,000�� rpm and frozen at ���80��C until further processing." qualityScore="0.8018867924528301" bFilter="false" nerList="13877 13886 13895"/><types:Sentence xmi:id="4095" sofa="12" begin="43958" end="44019" id="244" text="Cells were washed in PBS and submitted to protein extraction." qualityScore="0.9" bFilter="false" nerList=""/><types:Sentence xmi:id="4107" sofa="12" begin="44019" end="44605" id="245" text="Protein extractionTotal protein extracts were prepared in 1% NP40 - HEPES buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche), and were clarified by centrifugation for 1 h at 16,000�� g, 4��C. Cell membranes were obtained as described below and solubilised in 1% CHAPSO - HEPES buffer and centrifuged at 16,000�� g for 1 h. Supernatants corresponding to the microsomal protein extracts were harvested and stored at ���80��C. Protein content of the extracts was estimated by the BCA protein assay reagent kit (Pierce)." qualityScore="0.8203125" bFilter="false" nerList="13915 13924 13933"/><types:Sentence xmi:id="4119" sofa="12" begin="44605" end="44718" id="246" text="Multi-step purification of human ��-secretase complexes with FAD-linked PS1 variants1) Cell membrane preparation." qualityScore="0.9473684210526316" bFilter="false" nerList="13952 13961"/><types:Sentence xmi:id="4131" sofa="12" begin="44719" end="45104" id="247" text="MEF PS1/PS2 DKO cells (1.0��109 cells) expressing NCT-V5, Flag-PEN2, APH1aL-HA and different forms of PS1: wild type (WT), or with FAD-linked variants or lacking the critical aspartate residues, were collected from 15 cm dishes and fully resuspended in 40 mL of MES buffer (50 mM MES, pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche)." qualityScore="0.7865168539325843" bFilter="false" nerList="13977 13986 13995 14004 14013 14022"/><types:Sentence xmi:id="4143" sofa="12" begin="45105" end="45253" id="248" text="Next, cells were passed four times through a high-pressure homogenizer (Emulsiflex-C5, Avestin Inc, ON Canada) at a pressure greater than 1,000 psi." qualityScore="0.9" bFilter="false" nerList="14050"/><types:Sentence xmi:id="4155" sofa="12" begin="45254" end="45389" id="249" text="Nuclei and unbroken cells were removed by centrifugation at 3,000�� g for 20 min at 4��C in a Beckman Coulter Allegra X-15R centrifuge." qualityScore="0.7931034482758621" bFilter="false" nerList=""/><types:Sentence xmi:id="4167" sofa="12" begin="45390" end="45587" id="250" text="The supernatant was collected and centrifuged at 100,000�� g for 1 h at 4��C in a SW32Ti rotor using a Beckman Coulter Optima L-80 ultracentrifuge to recover the membrane preparation in the pellet." qualityScore="0.8205128205128205" bFilter="false" nerList=""/><types:Sentence xmi:id="4179" sofa="12" begin="45588" end="45608" id="251" text="2) Bicarbonate wash." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4191" sofa="12" begin="45609" end="45800" id="252" text="The membrane pellet was fully resuspended in 1.6 mL of ice cold sodium bicarbonate buffer (0.1 M NaHCO3, pH 11.3) by pipetting up and down at least 30 times, and incubated at 4��C for 20 min." qualityScore="0.7555555555555555" bFilter="false" nerList=""/><types:Sentence xmi:id="4203" sofa="12" begin="45801" end="45908" id="253" text="The washed membranes were then centrifuged at 100,000�� g for 1 h at 4��C and stored at ���80��C until use." qualityScore="0.7666666666666666" bFilter="false" nerList=""/><types:Sentence xmi:id="4215" sofa="12" begin="45909" end="45953" id="254" text="3) Solubilisation of ��-secretase complexes." qualityScore="0.8888888888888888" bFilter="false" nerList="14067"/><types:Sentence xmi:id="4227" sofa="12" begin="45954" end="46091" id="255" text="The bicarbonate-washed membranes were fully resuspended in 1.7 mL of 1% CHAPSO - HEPES buffer by pipetting up and down at least 30 times." qualityScore="0.7857142857142857" bFilter="false" nerList=""/><types:Sentence xmi:id="4239" sofa="12" begin="46092" end="46289" id="256" text="The membranes were then incubated at 4��C for 1 h. To pellet the insoluble material, the solution was centrifuged at 16,000�� g at 4��C for 1 h, the pellet was discarded, and the supernatant saved." qualityScore="0.8260869565217391" bFilter="false" nerList=""/><types:Sentence xmi:id="4251" sofa="12" begin="46290" end="46359" id="257" text="This lysate is defined as ���solubilised ��-secretase preparation���." qualityScore="1.0" bFilter="false" nerList="14082"/><types:Sentence xmi:id="4263" sofa="12" begin="46360" end="46495" id="258" text="Next, these freshly prepared solubilised preparations were used for affinity purification of ��-secretase complexes as described below." qualityScore="1.0" bFilter="false" nerList="14095"/><types:Sentence xmi:id="4275" sofa="12" begin="46496" end="46534" id="259" text="4) Anti-Flag M2 affinity purification." qualityScore="0.8571428571428572" bFilter="false" nerList="14108"/><types:Sentence xmi:id="4287" sofa="12" begin="46535" end="46960" id="260" text="The solubilised ��-secretase preparations were first diluted 1:2 with HEPES buffer, and further diluted 1:6 with 0.1% digitonin - TBS buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) (final detergent concentration: 0.08% CHAPSO, 0.08% digitonin) and incubated overnight at 4��C with agitation after adding 200 ��L of anti-Flag M2 affinity resin beads (Sigma-Aldrich) that had been pre-equilibrated in 0.1% Digitonin - TBS buffer." qualityScore="0.7575757575757576" bFilter="false" nerList="14121 14130"/><types:Sentence xmi:id="4299" sofa="12" begin="46961" end="47145" id="261" text="The beads were washed 3 times in the same buffer, and the bound proteins were eluted over 4 h at 4��C with 0.4 mL of this buffer containing 200 ��g/mL of Flag peptides (Sigma-Aldrich)." qualityScore="0.8372093023255813" bFilter="false" nerList=""/><types:Sentence xmi:id="4311" sofa="12" begin="47146" end="47284" id="262" text="This elution step was repeated once for 1 h at 4��C and the eluted fractions were pooled and designated ���M2 pooled 800 ��L fractions���." qualityScore="0.8387096774193549" bFilter="false" nerList=""/><types:Sentence xmi:id="4323" sofa="12" begin="47285" end="47318" id="263" text="5) Anti-V5 affinity purification." qualityScore="0.8333333333333334" bFilter="false" nerList=""/><types:Sentence xmi:id="4335" sofa="12" begin="47319" end="47563" id="264" text="The M2 pooled fractions (volume made up to 1 mL with 0.1% Digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-V5 affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin-TBS buffer." qualityScore="0.8035714285714286" bFilter="false" nerList="14149"/><types:Sentence xmi:id="4347" sofa="12" begin="47564" end="47745" id="265" text="The beads were washed 3 times in the same buffer, and the bound proteins were eluted for 1 h at 4��C with 0.4 mL of this buffer containing 500 ��g/mL of V5 peptides (Sigma-Aldrich)." qualityScore="0.8372093023255813" bFilter="false" nerList="14162"/><types:Sentence xmi:id="4359" sofa="12" begin="47746" end="47871" id="266" text="This elution step was repeated 4 times, and the eluted fractions were pooled and designated ���V5 pooled 1.6 mL fractions���." qualityScore="0.88" bFilter="false" nerList="14175"/><types:Sentence xmi:id="4371" sofa="12" begin="47872" end="47905" id="267" text="6) Anti-HA affinity purification." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4383" sofa="12" begin="47906" end="48184" id="268" text="As a final purification step, the V5 pooled fractions (volume made up to 1.8 mL with 0.1% digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-HA affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin - TBS buffer." qualityScore="0.8" bFilter="false" nerList=""/><types:Sentence xmi:id="4395" sofa="12" begin="48185" end="48368" id="269" text="The beads were washed 3 times in the same buffer, and the bound proteins were eluted overnight at 4��C with 0.2 mL of this buffer containing 200 ��g/mL of HA peptides (Sigma-Aldrich)." qualityScore="0.8292682926829268" bFilter="false" nerList="14189"/><types:Sentence xmi:id="4407" sofa="12" begin="48369" end="48531" id="270" text="This elution step was repeated once, for 1 h at 4��C, and the two eluted fractions were kept separately, designated ���HA fraction E1��� and ���HA fraction E2���." qualityScore="0.8780487804878049" bFilter="false" nerList=""/><types:Sentence xmi:id="4419" sofa="12" begin="48531" end="48606" id="271" text="Co-immunoprecipitationCo-IPs were performed on microsomal protein extracts." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="4431" sofa="12" begin="48607" end="48848" id="272" text="Briefly, 100 ��g of proteins were diluted in a final volume of 1 mL of 1% CHAPSO - HEPES extraction buffer containing protease inhibitors (Roche), and 50 ��L of pre-equilibrated anti-Flag or anti-HA affinity beads (Sigma-Aldrich) were added." qualityScore="0.8518518518518519" bFilter="false" nerList="14204 14213"/><types:Sentence xmi:id="4443" sofa="12" begin="48849" end="48972" id="273" text="Samples were next incubated overnight at 4��C on a rotator wheel and were washed three times in 0.2% CHAPSO - HEPES buffer." qualityScore="0.7777777777777778" bFilter="false" nerList=""/><types:Sentence xmi:id="4455" sofa="12" begin="48973" end="49092" id="274" text="Finally, beads were resuspended in 50 ��L of 0.2% CHAPSO - HEPES buffer and were used for in vitro ��-secretase assays." qualityScore="0.8" bFilter="false" nerList="14230"/><types:Sentence xmi:id="4467" sofa="12" begin="49092" end="49211" id="275" text="In vitro ��-secretase activity assaysIn vitro ��-secretase activity assays were performed as previously described [27]." qualityScore="0.9545454545454546" bFilter="false" nerList="14243 14252"/><types:Sentence xmi:id="4479" sofa="12" begin="49214" end="49607" id="276" text="-Secretase APP-based substrates were expressed in E. coli transfected with plasmids pET21-C100-Flag or pET21-C100-His as a fusion protein consisting of a Met for translation initiation, and either the Flag tag sequence (C100-Flag) or the His tag sequence (C100-His), and were affinity purified using an anti-Flag resin (M2, Sigma-Aldrich) or an Ni-NTA agarose resin (Invitrogen), respectively." qualityScore="0.9620253164556962" bFilter="false" nerList="14268 14277 14286"/><types:Sentence xmi:id="4491" sofa="12" begin="49608" end="49765" id="277" text="In vitro assays were performed at 37��C for 4 h, with 1 ��M of recombinant substrate, 0.025% phosphatidylethanolamine (PE) and 0.1% phosphatidylcholine (PC)." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4503" sofa="12" begin="49768" end="50202" id="278" text="-Secretase activity was quantified by measuring the amount of AICD and A�� generated during the reaction, by immunoblot or sandwich ELISA respectively, as described below.SDS-PAGE, Native PAGE, Western blotting and antibodiesTotal or microsomal protein extracts were resolved by electrophoresis on NuPAGE�� Novex�� 4���12% Bis-Tris Gels (Invitrogen) or on standard 12% acrylamide/bisacrylamide Tris Glycine gels for SDS-PAGE analysis." qualityScore="0.8625" bFilter="false" nerList="14305 14314 14323"/><types:Sentence xmi:id="4515" sofa="12" begin="50203" end="50352" id="279" text="Purified ��-secretase was resolved by electrophoresis on NativePAGE��� Novex�� Bis-Tris 4���16% Gels for Blue Native (BN)-PAGE analysis (Invitrogen)." qualityScore="0.8857142857142857" bFilter="false" nerList="14342"/><types:Sentence xmi:id="4527" sofa="12" begin="50353" end="50447" id="280" text="Silver staining was performed directly on gel according to manufacturer instructions (Biorad)." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="4539" sofa="12" begin="50448" end="50902" id="281" text="For immunoblot analysis, gels were transferred to nitrocellulose or PVDF membranes (Whatman), and probed with the following antibodies: anti-Nicastrin NCT164 (BD Bioscience), anti-V5-tag for NCT-V5 (Covance), MAB1563 (Millipore) or ab10281 (Abcam) for PS1 NTF, MAB5232 for PS1 CTF (Millipore), 3F10 for APH1aL-HA (Roche), anti-Flag M2 for Flag-PEN-2 or C100-Flag (Sigma-Aldrich), A8717 for APP CTF (Sigma-Aldrich), and A2066 for ��-actin (Sigma-Aldrich)." qualityScore="0.9038461538461539" bFilter="false" nerList="14356 14365 14374 14383 14392 14401 14410 14419 14428 14437 14446 14455 14464 14473"/><types:Sentence xmi:id="4551" sofa="12" begin="50903" end="50984" id="282" text="Anti-mouse/rabbit/rat IgG conjugated to Alexa 680 were purchased from Invitrogen." qualityScore="0.9230769230769231" bFilter="false" nerList="14525"/><types:Sentence xmi:id="4563" sofa="12" begin="50985" end="51071" id="283" text="The Odyssey infrared imaging system (LICOR) was used to detect the fluorescent signal." qualityScore="0.9333333333333333" bFilter="false" nerList=""/><types:Sentence xmi:id="4575" sofa="12" begin="51071" end="51248" id="284" text="Quantification of A�� peptidesA�� peptides from the ��-secretase assays described above were quantified by sandwich ELISA according to the protocol provided by the manufacturer." qualityScore="0.935483870967742" bFilter="false" nerList="14539 14548"/><types:Sentence xmi:id="4587" sofa="12" begin="51249" end="51370" id="285" text="Three kits were used to detect human A��1���40(Invitrogen KHB3481) and A��1���42 (Invitrogen KHB3544 and Wako 269-64401)." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4599" sofa="12" begin="51370" end="51407" id="286" text="Supporting Information Top Figure S1." qualityScore="1.0" bFilter="false" nerList="14564"/><types:Sentence xmi:id="4611" sofa="12" begin="51408" end="51511" id="287" text="Characterization of stable cell lines overexpressing human FAD-linked PS1 variants in MEF PS1/2���/���." qualityScore="0.8" bFilter="false" nerList="14577"/><types:Sentence xmi:id="4623" sofa="12" begin="51512" end="51758" id="288" text="Presenilin double-knockout mouse embryonic fibroblasts were stably transduced with lentiviral vectors carrying genes encoding hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned." qualityScore="0.9459459459459459" bFilter="false" nerList="14590"/><types:Sentence xmi:id="4635" sofa="12" begin="51759" end="51821" id="289" text="Two clones per PS1 variant were selected for characterization." qualityScore="1.0" bFilter="false" nerList="14603"/><types:Sentence xmi:id="4647" sofa="12" begin="51822" end="52166" id="290" text="(A) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with various antibodies to detect the endogenous ��-secretase core components: NCT (NCT164), hPS1 (NTF, MAB1563), and PEN2 (UD1), and with an antibody for APP (A8717)." qualityScore="0.88" bFilter="false" nerList="14616 14625 14634 14643 14652 14661 14670"/><types:Sentence xmi:id="4659" sofa="12" begin="52169" end="52206" id="291" text="-Actin was used as a loading control." qualityScore="1.0" bFilter="false" nerList="14701"/><types:Sentence xmi:id="4671" sofa="12" begin="52207" end="52247" id="292" text="Each lane represents one selected clone." qualityScore="1.0" bFilter="false" nerList=""/><types:Sentence xmi:id="4683" sofa="12" begin="52248" end="52356" id="293" text="(B) ��-Secretase activity assays were performed with microsomal extracts prepared in 1% CHAPSO-HEPES buffer." qualityScore="0.8095238095238095" bFilter="false" nerList="14715"/><types:Sentence xmi:id="4695" sofa="12" begin="52357" end="52554" id="294" text="Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag)." qualityScore="0.7560975609756098" bFilter="false" nerList=""/><types:Sentence xmi:id="4707" sofa="12" begin="52555" end="52649" id="295" text="Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563)." qualityScore="0.8947368421052632" bFilter="false" nerList="14729"/><types:Sentence xmi:id="4719" sofa="12" begin="52650" end="52717" id="296" text="PS1 immunostaining was used to assess the amount of input material." qualityScore="1.0" bFilter="false" nerList="14742"/><types:Sentence xmi:id="4731" sofa="12" begin="52718" end="52866" id="297" text="* Indicates a non-specific band, which was not detected in microsomal protein extracts of the same cell lines using the same antibody (MAB1563) (B)." qualityScore="0.9666666666666667" bFilter="false" nerList=""/><types:Sentence xmi:id="4755" sofa="12" begin="53008" end="53023" id="298" text="CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated. (TIF)Figure S2." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4767" sofa="12" begin="53024" end="53121" id="299" text="APP-CTF profiles in WT MEF, MEF PS1/2���/��� and �� - PS1/2 transduced with the SPA4CT construct." qualityScore="0.7666666666666666" bFilter="false" nerList="14756 14765 14774"/><types:Sentence xmi:id="4779" sofa="12" begin="53122" end="53323" id="300" text="WT MEF, MEF PS1/2���/��� and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36])." qualityScore="0.7647058823529411" bFilter="false" nerList="14793 14802 14811 14820"/><types:Sentence xmi:id="4803" sofa="12" begin="53518" end="53533" id="301" text="Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717). (TIF)Figure S3." qualityScore="0.813953488372093" bFilter="false" nerList="14842"/><types:Sentence xmi:id="4815" sofa="12" begin="53534" end="53578" id="302" text="APH1 isoforms expressed in MEF PS1/2���/���." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4827" sofa="12" begin="53579" end="53731" id="303" text="Total RNAs were extracted from presenilin double-knockout MEFs, using standard procedures (Qiagen RNAeasy kit) and were quantified by spectrophotometry." qualityScore="1.0" bFilter="false" nerList="14855"/><types:Sentence xmi:id="4839" sofa="12" begin="53732" end="54072" id="304" text="One microgram of total RNAs was reverse transcribed for 1 h at 42��C by using the ImProm-II reverse transcription system (Promega) and oligo-dT primer in a final volume of 20 ��L. PCR was next performed for each APH1 isoform on 1 ��L of RT reaction by using the Roche PCR kit under standard conditions and the primers described in Table S1." qualityScore="0.8305555555555556" bFilter="false" nerList="14868"/><types:Sentence xmi:id="4851" sofa="12" begin="54073" end="54220" id="305" text="The following cycling conditions were applied for all reactions: 94��C, 3 min; 30 cycles of [94��C, 30 s; 58��C, 30 s; 70��C, 40 s]; 70��C, 10 min." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4875" sofa="12" begin="54315" end="54329" id="306" text="PCR products were separated on a 2% agarose gel and visualized using Alpha Innotech UV imager. (TIF)Table S1." qualityScore="0.7636363636363637" bFilter="false" nerList=""/><types:Sentence xmi:id="4887" sofa="12" begin="54330" end="54387" id="307" text="Primers used to detect APH1 isoforms in MEF PS1/2���/���." qualityScore="0.8" bFilter="false" nerList="14882"/><types:Sentence xmi:id="4911" sofa="12" begin="54411" end="54684" id="308" text="F: Forward, R: Reverse. (DOC)Acknowledgments Top We are grateful to B. De Strooper for the WT and PS1���/��� PS2���/��� KO mouse embryonic fibroblasts, to C. Saura for the PS1 ��E9, to M. Wolfe for the PS1 D257A and PS1 D385A cDNAs, and to D. Selkoe for the APH1aL-HA, NCT-V5, and Flag-PEN2 cDNAs." qualityScore="0.872093023255814" bFilter="false" nerList="14895 14904 14913 14922 14931 14940 14949"/><types:Sentence xmi:id="4923" sofa="12" begin="54685" end="54782" id="309" text="We also thank J.R. Alattia, C. Schweizer, and A. Alahari for critical readings of the manuscript." qualityScore="0.8181818181818181" bFilter="false" nerList=""/><types:Sentence xmi:id="4935" sofa="12" begin="54782" end="54854" id="310" text="Author Contributions Top Conceived and designed the experiments: MC PCF." qualityScore="0.8181818181818181" bFilter="false" nerList=""/><types:Sentence xmi:id="4947" sofa="12" begin="54855" end="54891" id="311" text="Performed the experiments: MC LA JH." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4959" sofa="12" begin="54892" end="54924" id="312" text="Analyzed the data: MC LA JH PCF." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4971" sofa="12" begin="54925" end="54949" id="313" text="Wrote the paper: MC PCF." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4983" sofa="12" begin="54950" end="54986" id="314" text="Edited the manuscript: MC LA JH PCF." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="4995" sofa="12" begin="54987" end="55015" id="315" text="Supervised the project: PCF." qualityScore="0.8" bFilter="false" nerList=""/><types:Sentence xmi:id="5007" sofa="12" begin="55015" end="55241" id="316" text="References Top Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5019" sofa="12" begin="55242" end="55264" id="317" text="Nature 376: 775���778." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5031" sofa="12" begin="55265" end="55452" id="318" text="Find this article online Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5043" sofa="12" begin="55453" end="55475" id="319" text="Nature 375: 754���760." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5055" sofa="12" begin="55476" end="55623" id="320" text="Find this article online Weihofen A, Martoglio B (2003) Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5067" sofa="12" begin="55624" end="55653" id="321" text="Trends Cell Biol 13: 71���78." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5079" sofa="12" begin="55654" end="55838" id="322" text="Find this article online Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5091" sofa="12" begin="55839" end="55866" id="323" text="Nat Cell Biol 2: 428���434." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5103" sofa="12" begin="55867" end="56076" id="324" text="Find this article online Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5115" sofa="12" begin="56077" end="56099" id="325" text="Nature 398: 513���517." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5127" sofa="12" begin="56100" end="56314" id="326" text="Find this article online Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ (2000) The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5139" sofa="12" begin="56315" end="56344" id="327" text="J Biol Chem 275: 3173���3178." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5151" sofa="12" begin="56345" end="56472" id="328" text="Find this article online Beel AJ, Sanders CR (2008) Substrate specificity of gamma-secretase and other intramembrane proteases." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5163" sofa="12" begin="56473" end="56507" id="329" text="Cell Mol Life Sci 65: 1311���1334." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5175" sofa="12" begin="56508" end="56708" id="330" text="Find this article online Bot N, Schweizer C, Ben Halima S, Fraering PC (2010) Processing of the synaptic cell-adhesion molecule neurexin-3{beta} by Alzheimer's disease {alpha}- and {gamma}-secretases." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5187" sofa="12" begin="56709" end="56721" id="331" text="J Biol Chem." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5199" sofa="12" begin="56722" end="56810" id="332" text="Find this article online Parks AL, Curtis D (2007) Presenilin diversifies its portfolio." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5211" sofa="12" begin="56811" end="56838" id="333" text="Trends Genet 23: 140���150." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5223" sofa="12" begin="56839" end="57064" id="334" text="Find this article online Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5235" sofa="12" begin="57065" end="57090" id="335" text="J Neurosci 25: 436���445." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5247" sofa="12" begin="57091" end="57297" id="336" text="Find this article online Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, et al. (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5259" sofa="12" begin="57298" end="57317" id="337" text="Neuron 56: 66���78." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5271" sofa="12" begin="57318" end="57518" id="338" text="Find this article online Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, et al. (2006) TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5283" sofa="12" begin="57519" end="57543" id="339" text="Nature 440: 1208���1212." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5295" sofa="12" begin="57544" end="57707" id="340" text="Find this article online He G, Luo W, Li P, Remmers C, Netzer WJ, et al. (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5307" sofa="12" begin="57708" end="57728" id="341" text="Nature 467: 95���98." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5319" sofa="12" begin="57729" end="57871" id="342" text="Find this article online Wakabayashi T, De Strooper B (2008) Presenilins: members of the gamma-secretase quartets, but part-time soloists too." qualityScore="0.762962962962963" bFilter="false" nerList="14983 14992"/><types:Sentence xmi:id="5331" sofa="12" begin="57872" end="57908" id="343" text="Physiology (Bethesda) 23: 194���204." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5343" sofa="12" begin="57909" end="58140" id="344" text="Find this article online Citron M, Westaway D, Xia W, Carlson G, Diehl T, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5355" sofa="12" begin="58141" end="58160" id="345" text="Nat Med 3: 67���72." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5367" sofa="12" begin="58161" end="58346" id="346" text="Find this article online Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, et al. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5379" sofa="12" begin="58347" end="58371" id="347" text="Neurology 59: 398���407." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5391" sofa="12" begin="58372" end="58534" id="348" text="Find this article online Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, et al. (1998) Increased Abeta42(43) from cell lines expressing presenilin 1 mutations." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5403" sofa="12" begin="58535" end="58560" id="349" text="Ann Neurol 43: 256���258." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5415" sofa="12" begin="58561" end="58767" id="350" text="Find this article online Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, et al. (1999) Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5427" sofa="12" begin="58768" end="58795" id="351" text="Neurosci Lett 265: 61���63." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5439" sofa="12" begin="58796" end="59011" id="352" text="Find this article online Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, et al. (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5451" sofa="12" begin="59012" end="59039" id="353" text="J Neurosci 20: 8717���8726." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5463" sofa="12" begin="59040" end="59294" id="354" text="Find this article online Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5475" sofa="12" begin="59295" end="59336" id="355" text="Proc Natl Acad Sci U S A 99: 8025���8030." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5487" sofa="12" begin="59337" end="59575" id="356" text="Find this article online Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y (2003) Distinct mechanisms by mutant presenilin 1 and 2 leading toincreased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5499" sofa="12" begin="59576" end="59605" id="357" text="Biochemistry 42: 1042���1052." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5511" sofa="12" begin="59606" end="59873" id="358" text="Find this article online Dowjat WK, Kuchna I, Wisniewski T, Wegiel J (2004) A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5523" sofa="12" begin="59874" end="59902" id="359" text="J Alzheimers Dis 6: 31���43." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5535" sofa="12" begin="59903" end="60083" id="360" text="Find this article online Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, et al. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5547" sofa="12" begin="60084" end="60110" id="361" text="J Neurochem 96: 732���742." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5559" sofa="12" begin="60111" end="60301" id="362" text="Find this article online Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, et al. (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5571" sofa="12" begin="60302" end="60325" id="363" text="Science 324: 639���642." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5583" sofa="12" begin="60326" end="60517" id="364" text="Find this article online Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, et al. (2003) Partial purification and characterization of gamma-secretase from post-mortem human brain." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5595" sofa="12" begin="60518" end="60549" id="365" text="J Biol Chem 278: 24277���24284." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5607" sofa="12" begin="60550" end="60710" id="366" text="Find this article online Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, et al. (2004) Purification and characterization of the human gamma-secretase complex." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5619" sofa="12" begin="60711" end="60740" id="367" text="Biochemistry 43: 9774���9789." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5631" sofa="12" begin="60741" end="60938" id="368" text="Find this article online Cacquevel M, Aeschbach L, Osenkowski P, Li D, Ye W, et al. (2008) Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5643" sofa="12" begin="60939" end="60966" id="369" text="J Neurochem 104: 210���220." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5655" sofa="12" begin="60967" end="61180" id="370" text="Find this article online Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, et al. (2006) Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5667" sofa="12" begin="61181" end="61223" id="371" text="Proc Natl Acad Sci U S A 103: 6889���6894." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5679" sofa="12" begin="61224" end="61389" id="372" text="Find this article online Osenkowski P, Li H, Ye W, Li D, Aeschbach L, et al. (2009) Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5691" sofa="12" begin="61390" end="61416" id="373" text="J Mol Biol 385: 642���652." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5703" sofa="12" begin="61417" end="61700" id="374" text="Find this article online Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, et al. (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5715" sofa="12" begin="61701" end="61744" id="375" text="Proc Natl Acad Sci U S A 96: 11872���11877." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5727" sofa="12" begin="61745" end="61992" id="376" text="Find this article online Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, et al. (2003) gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5739" sofa="12" begin="61993" end="62021" id="377" text="J Cell Sci 116: 1127���1136." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5751" sofa="12" begin="62022" end="62291" id="378" text="Find this article online Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, et al. (2003) Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5763" sofa="12" begin="62292" end="62323" id="379" text="J Biol Chem 278: 43430���43436." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5775" sofa="12" begin="62324" end="62501" id="380" text="Find this article online Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5787" sofa="12" begin="62502" end="62523" id="381" text="Neuron 17: 181���190." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5799" sofa="12" begin="62524" end="62713" id="382" text="Find this article online Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, et al. (2007) Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5811" sofa="12" begin="62714" end="62745" id="383" text="J Clin Invest 117: 1230���1239." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5823" sofa="12" begin="62746" end="62966" id="384" text="Find this article online Heilig EA, Xia W, Shen J, Kelleher RJ (2010) A presenilin-1 mutation identified in familial Alzheimer's disease with cotton wool plaques causes nearly complete loss of {gamma}-secretase activity." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5835" sofa="12" begin="62967" end="62979" id="385" text="J Biol Chem." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5847" sofa="12" begin="62980" end="63135" id="386" text="Find this article online Lichtenthaler SF, Multhaup G, Masters CL, Beyreuther K (1999) A novel substrate for analyzing Alzheimer's disease gamma-secretase." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5859" sofa="12" begin="63136" end="63164" id="387" text="FEBS letters 453: 288���292." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5871" sofa="12" begin="63165" end="63434" id="388" text="Find this article online Fraering PC, LaVoie MJ, Ye W, Ostaszewski BL, Kimberly WT, et al. (2004) Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5883" sofa="12" begin="63435" end="63462" id="389" text="Biochemistry 43: 323���333." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5895" sofa="12" begin="63463" end="63621" id="390" text="Find this article online Duff K, Eckman C, Zehr C, Yu X, Prada CM, et al. (1996) Increased amyloid-beta42(43) in brainsof mice expressing mutant presenilin 1." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5907" sofa="12" begin="63622" end="63644" id="391" text="Nature 383: 710���713." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5919" sofa="12" begin="63645" end="63900" id="392" text="Find this article online Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5931" sofa="12" begin="63901" end="63920" id="393" text="Neuron 13: 45���53." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5943" sofa="12" begin="63921" end="64106" id="394" text="Find this article online Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, et al. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5955" sofa="12" begin="64107" end="64134" id="395" text="J Biol Chem 267: 546���554." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5967" sofa="12" begin="64135" end="64363" id="396" text="Find this article online Jan A, Gokce O, Luthi-Carter R, Lashuel HA (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5979" sofa="12" begin="64364" end="64395" id="397" text="J Biol Chem 283: 28176���28189." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="5991" sofa="12" begin="64396" end="64622" id="398" text="Find this article online Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease." qualityScore="0.7902439024390244" bFilter="false" nerList="15008"/><types:Sentence xmi:id="6003" sofa="12" begin="64623" end="64652" id="399" text="Biochemistry 32: 4693���4697." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="6015" sofa="12" begin="64653" end="64937" id="400" text="Find this article online Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="6027" sofa="12" begin="64938" end="64959" id="401" text="Nat Med 2: 864���870." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="6039" sofa="12" begin="64960" end="65181" id="402" text="Find this article online Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="6051" sofa="12" begin="65182" end="65202" id="403" text="Nat Med 4: 97���100." qualityScore="0.0" bFilter="true"/><types:Sentence xmi:id="15261" sofa="12" begin="0" end="691" id="0" text="PLoS ONE: Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesOpen AccessResearch ArticleAlzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase ComplexesMatthias Cacquevel, Lor��ne Aeschbach, Jemila Houacine, Patrick C. Fraering*��cole Polytechnique F��d��rale de Lausanne, Brain Mind Institute, Laboratory of Molecular and Cellular Biology of Alzheimer's Disease, Lausanne, SwitzerlandAbstract Top BackgroundMutations linked to early onset, familial forms of Alzheimer's disease (FAD) are found most frequently in PSEN1, the gene encoding presenilin-1 (PS1)." qualityScore="0.0" bFilter="false" nerList="21406 21415 21424 21433 21442 21451 21460 21469"/><types:Sentence xmi:id="15273" sofa="12" begin="692" end="984" id="1" text="Together with nicastrin (NCT), anterior pharynx-defective protein 1 (APH1), and presenilin enhancer 2 (PEN2), the catalytic subunit PS1 constitutes the core of the ��-secretase complex and contributes to the proteolysis of the amyloid precursor protein (APP) into amyloid-beta (A��) peptides." qualityScore="0.0" bFilter="false" nerList="21503 21512 21521 21530 21539 21548 21557"/><types:Sentence xmi:id="15285" sofa="12" begin="985" end="1216" id="2" text="Although there is a growing consensus that FAD-linked PS1 mutations affect A�� production by enhancing the A��1���42/A��1���40 ratio, it remains unclear whether and how they affect the generation of APP intracellular domain (AICD)." qualityScore="0.0" bFilter="false" nerList="21588 21597 21606"/><types:Sentence xmi:id="15297" sofa="12" begin="1217" end="1409" id="3" text="Moreover, controversy exists as to how PS1 mutations exert their effects in different experimental systems, by either increasing A��1���42 production, decreasing A��1���40 production, or both." qualityScore="0.0" bFilter="false" nerList="21625"/><types:Sentence xmi:id="15309" sofa="12" begin="1410" end="1620" id="4" text="Because it could be explained by the heterogeneity in the composition of ��-secretase, we purified to homogeneity complexes made of human NCT, APH1aL, PEN2, and the pathogenic PS1 mutants L166P, ��E9, or P436Q." qualityScore="0.0" bFilter="false" nerList="21638 21647 21656 21665"/><types:Sentence xmi:id="15321" sofa="12" begin="1620" end="1854" id="5" text="Methodology/Principal FindingsWe took advantage of a mouse embryonic fibroblast cell line lacking PS1 and PS2 to generate different stable cell lines overexpressing human ��-secretase complexes with different FAD-linked PS1 mutations." qualityScore="0.0" bFilter="false" nerList="21687 21696 21705 21714"/><types:Sentence xmi:id="15333" sofa="12" begin="1855" end="1976" id="6" text="A multi-step affinity purification procedure was used to isolate semi-purified or highly purified ��-secretase complexes." qualityScore="0.0" bFilter="false" nerList="21736"/><types:Sentence xmi:id="15345" sofa="12" begin="1977" end="2204" id="7" text="The functional characterization of these complexes revealed that all PS1 FAD-linked mutations caused a loss of ��-secretase activity phenotype, in terms of A��1���40, A��1���42 and APP intracellular domain productions in vitro." qualityScore="0.0" bFilter="false" nerList="21749 21758 21767 21776"/><types:Sentence xmi:id="15357" sofa="12" begin="2204" end="2461" id="8" text="Conclusion/SignificanceOur data support the view that PS1 mutations lead to a strong ��-secretase loss-of-function phenotype and an increased A��1���42/A��1���40 ratio, two mechanisms that are potentially involved in the pathogenesis of Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="21798 21807"/><types:Sentence xmi:id="15369" sofa="12" begin="2461" end="2653" id="9" text="Citation: Cacquevel M, Aeschbach L, Houacine J, Fraering PC (2012) Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified ��-Secretase Complexes." qualityScore="0.0" bFilter="false" nerList="21823 21832"/><types:Sentence xmi:id="15381" sofa="12" begin="2654" end="2676" id="10" text="PLoS ONE 7(4): e35133." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15393" sofa="12" begin="2677" end="2697" id="11" text="doi:10.1371/journal." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15405" sofa="12" begin="2697" end="2881" id="12" text="pone.0035133Editor: Stefano L. Sensi, University G. D'Annunzio, ItalyReceived: February 20, 2012; Accepted: March 13, 2012; Published: April 18, 2012Copyright: �� 2012 Cacquevel et al." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15417" sofa="12" begin="2882" end="3117" id="13" text="This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15429" sofa="12" begin="3117" end="3369" id="14" text="Funding: This work was supported by the Swiss National Foundation (to and LA and PCF; grant 31003A_134938/1) and the National Centre for Competence in Research (���Neuronal Plasticity and Repair��� (to JH and PCF)), and the Strauss foundation (to PCF)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15441" sofa="12" begin="3370" end="3576" id="15" text="The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Competing interests: The authors have declared that no competing interests exist." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15453" sofa="12" begin="3576" end="3881" id="16" text="* E-mail: patrick.fraering@epfl.chIntroduction Top Since their discovery in 1995 and their association with early onset familial Alzheimer's disease (FAD) [1], [2], the presenilin genes PSEN1 and PSEN2 have been widely studied, and the complexity of their biological role is becoming increasingly evident." qualityScore="0.0" bFilter="false" nerList="21854 21863"/><types:Sentence xmi:id="15465" sofa="12" begin="3882" end="4114" id="17" text="PSEN1 and PSEN2 encode transmembrane proteins PS1 and PS2, respectively, that constitute the catalytic core of ��-secretase, the founding member of an emerging class of unconventional, Intramembrane-Cleaving Proteases (I-CLiPs) [3]." qualityScore="0.0" bFilter="false" nerList="21879 21888 21897 21906 21915"/><types:Sentence xmi:id="15477" sofa="12" begin="4115" end="4301" id="18" text="Active ��-secretase is a multiprotein complex composed of PS1 or PS2 together with nicastrin (NCT), the anterior pharynx-defective protein 1 (APH1), and the presenilin enhancer 2 (PEN2)." qualityScore="0.0" bFilter="false" nerList="21940 21949 21958 21967 21976 21985"/><types:Sentence xmi:id="15489" sofa="12" begin="4302" end="4620" id="19" text="Experimental evidence such as the binding of transition-state analogue ��-secretase inhibitors to PS1 [4], as well as the abolishment of ��-secretase activity when PS1 lacks the aspartate residues critical for proteolysis [4], [5], [6], have confirmed that presenilins harbour the active site of the enzymatic complex." qualityScore="0.0" bFilter="false" nerList="22013 22022"/><types:Sentence xmi:id="15501" sofa="12" begin="4620" end="4710" id="20" text="PS1 and PS2 play fundamental roles in cell signalling as part of the ��-secretase complex." qualityScore="0.0" bFilter="false" nerList="22038 22047 22056"/><types:Sentence xmi:id="15513" sofa="12" begin="4711" end="4901" id="21" text="The latter cleaves numerous type-I membrane proteins in their transmembrane domain [7], releasing their corresponding intracellular domains, which are capable of influencing gene expression." qualityScore="0.0" bFilter="false" nerList="22075"/><types:Sentence xmi:id="15525" sofa="12" begin="4902" end="5185" id="22" text="For some substrates like NOTCH1 or ERBB4, the ��-secretase cleavage is essential for their biological function, whereas for other substrates like DCC or NEUREXIN-3�� [8], the possible role of the cleavage in signalling events has not been formally established (see [9] for a review)." qualityScore="0.0" bFilter="false" nerList="22088 22097 22106"/><types:Sentence xmi:id="15537" sofa="12" begin="5186" end="5403" id="23" text="The amyloid precursor protein (APP) is processed by the successive actions of ��-secretase (BACE1) and ��-secretase, generating amyloid-beta peptides (A��) of different lengths, ranging from 37 to 46 amino acids [10]." qualityScore="0.0" bFilter="false" nerList="22125 22134 22143 22152 22161 22170"/><types:Sentence xmi:id="15549" sofa="12" begin="5404" end="5670" id="24" text="Cleavage of the APP C-terminal fragments (APP-CTFs) by ��-secretase also releases the APP intracellular domain (AICD), which has been recently involved in the regulation of brain ApoE expression, a major genetic determinant of AD, and in cholesterol metabolism [11]." qualityScore="0.0" bFilter="false" nerList="22198 22207 22216 22225"/><types:Sentence xmi:id="15561" sofa="12" begin="5671" end="5805" id="25" text="In addition, PS1 has been shown to interact with a growing list of proteins that modulate ��-secretase activity [9], [12], [13], [14]." qualityScore="0.0" bFilter="false" nerList="22247 22256"/><types:Sentence xmi:id="15573" sofa="12" begin="5805" end="5981" id="26" text="In a pathological context, 185 missense mutations in PSEN1 and 13 mutations in PSEN2 have been identified and found to be associated with FAD (www.molgen.ua.ac.be/ADMutations)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15585" sofa="12" begin="5982" end="6264" id="27" text="It was initially suggested that such mutations lead to a toxic gain of function because they are associated with a relative increased production of longer and more hydrophobic A�� species, mainly A��1���42, that accumulate and aggregate early in the course of thedisease [15], [16]." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15597" sofa="12" begin="6265" end="6428" id="28" text="Similar phenotypes have been observed by independent groups in cell-based studies performed with different mammalian cell lines [17], [18], [19], [20], [21], [22]." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15609" sofa="12" begin="6429" end="6613" id="29" text="Despite this growing consensus, the above-mentioned studies provided conflicting results regarding the relative proportions of A��42, A��40, and AICD resulting from the PSEN mutations." qualityScore="0.0" bFilter="false" nerList="22275 22284"/><types:Sentence xmi:id="15621" sofa="12" begin="6614" end="6820" id="30" text="On one hand, a gain-of-function phenotype was suggested due to the observed increase in A��42 production, accompanied or not with reduced A��40 production, thereby leading to an increased A��42/A��40 ratio." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15633" sofa="12" begin="6821" end="6908" id="31" text="On the other hand, reduced AICD production suggested a loss-of-function phenotype [20]." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15645" sofa="12" begin="6909" end="7102" id="32" text="Differences in the methodologies and cell types used to assess the effects of PSEN mutations on A�� and AICD productions can explain this controversy as to how PS mutations exert their effects." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15657" sofa="12" begin="7103" end="7305" id="33" text="For example, endogenous PS has been suggested to affect such analysis, as the FAD-linked PSEN1 mutations led to a decrease in the total amount of A�� generated in PS1 and PS2 double knockout cells [23]." qualityScore="0.0" bFilter="false" nerList="22303 22312 22321"/><types:Sentence xmi:id="15669" sofa="12" begin="7306" end="7584" id="34" text="Next, it has been reported that ��-secretase complexes are heterogeneous in composition (with two PS genes and three APH1 isoforms, six combinations of ��-secretase are possible), with distinct functional properties influencing the relative amount of A�� species generated [24]." qualityScore="0.0" bFilter="false" nerList="22340 22349 22358 22367"/><types:Sentence xmi:id="15681" sofa="12" begin="7585" end="7781" id="35" text="In order to investigate the biochemical and functional properties of ��-secretase in cell-free systems, we and others have recently purified this enzymatic complex to homogeneity [25], [26], [27]." qualityScore="0.0" bFilter="false" nerList="22389"/><types:Sentence xmi:id="15693" sofa="12" begin="7782" end="8109" id="36" text="In particular, protocols for the high-grade purification of proteolytically active ��-secretase constituted of NCT, APH1aL, PEN2 and wild-type PS1 [26], [27] allowed the reconstitution of 3D structures at 15 �� and 12 �� resolution by EM and cryo-EM and gave new insights on the structure and activity of the enzyme [28], [29]." qualityScore="0.0" bFilter="false" nerList="22402 22411 22420 22429"/><types:Sentence xmi:id="15705" sofa="12" begin="8110" end="8179" id="37" text="However, these studies were exclusively focused on the wild-type PS1." qualityScore="0.0" bFilter="false" nerList="22451"/><types:Sentence xmi:id="15717" sofa="12" begin="8180" end="8352" id="38" text="Here, we report for the first time the functional characterization of highly purified and homogenous human ��-secretase particles carrying different FAD-linked PS1 mutants." qualityScore="0.0" bFilter="false" nerList="22464 22473"/><types:Sentence xmi:id="15729" sofa="12" begin="8353" end="8483" id="39" text="Our biochemical and functional findings strongly suggest that pathogenic mutations in PSEN1 cause a loss of ��-secretase activity." qualityScore="0.0" bFilter="false" nerList="22489 22498"/><types:Sentence xmi:id="15741" sofa="12" begin="8483" end="8893" id="40" text="Results Top Generation, selection and characterization of stable cell lines overexpressing ��-secretase complexes with FAD-linked PS1 mutantsIn order to facilitate high-grade purification of homogenous human ��-secretase complexes containing different PS1 variants, we took advantage of a previously generated mouse embryonic fibroblast (MEF) cell line that lacks the two presenilins (PS1/2���/���) [30], [31]." qualityScore="0.0" bFilter="false" nerList="22514 22523 22532 22541"/><types:Sentence xmi:id="15753" sofa="12" begin="8894" end="9231" id="41" text="Our global strategy consisted in producing stable cell lines, on a PS1/2���/��� background, that overexpress tagged versions of the three human ��-secretase subunits NCT, APH1 and PEN2 together with different variants of human PS1, and to purify the different human ��-secretase complexes by three sequential affinity purification steps." qualityScore="0.0" bFilter="false" nerList="22563 22572 22581 22590 22599"/><types:Sentence xmi:id="15765" sofa="12" begin="9232" end="9328" id="42" text="This strategy allowed us to exclude a possible co-purification of mouse ��-secretase components." qualityScore="0.0" bFilter="false" nerList="22624"/><types:Sentence xmi:id="15777" sofa="12" begin="9329" end="9519" id="43" text="First, a parental cell line was generated by co-transducing lentiviral vectors of human NCT-V5 (hNCT-V5), human APH1aL-HA (hAPH1aL-HA) and human Flag-PEN2 (Flag-hPEN2) into MEF PS1/2���/���." qualityScore="0.0" bFilter="false" nerList="22637 22646 22655 22664"/><types:Sentence xmi:id="15789" sofa="12" begin="9520" end="9671" id="44" text="Lentivectors are stably integrated into the cell genome and allow the generation of cell lines overexpressing multiple genes in a short period of time." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15801" sofa="12" begin="9672" end="10239" id="45" text="Next, the clone expressing the highest levels of all three recombinant proteins was selected (designated �� - PS1/2) and used as the parental cell line that was further transduced with lentivectors carrying the following different human PS1 variants: PS1-WT, three dominant-negative forms of PS1 that lack the crucial, catalytic site aspartate residues (D257A, D385A, and both D257A/D385A referred to as DDAA later in the article), and three FAD-linked PS1 mutants (L166P, ��E9 and P436Q, with mean disease onset at 24 years, 45.5 years and 28.3 years, respectively)." qualityScore="0.0" bFilter="false" nerList="22687 22696 22705 22714 22723 22732"/><types:Sentence xmi:id="15813" sofa="12" begin="10239" end="10398" id="46" text="For each PS1 variant, two individual clones were selected based on the expression levels of the recombinant proteins, and extensively characterized (Figure 1)." qualityScore="0.0" bFilter="false" nerList="22760 22769"/><types:Sentence xmi:id="15825" sofa="12" begin="10399" end="10535" id="47" text="To distinguish those cell lines overexpressing all ��-sectease components from wild-type MEFs, they are collectively designated ��-MEFs." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15837" sofa="12" begin="10536" end="10691" id="48" text="As shown in Figure 1A, the analysis of total protein extracts confirmed that PS is required for the maturation of NCT and the stability of PEN2 [23], [32]." qualityScore="0.0" bFilter="false" nerList="22786 22795 22804"/><types:Sentence xmi:id="15849" sofa="12" begin="10692" end="10847" id="49" text="As expected, and when compared to the parental ��- PS1/2 cell line, higher levels of the mature form of NCT were observed in all PS1-overexpressing clones." qualityScore="0.0" bFilter="false" nerList="22823"/><types:Sentence xmi:id="15861" sofa="12" begin="10848" end="10952" id="50" text="In contrast to PEN2, APH1aL levels were relatively similar in all PS1 clones and the parental cell line." qualityScore="0.0" bFilter="false" nerList="22836 22845 22854"/><types:Sentence xmi:id="15873" sofa="12" begin="10953" end="11175" id="51" text="Indeed, and as previously reported [23], [32], PEN2 levels were higher in the clones overexpressing WT PS1 and FAD-linked PS1 mutants, and to a lesser extent in the clones overexpressing the dominant negative forms of PS1." qualityScore="0.0" bFilter="false" nerList="22873 22882 22891 22900"/><types:Sentence xmi:id="15885" sofa="12" begin="11176" end="11298" id="52" text="Interestingly, PEN2 migrated on the gel as an apparent double band, possibly reflecting a post-translational modification." qualityScore="0.0" bFilter="false" nerList="22922"/><types:Sentence xmi:id="15897" sofa="12" begin="11299" end="11394" id="53" text="Different patterns of PS1 expression and autoproteolysis were observed in the different clones." qualityScore="0.0" bFilter="false" nerList="22935"/><types:Sentence xmi:id="15909" sofa="12" begin="11395" end="11589" id="54" text="First, and in sharp contrast to the other clones, those expressing PS1-WT or PS1-L166P displayed higher levels of PS1-NTF and PS1-CTF fragments compared with full-length PS1 (PS1-FL; Figure 1A)." qualityScore="0.0" bFilter="false" nerList="22948 22957 22966 22975 22984 22993"/><types:Sentence xmi:id="15921" sofa="12" begin="11590" end="11736" id="55" text="As estimated by densitometry, the NTF fragments of PS1-WT and PS1-L166P account for 87��2% and 79��7% of total PS1 (PS1-NTF+PS1-FL), respectively." qualityScore="0.0" bFilter="false" nerList="23021 23030 23039 23048 23057"/><types:Sentence xmi:id="15933" sofa="12" begin="11737" end="12036" id="56" text="Next, the PS1-��E9 clones did not show any detectable NTF or CTF fragments, as previously described [33], while P436Q and the three dominant negative variants of PS1 were characterized by low levels of PS1-NTF and PS1-CTF fragments, suggesting that these variants were less prone to endoproteolysis." qualityScore="0.0" bFilter="false" nerList="23082 23091 23100 23109 23118"/><types:Sentence xmi:id="15945" sofa="12" begin="12036" end="12054" id="57" text="thumbnailFigure 1." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="15957" sofa="12" begin="12055" end="12165" id="58" text="Generation of stable cell lines overexpressing all human ��-secretase components with FAD-linked PS1 variants." qualityScore="0.0" bFilter="false" nerList="23144"/><types:Sentence xmi:id="15969" sofa="12" begin="12165" end="12437" id="59" text="MEF PS1/2���/��� were stably co-transduced with lentiviral vectors carrying genes encoding hNCT-V5, Flag-hPEN2, hAPH1aL-HA and clones were isolated by limiting dilution to generate a cell line, designated as ��- PS1/2, that overexpresses high amount of the three subunits." qualityScore="0.0" bFilter="false" nerList="23157"/><types:Sentence xmi:id="15981" sofa="12" begin="12440" end="12602" id="60" text="- PS1/2 MEFs were further transduced with hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned." qualityScore="0.0" bFilter="false" nerList="23170"/><types:Sentence xmi:id="15993" sofa="12" begin="12603" end="12860" id="61" text="Each clone, derived form the ��- PS1/2, was conveniently named according to the mutation present in PS1 preceded by the symbol �� and followed by the number of the clone (��-MEF) in order to distinguish them from wild-type MEF (WT MEF) and MEF PS1/2���/���." qualityScore="0.0" bFilter="false" nerList="23183 23192"/><types:Sentence xmi:id="16005" sofa="12" begin="12861" end="12932" id="62" text="Two clones per ��-secretase variant were selected for characterization." qualityScore="0.0" bFilter="false" nerList="23208"/><types:Sentence xmi:id="16017" sofa="12" begin="12933" end="13298" id="63" text="(A���B) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 4���12% Bis-Tris or 12% Tris-Glycine gels and analysed by immunostaining to detect the ��-secretase core components NCT (NCT164), PS1 (NTF, MAB1563; CTF; MAB5232), APH1aL-HA (3F10), and Flag-PEN2 (M2) (A), and endogenous APP (A8717) (B)." qualityScore="0.0" bFilter="false" nerList="23221 23230 23239 23248 23257"/><types:Sentence xmi:id="16029" sofa="12" begin="13301" end="13338" id="64" text="-Actin was used as a loading control." qualityScore="0.0" bFilter="false" nerList="23282"/><types:Sentence xmi:id="16041" sofa="12" begin="13339" end="13379" id="65" text="Each lane represents one selected clone." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16053" sofa="12" begin="13380" end="13521" id="66" text="CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16065" sofa="12" begin="13521" end="13541" id="67" text="doi:10.1371/journal." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16077" sofa="12" begin="13541" end="13554" id="68" text="pone.0035133." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16089" sofa="12" begin="13554" end="13647" id="69" text="g001 We next investigated the effects of PSEN1 mutations on the processing of endogenous APP." qualityScore="0.0" bFilter="false" nerList="23299 23308"/><types:Sentence xmi:id="16101" sofa="12" begin="13648" end="14013" id="70" text="As expected, and as indicated by increased levels of intracellular APP-CTFs (a common characteristic among known substrates in response to ��-secretase pharmacological inhibition), the activity of ��-secretase was significantly altered in the PS deficient parental �� - PS1/2 cell line as well as in all clones expressing dominant negative forms of PS1 (Figure 1B)." qualityScore="0.0" bFilter="false" nerList="23324 23333 23342"/><types:Sentence xmi:id="16113" sofa="12" begin="14014" end="14194" id="71" text="In the clones expressing PS1-WT, APP-CTFs were almost undetectable due to high ��-secretase activity, while clones expressing PS1-L166P or PS1-P436Q displayed APP-CTF accumulation." qualityScore="0.0" bFilter="false" nerList="23361 23370 23379 23388"/><types:Sentence xmi:id="16125" sofa="12" begin="14195" end="14268" id="72" text="In PS1-��E9 clones, a mild APP-CTF accumulation was observed (Figure 1B)." qualityScore="0.0" bFilter="false" nerList="23410"/><types:Sentence xmi:id="16137" sofa="12" begin="14269" end="14581" id="73" text="Although a poor recovery of ��-secretase activity for the PS1-L166P and a comparatively better performance of PS1-��E9 have been reported by others under similar experimental conditions [23], the potential of PS1-P436Q mutation to restore the processing of endogenous APP-CTFs has never been assessed [34], [35]." qualityScore="0.0" bFilter="false" nerList="23423 23432 23441 23450"/><types:Sentence xmi:id="16149" sofa="12" begin="14582" end="14904" id="74" text="Importantly, all observations described above for the cells overexpressing simultaneously hNCT-V5, hAPH1aL-HA, Flag-hPEN2 and the different PS1 variants are very consistent with those made in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other ��-secretase components (cf. Figure S1A)." qualityScore="0.0" bFilter="false" nerList="23472 23481 23490 23499"/><types:Sentence xmi:id="16161" sofa="12" begin="14905" end="15070" id="75" text="These data suggest that the effect of FAD mutations in PS1 on APP-CTFs accumulation was similar in presence or absence of other human components of the ��-secretase." qualityScore="0.0" bFilter="false" nerList="23521 23530 23539 23548"/><types:Sentence xmi:id="16173" sofa="12" begin="15070" end="15179" id="76" text="Next, we further investigated the effect of PS1 variants on the cellular production/secretion of A�� species." qualityScore="0.0" bFilter="false" nerList="23570"/><types:Sentence xmi:id="16185" sofa="12" begin="15180" end="15323" id="77" text="For this purpose, and as described elsewhere [36], we used an APP-based ��-secretase substrate with a Flag tag at its C-terminus (SPA4CT-Flag)." qualityScore="0.0" bFilter="false" nerList="23583"/><types:Sentence xmi:id="16197" sofa="12" begin="15324" end="15560" id="78" text="This substrate was transduced in the above-described ��-secretase overexpressing stable cell lines (��-MEFs) as well as in wild-type MEFs, and APP-CTFs and A�� levels were measured in cell lysate and cell media, respectively (Figure 2)." qualityScore="0.0" bFilter="false" nerList="23596 23605 23614"/><types:Sentence xmi:id="16209" sofa="12" begin="15561" end="15792" id="79" text="Under these conditions, the overexpression of SPA4CT-Flag led to an accumulation of two bands corresponding to the exogenous substrate, associated with a concomitant decrease of endogenous APP-CTFs levels (Figure 2A and Figure S2)." qualityScore="0.0" bFilter="false" nerList="23633"/><types:Sentence xmi:id="16221" sofa="12" begin="15793" end="16022" id="80" text="As estimated by ELISA, a three-fold increase in A��1���40 and A��1���42 levels was observed in the cell culture media of cell lines overexpressing human ��-secretase (��-MEF WT), in comparison to untransduced WT MEFs (Figure 2B)." qualityScore="0.0" bFilter="false" nerList="23646 23655 23664"/><types:Sentence xmi:id="16233" sofa="12" begin="16023" end="16204" id="81" text="Also, the average A��1���42/A��1���40 ratios were not significantly different in those cell lines (Mean �� SD: ��-MEF WT#5: 0.30��0.01; ��-MEF WT#8: 0.29��0.01; WT MEF: 0.19��0.06)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16245" sofa="12" begin="16205" end="16480" id="82" text="Next, overexpression of SPA4CT-Flag in ��-MEFs led to the pronounced intracellular accumulation of APP-CTFs in cells overexpressing the PS1 aspartate mutants (Figure 2C), and to the secretion in the cell culture media of different A�� levels as measured by ELISA (Figure 2D)." qualityScore="0.0" bFilter="false" nerList="23684 23693 23702"/><types:Sentence xmi:id="16257" sofa="12" begin="16481" end="16599" id="83" text="First, only traces of both A��1���40 and A��1���42 were detected in ��-MEFs overexpressing PS1 with aspartate mutants." qualityScore="0.0" bFilter="false" nerList="23721 23730 23739"/><types:Sentence xmi:id="16269" sofa="12" begin="16600" end="16746" id="84" text="Next, ��-MEFs overexpressing PS1 with FAD-linked mutations displayed a pronounced variability in A�� levels when compared to the wild-type clones." qualityScore="0.0" bFilter="false" nerList="23758"/><types:Sentence xmi:id="16281" sofa="12" begin="16747" end="17081" id="85" text="Overall, the average A��1���40 levels were decreased in these cell lines (Mean of two clones in pg/mL �� SD: WT: 224.6��0.1, L166P: 84.3��34.2, ��E9: 167.2��40.7, P436Q: 82.8��74.7), while the A��1���42 levels were increased (Mean of two clones in pg/mL �� SD: WT: 69.9��7.9, L166P: 310.7��81.0, ��E9: 94.4��18.5, P436Q: 141.1��98.5)." qualityScore="0.0" bFilter="false" nerList="23771"/><types:Sentence xmi:id="16293" sofa="12" begin="17082" end="17350" id="86" text="Consistent with previously reported data, the A��1���42/A��1���40 ratios were increased in all ��-MEF clones overexpressing PS1 with FAD-linked mutations (Figure 2D) (Mean of two clones pg/mL �� SD: WT: 0.31��0.03, L166P: 3.8��0.58, ��E9: 0.6��0.03, P436Q: 2.0��0.59)." qualityScore="0.0" bFilter="false" nerList="23784 23793"/><types:Sentence xmi:id="16305" sofa="12" begin="17350" end="17368" id="87" text="thumbnailFigure 2." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16317" sofa="12" begin="17369" end="17472" id="88" text="A�� production in cell lines overexpressing human ��-secretase components with FAD-linked PS1 variants." qualityScore="0.0" bFilter="false" nerList="23810"/><types:Sentence xmi:id="16329" sofa="12" begin="17472" end="17692" id="89" text="WT MEF, ��-MEF and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36]) and a Flag Tag in C-terminus." qualityScore="0.0" bFilter="false" nerList="23823 23832 23841"/><types:Sentence xmi:id="16341" sofa="12" begin="17693" end="17894" id="90" text="Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717) (A, C)." qualityScore="0.0" bFilter="false" nerList="23860"/><types:Sentence xmi:id="16353" sofa="12" begin="17895" end="17992" id="91" text="A��1���40 and A��1���42 levels were also measured in the corresponding cell culture media (B, D)." qualityScore="0.0" bFilter="false" nerList="23873 23882"/><types:Sentence xmi:id="16365" sofa="12" begin="17993" end="18057" id="92" text="Data corresponds to three independent experiments (Mean �� SEM)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16377" sofa="12" begin="18057" end="18077" id="93" text="doi:10.1371/journal." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16389" sofa="12" begin="18077" end="18090" id="94" text="pone.0035133." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16401" sofa="12" begin="18090" end="18288" id="95" text="g002 FAD-linked PS1 mutations alter the activity of semi-purified ��-secretase complexesWe next assessed the activity of ��-secretase with FAD-linked PS1 mutations in microsomal extracts of ��-MEFs." qualityScore="0.0" bFilter="false" nerList="23901 23910 23919 23928"/><types:Sentence xmi:id="16413" sofa="12" begin="18289" end="18516" id="96" text="Membrane protein extracts were prepared and ��-secretase activity was assayed on an exogenous recombinant APP-based substrate consisting of the C-terminal 99 amino acid residues of APP, and referred to as C100-Flag (Figure 3A)." qualityScore="0.0" bFilter="false" nerList="23950 23959 23968"/><types:Sentence xmi:id="16425" sofa="12" begin="18517" end="18633" id="97" text="The generation of the cleavage product AICD-Flag was detected by Western blot analysis and measured by densitometry." qualityScore="0.0" bFilter="false" nerList="23987"/><types:Sentence xmi:id="16437" sofa="12" begin="18634" end="18805" id="98" text="As shown in Figure 3A, the levels of AICD-Flag generated from the PS1-L166P and PS1-��E9 clones accounted for 42��1% and 13��6% of that in the PS1-WT clones, respectively." qualityScore="0.0" bFilter="false" nerList="24000 24009 24018"/><types:Sentence xmi:id="16449" sofa="12" begin="18806" end="18933" id="99" text="AICD-Flag was undetectable in the clones expressing PS1-P436Q as well as in the three dominant negative aspartate PS1 variants." qualityScore="0.0" bFilter="false" nerList="24037"/><types:Sentence xmi:id="16461" sofa="12" begin="18934" end="19099" id="100" text="Similar results were observed in MEF PS1/2���/��� cells overexpressing only the PS1 variants, in the absence of the other human ��-secretase components (Figure S1B)." qualityScore="0.0" bFilter="false" nerList="24050 24059"/><types:Sentence xmi:id="16473" sofa="12" begin="19099" end="19117" id="101" text="thumbnailFigure 3." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16497" sofa="12" begin="19210" end="19335" id="102" text="Enzymatic activity of partially purified ��-secretase complexes with FAD-linked PS1 mutants. (A) ��-Secretase activity assays performed with ��-MEF and �� - PS1/2 microsomal extracts prepared in 1% CHAPSO-HEPES buffer." qualityScore="0.0" bFilter="false" nerList="24076 24085 24094"/><types:Sentence xmi:id="16509" sofa="12" begin="19336" end="19533" id="103" text="Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16521" sofa="12" begin="19534" end="19628" id="104" text="Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563)." qualityScore="0.0" bFilter="false" nerList="24114"/><types:Sentence xmi:id="16533" sofa="12" begin="19629" end="19756" id="105" text="The relative amounts of AICD-Flag generated in the reactions, reflecting ��-secretase activity, were estimated by densitometry." qualityScore="0.0" bFilter="false" nerList="24127"/><types:Sentence xmi:id="16545" sofa="12" begin="19757" end="19824" id="106" text="PS1 immunostaining was used to assess the amount of input material." qualityScore="0.0" bFilter="false" nerList="24140"/><types:Sentence xmi:id="16557" sofa="12" begin="19825" end="20036" id="107" text="(B) Equal amounts of microsomal proteins were immunoprecipitated overnight at 4��C with either anti-Flag M2 or anti-HA affinity resins, and submitted to a C100-His assay according to the same protocol as in (A)." qualityScore="0.0" bFilter="false" nerList="24153 24162 24171"/><types:Sentence xmi:id="16569" sofa="12" begin="20037" end="20187" id="108" text="Protein samples were separated by SDS-PAGE and analysed by immunostaining for ��-secretase subunits ((NCT164 (NCT), MAB1563 (PS1-NTF), or UD1 (PEN2))." qualityScore="0.0" bFilter="false" nerList="24190 24199 24208 24217 24226 24235"/><types:Sentence xmi:id="16581" sofa="12" begin="20188" end="20272" id="109" text="AICD-His cleavage products were immunostained with an anti-APP-CTF antibody (A8717)." qualityScore="0.0" bFilter="false" nerList="24263 24272"/><types:Sentence xmi:id="16593" sofa="12" begin="20273" end="20342" id="110" text="*Indicates a non-specific band corresponding to the IgG light chains." qualityScore="0.0" bFilter="false" nerList="24288"/><types:Sentence xmi:id="16605" sofa="12" begin="20343" end="20546" id="111" text="(C) A��1���40 and A��1���42 were quantified by sandwich ELISA and represented in pg/mL (left Y-axis) or in percentage (right Y-axis) of the mean of A��1���40 levels generated by the two wild-type clones." qualityScore="0.0" bFilter="false" nerList="24301"/><types:Sentence xmi:id="16617" sofa="12" begin="20547" end="20611" id="112" text="A��1���42/A��1���40 ratios are indicated on the top of the bars." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16629" sofa="12" begin="20612" end="20710" id="113" text="The results were confirmed in three independent experiments and a representative dataset is shown." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16641" sofa="12" begin="20710" end="20730" id="114" text="doi:10.1371/journal." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16653" sofa="12" begin="20730" end="20743" id="115" text="pone.0035133." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16665" sofa="12" begin="20743" end="20813" id="116" text="g003 We next performed activity assays under semi-purified conditions." qualityScore="0.0" bFilter="false" nerList="24318"/><types:Sentence xmi:id="16677" sofa="12" begin="20814" end="20996" id="117" text="To do so, ��-secretase complexes from the different clones were co-immunoprecipitated from microsomal extracts and their activities were assayed in vitro with the C100-His substrate." qualityScore="0.0" bFilter="false" nerList="24331 24340"/><types:Sentence xmi:id="16689" sofa="12" begin="20997" end="21257" id="118" text="Two immunoprecipitation protocols using two affinity resins (anti-Flag M2 and anti-HA 3F10, targeting respectively Flag-PEN2 and APH1aL-HA) were compared to exclude a possible heterogeneity of ��-secretase complexes potentially generated under such conditions." qualityScore="0.0" bFilter="false" nerList="24356 24365 24374 24383"/><types:Sentence xmi:id="16701" sofa="12" begin="21258" end="21480" id="119" text="As shown in Figure 3B, the anti-Flag and anti-HA resins immunoprecipitated similar levels of NCT, PS1 and PEN2 and the activity of the ��-secretase complexes was similar regardless of the affinity resins used (Figures 3B)." qualityScore="0.0" bFilter="false" nerList="24405 24414 24423 24432 24441 24450"/><types:Sentence xmi:id="16713" sofa="12" begin="21481" end="21710" id="120" text="In agreement with the assays performed using microsomal extracts (Figure 3A), those performed with semi-purified complexes revealed that FAD-linked mutants drastically reduced AICD generation, when compared to PS1-WT (Figure 3B)." qualityScore="0.0" bFilter="false" nerList="24478 24487"/><types:Sentence xmi:id="16725" sofa="12" begin="21711" end="21897" id="121" text="Furthermore, levels of A��1���40 produced from PS1-L166P, PS1-��E9 and P436Q variants fell respectively to ~6%, ~1.5% and ~0.5%, when compared to these produced from PS1-WT ��-secretase." qualityScore="0.0" bFilter="false" nerList="24503 24512 24521 24530"/><types:Sentence xmi:id="16737" sofa="12" begin="21898" end="22115" id="122" text="Following the same tendency, A��1���42 levels generated from PS1-L166P, PS1-��E9 and PS1-P436Q ��-secretase variants were respectively estimated to ~20%, ~5% and ~3% of these produced with PS1-WT-containing complexes." qualityScore="0.0" bFilter="false" nerList="24552 24561 24570 24579 24588"/><types:Sentence xmi:id="16749" sofa="12" begin="22116" end="22285" id="123" text="The A��1-42/A��1���40 ratio measured for WT ��-MEFs was consistent with our cell-based data (compare Figures 2D and 3C), validating our in vitro experimental conditions." qualityScore="0.0" bFilter="false" nerList="24613"/><types:Sentence xmi:id="16761" sofa="12" begin="22286" end="22414" id="124" text="Interestingly, an overall A��1���42/A��1���40 ratio of ~1 was estimated for all PS1 mutants, with the exception of P436Q#4 (~2)." qualityScore="0.0" bFilter="false" nerList="24626"/><types:Sentence xmi:id="16773" sofa="12" begin="22415" end="22543" id="125" text="However, in the latter, the ratio may have been overestimated because the A��1���40 levels measured were at the detection limit." qualityScore="0.0" bFilter="false" nerList="24639"/><types:Sentence xmi:id="16785" sofa="12" begin="22544" end="22703" id="126" text="This similarity in the A��1���42/A��1���40 ratios generated by the different mutantshas, to the best of our knowledge, never been observed in previous studies." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16797" sofa="12" begin="22703" end="23048" id="127" text="Highly purified ��-secretase complexes with FAD-linked PS1 mutants display a loss-of-function phenotypeIn order to further investigate how PS1 variants affect APP-CTF cleavage and to validate our observations performed in semi-purified conditions, we purified to homogeneity ��-secretase complexes from the selected clones described in Figure 1." qualityScore="0.0" bFilter="false" nerList="24653 24662 24671 24680"/><types:Sentence xmi:id="16809" sofa="12" begin="23049" end="23232" id="128" text="The purification process (described in details under Materials &amp; Methods and depicted in Figure 4A) involved three sequential affinity purifications starting from microsomal extracts." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16821" sofa="12" begin="23233" end="23409" id="129" text="Since all cell lines were generated on a PS knockout background, this strategy allowed us to purify exclusively and selectively ��-secretase complexes made of human components." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16833" sofa="12" begin="23410" end="23667" id="130" text="As highlighted in Figure 4B, our protocol led to the production of stable, high molecular weight ��-secretase complexes (HMWCs) with an apparent molecular mass on Blue Native (BN)-PAGE of ~350 kDa, which is consistent with previous reports [26], [27], [37]." qualityScore="0.0" bFilter="false" nerList="24704"/><types:Sentence xmi:id="16845" sofa="12" begin="23668" end="23907" id="131" text="The silver stained particles on the BN gel confirmed the high purity of these complexes (Figure 4B, upper panel), for which the identity was established by cross-reactivity with antibodies specific to NCT and PS1 (Figure 4B, lower panels)." qualityScore="0.0" bFilter="false" nerList="24717 24726"/><types:Sentence xmi:id="16857" sofa="12" begin="23908" end="24221" id="132" text="As the main goal of this experiment was to compare the efficacy of the different ��-secretase complexes to process APP-based substrates, it is important to note that the final yields of the complexes purified from the different clones were very similar (Figure 4B), thus facilitating further comparative analyses." qualityScore="0.0" bFilter="false" nerList="24742"/><types:Sentence xmi:id="16869" sofa="12" begin="24222" end="24446" id="133" text="The immunoblot analysis of the purified complexes (Figure 4C) confirmed the presence of all core components (NCT-V5, APH1aL-HA, Flag-PEN2 and PS1) and globally recapitulates the maturation processes observed in the Figure 1." qualityScore="0.0" bFilter="false" nerList="24755 24764 24773 24782"/><types:Sentence xmi:id="16881" sofa="12" begin="24447" end="24792" id="134" text="Interestingly, the relative PS1-NTF/CTF to PS1-FL ratios in the purified ��-secretase complexes containing the three PS1 dominant-negative or the PS1-P436Q variants were higher than those estimated in the whole cell extracts before purification (Figure 1A), indicating that endoproteolysis of PS1 was not completely abolished by these mutations." qualityScore="0.0" bFilter="false" nerList="24804 24813 24822 24831 24840 24849"/><types:Sentence xmi:id="16893" sofa="12" begin="24793" end="25123" id="135" text="To assess how FAD-linked mutations in PS1 affect ��-secretase activity in these purified complexes, we performed in vitro assays by using C100-Flag substrate (Figure 3A) and equal amounts of the different purified complexes, immediately after the purification to avoid freezing/thawing cycles that might affect enzymatic activity." qualityScore="0.0" bFilter="false" nerList="24877"/><types:Sentence xmi:id="16905" sofa="12" begin="25124" end="25268" id="136" text="As shown in Figure 5A, ��-secretase activity based on AICD-Flag production was easily detected in complexes purified from the two PS1-WT clones." qualityScore="0.0" bFilter="false" nerList="24890 24899"/><types:Sentence xmi:id="16917" sofa="12" begin="25269" end="25411" id="137" text="This is in sharp contrast to the other purified complexes that did not generate detectable AICD under our experimental conditions (Figure 5A)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="16929" sofa="12" begin="25412" end="25571" id="138" text="Next, sandwich ELISAs directed against A��1���40 and A��1���42 were performed in order to further characterize the specific activity of the purified complexes." qualityScore="0.0" bFilter="false" nerList="24916 24925"/><types:Sentence xmi:id="16941" sofa="12" begin="25572" end="25853" id="139" text="Reflecting the levels of AICD and considering the detection limits of our sandwich ELISA, the production of both A�� species by ��-secretase complexes containing PS1-WT was at least 10-fold higher than in complexes with the FAD-linked or dominant-negative PS1 variants (Figure 5B)." qualityScore="0.0" bFilter="false" nerList="24941 24950"/><types:Sentence xmi:id="16953" sofa="12" begin="25854" end="26079" id="140" text="The A��1���42/A��1���40 ratio measured in PS1-WT ��-secretase complexes (~0.22) was similar to that previously reported [26], [27], thus excluding a possible qualitative alteration of ��-secretase activity with this protocol." qualityScore="0.0" bFilter="false" nerList="24966 24975"/><types:Sentence xmi:id="16965" sofa="12" begin="26080" end="26279" id="141" text="Together, our results strongly support the hypothesis that the pathogenic L166P, ��E9, and P436Q mutations in PSEN1 cause a drastic loss (at least 90% as estimated by ELISA) of ��-secretase activity." qualityScore="0.0" bFilter="false" nerList="24991 25000"/><types:Sentence xmi:id="16977" sofa="12" begin="26279" end="26297" id="142" text="thumbnailFigure 4." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17001" sofa="12" begin="26382" end="26452" id="143" text="High-grade purification of human ��-secretase complexes with FAD-linked PS1 mutants. (A) Schematic representation of the ��-secretase purification process." qualityScore="0.0" bFilter="false" nerList="25017 25026 25035"/><types:Sentence xmi:id="17013" sofa="12" begin="26453" end="26620" id="144" text="Briefly, Presenilin double-knockout MEFs were used to first generate cell lines that stably overexpress human ��-secretase complexes containing different PS1 variants." qualityScore="0.0" bFilter="false" nerList="25054 25063"/><types:Sentence xmi:id="17025" sofa="12" begin="26621" end="26735" id="145" text="Next, these cell lines were used for a multi-step purification procedure as described in the material and methods." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17037" sofa="12" begin="26736" end="26832" id="146" text="(B) Blue-Native PAGE analysis of purified ��-secretase complexes made of different PS1 variants." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17049" sofa="12" begin="26833" end="27097" id="147" text="Equal volumes of the different purified ��-secretase preparations were separated by native-PAGE on a 4���16% Bis-Tris gel, and stained with silver nitrate (top panel), or immunostained for NCT (NCT164, middle panel) or PS1-NTF (ab10281, bottom panel) as indicated." qualityScore="0.0" bFilter="false" nerList="25081 25090 25099 25108"/><types:Sentence xmi:id="17061" sofa="12" begin="27100" end="27196" id="148" text="-Secretase complexes appeared on the gel as high molecular weight complexes (HMWCs) of ~350 kDa." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17073" sofa="12" begin="27197" end="27255" id="149" text="Note that the levels of HMWCs were similar for all clones." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17085" sofa="12" begin="27256" end="27526" id="150" text="(C) Equal volumes of purified ��-secretase complexes with FAD-linked PS1 mutants were separated under denaturing conditions (SDS-PAGE) and immunostained with anti-NCT (NCT164), anti-PS1-NTF (MAB1563), anti-PS1-CTF (MAB5232), anti-HA (3F10), or anti-Flag (M2) antibodies." qualityScore="0.0" bFilter="false" nerList="25132 25141 25150 25159 25168"/><types:Sentence xmi:id="17097" sofa="12" begin="27527" end="27607" id="151" text="Two independent purifications were performed on each clone with similar results." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17109" sofa="12" begin="27608" end="27642" id="152" text="A representative dataset is shown." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17121" sofa="12" begin="27642" end="27662" id="153" text="doi:10.1371/journal." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17133" sofa="12" begin="27662" end="27675" id="154" text="pone.0035133." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17145" sofa="12" begin="27675" end="27698" id="155" text="g004 thumbnailFigure 5." qualityScore="0.0" bFilter="false" nerList="25197"/><types:Sentence xmi:id="17157" sofa="12" begin="27699" end="27801" id="156" text="Enzymatic activity of highly purified ��-secretase complexes with FAD-linked or aspartate PS1 mutants." qualityScore="0.0" bFilter="false" nerList="25210 25219"/><types:Sentence xmi:id="17169" sofa="12" begin="27801" end="27957" id="157" text="Equal amounts of the different purified ��-secretase preparations characterized in Figure 4 were tested for activity on C100-Flag, as described in Figure 3." qualityScore="0.0" bFilter="false" nerList="25235"/><types:Sentence xmi:id="17181" sofa="12" begin="27958" end="28165" id="158" text="The resulting cleavage products were separated by SDS-PAGE and detected by immunostaining with an anti-Flag antibody (M2) for C100-Flag or AICD-Flag (A), and by sandwich ELISA for A��1���40 or A��1���42 (B)." qualityScore="0.0" bFilter="false" nerList="25248 25257 25266"/><types:Sentence xmi:id="17193" sofa="12" begin="28166" end="28328" id="159" text="Note that the levels of A�� produced from FAD-linked ��-secretase complexes were all in the non-linear range of the ELISA standards, close to the detection limit." qualityScore="0.0" bFilter="false" nerList="25285"/><types:Sentence xmi:id="17205" sofa="12" begin="28329" end="28428" id="160" text="Whenever possible, A��1���42/A��1���40 ratios were quantified and indicated on the top of the bars." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17217" sofa="12" begin="28429" end="28522" id="161" text="Two independent purifications were performed on each clone and similar results were obtained." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17229" sofa="12" begin="28523" end="28557" id="162" text="A representative dataset is shown." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17241" sofa="12" begin="28557" end="28577" id="163" text="doi:10.1371/journal." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17253" sofa="12" begin="28577" end="28590" id="164" text="pone.0035133." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17265" sofa="12" begin="28590" end="28758" id="165" text="g005 Discussion Top Several conflicting results as to how Alzheimer's disease-linked mutations in PSEN1 affect the processing of APP by ��-secretase have been reported." qualityScore="0.0" bFilter="false" nerList="25303 25312 25321 25330"/><types:Sentence xmi:id="17277" sofa="12" begin="28759" end="28905" id="166" text="First, it has been previously reported that transgenic animals with FAD-linked PS1 mutations show increasing brain levels of A��1���42 [15], [38]." qualityScore="0.0" bFilter="false" nerList="25352"/><types:Sentence xmi:id="17289" sofa="12" begin="28906" end="29176" id="167" text="Since A��1���42, the first A�� specie deposited in the brain of AD patients [16], [39], is more prone to aggregation when compared to shorter A�� species [40], [41], [42], it has been implicated in the seeding of amyloid plaques in AD patients with PSEN1 mutations [43]." qualityScore="0.0" bFilter="false" nerList="25365"/><types:Sentence xmi:id="17301" sofa="12" begin="29177" end="29352" id="168" text="This was further validated in vivo as the overexpression of PS1 mutants in APP transgenic mice accelerated the rate of A�� accumulation and deposition in the brain [44], [45]." qualityScore="0.0" bFilter="false" nerList="25378 25387"/><types:Sentence xmi:id="17313" sofa="12" begin="29353" end="29529" id="169" text="However, Bentahir and colleagues challenged this view by showing that several PSEN1 mutations were also capable to decrease total A�� production in PS1/PS2 knockout cells [23]." qualityScore="0.0" bFilter="false" nerList="25403"/><types:Sentence xmi:id="17325" sofa="12" begin="29530" end="29638" id="170" text="These findings suggested that endogenous PS1 and PS2 may influence the mutant phenotype in cells or in vivo." qualityScore="0.0" bFilter="false" nerList="25416 25425"/><types:Sentence xmi:id="17337" sofa="12" begin="29639" end="29782" id="171" text="By extension, we hypothesized that the other components of ��-secretase, namely APH1, NCT and PEN2, may influence the mutant phenotype as well." qualityScore="0.0" bFilter="false" nerList="25441 25450 25459 25468"/><types:Sentence xmi:id="17349" sofa="12" begin="29783" end="30005" id="172" text="Indeed, ��-secretase complexes are heterogeneous in composition due to the existence of two human APH1 genes, APH1a and APH1b, and two splicing isoforms of APH1a (S and L), as well as two presenilin genes, PSEN1 and PSEN2." qualityScore="0.0" bFilter="false" nerList="25490 25499 25508 25517 25526 25535 25544 25553"/><types:Sentence xmi:id="17361" sofa="12" begin="30006" end="30138" id="173" text="Therefore, it is plausible that a single mutation in PSEN1 confers different catalytic properties to distinct ��-secretase subtypes." qualityScore="0.0" bFilter="false" nerList="25587"/><types:Sentence xmi:id="17373" sofa="12" begin="30139" end="30246" id="174" text="This hypothesis is supported by recent investigations showing that APH1 variants can modulate A�� profiles." qualityScore="0.0" bFilter="false" nerList="25600"/><types:Sentence xmi:id="17385" sofa="12" begin="30247" end="30391" id="175" text="When compared to APH1aS or L, overexpression of APH1b in MEF knockout for all APH1 genes led to increased production of longer A�� species [24]." qualityScore="0.0" bFilter="false" nerList="25613 25622 25631"/><types:Sentence xmi:id="17397" sofa="12" begin="30392" end="30570" id="176" text="With this regard, it is important to note that all four mouse variants of APH1 are expressed in the MEF cell line used in previous studies [23] and employed here (cf. Figure S3)." qualityScore="0.0" bFilter="false" nerList="25650"/><types:Sentence xmi:id="17409" sofa="12" begin="30571" end="30952" id="177" text="Since the phenotype of PS1 mutations have mainly been assessed in vivo or in cell-based systems, we investigated the effects of FAD-linked PS1 mutants on the processing of APP-CTFs in cell-free systems, by using semi-purified and purified enzymatic complexes isolated from MEF PS1/PS2 double knockout cells stably overexpressing differentially tagged human ��-secretase components." qualityScore="0.0" bFilter="false" nerList="25663 25672 25681 25690 25699"/><types:Sentence xmi:id="17421" sofa="12" begin="30953" end="31176" id="178" text="Under these conditions, the biochemical and functional properties of ��-secretase complexes bearing either FAD-linked PS1 mutants (L166P, ��E9, and P436Q), dominant-negative forms of PS1 or wild-type PS1 were characterized." qualityScore="0.0" bFilter="false" nerList="25724 25733 25742 25751"/><types:Sentence xmi:id="17433" sofa="12" begin="31177" end="31420" id="179" text="The activity of ��-secretase with PS1-WT was similar to that reported for ��-secretase purified from our CHO cells overexpressing NCT-V5, APH1aL, Flag-PEN2 and PS1-WT [26], [27], that resulted in A��1���42/A��1���40 ratios between 0.1 and 0.3." qualityScore="0.0" bFilter="false" nerList="25773 25782 25791 25800 25809 25818 25827"/><types:Sentence xmi:id="17445" sofa="12" begin="31421" end="31581" id="180" text="In contrast, we found a major loss in the activity of ��-secretase complexes containing either the dominant-negative PS1 variants or the FAD-linked PS1 mutants." qualityScore="0.0" bFilter="false" nerList="25858 25867 25876"/><types:Sentence xmi:id="17457" sofa="12" begin="31582" end="31779" id="181" text="Although a total loss of activity was expected for the dominant negative forms of ��-secretase [5], [6], [32], the drastic loss of activity seen here with the FAD-linked PS1 mutants was unexpected." qualityScore="0.0" bFilter="false" nerList="25895"/><types:Sentence xmi:id="17469" sofa="12" begin="31780" end="31964" id="182" text="Indeed, the PS1-L166P variant has previously been reported to increase A��1���42 levels both in vivo [46] and in vitro [20], in the presence of endogenous PS1, PS2 and APH1 components." qualityScore="0.0" bFilter="false" nerList="25908 25917 25926 25935 25944"/><types:Sentence xmi:id="17481" sofa="12" begin="31965" end="32101" id="183" text="In contrast, Bentahir and colleagues found that PS1-L166P decreased both A��1���40 and A��1���42 production in a PS knockout background." qualityScore="0.0" bFilter="false" nerList="25969 25978"/><types:Sentence xmi:id="17493" sofa="12" begin="32102" end="32250" id="184" text="These results are consistent with our in vitro data, although the reduction in A��1���42 and A��1���40 production was more pronounced in our system." qualityScore="0.0" bFilter="false" nerList="25994 26003"/><types:Sentence xmi:id="17505" sofa="12" begin="32251" end="32383" id="185" text="However, they differ from our cell-based data in which we observed an increase in A��1���42 associated with a decrease in A��1���40." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17517" sofa="12" begin="32384" end="32541" id="186" text="Taken together, these data suggest that the overexpression of the other human components of ��-secretase can influence the phenotype of FAD-linked mutations." qualityScore="0.0" bFilter="false" nerList="26020"/><types:Sentence xmi:id="17529" sofa="12" begin="32542" end="32725" id="187" text="Another possible explanation for these discrepancies comes from the use, in previously described cellular systems, of APP carrying the Swedish mutation (K670M/N671L) [20], [23], [46]." qualityScore="0.0" bFilter="false" nerList="26033"/><types:Sentence xmi:id="17541" sofa="12" begin="32726" end="32859" id="188" text="Initially, this APP variant was shown to enhance the production of all A�� species by favouring its ��-secretase cleavage [47], [48]." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17553" sofa="12" begin="32860" end="33009" id="189" text="However, Munter and colleagues recently demonstrated that the APP Swedish mutation can also affect the specificity of the ��-secretase cleavage [49]." qualityScore="0.0" bFilter="false" nerList="26047"/><types:Sentence xmi:id="17565" sofa="12" begin="33010" end="33235" id="190" text="In particular, these authors showed that over-expression of APP Swedish in a neuronal cell line led to a 4-fold increase in secreted A��42, associated with only a 2-fold increase of total A��, compared with the wild-type APP." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17577" sofa="12" begin="33236" end="33396" id="191" text="Therefore, one cannot exclude the possibility of differential interactions between PS1-WT or PS1 variants and different APP variants, as suggested earlier [50]." qualityScore="0.0" bFilter="false" nerList="26061"/><types:Sentence xmi:id="17589" sofa="12" begin="33396" end="33671" id="192" text="As far as the PS1-��E9 mutant is concerned, previous cell-based studies have reported a decrease in A��40 levels associated with an increase in A��42 levels [51], [52], or no changes in A��40 levels despite increased A��42 levels [53], or a decrease in both A�� species [23]." qualityScore="0.0" bFilter="false" nerList="26074 26083 26092 26101"/><types:Sentence xmi:id="17601" sofa="12" begin="33672" end="33929" id="193" text="In the present study, A��1���40, A��1���42, as well as AICD levels generated from purified ��-secretase complexes with PS1-��E9 were close to the limit of detection, resulting in a loss of at least 95% of the ��-secretase activity compared to wild-type PS1." qualityScore="0.0" bFilter="false" nerList="26123 26132 26141 26150 26159 26168 26177"/><types:Sentence xmi:id="17613" sofa="12" begin="33930" end="34080" id="194" text="Similarly, we found a near to complete loss of ��-secretase activity for complexes with the aggressive PS1-P436Q mutant (mean onset: 28.3 years) [54]." qualityScore="0.0" bFilter="false" nerList="26208 26217"/><types:Sentence xmi:id="17625" sofa="12" begin="34081" end="34238" id="195" text="Consistent with a recent study [35], and in contrast to PS1-L166P, the maturation of the full-length PS1-P436Q protein into PS1-NTF and PS1-CTF was impaired." qualityScore="0.0" bFilter="false" nerList="26233 26242 26251 26260"/><types:Sentence xmi:id="17637" sofa="12" begin="34239" end="34566" id="196" text="Interestingly, the same study also reported that P436Q variant showed a decreased ��-secretase activity and A��40 and A��42 secretion in PS1/PS2 double knockout cells (~75% or ~50% of the control for A��40 or A��42, respectively), but to a lesser extent than what we measured in this study (more than 97% for both A�� species)." qualityScore="0.0" bFilter="false" nerList="26282 26291 26300 26309 26318"/><types:Sentence xmi:id="17649" sofa="12" begin="34566" end="34792" id="197" text="Overall, our data show that, under our experimental conditions, the FAD-linked PS1 mutants cause a drastic loss of activity (at least 90%) in the highly purified and homogeneous as well as semi-purified ��-secretase complexes." qualityScore="0.0" bFilter="false" nerList="26343 26352"/><types:Sentence xmi:id="17661" sofa="12" begin="34793" end="34903" id="198" text="This loss-of-function is asymmetrical as A��1���42 levels were relatively less affected than A��1���40 levels." qualityScore="0.0" bFilter="false" nerList="26368 26377"/><types:Sentence xmi:id="17673" sofa="12" begin="34904" end="35045" id="199" text="Interestingly, the ratio between the two A�� species was similar for the variants tested here (~1), suggesting a common modulatory mechanism." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17685" sofa="12" begin="35046" end="35264" id="200" text="Our findings further support a model in which the subtype of ��-secretase containing APH1aL and FAD-linked PS1 mutants generates a higher A��42/A��40 ratio compared to PS1-WT, as previously observed in vivo [15], [38]." qualityScore="0.0" bFilter="false" nerList="26394 26403 26412 26421"/><types:Sentence xmi:id="17697" sofa="12" begin="35265" end="35511" id="201" text="Taken together, the overall reduction in A�� levels strongly suggest that other regulatory mechanisms or cellular components may exist and account for the strong amyloid pathology observed in AD patients carrying these FAD-linked PSEN1 mutations." qualityScore="0.0" bFilter="false" nerList="26443 26452"/><types:Sentence xmi:id="17709" sofa="12" begin="35512" end="35682" id="202" text="In agreement with this hypothesis, we report that the phenotype of FAD-linked PSEN1 mutations is different whether we consider the cell-based or the cell-free conditions." qualityScore="0.0" bFilter="false" nerList="26468"/><types:Sentence xmi:id="17721" sofa="12" begin="35683" end="35815" id="203" text="Indeed, even if A��42/A��40 ratios were globally increased in both experimental conditions, A�� production was strikingly different." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17733" sofa="12" begin="35815" end="35947" id="204" text="One possible explanation would be that specific subtypes of ��-secretase complexes are less affected than others by PSEN1 mutations." qualityScore="0.0" bFilter="false" nerList="26482 26491"/><types:Sentence xmi:id="17745" sofa="12" begin="35948" end="36079" id="205" text="For instance, it remains unknown whether ��-secretase complexes carrying APH1b or APH1aS are similarly affected by PSEN1 mutations." qualityScore="0.0" bFilter="false" nerList="26507 26516 26525"/><types:Sentence xmi:id="17757" sofa="12" begin="36080" end="36371" id="206" text="In support to that regard, Winkler and colleagues recently purified human ��-secretase with PS1-L166P and observed that such complexes, containing both APH1a and AHP1b, led to increased A��1���42 production associated with decreased A��1���40 production, as compared to the PS1-WT complexes." qualityScore="0.0" bFilter="false" nerList="26544 26553 26562 26571 26580 26589"/><types:Sentence xmi:id="17769" sofa="12" begin="36372" end="36595" id="207" text="Another possible explanation would be that purified ��-secretase complexes lack binding partners modulating the processing of APP-based substrates, due to purification conditions affecting physical interactions of proteins." qualityScore="0.0" bFilter="false" nerList="26617"/><types:Sentence xmi:id="17781" sofa="12" begin="36596" end="36691" id="208" text="These include TMP21 or the recently reported ��-secretase activating protein (GSAP) [12], [13]." qualityScore="0.0" bFilter="false" nerList="26630 26639"/><types:Sentence xmi:id="17793" sofa="12" begin="36692" end="36756" id="209" text="Further biochemical analyses are needed to test this hypothesis." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17805" sofa="12" begin="36756" end="36860" id="210" text="The loss of activity in ��-secretase containing PS1 variants also leads to decreased generation of AICD." qualityScore="0.0" bFilter="false" nerList="26656 26665"/><types:Sentence xmi:id="17817" sofa="12" begin="36861" end="37087" id="211" text="As AICD is involved in the transcriptional regulation of several genes, including the neprilysin [55], and the lipoprotein receptor, LRP1 [11], it is likely that mutations in PSEN1 impair the regulation of these genes in vivo." qualityScore="0.0" bFilter="false" nerList="26681 26690"/><types:Sentence xmi:id="17829" sofa="12" begin="37088" end="37225" id="212" text="For instance, it is possible that unknown genes transcriptionally regulated in vivo by the AICD might influence A�� metabolism in return." qualityScore="0.0" bFilter="false" nerList="26706"/><types:Sentence xmi:id="17841" sofa="12" begin="37226" end="37458" id="213" text="In support to these views, Veeraraghavalu and colleagues recently demonstrated that Notch signalling was impaired in transgenic mice overexpressing PS1 mutants, albeit in the presence of endogenous PS1-WT and all APH1 isoforms [56]." qualityScore="0.0" bFilter="false" nerList="26719 26728 26737 26746"/><types:Sentence xmi:id="17853" sofa="12" begin="37459" end="37684" id="214" text="They found decreased self-renewal and differentiation of neuronal precursor cells in the subventricular zone, suggesting that the loss-of-function phenotype of PSEN1 mutations can also be observed in heterogeneous conditions." qualityScore="0.0" bFilter="false" nerList="26768"/><types:Sentence xmi:id="17865" sofa="12" begin="37685" end="37909" id="215" text="These results are reminiscent of the previous report from Saura and colleagues showing that conditional inactivation of both presenilins in vivo induces age-dependent neurodegeneration associated with memory impairment [57]." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="17877" sofa="12" begin="37910" end="38076" id="216" text="Altogether, the above-described data suggest that alternative pathways of neurodegeneration related to loss of ��-secretase functions are possible and relevant to AD." qualityScore="0.0" bFilter="false" nerList="26782"/><types:Sentence xmi:id="17889" sofa="12" begin="38077" end="38232" id="217" text="They further support the concept that modulating rather than inhibiting ��-secretase activity would be a more appropriate therapeutic strategy for AD [58]." qualityScore="0.0" bFilter="false" nerList="26795"/><types:Sentence xmi:id="17901" sofa="12" begin="38233" end="38443" id="218" text="Supporting this view, the ��-secretase inhibitor Semagacestat tested in phase III clinical trials not only failed to slow cognitive decline in patients with mild-to-moderate AD, but actually made it worse [59]." qualityScore="0.0" bFilter="false" nerList="26808"/><types:Sentence xmi:id="17913" sofa="12" begin="38443" end="38708" id="219" text="Collectively, our findings support a model in which FAD-linked mutations in PSEN1 likely induce A�� pathology by perturbing the relative ratio between A�� species and by impairing developmental and cellular signalling pathways controlled by ��-secretase substrates." qualityScore="0.0" bFilter="false" nerList="26821 26830"/><types:Sentence xmi:id="17925" sofa="12" begin="38709" end="38821" id="220" text="This deleterious dual effect might explain why FAD-linked PSEN1 mutations cause early onset Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="26846"/><types:Sentence xmi:id="17937" sofa="12" begin="38822" end="39204" id="221" text="Since it has been established that A�� and AICD are generated following the processing by ��-secretase at two distinct gamma- and epsilon-cleavage sites in APP [60], further investigation is now required to better understand whether and how FAD mutations in PS1 differentially affect the epsilon versus gamma-cleavage sites in APP, as well as in other known ��-secretase substrates." qualityScore="0.0" bFilter="false" nerList="26859 26868 26877 26886 26895 26904 26913 26922"/><types:Sentence xmi:id="17949" sofa="12" begin="39204" end="39429" id="222" text="Materials and Methods Top DNA Constructs and mutagenesisNCT-V5, Flag-PEN2, APH1aL-HA, wild-type PS1 human cDNAs (PS1-WT) were obtained from D. Selkoe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA)." qualityScore="0.0" bFilter="false" nerList="26956 26965 26974 26983 26992"/><types:Sentence xmi:id="17961" sofa="12" begin="39430" end="39515" id="223" text="PS1 ��E9 cDNA was obtained from C. Saura (Universitat Aut��noma de Barcelona, Spain)." qualityScore="0.0" bFilter="false" nerList="27017"/><types:Sentence xmi:id="17973" sofa="12" begin="39516" end="39649" id="224" text="PS1 D257A and PS1 D385A cDNAs were obtained from M. Wolfe (Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA)." qualityScore="0.0" bFilter="false" nerList="27030 27039"/><types:Sentence xmi:id="17985" sofa="12" begin="39650" end="40127" id="225" text="Mutations in PSEN1, namely, L166P and P436Q, were generated by PCR-based mutagenesis on the plasmid pcDNA3.1/Zeo(+)-PS1-WT using T7 or BGH primers (specific to the plasmid DNA sequence) together with the corresponding primers: L166P Rv: 5��� CAG CAA CAA Taa gct tGA TAT AAT AGG 3���; L166P Fw: 5��� CTT ATT ATA TCa agc ttA TTG TTG CTG 3���; P436Q Rv: 5��� TCG AGT TTA Gaa gct tTC TTG AAA ATG GCA AGG AG 3���; P436Q Fw: 5��� TCG AGT TTA Gaa gct tTG CCA GCT CTT CAA ATC TCC 3���." qualityScore="0.0" bFilter="false" nerList="27055 27064 27073 27082 27091 27100 27109 27118 27127 27136 27145"/><types:Sentence xmi:id="17997" sofa="12" begin="40128" end="40211" id="226" text="The sequences corresponding to enzyme restriction sites are given in small letters." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18009" sofa="12" begin="40212" end="40330" id="227" text="The PCR fragments were next digested with BamHI/HindIII and HindIII/XhoI respectively, and were subcloned into pcDNA3." qualityScore="0.0" bFilter="false" nerList="27189 27198"/><types:Sentence xmi:id="18021" sofa="12" begin="40331" end="40450" id="228" text="PS1 D257A/D385A (DDAA) was obtained by subcloning the DraI/XhoI digested fragment of PS1 D385A into pcDNA3.1-PS1 D257A." qualityScore="0.0" bFilter="false" nerList="27214 27223 27232"/><types:Sentence xmi:id="18033" sofa="12" begin="40451" end="40924" id="229" text="The APP based substrate SPA4CT-Flag, corresponding to the signal peptide of APP fused to the APP-C99-Flag with a small linker region (DA) [36], was obtained by removing the HindIII/EcoRI fragment of pcDNA3-APP695-Flag and inserting the following annealed primers: 5��� AGC TTA TGC TGC CCG GTT TG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT CGG GCG GAT GCA GAT GCA G 3��� and 5��� AAT TCT GCA TCT GCA TCC GCC CGA GCC GTC CAG GCG GCC AGC AGG AGC AGT GCC AAA CCG GGC AGC ATA 3���." qualityScore="0.0" bFilter="false" nerList="27251 27260 27269 27278 27287 27296"/><types:Sentence xmi:id="18045" sofa="12" begin="40925" end="41097" id="230" text="All constructs were next subcloned into the self-inactivated vector pSIN-PGK-WHV cassette (a kind gift from R. Zufferey, Brain Mind Institute, EPFL, Lausanne, Switzerland)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18057" sofa="12" begin="41098" end="41206" id="231" text="Inserts for plasmids pET21-C100-Flag, and pET21-C100-His were generated by PCR as previously described [27]." qualityScore="0.0" bFilter="false" nerList="27325 27334"/><types:Sentence xmi:id="18069" sofa="12" begin="41207" end="41316" id="232" text="Plasmids pMD2G and psPAX2 were obtained from D. Trono (Global Health Institute, EPFL, Lausanne, Switzerland)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18081" sofa="12" begin="41316" end="41502" id="233" text="Lentivector productionReplication-defective lentiviral particles were produced by a three-plasmid transient transfection of cells from the human embryonic kidney HEK 293T cell line [61]." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18093" sofa="12" begin="41503" end="41775" id="234" text="Briefly, cells were incubated in 10 cm dishes until they reached 70% confluence and were transiently co-transfected by the calcium phosphate method, with 5 ��g of envelope plasmid (pMD2G), 15 ��g of packaging plasmid (psPAX2), and 20 ��g of vector plasmids (pSIN-PGK-WHV)." qualityScore="0.0" bFilter="false" nerList="27352"/><types:Sentence xmi:id="18105" sofa="12" begin="41776" end="41942" id="235" text="Cells were incubated overnight with DNA-calcium precipitates, washed twice with Dulbecco's modified Eagle's medium (DMEM, Invitrogen) and incubated with 7 mL of DMEM." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18117" sofa="12" begin="41943" end="42165" id="236" text="After 24 h, the conditioned medium was harvested and cells were incubated a second time with 7 mL of DMEM for 24 h. Media were then pooled, passed through 0.45 ��m filter, and stored at ���80��C as 2 mL aliquots until use." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18129" sofa="12" begin="42166" end="42302" id="237" text="A p24 ELISA (Zeptometrix corporation) was performed on each batch of media in order to evaluate the number of viral particles generated." qualityScore="0.0" bFilter="false" nerList="27367"/><types:Sentence xmi:id="18141" sofa="12" begin="42302" end="42667" id="238" text="Generation of stable cell lines through multiple gene transductionsMouse Embryonic Fibroblasts (MEFs, obtained from B. De Strooper, Flanders University Institute of Biotechnology, Belgium) defective in PSEN1 and PSEN2 [30], [31] were cultivated in 10 cm dishes in DMEM, supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin (P/S) (Invitrogen)." qualityScore="0.0" bFilter="false" nerList="27380 27389"/><types:Sentence xmi:id="18153" sofa="12" begin="42668" end="42849" id="239" text="A first set of stable cell lines was generated by co-transducing NCT-V5, APH1aL-HA, and Flag-PEN2 containing lentiviral vectors (LV) repeatedly for two weeks at each passage (1/20)." qualityScore="0.0" bFilter="false" nerList="27405 27414"/><types:Sentence xmi:id="18165" sofa="12" begin="42850" end="42999" id="240" text="Ten clones were isolated by the limiting dilution method and were further screened for NCT-V5, Flag-PEN2 and APH1aL-HA expression by immunodetection." qualityScore="0.0" bFilter="false" nerList="27430 27439 27448"/><types:Sentence xmi:id="18177" sofa="12" begin="43000" end="43336" id="241" text="The clone that showed the highest expression of the three proteins (designated �� - PS1/2) was used as the parental cell line to generate the stable cell lines expressing different PS1 variants, by the same method and by using lentiviral vectors carrying human PS1-WT, PS1-L166P, PS1-��E9, PS1-P436Q, PS1-D257A, PS1-D385A, and PS1-DDAA." qualityScore="0.0" bFilter="false" nerList="27467 27476 27485 27494 27503 27512 27521 27530"/><types:Sentence xmi:id="18189" sofa="12" begin="43337" end="43477" id="242" text="For each PS1 variant, five clones were selected for a full characterization and two of them were further used for ��-secretase purification." qualityScore="0.0" bFilter="false" nerList="27564"/><types:Sentence xmi:id="18201" sofa="12" begin="43478" end="43957" id="243" text="For SPA4CT overexpression experiments, 500,000 cells of each clone were exposed to the same arbitrary dose of lentiviral vectors carrying human SPA4CT-Flag in 2 mL of DMEM, 1% FBS, P/S and were plated in 6-wells plates for 72 h. The medium was next replaced by fresh DMEM, 2% FBS, P/S for 24 h. Finally, cell culture medium was harvested, supplemented with protease inhibitor cocktail (Roche), centrifuged for 3 min at 1,000�� rpm and frozen at ���80��C until further processing." qualityScore="0.0" bFilter="false" nerList="27577 27586 27595"/><types:Sentence xmi:id="18213" sofa="12" begin="43958" end="44019" id="244" text="Cells were washed in PBS and submitted to protein extraction." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18225" sofa="12" begin="44019" end="44605" id="245" text="Protein extractionTotal protein extracts were prepared in 1% NP40 - HEPES buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche), and were clarified by centrifugation for 1 h at 16,000�� g, 4��C. Cell membranes were obtained as described below and solubilised in 1% CHAPSO - HEPES buffer and centrifuged at 16,000�� g for 1 h. Supernatants corresponding to the microsomal protein extracts were harvested and stored at ���80��C. Protein content of the extracts was estimated by the BCA protein assay reagent kit (Pierce)." qualityScore="0.0" bFilter="false" nerList="27615 27624 27633"/><types:Sentence xmi:id="18237" sofa="12" begin="44605" end="44718" id="246" text="Multi-step purification of human ��-secretase complexes with FAD-linked PS1 variants1) Cell membrane preparation." qualityScore="0.0" bFilter="false" nerList="27652 27661"/><types:Sentence xmi:id="18249" sofa="12" begin="44719" end="45104" id="247" text="MEF PS1/PS2 DKO cells (1.0��109 cells) expressing NCT-V5, Flag-PEN2, APH1aL-HA and different forms of PS1: wild type (WT), or with FAD-linked variants or lacking the critical aspartate residues, were collected from 15 cm dishes and fully resuspended in 40 mL of MES buffer (50 mM MES, pH 6.0, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2), supplemented with protease inhibitor cocktail (Roche)." qualityScore="0.0" bFilter="false" nerList="27677 27686 27695 27704 27713 27722"/><types:Sentence xmi:id="18261" sofa="12" begin="45105" end="45253" id="248" text="Next, cells were passed four times through a high-pressure homogenizer (Emulsiflex-C5, Avestin Inc, ON Canada) at a pressure greater than 1,000 psi." qualityScore="0.0" bFilter="false" nerList="27750"/><types:Sentence xmi:id="18273" sofa="12" begin="45254" end="45389" id="249" text="Nuclei and unbroken cells were removed by centrifugation at 3,000�� g for 20 min at 4��C in a Beckman Coulter Allegra X-15R centrifuge." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18285" sofa="12" begin="45390" end="45587" id="250" text="The supernatant was collected and centrifuged at 100,000�� g for 1 h at 4��C in a SW32Ti rotor using a Beckman Coulter Optima L-80 ultracentrifuge to recover the membrane preparation in the pellet." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18297" sofa="12" begin="45588" end="45608" id="251" text="2) Bicarbonate wash." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18309" sofa="12" begin="45609" end="45800" id="252" text="The membrane pellet was fully resuspended in 1.6 mL of ice cold sodium bicarbonate buffer (0.1 M NaHCO3, pH 11.3) by pipetting up and down at least 30 times, and incubated at 4��C for 20 min." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18321" sofa="12" begin="45801" end="45908" id="253" text="The washed membranes were then centrifuged at 100,000�� g for 1 h at 4��C and stored at ���80��C until use." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18333" sofa="12" begin="45909" end="45953" id="254" text="3) Solubilisation of ��-secretase complexes." qualityScore="0.0" bFilter="false" nerList="27768"/><types:Sentence xmi:id="18345" sofa="12" begin="45954" end="46091" id="255" text="The bicarbonate-washed membranes were fully resuspended in 1.7 mL of 1% CHAPSO - HEPES buffer by pipetting up and down at least 30 times." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18357" sofa="12" begin="46092" end="46289" id="256" text="The membranes were then incubated at 4��C for 1 h. To pellet the insoluble material, the solution was centrifuged at 16,000�� g at 4��C for 1 h, the pellet was discarded, and the supernatant saved." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18369" sofa="12" begin="46290" end="46359" id="257" text="This lysate is defined as ���solubilised ��-secretase preparation���." qualityScore="0.0" bFilter="false" nerList="27783"/><types:Sentence xmi:id="18381" sofa="12" begin="46360" end="46495" id="258" text="Next, these freshly prepared solubilised preparations were used for affinity purification of ��-secretase complexes as described below." qualityScore="0.0" bFilter="false" nerList="27796"/><types:Sentence xmi:id="18393" sofa="12" begin="46496" end="46534" id="259" text="4) Anti-Flag M2 affinity purification." qualityScore="0.0" bFilter="false" nerList="27809"/><types:Sentence xmi:id="18405" sofa="12" begin="46535" end="46960" id="260" text="The solubilised ��-secretase preparations were first diluted 1:2 with HEPES buffer, and further diluted 1:6 with 0.1% digitonin - TBS buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) (final detergent concentration: 0.08% CHAPSO, 0.08% digitonin) and incubated overnight at 4��C with agitation after adding 200 ��L of anti-Flag M2 affinity resin beads (Sigma-Aldrich) that had been pre-equilibrated in 0.1% Digitonin - TBS buffer." qualityScore="0.0" bFilter="false" nerList="27822 27831"/><types:Sentence xmi:id="18417" sofa="12" begin="46961" end="47145" id="261" text="The beads were washed 3 times in the same buffer, and the bound proteins were eluted over 4 h at 4��C with 0.4 mL of this buffer containing 200 ��g/mL of Flag peptides (Sigma-Aldrich)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18429" sofa="12" begin="47146" end="47284" id="262" text="This elution step was repeated once for 1 h at 4��C and the eluted fractions were pooled and designated ���M2 pooled 800 ��L fractions���." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18441" sofa="12" begin="47285" end="47318" id="263" text="5) Anti-V5 affinity purification." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18453" sofa="12" begin="47319" end="47563" id="264" text="The M2 pooled fractions (volume made up to 1 mL with 0.1% Digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-V5 affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin-TBS buffer." qualityScore="0.0" bFilter="false" nerList="27850"/><types:Sentence xmi:id="18465" sofa="12" begin="47564" end="47745" id="265" text="The beads were washed 3 times in the same buffer, and the bound proteins were eluted for 1 h at 4��C with 0.4 mL of this buffer containing 500 ��g/mL of V5 peptides (Sigma-Aldrich)." qualityScore="0.0" bFilter="false" nerList="27863"/><types:Sentence xmi:id="18477" sofa="12" begin="47746" end="47871" id="266" text="This elution step was repeated 4 times, and the eluted fractions were pooled and designated ���V5 pooled 1.6 mL fractions���." qualityScore="0.0" bFilter="false" nerList="27876"/><types:Sentence xmi:id="18489" sofa="12" begin="47872" end="47905" id="267" text="6) Anti-HA affinity purification." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18501" sofa="12" begin="47906" end="48184" id="268" text="As a final purification step, the V5 pooled fractions (volume made up to 1.8 mL with 0.1% digitonin - TBS buffer) were next incubated overnight at 4��C under agitation with 200 ��L of anti-HA affinity resin beads (Sigma-Aldrich), pre-equilibrated in 0.1% digitonin - TBS buffer." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18513" sofa="12" begin="48185" end="48368" id="269" text="The beads were washed 3 times in the same buffer, and the bound proteins were eluted overnight at 4��C with 0.2 mL of this buffer containing 200 ��g/mL of HA peptides (Sigma-Aldrich)." qualityScore="0.0" bFilter="false" nerList="27891"/><types:Sentence xmi:id="18525" sofa="12" begin="48369" end="48531" id="270" text="This elution step was repeated once, for 1 h at 4��C, and the two eluted fractions were kept separately, designated ���HA fraction E1��� and ���HA fraction E2���." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18537" sofa="12" begin="48531" end="48606" id="271" text="Co-immunoprecipitationCo-IPs were performed on microsomal protein extracts." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18549" sofa="12" begin="48607" end="48848" id="272" text="Briefly, 100 ��g of proteins were diluted in a final volume of 1 mL of 1% CHAPSO - HEPES extraction buffer containing protease inhibitors (Roche), and 50 ��L of pre-equilibrated anti-Flag or anti-HA affinity beads (Sigma-Aldrich) were added." qualityScore="0.0" bFilter="false" nerList="27906 27915"/><types:Sentence xmi:id="18561" sofa="12" begin="48849" end="48972" id="273" text="Samples were next incubated overnight at 4��C on a rotator wheel and were washed three times in 0.2% CHAPSO - HEPES buffer." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18573" sofa="12" begin="48973" end="49092" id="274" text="Finally, beads were resuspended in 50 ��L of 0.2% CHAPSO - HEPES buffer and were used for in vitro ��-secretase assays." qualityScore="0.0" bFilter="false" nerList="27932"/><types:Sentence xmi:id="18585" sofa="12" begin="49092" end="49211" id="275" text="In vitro ��-secretase activity assaysIn vitro ��-secretase activity assays were performed as previously described [27]." qualityScore="0.0" bFilter="false" nerList="27945 27954"/><types:Sentence xmi:id="18597" sofa="12" begin="49214" end="49607" id="276" text="-Secretase APP-based substrates were expressed in E. coli transfected with plasmids pET21-C100-Flag or pET21-C100-His as a fusion protein consisting of a Met for translation initiation, and either the Flag tag sequence (C100-Flag) or the His tag sequence (C100-His), and were affinity purified using an anti-Flag resin (M2, Sigma-Aldrich) or an Ni-NTA agarose resin (Invitrogen), respectively." qualityScore="0.0" bFilter="false" nerList="27970 27979 27988"/><types:Sentence xmi:id="18609" sofa="12" begin="49608" end="49765" id="277" text="In vitro assays were performed at 37��C for 4 h, with 1 ��M of recombinant substrate, 0.025% phosphatidylethanolamine (PE) and 0.1% phosphatidylcholine (PC)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18621" sofa="12" begin="49768" end="50202" id="278" text="-Secretase activity was quantified by measuring the amount of AICD and A�� generated during the reaction, by immunoblot or sandwich ELISA respectively, as described below.SDS-PAGE, Native PAGE, Western blotting and antibodiesTotal or microsomal protein extracts were resolved by electrophoresis on NuPAGE�� Novex�� 4���12% Bis-Tris Gels (Invitrogen) or on standard 12% acrylamide/bisacrylamide Tris Glycine gels for SDS-PAGE analysis." qualityScore="0.0" bFilter="false" nerList="28008 28017 28026"/><types:Sentence xmi:id="18633" sofa="12" begin="50203" end="50352" id="279" text="Purified ��-secretase was resolved by electrophoresis on NativePAGE��� Novex�� Bis-Tris 4���16% Gels for Blue Native (BN)-PAGE analysis (Invitrogen)." qualityScore="0.0" bFilter="false" nerList="28045"/><types:Sentence xmi:id="18645" sofa="12" begin="50353" end="50447" id="280" text="Silver staining was performed directly on gel according to manufacturer instructions (Biorad)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18657" sofa="12" begin="50448" end="50902" id="281" text="For immunoblot analysis, gels were transferred to nitrocellulose or PVDF membranes (Whatman), and probed with the following antibodies: anti-Nicastrin NCT164 (BD Bioscience), anti-V5-tag for NCT-V5 (Covance), MAB1563 (Millipore) or ab10281 (Abcam) for PS1 NTF, MAB5232 for PS1 CTF (Millipore), 3F10 for APH1aL-HA (Roche), anti-Flag M2 for Flag-PEN-2 or C100-Flag (Sigma-Aldrich), A8717 for APP CTF (Sigma-Aldrich), and A2066 for ��-actin (Sigma-Aldrich)." qualityScore="0.0" bFilter="false" nerList="28059 28068 28077 28086 28095 28104 28113 28122 28131 28140 28149 28158 28167 28176"/><types:Sentence xmi:id="18669" sofa="12" begin="50903" end="50984" id="282" text="Anti-mouse/rabbit/rat IgG conjugated to Alexa 680 were purchased from Invitrogen." qualityScore="0.0" bFilter="false" nerList="28228"/><types:Sentence xmi:id="18681" sofa="12" begin="50985" end="51071" id="283" text="The Odyssey infrared imaging system (LICOR) was used to detect the fluorescent signal." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18693" sofa="12" begin="51071" end="51248" id="284" text="Quantification of A�� peptidesA�� peptides from the ��-secretase assays described above were quantified by sandwich ELISA according to the protocol provided by the manufacturer." qualityScore="0.0" bFilter="false" nerList="28242 28251"/><types:Sentence xmi:id="18705" sofa="12" begin="51249" end="51370" id="285" text="Three kits were used to detect human A��1���40(Invitrogen KHB3481) and A��1���42 (Invitrogen KHB3544 and Wako 269-64401)." qualityScore="0.0" bFilter="false" nerList="28267 28276 28285"/><types:Sentence xmi:id="18717" sofa="12" begin="51370" end="51407" id="286" text="Supporting Information Top Figure S1." qualityScore="0.0" bFilter="false" nerList="28304"/><types:Sentence xmi:id="18729" sofa="12" begin="51408" end="51511" id="287" text="Characterization of stable cell lines overexpressing human FAD-linked PS1 variants in MEF PS1/2���/���." qualityScore="0.0" bFilter="false" nerList="28317"/><types:Sentence xmi:id="18741" sofa="12" begin="51512" end="51758" id="288" text="Presenilin double-knockout mouse embryonic fibroblasts were stably transduced with lentiviral vectors carrying genes encoding hPS1 variants harbouring FAD-linked mutations or mutations in the catalytic aspartate residue(s), or PS1-WT, and cloned." qualityScore="0.0" bFilter="false" nerList="28330"/><types:Sentence xmi:id="18753" sofa="12" begin="51759" end="51821" id="289" text="Two clones per PS1 variant were selected for characterization." qualityScore="0.0" bFilter="false" nerList="28343"/><types:Sentence xmi:id="18765" sofa="12" begin="51822" end="52166" id="290" text="(A) Whole cell protein extracts of the different cell lines were prepared in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with various antibodies to detect the endogenous ��-secretase core components: NCT (NCT164), hPS1 (NTF, MAB1563), and PEN2 (UD1), and with an antibody for APP (A8717)." qualityScore="0.0" bFilter="false" nerList="28356 28365 28374 28383 28392 28401 28410"/><types:Sentence xmi:id="18777" sofa="12" begin="52169" end="52206" id="291" text="-Actin was used as a loading control." qualityScore="0.0" bFilter="false" nerList="28441"/><types:Sentence xmi:id="18789" sofa="12" begin="52207" end="52247" id="292" text="Each lane represents one selected clone." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18801" sofa="12" begin="52248" end="52356" id="293" text="(B) ��-Secretase activity assays were performed with microsomal extracts prepared in 1% CHAPSO-HEPES buffer." qualityScore="0.0" bFilter="false" nerList="28455"/><types:Sentence xmi:id="18813" sofa="12" begin="52357" end="52554" id="294" text="Equal protein levels from the different extracts were diluted to 0.25% CHAPSO-HEPES buffer and incubated for 4 h at 37��C with lipids and 1 ��M of recombinant human APP-based substrate (C100-Flag)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18825" sofa="12" begin="52555" end="52649" id="295" text="Samples were analyzed by SDS-PAGE and immunostained with anti-Flag (M2) or anti-PS1 (MAB1563)." qualityScore="0.0" bFilter="false" nerList="28469"/><types:Sentence xmi:id="18837" sofa="12" begin="52650" end="52717" id="296" text="PS1 immunostaining was used to assess the amount of input material." qualityScore="0.0" bFilter="false" nerList="28482"/><types:Sentence xmi:id="18849" sofa="12" begin="52718" end="52866" id="297" text="* Indicates a non-specific band, which was not detected in microsomal protein extracts of the same cell lines using the same antibody (MAB1563) (B)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18873" sofa="12" begin="53008" end="53023" id="298" text="CTF: C-terminal fragment, FL: full-length, im.: immature NCT; m.: mature NCT, N: N-glycosylated, NTF: N-terminal fragment, O: O-glycosylated. (TIF)Figure S2." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18885" sofa="12" begin="53024" end="53121" id="299" text="APP-CTF profiles in WT MEF, MEF PS1/2���/��� and �� - PS1/2 transduced with the SPA4CT construct." qualityScore="0.0" bFilter="false" nerList="28497 28506 28515"/><types:Sentence xmi:id="18897" sofa="12" begin="53122" end="53323" id="300" text="WT MEF, MEF PS1/2���/��� and �� - PS1/2 were transduced with an APP-based substrate corresponding to the 99 C-terminal residues of human APP fused to the APP signal peptide in N-terminus (SPA4CT [36])." qualityScore="0.0" bFilter="false" nerList="28534 28543 28552 28561"/><types:Sentence xmi:id="18921" sofa="12" begin="53518" end="53533" id="301" text="Cell proteins were extracted in 1% NP40-HEPES buffer, separated by SDS-PAGE on 12% Tris-Glycine gels and analysed by immunostaining with an antibody targeting the C-terminal part of APP (A8717). (TIF)Figure S3." qualityScore="0.0" bFilter="false" nerList="28583"/><types:Sentence xmi:id="18933" sofa="12" begin="53534" end="53578" id="302" text="APH1 isoforms expressed in MEF PS1/2���/���." qualityScore="0.0" bFilter="false" nerList="28596"/><types:Sentence xmi:id="18945" sofa="12" begin="53579" end="53731" id="303" text="Total RNAs were extracted from presenilin double-knockout MEFs, using standard procedures (Qiagen RNAeasy kit) and were quantified by spectrophotometry." qualityScore="0.0" bFilter="false" nerList="28609"/><types:Sentence xmi:id="18957" sofa="12" begin="53732" end="54072" id="304" text="One microgram of total RNAs was reverse transcribed for 1 h at 42��C by using the ImProm-II reverse transcription system (Promega) and oligo-dT primer in a final volume of 20 ��L. PCR was next performed for each APH1 isoform on 1 ��L of RT reaction by using the Roche PCR kit under standard conditions and the primers described in Table S1." qualityScore="0.0" bFilter="false" nerList="28622"/><types:Sentence xmi:id="18969" sofa="12" begin="54073" end="54220" id="305" text="The following cycling conditions were applied for all reactions: 94��C, 3 min; 30 cycles of [94��C, 30 s; 58��C, 30 s; 70��C, 40 s]; 70��C, 10 min." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="18993" sofa="12" begin="54315" end="54329" id="306" text="PCR products were separated on a 2% agarose gel and visualized using Alpha Innotech UV imager. (TIF)Table S1." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19005" sofa="12" begin="54330" end="54387" id="307" text="Primers used to detect APH1 isoforms in MEF PS1/2���/���." qualityScore="0.0" bFilter="false" nerList="28637"/><types:Sentence xmi:id="19029" sofa="12" begin="54411" end="54684" id="308" text="F: Forward, R: Reverse. (DOC)Acknowledgments Top We are grateful to B. De Strooper for the WT and PS1���/��� PS2���/��� KO mouse embryonic fibroblasts, to C. Saura for the PS1 ��E9, to M. Wolfe for the PS1 D257A and PS1 D385A cDNAs, and to D. Selkoe for the APH1aL-HA, NCT-V5, and Flag-PEN2 cDNAs." qualityScore="0.0" bFilter="false" nerList="28650 28659 28668 28677 28686 28695 28704"/><types:Sentence xmi:id="19041" sofa="12" begin="54685" end="54782" id="309" text="We also thank J.R. Alattia, C. Schweizer, and A. Alahari for critical readings of the manuscript." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19053" sofa="12" begin="54782" end="54854" id="310" text="Author Contributions Top Conceived and designed the experiments: MC PCF." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19065" sofa="12" begin="54855" end="54891" id="311" text="Performed the experiments: MC LA JH." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19077" sofa="12" begin="54892" end="54924" id="312" text="Analyzed the data: MC LA JH PCF." qualityScore="0.0" bFilter="false" nerList="28738"/><types:Sentence xmi:id="19089" sofa="12" begin="54925" end="54949" id="313" text="Wrote the paper: MC PCF." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19101" sofa="12" begin="54950" end="54986" id="314" text="Edited the manuscript: MC LA JH PCF." qualityScore="0.0" bFilter="false" nerList="28752"/><types:Sentence xmi:id="19113" sofa="12" begin="54987" end="55015" id="315" text="Supervised the project: PCF." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19125" sofa="12" begin="55015" end="55241" id="316" text="References Top Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19137" sofa="12" begin="55242" end="55264" id="317" text="Nature 376: 775���778." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19149" sofa="12" begin="55265" end="55452" id="318" text="Find this article online Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19161" sofa="12" begin="55453" end="55475" id="319" text="Nature 375: 754���760." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19173" sofa="12" begin="55476" end="55623" id="320" text="Find this article online Weihofen A, Martoglio B (2003) Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides." qualityScore="0.0" bFilter="false" nerList="28770"/><types:Sentence xmi:id="19185" sofa="12" begin="55624" end="55653" id="321" text="Trends Cell Biol 13: 71���78." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19197" sofa="12" begin="55654" end="55838" id="322" text="Find this article online Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1." qualityScore="0.0" bFilter="false" nerList="28784"/><types:Sentence xmi:id="19209" sofa="12" begin="55839" end="55866" id="323" text="Nat Cell Biol 2: 428���434." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19221" sofa="12" begin="55867" end="56076" id="324" text="Find this article online Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity." qualityScore="0.0" bFilter="false" nerList="28798 28807"/><types:Sentence xmi:id="19233" sofa="12" begin="56077" end="56099" id="325" text="Nature 398: 513���517." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19245" sofa="12" begin="56100" end="56314" id="326" text="Find this article online Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ (2000) The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation." qualityScore="0.0" bFilter="false" nerList="28824 28833 28842"/><types:Sentence xmi:id="19257" sofa="12" begin="56315" end="56344" id="327" text="J Biol Chem 275: 3173���3178." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19269" sofa="12" begin="56345" end="56472" id="328" text="Find this article online Beel AJ, Sanders CR (2008) Substrate specificity of gamma-secretase and other intramembrane proteases." qualityScore="0.0" bFilter="false" nerList="28862"/><types:Sentence xmi:id="19281" sofa="12" begin="56473" end="56507" id="329" text="Cell Mol Life Sci 65: 1311���1334." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19293" sofa="12" begin="56508" end="56708" id="330" text="Find this article online Bot N, Schweizer C, Ben Halima S, Fraering PC (2010) Processing of the synaptic cell-adhesion molecule neurexin-3{beta} by Alzheimer's disease {alpha}- and {gamma}-secretases." qualityScore="0.0" bFilter="false" nerList="28876 28885"/><types:Sentence xmi:id="19305" sofa="12" begin="56709" end="56721" id="331" text="J Biol Chem." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19317" sofa="12" begin="56722" end="56810" id="332" text="Find this article online Parks AL, Curtis D (2007) Presenilin diversifies its portfolio." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19329" sofa="12" begin="56811" end="56838" id="333" text="Trends Genet 23: 140���150." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19341" sofa="12" begin="56839" end="57064" id="334" text="Find this article online Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase." qualityScore="0.0" bFilter="false" nerList="28904 28913"/><types:Sentence xmi:id="19353" sofa="12" begin="57065" end="57090" id="335" text="J Neurosci 25: 436���445." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19365" sofa="12" begin="57091" end="57297" id="336" text="Find this article online Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, et al. (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1." qualityScore="0.0" bFilter="false" nerList="28930 28939 28948 28957"/><types:Sentence xmi:id="19377" sofa="12" begin="57298" end="57317" id="337" text="Neuron 56: 66���78." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19389" sofa="12" begin="57318" end="57518" id="338" text="Find this article online Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, et al. (2006) TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity." qualityScore="0.0" bFilter="false" nerList="28980 28989 28998"/><types:Sentence xmi:id="19401" sofa="12" begin="57519" end="57543" id="339" text="Nature 440: 1208���1212." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19413" sofa="12" begin="57544" end="57707" id="340" text="Find this article online He G, Luo W, Li P, Remmers C, Netzer WJ, et al. (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="29018 29027"/><types:Sentence xmi:id="19425" sofa="12" begin="57708" end="57728" id="341" text="Nature 467: 95���98." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19437" sofa="12" begin="57729" end="57871" id="342" text="Find this article online Wakabayashi T, De Strooper B (2008) Presenilins: members of the gamma-secretase quartets, but part-time soloists too." qualityScore="0.0" bFilter="false" nerList="29044 29053"/><types:Sentence xmi:id="19449" sofa="12" begin="57872" end="57908" id="343" text="Physiology (Bethesda) 23: 194���204." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19461" sofa="12" begin="57909" end="58140" id="344" text="Find this article online Citron M, Westaway D, Xia W, Carlson G, Diehl T, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice." qualityScore="0.0" bFilter="false" nerList="29070 29079 29088"/><types:Sentence xmi:id="19473" sofa="12" begin="58141" end="58160" id="345" text="Nat Med 3: 67���72." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19485" sofa="12" begin="58161" end="58346" id="346" text="Find this article online Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, et al. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="29108"/><types:Sentence xmi:id="19497" sofa="12" begin="58347" end="58371" id="347" text="Neurology 59: 398���407." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19509" sofa="12" begin="58372" end="58534" id="348" text="Find this article online Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, et al. (1998) Increased Abeta42(43) from cell lines expressing presenilin 1 mutations." qualityScore="0.0" bFilter="false" nerList="29122 29131 29140"/><types:Sentence xmi:id="19521" sofa="12" begin="58535" end="58560" id="349" text="Ann Neurol 43: 256���258." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19533" sofa="12" begin="58561" end="58767" id="350" text="Find this article online Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, et al. (1999) Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="29160"/><types:Sentence xmi:id="19545" sofa="12" begin="58768" end="58795" id="351" text="Neurosci Lett 265: 61���63." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19557" sofa="12" begin="58796" end="59011" id="352" text="Find this article online Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, et al. (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability." qualityScore="0.0" bFilter="false" nerList="29174 29183 29192"/><types:Sentence xmi:id="19569" sofa="12" begin="59012" end="59039" id="353" text="J Neurosci 20: 8717���8726." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19581" sofa="12" begin="59040" end="59294" id="354" text="Find this article online Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production." qualityScore="0.0" bFilter="false" nerList="29212 29221"/><types:Sentence xmi:id="19593" sofa="12" begin="59295" end="59336" id="355" text="Proc Natl Acad Sci U S A 99: 8025���8030." qualityScore="0.0" bFilter="false" nerList="29237"/><types:Sentence xmi:id="19605" sofa="12" begin="59337" end="59575" id="356" text="Find this article online Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y (2003) Distinct mechanisms by mutant presenilin 1 and 2 leading toincreased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells." qualityScore="0.0" bFilter="false" nerList="29250"/><types:Sentence xmi:id="19617" sofa="12" begin="59576" end="59605" id="357" text="Biochemistry 42: 1042���1052." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19629" sofa="12" begin="59606" end="59873" id="358" text="Find this article online Dowjat WK, Kuchna I, Wisniewski T, Wegiel J (2004) A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations." qualityScore="0.0" bFilter="false" nerList="29264 29273 29282"/><types:Sentence xmi:id="19641" sofa="12" begin="59874" end="59902" id="359" text="J Alzheimers Dis 6: 31���43." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19653" sofa="12" begin="59903" end="60083" id="360" text="Find this article online Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, et al. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms." qualityScore="0.0" bFilter="false" nerList="29302"/><types:Sentence xmi:id="19665" sofa="12" begin="60084" end="60110" id="361" text="J Neurochem 96: 732���742." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19677" sofa="12" begin="60111" end="60301" id="362" text="Find this article online Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, et al. (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="29316 29325"/><types:Sentence xmi:id="19689" sofa="12" begin="60302" end="60325" id="363" text="Science 324: 639���642." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19701" sofa="12" begin="60326" end="60517" id="364" text="Find this article online Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, et al. (2003) Partial purification and characterization of gamma-secretase from post-mortem human brain." qualityScore="0.0" bFilter="false" nerList="29342"/><types:Sentence xmi:id="19713" sofa="12" begin="60518" end="60549" id="365" text="J Biol Chem 278: 24277���24284." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19725" sofa="12" begin="60550" end="60710" id="366" text="Find this article online Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, et al. (2004) Purification and characterization of the human gamma-secretase complex." qualityScore="0.0" bFilter="false" nerList="29356"/><types:Sentence xmi:id="19737" sofa="12" begin="60711" end="60740" id="367" text="Biochemistry 43: 9774���9789." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19749" sofa="12" begin="60741" end="60938" id="368" text="Find this article online Cacquevel M, Aeschbach L, Osenkowski P, Li D, Ye W, et al. (2008) Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="29370"/><types:Sentence xmi:id="19761" sofa="12" begin="60939" end="60966" id="369" text="J Neurochem 104: 210���220." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19773" sofa="12" begin="60967" end="61180" id="370" text="Find this article online Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, et al. (2006) Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores." qualityScore="0.0" bFilter="false" nerList="29384"/><types:Sentence xmi:id="19785" sofa="12" begin="61181" end="61223" id="371" text="Proc Natl Acad Sci U S A 103: 6889���6894." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19797" sofa="12" begin="61224" end="61389" id="372" text="Find this article online Osenkowski P, Li H, Ye W, Li D, Aeschbach L, et al. (2009) Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution." qualityScore="0.0" bFilter="false" nerList="29398"/><types:Sentence xmi:id="19809" sofa="12" begin="61390" end="61416" id="373" text="J Mol Biol 385: 642���652." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19821" sofa="12" begin="61417" end="61700" id="374" text="Find this article online Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, et al. (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency." qualityScore="0.0" bFilter="false" nerList="29412 29421"/><types:Sentence xmi:id="19833" sofa="12" begin="61701" end="61744" id="375" text="Proc Natl Acad Sci U S A 96: 11872���11877." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19845" sofa="12" begin="61745" end="61992" id="376" text="Find this article online Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, et al. (2003) gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation." qualityScore="0.0" bFilter="false" nerList="29438 29447"/><types:Sentence xmi:id="19857" sofa="12" begin="61993" end="62021" id="377" text="J Cell Sci 116: 1127���1136." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19869" sofa="12" begin="62022" end="62291" id="378" text="Find this article online Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, et al. (2003) Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin." qualityScore="0.0" bFilter="false" nerList="29464 29473"/><types:Sentence xmi:id="19881" sofa="12" begin="62292" end="62323" id="379" text="J Biol Chem 278: 43430���43436." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19893" sofa="12" begin="62324" end="62501" id="380" text="Find this article online Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo." qualityScore="0.0" bFilter="false" nerList="29490 29499"/><types:Sentence xmi:id="19905" sofa="12" begin="62502" end="62523" id="381" text="Neuron 17: 181���190." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19917" sofa="12" begin="62524" end="62713" id="382" text="Find this article online Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, et al. (2007) Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1." qualityScore="0.0" bFilter="false" nerList="29516 29525 29534"/><types:Sentence xmi:id="19929" sofa="12" begin="62714" end="62745" id="383" text="J Clin Invest 117: 1230���1239." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19941" sofa="12" begin="62746" end="62966" id="384" text="Find this article online Heilig EA, Xia W, Shen J, Kelleher RJ (2010) A presenilin-1 mutation identified in familial Alzheimer's disease with cotton wool plaques causes nearly complete loss of {gamma}-secretase activity." qualityScore="0.0" bFilter="false" nerList="29554 29563 29572"/><types:Sentence xmi:id="19953" sofa="12" begin="62967" end="62979" id="385" text="J Biol Chem." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19965" sofa="12" begin="62980" end="63135" id="386" text="Find this article online Lichtenthaler SF, Multhaup G, Masters CL, Beyreuther K (1999) A novel substrate for analyzing Alzheimer's disease gamma-secretase." qualityScore="0.0" bFilter="false" nerList="29592"/><types:Sentence xmi:id="19977" sofa="12" begin="63136" end="63164" id="387" text="FEBS letters 453: 288���292." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="19989" sofa="12" begin="63165" end="63434" id="388" text="Find this article online Fraering PC, LaVoie MJ, Ye W, Ostaszewski BL, Kimberly WT, et al. (2004) Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex." qualityScore="0.0" bFilter="false" nerList="29606 29615 29624"/><types:Sentence xmi:id="20001" sofa="12" begin="63435" end="63462" id="389" text="Biochemistry 43: 323���333." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20013" sofa="12" begin="63463" end="63621" id="390" text="Find this article online Duff K, Eckman C, Zehr C, Yu X, Prada CM, et al. (1996) Increased amyloid-beta42(43) in brainsof mice expressing mutant presenilin 1." qualityScore="0.0" bFilter="false" nerList="29644 29653 29662 29671"/><types:Sentence xmi:id="20025" sofa="12" begin="63622" end="63644" id="391" text="Nature 383: 710���713." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20037" sofa="12" begin="63645" end="63900" id="392" text="Find this article online Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20049" sofa="12" begin="63901" end="63920" id="393" text="Neuron 13: 45���53." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20061" sofa="12" begin="63921" end="64106" id="394" text="Find this article online Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, et al. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs." qualityScore="0.0" bFilter="false" nerList="29696 29705"/><types:Sentence xmi:id="20073" sofa="12" begin="64107" end="64134" id="395" text="J Biol Chem 267: 546���554." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20085" sofa="12" begin="64135" end="64363" id="396" text="Find this article online Jan A, Gokce O, Luthi-Carter R, Lashuel HA (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity." qualityScore="0.0" bFilter="false" nerList="29722 29731 29740"/><types:Sentence xmi:id="20097" sofa="12" begin="64364" end="64395" id="397" text="J Biol Chem 283: 28176���28189." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20109" sofa="12" begin="64396" end="64622" id="398" text="Find this article online Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="29760"/><types:Sentence xmi:id="20121" sofa="12" begin="64623" end="64652" id="399" text="Biochemistry 32: 4693���4697." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20133" sofa="12" begin="64653" end="64937" id="400" text="Find this article online Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease." qualityScore="0.0" bFilter="false" nerList="29774 29783 29792 29801"/><types:Sentence xmi:id="20145" sofa="12" begin="64938" end="64959" id="401" text="Nat Med 2: 864���870." qualityScore="0.0" bFilter="false" nerList=""/><types:Sentence xmi:id="20157" sofa="12" begin="64960" end="65181" id="402" text="Find this article online Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes." qualityScore="0.0" bFilter="false" nerList="29824 29833"/><types:Sentence xmi:id="20169" sofa="12" begin="65182" end="65202" id="403" text="Nat Med 4: 97���100." qualityScore="0.0" bFilter="false" nerList=""/><cas:NonEmptyFSList xmi:id="6075" head="1143" tail="6078"/><cas:NonEmptyFSList xmi:id="20193" head="15261" tail="20196"/><cas:EmptyFSList xmi:id="21405"/><cas:NonEmptyFSList xmi:id="21402" head="20169" tail="21405"/><cas:NonEmptyFSList xmi:id="21399" head="20157" tail="21402"/><cas:NonEmptyFSList xmi:id="21396" head="20145" tail="21399"/><cas:NonEmptyFSList xmi:id="21393" head="20133" tail="21396"/><cas:NonEmptyFSList xmi:id="21390" head="20121" tail="21393"/><cas:NonEmptyFSList xmi:id="21387" head="20109" tail="21390"/><cas:NonEmptyFSList xmi:id="21384" head="20097" tail="21387"/><cas:NonEmptyFSList xmi:id="21381" head="20085" tail="21384"/><cas:NonEmptyFSList xmi:id="21378" head="20073" tail="21381"/><cas:NonEmptyFSList xmi:id="21375" head="20061" tail="21378"/><cas:NonEmptyFSList xmi:id="21372" head="20049" tail="21375"/><cas:NonEmptyFSList xmi:id="21369" head="20037" tail="21372"/><cas:NonEmptyFSList xmi:id="21366" head="20025" tail="21369"/><cas:NonEmptyFSList xmi:id="21363" head="20013" tail="21366"/><cas:NonEmptyFSList xmi:id="21360" head="20001" tail="21363"/><cas:NonEmptyFSList xmi:id="21357" head="19989" tail="21360"/><cas:NonEmptyFSList xmi:id="21354" head="19977" tail="21357"/><cas:NonEmptyFSList xmi:id="21351" head="19965" tail="21354"/><cas:NonEmptyFSList xmi:id="21348" head="19953" tail="21351"/><cas:NonEmptyFSList xmi:id="21345" head="19941" tail="21348"/><cas:NonEmptyFSList xmi:id="21342" head="19929" tail="21345"/><cas:NonEmptyFSList xmi:id="21339" head="19917" tail="21342"/><cas:NonEmptyFSList xmi:id="21336" head="19905" tail="21339"/><cas:NonEmptyFSList xmi:id="21333" head="19893" tail="21336"/><cas:NonEmptyFSList xmi:id="21330" head="19881" tail="21333"/><cas:NonEmptyFSList xmi:id="21327" head="19869" tail="21330"/><cas:NonEmptyFSList xmi:id="21324" head="19857" tail="21327"/><cas:NonEmptyFSList xmi:id="21321" head="19845" tail="21324"/><cas:NonEmptyFSList xmi:id="21318" head="19833" tail="21321"/><cas:NonEmptyFSList xmi:id="21315" head="19821" tail="21318"/><cas:NonEmptyFSList xmi:id="21312" head="19809" tail="21315"/><cas:NonEmptyFSList xmi:id="21309" head="19797" tail="21312"/><cas:NonEmptyFSList xmi:id="21306" head="19785" tail="21309"/><cas:NonEmptyFSList xmi:id="21303" head="19773" tail="21306"/><cas:NonEmptyFSList xmi:id="21300" head="19761" tail="21303"/><cas:NonEmptyFSList xmi:id="21297" head="19749" tail="21300"/><cas:NonEmptyFSList xmi:id="21294" head="19737" tail="21297"/><cas:NonEmptyFSList xmi:id="21291" head="19725" tail="21294"/><cas:NonEmptyFSList xmi:id="21288" head="19713" tail="21291"/><cas:NonEmptyFSList xmi:id="21285" head="19701" tail="21288"/><cas:NonEmptyFSList xmi:id="21282" head="19689" tail="21285"/><cas:NonEmptyFSList xmi:id="21279" head="19677" tail="21282"/><cas:NonEmptyFSList xmi:id="21276" head="19665" tail="21279"/><cas:NonEmptyFSList xmi:id="21273" head="19653" tail="21276"/><cas:NonEmptyFSList xmi:id="21270" head="19641" tail="21273"/><cas:NonEmptyFSList xmi:id="21267" head="19629" tail="21270"/><cas:NonEmptyFSList xmi:id="21264" head="19617" tail="21267"/><cas:NonEmptyFSList xmi:id="21261" head="19605" tail="21264"/><cas:NonEmptyFSList xmi:id="21258" head="19593" tail="21261"/><cas:NonEmptyFSList xmi:id="21255" head="19581" tail="21258"/><cas:NonEmptyFSList xmi:id="21252" head="19569" tail="21255"/><cas:NonEmptyFSList xmi:id="21249" head="19557" tail="21252"/><cas:NonEmptyFSList xmi:id="21246" head="19545" tail="21249"/><cas:NonEmptyFSList xmi:id="21243" head="19533" tail="21246"/><cas:NonEmptyFSList xmi:id="21240" head="19521" tail="21243"/><cas:NonEmptyFSList xmi:id="21237" head="19509" tail="21240"/><cas:NonEmptyFSList xmi:id="21234" head="19497" tail="21237"/><cas:NonEmptyFSList xmi:id="21231" head="19485" tail="21234"/><cas:NonEmptyFSList xmi:id="21228" head="19473" tail="21231"/><cas:NonEmptyFSList xmi:id="21225" head="19461" tail="21228"/><cas:NonEmptyFSList xmi:id="21222" head="19449" tail="21225"/><cas:NonEmptyFSList xmi:id="21219" head="19437" tail="21222"/><cas:NonEmptyFSList xmi:id="21216" head="19425" tail="21219"/><cas:NonEmptyFSList xmi:id="21213" head="19413" tail="21216"/><cas:NonEmptyFSList xmi:id="21210" head="19401" tail="21213"/><cas:NonEmptyFSList xmi:id="21207" head="19389" tail="21210"/><cas:NonEmptyFSList xmi:id="21204" head="19377" tail="21207"/><cas:NonEmptyFSList xmi:id="21201" head="19365" tail="21204"/><cas:NonEmptyFSList xmi:id="21198" head="19353" tail="21201"/><cas:NonEmptyFSList xmi:id="21195" head="19341" tail="21198"/><cas:NonEmptyFSList xmi:id="21192" head="19329" tail="21195"/><cas:NonEmptyFSList xmi:id="21189" head="19317" tail="21192"/><cas:NonEmptyFSList xmi:id="21186" head="19305" tail="21189"/><cas:NonEmptyFSList xmi:id="21183" head="19293" tail="21186"/><cas:NonEmptyFSList xmi:id="21180" head="19281" tail="21183"/><cas:NonEmptyFSList xmi:id="21177" head="19269" tail="21180"/><cas:NonEmptyFSList xmi:id="21174" head="19257" tail="21177"/><cas:NonEmptyFSList xmi:id="21171" head="19245" tail="21174"/><cas:NonEmptyFSList xmi:id="21168" head="19233" tail="21171"/><cas:NonEmptyFSList xmi:id="21165" head="19221" tail="21168"/><cas:NonEmptyFSList xmi:id="21162" head="19209" tail="21165"/><cas:NonEmptyFSList xmi:id="21159" head="19197" tail="21162"/><cas:NonEmptyFSList xmi:id="21156" head="19185" tail="21159"/><cas:NonEmptyFSList xmi:id="21153" head="19173" tail="21156"/><cas:NonEmptyFSList xmi:id="21150" head="19161" tail="21153"/><cas:NonEmptyFSList xmi:id="21147" head="19149" tail="21150"/><cas:NonEmptyFSList xmi:id="21144" head="19137" tail="21147"/><cas:NonEmptyFSList xmi:id="21141" head="19125" tail="21144"/><cas:NonEmptyFSList xmi:id="21138" head="19113" tail="21141"/><cas:NonEmptyFSList xmi:id="21135" head="19101" tail="21138"/><cas:NonEmptyFSList xmi:id="21132" head="19089" tail="21135"/><cas:NonEmptyFSList xmi:id="21129" head="19077" tail="21132"/><cas:NonEmptyFSList xmi:id="21126" head="19065" tail="21129"/><cas:NonEmptyFSList xmi:id="21123" head="19053" tail="21126"/><cas:NonEmptyFSList xmi:id="21120" head="19041" tail="21123"/><cas:NonEmptyFSList xmi:id="21117" head="19029" tail="21120"/><cas:NonEmptyFSList xmi:id="21114" head="19005" tail="21117"/><cas:NonEmptyFSList xmi:id="21111" head="18993" tail="21114"/><cas:NonEmptyFSList xmi:id="21108" head="18969" tail="21111"/><cas:NonEmptyFSList xmi:id="21105" head="18957" tail="21108"/><cas:NonEmptyFSList xmi:id="21102" head="18945" tail="21105"/><cas:NonEmptyFSList xmi:id="21099" head="18933" tail="21102"/><cas:NonEmptyFSList xmi:id="21096" head="18921" tail="21099"/><cas:NonEmptyFSList xmi:id="21093" head="18897" tail="21096"/><cas:NonEmptyFSList xmi:id="21090" head="18885" tail="21093"/><cas:NonEmptyFSList xmi:id="21087" head="18873" tail="21090"/><cas:NonEmptyFSList xmi:id="21084" head="18849" tail="21087"/><cas:NonEmptyFSList xmi:id="21081" head="18837" tail="21084"/><cas:NonEmptyFSList xmi:id="21078" head="18825" tail="21081"/><cas:NonEmptyFSList xmi:id="21075" head="18813" tail="21078"/><cas:NonEmptyFSList xmi:id="21072" head="18801" tail="21075"/><cas:NonEmptyFSList xmi:id="21069" head="18789" tail="21072"/><cas:NonEmptyFSList xmi:id="21066" head="18777" tail="21069"/><cas:NonEmptyFSList xmi:id="21063" head="18765" tail="21066"/><cas:NonEmptyFSList xmi:id="21060" head="18753" tail="21063"/><cas:NonEmptyFSList xmi:id="21057" head="18741" tail="21060"/><cas:NonEmptyFSList xmi:id="21054" head="18729" tail="21057"/><cas:NonEmptyFSList xmi:id="21051" head="18717" tail="21054"/><cas:NonEmptyFSList xmi:id="21048" head="18705" tail="21051"/><cas:NonEmptyFSList xmi:id="21045" head="18693" tail="21048"/><cas:NonEmptyFSList xmi:id="21042" head="18681" tail="21045"/><cas:NonEmptyFSList xmi:id="21039" head="18669" tail="21042"/><cas:NonEmptyFSList xmi:id="21036" head="18657" tail="21039"/><cas:NonEmptyFSList xmi:id="21033" head="18645" tail="21036"/><cas:NonEmptyFSList xmi:id="21030" head="18633" tail="21033"/><cas:NonEmptyFSList xmi:id="21027" head="18621" tail="21030"/><cas:NonEmptyFSList xmi:id="21024" head="18609" tail="21027"/><cas:NonEmptyFSList xmi:id="21021" head="18597" tail="21024"/><cas:NonEmptyFSList xmi:id="21018" head="18585" tail="21021"/><cas:NonEmptyFSList xmi:id="21015" head="18573" tail="21018"/><cas:NonEmptyFSList xmi:id="21012" head="18561" tail="21015"/><cas:NonEmptyFSList xmi:id="21009" head="18549" tail="21012"/><cas:NonEmptyFSList xmi:id="21006" head="18537" tail="21009"/><cas:NonEmptyFSList xmi:id="21003" head="18525" tail="21006"/><cas:NonEmptyFSList xmi:id="21000" head="18513" tail="21003"/><cas:NonEmptyFSList xmi:id="20997" head="18501" tail="21000"/><cas:NonEmptyFSList xmi:id="20994" head="18489" tail="20997"/><cas:NonEmptyFSList xmi:id="20991" head="18477" tail="20994"/><cas:NonEmptyFSList xmi:id="20988" head="18465" tail="20991"/><cas:NonEmptyFSList xmi:id="20985" head="18453" tail="20988"/><cas:NonEmptyFSList xmi:id="20982" head="18441" tail="20985"/><cas:NonEmptyFSList xmi:id="20979" head="18429" tail="20982"/><cas:NonEmptyFSList xmi:id="20976" head="18417" tail="20979"/><cas:NonEmptyFSList xmi:id="20973" head="18405" tail="20976"/><cas:NonEmptyFSList xmi:id="20970" head="18393" tail="20973"/><cas:NonEmptyFSList xmi:id="20967" head="18381" tail="20970"/><cas:NonEmptyFSList xmi:id="20964" head="18369" tail="20967"/><cas:NonEmptyFSList xmi:id="20961" head="18357" tail="20964"/><cas:NonEmptyFSList xmi:id="20958" head="18345" tail="20961"/><cas:NonEmptyFSList xmi:id="20955" head="18333" tail="20958"/><cas:NonEmptyFSList xmi:id="20952" head="18321" tail="20955"/><cas:NonEmptyFSList xmi:id="20949" head="18309" tail="20952"/><cas:NonEmptyFSList xmi:id="20946" head="18297" tail="20949"/><cas:NonEmptyFSList xmi:id="20943" head="18285" tail="20946"/><cas:NonEmptyFSList xmi:id="20940" head="18273" tail="20943"/><cas:NonEmptyFSList xmi:id="20937" head="18261" tail="20940"/><cas:NonEmptyFSList xmi:id="20934" head="18249" tail="20937"/><cas:NonEmptyFSList xmi:id="20931" head="18237" tail="20934"/><cas:NonEmptyFSList xmi:id="20928" head="18225" tail="20931"/><cas:NonEmptyFSList xmi:id="20925" head="18213" tail="20928"/><cas:NonEmptyFSList xmi:id="20922" head="18201" tail="20925"/><cas:NonEmptyFSList xmi:id="20919" head="18189" tail="20922"/><cas:NonEmptyFSList xmi:id="20916" head="18177" tail="20919"/><cas:NonEmptyFSList xmi:id="20913" head="18165" tail="20916"/><cas:NonEmptyFSList xmi:id="20910" head="18153" tail="20913"/><cas:NonEmptyFSList xmi:id="20907" head="18141" tail="20910"/><cas:NonEmptyFSList xmi:id="20904" head="18129" tail="20907"/><cas:NonEmptyFSList xmi:id="20901" head="18117" tail="20904"/><cas:NonEmptyFSList xmi:id="20898" head="18105" tail="20901"/><cas:NonEmptyFSList xmi:id="20895" head="18093" tail="20898"/><cas:NonEmptyFSList xmi:id="20892" head="18081" tail="20895"/><cas:NonEmptyFSList xmi:id="20889" head="18069" tail="20892"/><cas:NonEmptyFSList xmi:id="20886" head="18057" tail="20889"/><cas:NonEmptyFSList xmi:id="20883" head="18045" tail="20886"/><cas:NonEmptyFSList xmi:id="20880" head="18033" tail="20883"/><cas:NonEmptyFSList xmi:id="20877" head="18021" tail="20880"/><cas:NonEmptyFSList xmi:id="20874" head="18009" tail="20877"/><cas:NonEmptyFSList xmi:id="20871" head="17997" tail="20874"/><cas:NonEmptyFSList xmi:id="20868" head="17985" tail="20871"/><cas:NonEmptyFSList xmi:id="20865" head="17973" tail="20868"/><cas:NonEmptyFSList xmi:id="20862" head="17961" tail="20865"/><cas:NonEmptyFSList xmi:id="20859" head="17949" tail="20862"/><cas:NonEmptyFSList xmi:id="20856" head="17937" tail="20859"/><cas:NonEmptyFSList xmi:id="20853" head="17925" tail="20856"/><cas:NonEmptyFSList xmi:id="20850" head="17913" tail="20853"/><cas:NonEmptyFSList xmi:id="20847" head="17901" tail="20850"/><cas:NonEmptyFSList xmi:id="20844" head="17889" tail="20847"/><cas:NonEmptyFSList xmi:id="20841" head="17877" tail="20844"/><cas:NonEmptyFSList xmi:id="20838" head="17865" tail="20841"/><cas:NonEmptyFSList xmi:id="20835" head="17853" tail="20838"/><cas:NonEmptyFSList xmi:id="20832" head="17841" tail="20835"/><cas:NonEmptyFSList xmi:id="20829" head="17829" tail="20832"/><cas:NonEmptyFSList xmi:id="20826" head="17817" tail="20829"/><cas:NonEmptyFSList xmi:id="20823" head="17805" tail="20826"/><cas:NonEmptyFSList xmi:id="20820" head="17793" tail="20823"/><cas:NonEmptyFSList xmi:id="20817" head="17781" tail="20820"/><cas:NonEmptyFSList xmi:id="20814" head="17769" tail="20817"/><cas:NonEmptyFSList xmi:id="20811" head="17757" tail="20814"/><cas:NonEmptyFSList xmi:id="20808" head="17745" tail="20811"/><cas:NonEmptyFSList xmi:id="20805" head="17733" tail="20808"/><cas:NonEmptyFSList xmi:id="20802" head="17721" tail="20805"/><cas:NonEmptyFSList xmi:id="20799" head="17709" tail="20802"/><cas:NonEmptyFSList xmi:id="20796" head="17697" tail="20799"/><cas:NonEmptyFSList xmi:id="20793" head="17685" tail="20796"/><cas:NonEmptyFSList xmi:id="20790" head="17673" tail="20793"/><cas:NonEmptyFSList xmi:id="20787" head="17661" tail="20790"/><cas:NonEmptyFSList xmi:id="20784" head="17649" tail="20787"/><cas:NonEmptyFSList xmi:id="20781" head="17637" tail="20784"/><cas:NonEmptyFSList xmi:id="20778" head="17625" tail="20781"/><cas:NonEmptyFSList xmi:id="20775" head="17613" tail="20778"/><cas:NonEmptyFSList xmi:id="20772" head="17601" tail="20775"/><cas:NonEmptyFSList xmi:id="20769" head="17589" tail="20772"/><cas:NonEmptyFSList xmi:id="20766" head="17577" tail="20769"/><cas:NonEmptyFSList xmi:id="20763" head="17565" tail="20766"/><cas:NonEmptyFSList xmi:id="20760" head="17553" tail="20763"/><cas:NonEmptyFSList xmi:id="20757" head="17541" tail="20760"/><cas:NonEmptyFSList xmi:id="20754" head="17529" tail="20757"/><cas:NonEmptyFSList xmi:id="20751" head="17517" tail="20754"/><cas:NonEmptyFSList xmi:id="20748" head="17505" tail="20751"/><cas:NonEmptyFSList xmi:id="20745" head="17493" tail="20748"/><cas:NonEmptyFSList xmi:id="20742" head="17481" tail="20745"/><cas:NonEmptyFSList xmi:id="20739" head="17469" tail="20742"/><cas:NonEmptyFSList xmi:id="20736" head="17457" tail="20739"/><cas:NonEmptyFSList xmi:id="20733" head="17445" tail="20736"/><cas:NonEmptyFSList xmi:id="20730" head="17433" tail="20733"/><cas:NonEmptyFSList xmi:id="20727" head="17421" tail="20730"/><cas:NonEmptyFSList xmi:id="20724" head="17409" tail="20727"/><cas:NonEmptyFSList xmi:id="20721" head="17397" tail="20724"/><cas:NonEmptyFSList xmi:id="20718" head="17385" tail="20721"/><cas:NonEmptyFSList xmi:id="20715" head="17373" tail="20718"/><cas:NonEmptyFSList xmi:id="20712" head="17361" tail="20715"/><cas:NonEmptyFSList xmi:id="20709" head="17349" tail="20712"/><cas:NonEmptyFSList xmi:id="20706" head="17337" tail="20709"/><cas:NonEmptyFSList xmi:id="20703" head="17325" tail="20706"/><cas:NonEmptyFSList xmi:id="20700" head="17313" tail="20703"/><cas:NonEmptyFSList xmi:id="20697" head="17301" tail="20700"/><cas:NonEmptyFSList xmi:id="20694" head="17289" tail="20697"/><cas:NonEmptyFSList xmi:id="20691" head="17277" tail="20694"/><cas:NonEmptyFSList xmi:id="20688" head="17265" tail="20691"/><cas:NonEmptyFSList xmi:id="20685" head="17253" tail="20688"/><cas:NonEmptyFSList xmi:id="20682" head="17241" tail="20685"/><cas:NonEmptyFSList xmi:id="20679" head="17229" tail="20682"/><cas:NonEmptyFSList xmi:id="20676" head="17217" tail="20679"/><cas:NonEmptyFSList xmi:id="20673" head="17205" tail="20676"/><cas:NonEmptyFSList xmi:id="20670" head="17193" tail="20673"/><cas:NonEmptyFSList xmi:id="20667" head="17181" tail="20670"/><cas:NonEmptyFSList xmi:id="20664" head="17169" tail="20667"/><cas:NonEmptyFSList xmi:id="20661" head="17157" tail="20664"/><cas:NonEmptyFSList xmi:id="20658" head="17145" tail="20661"/><cas:NonEmptyFSList xmi:id="20655" head="17133" tail="20658"/><cas:NonEmptyFSList xmi:id="20652" head="17121" tail="20655"/><cas:NonEmptyFSList xmi:id="20649" head="17109" tail="20652"/><cas:NonEmptyFSList xmi:id="20646" head="17097" tail="20649"/><cas:NonEmptyFSList xmi:id="20643" head="17085" tail="20646"/><cas:NonEmptyFSList xmi:id="20640" head="17073" tail="20643"/><cas:NonEmptyFSList xmi:id="20637" head="17061" tail="20640"/><cas:NonEmptyFSList xmi:id="20634" head="17049" tail="20637"/><cas:NonEmptyFSList xmi:id="20631" head="17037" tail="20634"/><cas:NonEmptyFSList xmi:id="20628" head="17025" tail="20631"/><cas:NonEmptyFSList xmi:id="20625" head="17013" tail="20628"/><cas:NonEmptyFSList xmi:id="20622" head="17001" tail="20625"/><cas:NonEmptyFSList xmi:id="20619" head="16977" tail="20622"/><cas:NonEmptyFSList xmi:id="20616" head="16965" tail="20619"/><cas:NonEmptyFSList xmi:id="20613" head="16953" tail="20616"/><cas:NonEmptyFSList xmi:id="20610" head="16941" tail="20613"/><cas:NonEmptyFSList xmi:id="20607" head="16929" tail="20610"/><cas:NonEmptyFSList xmi:id="20604" head="16917" tail="20607"/><cas:NonEmptyFSList xmi:id="20601" head="16905" tail="20604"/><cas:NonEmptyFSList xmi:id="20598" head="16893" tail="20601"/><cas:NonEmptyFSList xmi:id="20595" head="16881" tail="20598"/><cas:NonEmptyFSList xmi:id="20592" head="16869" tail="20595"/><cas:NonEmptyFSList xmi:id="20589" head="16857" tail="20592"/><cas:NonEmptyFSList xmi:id="20586" head="16845" tail="20589"/><cas:NonEmptyFSList xmi:id="20583" head="16833" tail="20586"/><cas:NonEmptyFSList xmi:id="20580" head="16821" tail="20583"/><cas:NonEmptyFSList xmi:id="20577" head="16809" tail="20580"/><cas:NonEmptyFSList xmi:id="20574" head="16797" tail="20577"/><cas:NonEmptyFSList xmi:id="20571" head="16785" tail="20574"/><cas:NonEmptyFSList xmi:id="20568" head="16773" tail="20571"/><cas:NonEmptyFSList xmi:id="20565" head="16761" tail="20568"/><cas:NonEmptyFSList xmi:id="20562" head="16749" tail="20565"/><cas:NonEmptyFSList xmi:id="20559" head="16737" tail="20562"/><cas:NonEmptyFSList xmi:id="20556" head="16725" tail="20559"/><cas:NonEmptyFSList xmi:id="20553" head="16713" tail="20556"/><cas:NonEmptyFSList xmi:id="20550" head="16701" tail="20553"/><cas:NonEmptyFSList xmi:id="20547" head="16689" tail="20550"/><cas:NonEmptyFSList xmi:id="20544" head="16677" tail="20547"/><cas:NonEmptyFSList xmi:id="20541" head="16665" tail="20544"/><cas:NonEmptyFSList xmi:id="20538" head="16653" tail="20541"/><cas:NonEmptyFSList xmi:id="20535" head="16641" tail="20538"/><cas:NonEmptyFSList xmi:id="20532" head="16629" tail="20535"/><cas:NonEmptyFSList xmi:id="20529" head="16617" tail="20532"/><cas:NonEmptyFSList xmi:id="20526" head="16605" tail="20529"/><cas:NonEmptyFSList xmi:id="20523" head="16593" tail="20526"/><cas:NonEmptyFSList xmi:id="20520" head="16581" tail="20523"/><cas:NonEmptyFSList xmi:id="20517" head="16569" tail="20520"/><cas:NonEmptyFSList xmi:id="20514" head="16557" tail="20517"/><cas:NonEmptyFSList xmi:id="20511" head="16545" tail="20514"/><cas:NonEmptyFSList xmi:id="20508" head="16533" tail="20511"/><cas:NonEmptyFSList xmi:id="20505" head="16521" tail="20508"/><cas:NonEmptyFSList xmi:id="20502" head="16509" tail="20505"/><cas:NonEmptyFSList xmi:id="20499" head="16497" tail="20502"/><cas:NonEmptyFSList xmi:id="20496" head="16473" tail="20499"/><cas:NonEmptyFSList xmi:id="20493" head="16461" tail="20496"/><cas:NonEmptyFSList xmi:id="20490" head="16449" tail="20493"/><cas:NonEmptyFSList xmi:id="20487" head="16437" tail="20490"/><cas:NonEmptyFSList xmi:id="20484" head="16425" tail="20487"/><cas:NonEmptyFSList xmi:id="20481" head="16413" tail="20484"/><cas:NonEmptyFSList xmi:id="20478" head="16401" tail="20481"/><cas:NonEmptyFSList xmi:id="20475" head="16389" tail="20478"/><cas:NonEmptyFSList xmi:id="20472" head="16377" tail="20475"/><cas:NonEmptyFSList xmi:id="20469" head="16365" tail="20472"/><cas:NonEmptyFSList xmi:id="20466" head="16353" tail="20469"/><cas:NonEmptyFSList xmi:id="20463" head="16341" tail="20466"/><cas:NonEmptyFSList xmi:id="20460" head="16329" tail="20463"/><cas:NonEmptyFSList xmi:id="20457" head="16317" tail="20460"/><cas:NonEmptyFSList xmi:id="20454" head="16305" tail="20457"/><cas:NonEmptyFSList xmi:id="20451" head="16293" tail="20454"/><cas:NonEmptyFSList xmi:id="20448" head="16281" tail="20451"/><cas:NonEmptyFSList xmi:id="20445" head="16269" tail="20448"/><cas:NonEmptyFSList xmi:id="20442" head="16257" tail="20445"/><cas:NonEmptyFSList xmi:id="20439" head="16245" tail="20442"/><cas:NonEmptyFSList xmi:id="20436" head="16233" tail="20439"/><cas:NonEmptyFSList xmi:id="20433" head="16221" tail="20436"/><cas:NonEmptyFSList xmi:id="20430" head="16209" tail="20433"/><cas:NonEmptyFSList xmi:id="20427" head="16197" tail="20430"/><cas:NonEmptyFSList xmi:id="20424" head="16185" tail="20427"/><cas:NonEmptyFSList xmi:id="20421" head="16173" tail="20424"/><cas:NonEmptyFSList xmi:id="20418" head="16161" tail="20421"/><cas:NonEmptyFSList xmi:id="20415" head="16149" tail="20418"/><cas:NonEmptyFSList xmi:id="20412" head="16137" tail="20415"/><cas:NonEmptyFSList xmi:id="20409" head="16125" tail="20412"/><cas:NonEmptyFSList xmi:id="20406" head="16113" tail="20409"/><cas:NonEmptyFSList xmi:id="20403" head="16101" tail="20406"/><cas:NonEmptyFSList xmi:id="20400" head="16089" tail="20403"/><cas:NonEmptyFSList xmi:id="20397" head="16077" tail="20400"/><cas:NonEmptyFSList xmi:id="20394" head="16065" tail="20397"/><cas:NonEmptyFSList xmi:id="20391" head="16053" tail="20394"/><cas:NonEmptyFSList xmi:id="20388" head="16041" tail="20391"/><cas:NonEmptyFSList xmi:id="20385" head="16029" tail="20388"/><cas:NonEmptyFSList xmi:id="20382" head="16017" tail="20385"/><cas:NonEmptyFSList xmi:id="20379" head="16005" tail="20382"/><cas:NonEmptyFSList xmi:id="20376" head="15993" tail="20379"/><cas:NonEmptyFSList xmi:id="20373" head="15981" tail="20376"/><cas:NonEmptyFSList xmi:id="20370" head="15969" tail="20373"/><cas:NonEmptyFSList xmi:id="20367" head="15957" tail="20370"/><cas:NonEmptyFSList xmi:id="20364" head="15945" tail="20367"/><cas:NonEmptyFSList xmi:id="20361" head="15933" tail="20364"/><cas:NonEmptyFSList xmi:id="20358" head="15921" tail="20361"/><cas:NonEmptyFSList xmi:id="20355" head="15909" tail="20358"/><cas:NonEmptyFSList xmi:id="20352" head="15897" tail="20355"/><cas:NonEmptyFSList xmi:id="20349" head="15885" tail="20352"/><cas:NonEmptyFSList xmi:id="20346" head="15873" tail="20349"/><cas:NonEmptyFSList xmi:id="20343" head="15861" tail="20346"/><cas:NonEmptyFSList xmi:id="20340" head="15849" tail="20343"/><cas:NonEmptyFSList xmi:id="20337" head="15837" tail="20340"/><cas:NonEmptyFSList xmi:id="20334" head="15825" tail="20337"/><cas:NonEmptyFSList xmi:id="20331" head="15813" tail="20334"/><cas:NonEmptyFSList xmi:id="20328" head="15801" tail="20331"/><cas:NonEmptyFSList xmi:id="20325" head="15789" tail="20328"/><cas:NonEmptyFSList xmi:id="20322" head="15777" tail="20325"/><cas:NonEmptyFSList xmi:id="20319" head="15765" tail="20322"/><cas:NonEmptyFSList xmi:id="20316" head="15753" tail="20319"/><cas:NonEmptyFSList xmi:id="20313" head="15741" tail="20316"/><cas:NonEmptyFSList xmi:id="20310" head="15729" tail="20313"/><cas:NonEmptyFSList xmi:id="20307" head="15717" tail="20310"/><cas:NonEmptyFSList xmi:id="20304" head="15705" tail="20307"/><cas:NonEmptyFSList xmi:id="20301" head="15693" tail="20304"/><cas:NonEmptyFSList xmi:id="20298" head="15681" tail="20301"/><cas:NonEmptyFSList xmi:id="20295" head="15669" tail="20298"/><cas:NonEmptyFSList xmi:id="20292" head="15657" tail="20295"/><cas:NonEmptyFSList xmi:id="20289" head="15645" tail="20292"/><cas:NonEmptyFSList xmi:id="20286" head="15633" tail="20289"/><cas:NonEmptyFSList xmi:id="20283" head="15621" tail="20286"/><cas:NonEmptyFSList xmi:id="20280" head="15609" tail="20283"/><cas:NonEmptyFSList xmi:id="20277" head="15597" tail="20280"/><cas:NonEmptyFSList xmi:id="20274" head="15585" tail="20277"/><cas:NonEmptyFSList xmi:id="20271" head="15573" tail="20274"/><cas:NonEmptyFSList xmi:id="20268" head="15561" tail="20271"/><cas:NonEmptyFSList xmi:id="20265" head="15549" tail="20268"/><cas:NonEmptyFSList xmi:id="20262" head="15537" tail="20265"/><cas:NonEmptyFSList xmi:id="20259" head="15525" tail="20262"/><cas:NonEmptyFSList xmi:id="20256" head="15513" tail="20259"/><cas:NonEmptyFSList xmi:id="20253" head="15501" tail="20256"/><cas:NonEmptyFSList xmi:id="20250" head="15489" tail="20253"/><cas:NonEmptyFSList xmi:id="20247" head="15477" tail="20250"/><cas:NonEmptyFSList xmi:id="20244" head="15465" tail="20247"/><cas:NonEmptyFSList xmi:id="20241" head="15453" tail="20244"/><cas:NonEmptyFSList xmi:id="20238" head="15441" tail="20241"/><cas:NonEmptyFSList xmi:id="20235" head="15429" tail="20238"/><cas:NonEmptyFSList xmi:id="20232" head="15417" tail="20235"/><cas:NonEmptyFSList xmi:id="20229" head="15405" tail="20232"/><cas:NonEmptyFSList xmi:id="20226" head="15393" tail="20229"/><cas:NonEmptyFSList xmi:id="20223" head="15381" tail="20226"/><cas:NonEmptyFSList xmi:id="20220" head="15369" tail="20223"/><cas:NonEmptyFSList xmi:id="20217" head="15357" tail="20220"/><cas:NonEmptyFSList xmi:id="20214" head="15345" tail="20217"/><cas:NonEmptyFSList xmi:id="20211" head="15333" tail="20214"/><cas:NonEmptyFSList xmi:id="20208" head="15321" tail="20211"/><cas:NonEmptyFSList xmi:id="20205" head="15309" tail="20208"/><cas:NonEmptyFSList xmi:id="20202" head="15297" tail="20205"/><cas:NonEmptyFSList xmi:id="20199" head="15285" tail="20202"/><cas:NonEmptyFSList xmi:id="20196" head="15273" tail="20199"/><cas:EmptyFSList xmi:id="7287"/><cas:NonEmptyFSList xmi:id="7284" head="6051" tail="7287"/><cas:NonEmptyFSList xmi:id="7281" head="6039" tail="7284"/><cas:NonEmptyFSList xmi:id="7278" head="6027" tail="7281"/><cas:NonEmptyFSList xmi:id="7275" head="6015" tail="7278"/><cas:NonEmptyFSList xmi:id="7272" head="6003" tail="7275"/><cas:NonEmptyFSList xmi:id="7269" head="5991" tail="7272"/><cas:NonEmptyFSList xmi:id="7266" head="5979" tail="7269"/><cas:NonEmptyFSList xmi:id="7263" head="5967" tail="7266"/><cas:NonEmptyFSList xmi:id="7260" head="5955" tail="7263"/><cas:NonEmptyFSList xmi:id="7257" head="5943" tail="7260"/><cas:NonEmptyFSList xmi:id="7254" head="5931" tail="7257"/><cas:NonEmptyFSList xmi:id="7251" head="5919" tail="7254"/><cas:NonEmptyFSList xmi:id="7248" head="5907" tail="7251"/><cas:NonEmptyFSList xmi:id="7245" head="5895" tail="7248"/><cas:NonEmptyFSList xmi:id="7242" head="5883" tail="7245"/><cas:NonEmptyFSList xmi:id="7239" head="5871" tail="7242"/><cas:NonEmptyFSList xmi:id="7236" head="5859" tail="7239"/><cas:NonEmptyFSList xmi:id="7233" head="5847" tail="7236"/><cas:NonEmptyFSList xmi:id="7230" head="5835" tail="7233"/><cas:NonEmptyFSList xmi:id="7227" head="5823" tail="7230"/><cas:NonEmptyFSList xmi:id="7224" head="5811" tail="7227"/><cas:NonEmptyFSList xmi:id="7221" head="5799" tail="7224"/><cas:NonEmptyFSList xmi:id="7218" head="5787" tail="7221"/><cas:NonEmptyFSList xmi:id="7215" head="5775" tail="7218"/><cas:NonEmptyFSList xmi:id="7212" head="5763" tail="7215"/><cas:NonEmptyFSList xmi:id="7209" head="5751" tail="7212"/><cas:NonEmptyFSList xmi:id="7206" head="5739" tail="7209"/><cas:NonEmptyFSList xmi:id="7203" head="5727" tail="7206"/><cas:NonEmptyFSList xmi:id="7200" head="5715" tail="7203"/><cas:NonEmptyFSList xmi:id="7197" head="5703" tail="7200"/><cas:NonEmptyFSList xmi:id="7194" head="5691" tail="7197"/><cas:NonEmptyFSList xmi:id="7191" head="5679" tail="7194"/><cas:NonEmptyFSList xmi:id="7188" head="5667" tail="7191"/><cas:NonEmptyFSList xmi:id="7185" head="5655" tail="7188"/><cas:NonEmptyFSList xmi:id="7182" head="5643" tail="7185"/><cas:NonEmptyFSList xmi:id="7179" head="5631" tail="7182"/><cas:NonEmptyFSList xmi:id="7176" head="5619" tail="7179"/><cas:NonEmptyFSList xmi:id="7173" head="5607" tail="7176"/><cas:NonEmptyFSList xmi:id="7170" head="5595" tail="7173"/><cas:NonEmptyFSList xmi:id="7167" head="5583" tail="7170"/><cas:NonEmptyFSList xmi:id="7164" head="5571" tail="7167"/><cas:NonEmptyFSList xmi:id="7161" head="5559" tail="7164"/><cas:NonEmptyFSList xmi:id="7158" head="5547" tail="7161"/><cas:NonEmptyFSList xmi:id="7155" head="5535" tail="7158"/><cas:NonEmptyFSList xmi:id="7152" head="5523" tail="7155"/><cas:NonEmptyFSList xmi:id="7149" head="5511" tail="7152"/><cas:NonEmptyFSList xmi:id="7146" head="5499" tail="7149"/><cas:NonEmptyFSList xmi:id="7143" head="5487" tail="7146"/><cas:NonEmptyFSList xmi:id="7140" head="5475" tail="7143"/><cas:NonEmptyFSList xmi:id="7137" head="5463" tail="7140"/><cas:NonEmptyFSList xmi:id="7134" head="5451" tail="7137"/><cas:NonEmptyFSList xmi:id="7131" head="5439" tail="7134"/><cas:NonEmptyFSList xmi:id="7128" head="5427" tail="7131"/><cas:NonEmptyFSList xmi:id="7125" head="5415" tail="7128"/><cas:NonEmptyFSList xmi:id="7122" head="5403" tail="7125"/><cas:NonEmptyFSList xmi:id="7119" head="5391" tail="7122"/><cas:NonEmptyFSList xmi:id="7116" head="5379" tail="7119"/><cas:NonEmptyFSList xmi:id="7113" head="5367" tail="7116"/><cas:NonEmptyFSList xmi:id="7110" head="5355" tail="7113"/><cas:NonEmptyFSList xmi:id="7107" head="5343" tail="7110"/><cas:NonEmptyFSList xmi:id="7104" head="5331" tail="7107"/><cas:NonEmptyFSList xmi:id="7101" head="5319" tail="7104"/><cas:NonEmptyFSList xmi:id="7098" head="5307" tail="7101"/><cas:NonEmptyFSList xmi:id="7095" head="5295" tail="7098"/><cas:NonEmptyFSList xmi:id="7092" head="5283" tail="7095"/><cas:NonEmptyFSList xmi:id="7089" head="5271" tail="7092"/><cas:NonEmptyFSList xmi:id="7086" head="5259" tail="7089"/><cas:NonEmptyFSList xmi:id="7083" head="5247" tail="7086"/><cas:NonEmptyFSList xmi:id="7080" head="5235" tail="7083"/><cas:NonEmptyFSList xmi:id="7077" head="5223" tail="7080"/><cas:NonEmptyFSList xmi:id="7074" head="5211" tail="7077"/><cas:NonEmptyFSList xmi:id="7071" head="5199" tail="7074"/><cas:NonEmptyFSList xmi:id="7068" head="5187" tail="7071"/><cas:NonEmptyFSList xmi:id="7065" head="5175" tail="7068"/><cas:NonEmptyFSList xmi:id="7062" head="5163" tail="7065"/><cas:NonEmptyFSList xmi:id="7059" head="5151" tail="7062"/><cas:NonEmptyFSList xmi:id="7056" head="5139" tail="7059"/><cas:NonEmptyFSList xmi:id="7053" head="5127" tail="7056"/><cas:NonEmptyFSList xmi:id="7050" head="5115" tail="7053"/><cas:NonEmptyFSList xmi:id="7047" head="5103" tail="7050"/><cas:NonEmptyFSList xmi:id="7044" head="5091" tail="7047"/><cas:NonEmptyFSList xmi:id="7041" head="5079" tail="7044"/><cas:NonEmptyFSList xmi:id="7038" head="5067" tail="7041"/><cas:NonEmptyFSList xmi:id="7035" head="5055" tail="7038"/><cas:NonEmptyFSList xmi:id="7032" head="5043" tail="7035"/><cas:NonEmptyFSList xmi:id="7029" head="5031" tail="7032"/><cas:NonEmptyFSList xmi:id="7026" head="5019" tail="7029"/><cas:NonEmptyFSList xmi:id="7023" head="5007" tail="7026"/><cas:NonEmptyFSList xmi:id="7020" head="4995" tail="7023"/><cas:NonEmptyFSList xmi:id="7017" head="4983" tail="7020"/><cas:NonEmptyFSList xmi:id="7014" head="4971" tail="7017"/><cas:NonEmptyFSList xmi:id="7011" head="4959" tail="7014"/><cas:NonEmptyFSList xmi:id="7008" head="4947" tail="7011"/><cas:NonEmptyFSList xmi:id="7005" head="4935" tail="7008"/><cas:NonEmptyFSList xmi:id="7002" head="4923" tail="7005"/><cas:NonEmptyFSList xmi:id="6999" head="4911" tail="7002"/><cas:NonEmptyFSList xmi:id="6996" head="4887" tail="6999"/><cas:NonEmptyFSList xmi:id="6993" head="4875" tail="6996"/><cas:NonEmptyFSList xmi:id="6990" head="4851" tail="6993"/><cas:NonEmptyFSList xmi:id="6987" head="4839" tail="6990"/><cas:NonEmptyFSList xmi:id="6984" head="4827" tail="6987"/><cas:NonEmptyFSList xmi:id="6981" head="4815" tail="6984"/><cas:NonEmptyFSList xmi:id="6978" head="4803" tail="6981"/><cas:NonEmptyFSList xmi:id="6975" head="4779" tail="6978"/><cas:NonEmptyFSList xmi:id="6972" head="4767" tail="6975"/><cas:NonEmptyFSList xmi:id="6969" head="4755" tail="6972"/><cas:NonEmptyFSList xmi:id="6966" head="4731" tail="6969"/><cas:NonEmptyFSList xmi:id="6963" head="4719" tail="6966"/><cas:NonEmptyFSList xmi:id="6960" head="4707" tail="6963"/><cas:NonEmptyFSList xmi:id="6957" head="4695" tail="6960"/><cas:NonEmptyFSList xmi:id="6954" head="4683" tail="6957"/><cas:NonEmptyFSList xmi:id="6951" head="4671" tail="6954"/><cas:NonEmptyFSList xmi:id="6948" head="4659" tail="6951"/><cas:NonEmptyFSList xmi:id="6945" head="4647" tail="6948"/><cas:NonEmptyFSList xmi:id="6942" head="4635" tail="6945"/><cas:NonEmptyFSList xmi:id="6939" head="4623" tail="6942"/><cas:NonEmptyFSList xmi:id="6936" head="4611" tail="6939"/><cas:NonEmptyFSList xmi:id="6933" head="4599" tail="6936"/><cas:NonEmptyFSList xmi:id="6930" head="4587" tail="6933"/><cas:NonEmptyFSList xmi:id="6927" head="4575" tail="6930"/><cas:NonEmptyFSList xmi:id="6924" head="4563" tail="6927"/><cas:NonEmptyFSList xmi:id="6921" head="4551" tail="6924"/><cas:NonEmptyFSList xmi:id="6918" head="4539" tail="6921"/><cas:NonEmptyFSList xmi:id="6915" head="4527" tail="6918"/><cas:NonEmptyFSList xmi:id="6912" head="4515" tail="6915"/><cas:NonEmptyFSList xmi:id="6909" head="4503" tail="6912"/><cas:NonEmptyFSList xmi:id="6906" head="4491" tail="6909"/><cas:NonEmptyFSList xmi:id="6903" head="4479" tail="6906"/><cas:NonEmptyFSList xmi:id="6900" head="4467" tail="6903"/><cas:NonEmptyFSList xmi:id="6897" head="4455" tail="6900"/><cas:NonEmptyFSList xmi:id="6894" head="4443" tail="6897"/><cas:NonEmptyFSList xmi:id="6891" head="4431" tail="6894"/><cas:NonEmptyFSList xmi:id="6888" head="4419" tail="6891"/><cas:NonEmptyFSList xmi:id="6885" head="4407" tail="6888"/><cas:NonEmptyFSList xmi:id="6882" head="4395" tail="6885"/><cas:NonEmptyFSList xmi:id="6879" head="4383" tail="6882"/><cas:NonEmptyFSList xmi:id="6876" head="4371" tail="6879"/><cas:NonEmptyFSList xmi:id="6873" head="4359" tail="6876"/><cas:NonEmptyFSList xmi:id="6870" head="4347" tail="6873"/><cas:NonEmptyFSList xmi:id="6867" head="4335" tail="6870"/><cas:NonEmptyFSList xmi:id="6864" head="4323" tail="6867"/><cas:NonEmptyFSList xmi:id="6861" head="4311" tail="6864"/><cas:NonEmptyFSList xmi:id="6858" head="4299" tail="6861"/><cas:NonEmptyFSList xmi:id="6855" head="4287" tail="6858"/><cas:NonEmptyFSList xmi:id="6852" head="4275" tail="6855"/><cas:NonEmptyFSList xmi:id="6849" head="4263" tail="6852"/><cas:NonEmptyFSList xmi:id="6846" head="4251" tail="6849"/><cas:NonEmptyFSList xmi:id="6843" head="4239" tail="6846"/><cas:NonEmptyFSList xmi:id="6840" head="4227" tail="6843"/><cas:NonEmptyFSList xmi:id="6837" head="4215" tail="6840"/><cas:NonEmptyFSList xmi:id="6834" head="4203" tail="6837"/><cas:NonEmptyFSList xmi:id="6831" head="4191" tail="6834"/><cas:NonEmptyFSList xmi:id="6828" head="4179" tail="6831"/><cas:NonEmptyFSList xmi:id="6825" head="4167" tail="6828"/><cas:NonEmptyFSList xmi:id="6822" head="4155" tail="6825"/><cas:NonEmptyFSList xmi:id="6819" head="4143" tail="6822"/><cas:NonEmptyFSList xmi:id="6816" head="4131" tail="6819"/><cas:NonEmptyFSList xmi:id="6813" head="4119" tail="6816"/><cas:NonEmptyFSList xmi:id="6810" head="4107" tail="6813"/><cas:NonEmptyFSList xmi:id="6807" head="4095" tail="6810"/><cas:NonEmptyFSList xmi:id="6804" head="4083" tail="6807"/><cas:NonEmptyFSList xmi:id="6801" head="4071" tail="6804"/><cas:NonEmptyFSList xmi:id="6798" head="4059" tail="6801"/><cas:NonEmptyFSList xmi:id="6795" head="4047" tail="6798"/><cas:NonEmptyFSList xmi:id="6792" head="4035" tail="6795"/><cas:NonEmptyFSList xmi:id="6789" head="4023" tail="6792"/><cas:NonEmptyFSList xmi:id="6786" head="4011" tail="6789"/><cas:NonEmptyFSList xmi:id="6783" head="3999" tail="6786"/><cas:NonEmptyFSList xmi:id="6780" head="3987" tail="6783"/><cas:NonEmptyFSList xmi:id="6777" head="3975" tail="6780"/><cas:NonEmptyFSList xmi:id="6774" head="3963" tail="6777"/><cas:NonEmptyFSList xmi:id="6771" head="3951" tail="6774"/><cas:NonEmptyFSList xmi:id="6768" head="3939" tail="6771"/><cas:NonEmptyFSList xmi:id="6765" head="3927" tail="6768"/><cas:NonEmptyFSList xmi:id="6762" head="3915" tail="6765"/><cas:NonEmptyFSList xmi:id="6759" head="3903" tail="6762"/><cas:NonEmptyFSList xmi:id="6756" head="3891" tail="6759"/><cas:NonEmptyFSList xmi:id="6753" head="3879" tail="6756"/><cas:NonEmptyFSList xmi:id="6750" head="3867" tail="6753"/><cas:NonEmptyFSList xmi:id="6747" head="3855" tail="6750"/><cas:NonEmptyFSList xmi:id="6744" head="3843" tail="6747"/><cas:NonEmptyFSList xmi:id="6741" head="3831" tail="6744"/><cas:NonEmptyFSList xmi:id="6738" head="3819" tail="6741"/><cas:NonEmptyFSList xmi:id="6735" head="3807" tail="6738"/><cas:NonEmptyFSList xmi:id="6732" head="3795" tail="6735"/><cas:NonEmptyFSList xmi:id="6729" head="3783" tail="6732"/><cas:NonEmptyFSList xmi:id="6726" head="3771" tail="6729"/><cas:NonEmptyFSList xmi:id="6723" head="3759" tail="6726"/><cas:NonEmptyFSList xmi:id="6720" head="3747" tail="6723"/><cas:NonEmptyFSList xmi:id="6717" head="3735" tail="6720"/><cas:NonEmptyFSList xmi:id="6714" head="3723" tail="6717"/><cas:NonEmptyFSList xmi:id="6711" head="3711" tail="6714"/><cas:NonEmptyFSList xmi:id="6708" head="3699" tail="6711"/><cas:NonEmptyFSList xmi:id="6705" head="3687" tail="6708"/><cas:NonEmptyFSList xmi:id="6702" head="3675" tail="6705"/><cas:NonEmptyFSList xmi:id="6699" head="3663" tail="6702"/><cas:NonEmptyFSList xmi:id="6696" head="3651" tail="6699"/><cas:NonEmptyFSList xmi:id="6693" head="3639" tail="6696"/><cas:NonEmptyFSList xmi:id="6690" head="3627" tail="6693"/><cas:NonEmptyFSList xmi:id="6687" head="3615" tail="6690"/><cas:NonEmptyFSList xmi:id="6684" head="3603" tail="6687"/><cas:NonEmptyFSList xmi:id="6681" head="3591" tail="6684"/><cas:NonEmptyFSList xmi:id="6678" head="3579" tail="6681"/><cas:NonEmptyFSList xmi:id="6675" head="3567" tail="6678"/><cas:NonEmptyFSList xmi:id="6672" head="3555" tail="6675"/><cas:NonEmptyFSList xmi:id="6669" head="3543" tail="6672"/><cas:NonEmptyFSList xmi:id="6666" head="3531" tail="6669"/><cas:NonEmptyFSList xmi:id="6663" head="3519" tail="6666"/><cas:NonEmptyFSList xmi:id="6660" head="3507" tail="6663"/><cas:NonEmptyFSList xmi:id="6657" head="3495" tail="6660"/><cas:NonEmptyFSList xmi:id="6654" head="3483" tail="6657"/><cas:NonEmptyFSList xmi:id="6651" head="3471" tail="6654"/><cas:NonEmptyFSList xmi:id="6648" head="3459" tail="6651"/><cas:NonEmptyFSList xmi:id="6645" head="3447" tail="6648"/><cas:NonEmptyFSList xmi:id="6642" head="3435" tail="6645"/><cas:NonEmptyFSList xmi:id="6639" head="3423" tail="6642"/><cas:NonEmptyFSList xmi:id="6636" head="3411" tail="6639"/><cas:NonEmptyFSList xmi:id="6633" head="3399" tail="6636"/><cas:NonEmptyFSList xmi:id="6630" head="3387" tail="6633"/><cas:NonEmptyFSList xmi:id="6627" head="3375" tail="6630"/><cas:NonEmptyFSList xmi:id="6624" head="3363" tail="6627"/><cas:NonEmptyFSList xmi:id="6621" head="3351" tail="6624"/><cas:NonEmptyFSList xmi:id="6618" head="3339" tail="6621"/><cas:NonEmptyFSList xmi:id="6615" head="3327" tail="6618"/><cas:NonEmptyFSList xmi:id="6612" head="3315" tail="6615"/><cas:NonEmptyFSList xmi:id="6609" head="3303" tail="6612"/><cas:NonEmptyFSList xmi:id="6606" head="3291" tail="6609"/><cas:NonEmptyFSList xmi:id="6603" head="3279" tail="6606"/><cas:NonEmptyFSList xmi:id="6600" head="3267" tail="6603"/><cas:NonEmptyFSList xmi:id="6597" head="3255" tail="6600"/><cas:NonEmptyFSList xmi:id="6594" head="3243" tail="6597"/><cas:NonEmptyFSList xmi:id="6591" head="3231" tail="6594"/><cas:NonEmptyFSList xmi:id="6588" head="3219" tail="6591"/><cas:NonEmptyFSList xmi:id="6585" head="3207" tail="6588"/><cas:NonEmptyFSList xmi:id="6582" head="3195" tail="6585"/><cas:NonEmptyFSList xmi:id="6579" head="3183" tail="6582"/><cas:NonEmptyFSList xmi:id="6576" head="3171" tail="6579"/><cas:NonEmptyFSList xmi:id="6573" head="3159" tail="6576"/><cas:NonEmptyFSList xmi:id="6570" head="3147" tail="6573"/><cas:NonEmptyFSList xmi:id="6567" head="3135" tail="6570"/><cas:NonEmptyFSList xmi:id="6564" head="3123" tail="6567"/><cas:NonEmptyFSList xmi:id="6561" head="3111" tail="6564"/><cas:NonEmptyFSList xmi:id="6558" head="3099" tail="6561"/><cas:NonEmptyFSList xmi:id="6555" head="3087" tail="6558"/><cas:NonEmptyFSList xmi:id="6552" head="3075" tail="6555"/><cas:NonEmptyFSList xmi:id="6549" head="3063" tail="6552"/><cas:NonEmptyFSList xmi:id="6546" head="3051" tail="6549"/><cas:NonEmptyFSList xmi:id="6543" head="3039" tail="6546"/><cas:NonEmptyFSList xmi:id="6540" head="3027" tail="6543"/><cas:NonEmptyFSList xmi:id="6537" head="3015" tail="6540"/><cas:NonEmptyFSList xmi:id="6534" head="3003" tail="6537"/><cas:NonEmptyFSList xmi:id="6531" head="2991" tail="6534"/><cas:NonEmptyFSList xmi:id="6528" head="2979" tail="6531"/><cas:NonEmptyFSList xmi:id="6525" head="2967" tail="6528"/><cas:NonEmptyFSList xmi:id="6522" head="2955" tail="6525"/><cas:NonEmptyFSList xmi:id="6519" head="2943" tail="6522"/><cas:NonEmptyFSList xmi:id="6516" head="2931" tail="6519"/><cas:NonEmptyFSList xmi:id="6513" head="2919" tail="6516"/><cas:NonEmptyFSList xmi:id="6510" head="2907" tail="6513"/><cas:NonEmptyFSList xmi:id="6507" head="2895" tail="6510"/><cas:NonEmptyFSList xmi:id="6504" head="2883" tail="6507"/><cas:NonEmptyFSList xmi:id="6501" head="2859" tail="6504"/><cas:NonEmptyFSList xmi:id="6498" head="2847" tail="6501"/><cas:NonEmptyFSList xmi:id="6495" head="2835" tail="6498"/><cas:NonEmptyFSList xmi:id="6492" head="2823" tail="6495"/><cas:NonEmptyFSList xmi:id="6489" head="2811" tail="6492"/><cas:NonEmptyFSList xmi:id="6486" head="2799" tail="6489"/><cas:NonEmptyFSList xmi:id="6483" head="2787" tail="6486"/><cas:NonEmptyFSList xmi:id="6480" head="2775" tail="6483"/><cas:NonEmptyFSList xmi:id="6477" head="2763" tail="6480"/><cas:NonEmptyFSList xmi:id="6474" head="2751" tail="6477"/><cas:NonEmptyFSList xmi:id="6471" head="2739" tail="6474"/><cas:NonEmptyFSList xmi:id="6468" head="2727" tail="6471"/><cas:NonEmptyFSList xmi:id="6465" head="2715" tail="6468"/><cas:NonEmptyFSList xmi:id="6462" head="2703" tail="6465"/><cas:NonEmptyFSList xmi:id="6459" head="2691" tail="6462"/><cas:NonEmptyFSList xmi:id="6456" head="2679" tail="6459"/><cas:NonEmptyFSList xmi:id="6453" head="2667" tail="6456"/><cas:NonEmptyFSList xmi:id="6450" head="2655" tail="6453"/><cas:NonEmptyFSList xmi:id="6447" head="2643" tail="6450"/><cas:NonEmptyFSList xmi:id="6444" head="2631" tail="6447"/><cas:NonEmptyFSList xmi:id="6441" head="2619" tail="6444"/><cas:NonEmptyFSList xmi:id="6438" head="2607" tail="6441"/><cas:NonEmptyFSList xmi:id="6435" head="2595" tail="6438"/><cas:NonEmptyFSList xmi:id="6432" head="2583" tail="6435"/><cas:NonEmptyFSList xmi:id="6429" head="2571" tail="6432"/><cas:NonEmptyFSList xmi:id="6426" head="2559" tail="6429"/><cas:NonEmptyFSList xmi:id="6423" head="2547" tail="6426"/><cas:NonEmptyFSList xmi:id="6420" head="2535" tail="6423"/><cas:NonEmptyFSList xmi:id="6417" head="2523" tail="6420"/><cas:NonEmptyFSList xmi:id="6414" head="2511" tail="6417"/><cas:NonEmptyFSList xmi:id="6411" head="2499" tail="6414"/><cas:NonEmptyFSList xmi:id="6408" head="2487" tail="6411"/><cas:NonEmptyFSList xmi:id="6405" head="2475" tail="6408"/><cas:NonEmptyFSList xmi:id="6402" head="2463" tail="6405"/><cas:NonEmptyFSList xmi:id="6399" head="2451" tail="6402"/><cas:NonEmptyFSList xmi:id="6396" head="2439" tail="6399"/><cas:NonEmptyFSList xmi:id="6393" head="2427" tail="6396"/><cas:NonEmptyFSList xmi:id="6390" head="2415" tail="6393"/><cas:NonEmptyFSList xmi:id="6387" head="2403" tail="6390"/><cas:NonEmptyFSList xmi:id="6384" head="2391" tail="6387"/><cas:NonEmptyFSList xmi:id="6381" head="2379" tail="6384"/><cas:NonEmptyFSList xmi:id="6378" head="2355" tail="6381"/><cas:NonEmptyFSList xmi:id="6375" head="2343" tail="6378"/><cas:NonEmptyFSList xmi:id="6372" head="2331" tail="6375"/><cas:NonEmptyFSList xmi:id="6369" head="2319" tail="6372"/><cas:NonEmptyFSList xmi:id="6366" head="2307" tail="6369"/><cas:NonEmptyFSList xmi:id="6363" head="2295" tail="6366"/><cas:NonEmptyFSList xmi:id="6360" head="2283" tail="6363"/><cas:NonEmptyFSList xmi:id="6357" head="2271" tail="6360"/><cas:NonEmptyFSList xmi:id="6354" head="2259" tail="6357"/><cas:NonEmptyFSList xmi:id="6351" head="2247" tail="6354"/><cas:NonEmptyFSList xmi:id="6348" head="2235" tail="6351"/><cas:NonEmptyFSList xmi:id="6345" head="2223" tail="6348"/><cas:NonEmptyFSList xmi:id="6342" head="2211" tail="6345"/><cas:NonEmptyFSList xmi:id="6339" head="2199" tail="6342"/><cas:NonEmptyFSList xmi:id="6336" head="2187" tail="6339"/><cas:NonEmptyFSList xmi:id="6333" head="2175" tail="6336"/><cas:NonEmptyFSList xmi:id="6330" head="2163" tail="6333"/><cas:NonEmptyFSList xmi:id="6327" head="2151" tail="6330"/><cas:NonEmptyFSList xmi:id="6324" head="2139" tail="6327"/><cas:NonEmptyFSList xmi:id="6321" head="2127" tail="6324"/><cas:NonEmptyFSList xmi:id="6318" head="2115" tail="6321"/><cas:NonEmptyFSList xmi:id="6315" head="2103" tail="6318"/><cas:NonEmptyFSList xmi:id="6312" head="2091" tail="6315"/><cas:NonEmptyFSList xmi:id="6309" head="2079" tail="6312"/><cas:NonEmptyFSList xmi:id="6306" head="2067" tail="6309"/><cas:NonEmptyFSList xmi:id="6303" head="2055" tail="6306"/><cas:NonEmptyFSList xmi:id="6300" head="2043" tail="6303"/><cas:NonEmptyFSList xmi:id="6297" head="2031" tail="6300"/><cas:NonEmptyFSList xmi:id="6294" head="2019" tail="6297"/><cas:NonEmptyFSList xmi:id="6291" head="2007" tail="6294"/><cas:NonEmptyFSList xmi:id="6288" head="1995" tail="6291"/><cas:NonEmptyFSList xmi:id="6285" head="1983" tail="6288"/><cas:NonEmptyFSList xmi:id="6282" head="1971" tail="6285"/><cas:NonEmptyFSList xmi:id="6279" head="1959" tail="6282"/><cas:NonEmptyFSList xmi:id="6276" head="1947" tail="6279"/><cas:NonEmptyFSList xmi:id="6273" head="1935" tail="6276"/><cas:NonEmptyFSList xmi:id="6270" head="1923" tail="6273"/><cas:NonEmptyFSList xmi:id="6267" head="1911" tail="6270"/><cas:NonEmptyFSList xmi:id="6264" head="1899" tail="6267"/><cas:NonEmptyFSList xmi:id="6261" head="1887" tail="6264"/><cas:NonEmptyFSList xmi:id="6258" head="1875" tail="6261"/><cas:NonEmptyFSList xmi:id="6255" head="1863" tail="6258"/><cas:NonEmptyFSList xmi:id="6252" head="1851" tail="6255"/><cas:NonEmptyFSList xmi:id="6249" head="1839" tail="6252"/><cas:NonEmptyFSList xmi:id="6246" head="1827" tail="6249"/><cas:NonEmptyFSList xmi:id="6243" head="1815" tail="6246"/><cas:NonEmptyFSList xmi:id="6240" head="1803" tail="6243"/><cas:NonEmptyFSList xmi:id="6237" head="1791" tail="6240"/><cas:NonEmptyFSList xmi:id="6234" head="1779" tail="6237"/><cas:NonEmptyFSList xmi:id="6231" head="1767" tail="6234"/><cas:NonEmptyFSList xmi:id="6228" head="1755" tail="6231"/><cas:NonEmptyFSList xmi:id="6225" head="1743" tail="6228"/><cas:NonEmptyFSList xmi:id="6222" head="1731" tail="6225"/><cas:NonEmptyFSList xmi:id="6219" head="1719" tail="6222"/><cas:NonEmptyFSList xmi:id="6216" head="1707" tail="6219"/><cas:NonEmptyFSList xmi:id="6213" head="1695" tail="6216"/><cas:NonEmptyFSList xmi:id="6210" head="1683" tail="6213"/><cas:NonEmptyFSList xmi:id="6207" head="1671" tail="6210"/><cas:NonEmptyFSList xmi:id="6204" head="1659" tail="6207"/><cas:NonEmptyFSList xmi:id="6201" head="1647" tail="6204"/><cas:NonEmptyFSList xmi:id="6198" head="1635" tail="6201"/><cas:NonEmptyFSList xmi:id="6195" head="1623" tail="6198"/><cas:NonEmptyFSList xmi:id="6192" head="1611" tail="6195"/><cas:NonEmptyFSList xmi:id="6189" head="1599" tail="6192"/><cas:NonEmptyFSList xmi:id="6186" head="1587" tail="6189"/><cas:NonEmptyFSList xmi:id="6183" head="1575" tail="6186"/><cas:NonEmptyFSList xmi:id="6180" head="1563" tail="6183"/><cas:NonEmptyFSList xmi:id="6177" head="1551" tail="6180"/><cas:NonEmptyFSList xmi:id="6174" head="1539" tail="6177"/><cas:NonEmptyFSList xmi:id="6171" head="1527" tail="6174"/><cas:NonEmptyFSList xmi:id="6168" head="1515" tail="6171"/><cas:NonEmptyFSList xmi:id="6165" head="1503" tail="6168"/><cas:NonEmptyFSList xmi:id="6162" head="1491" tail="6165"/><cas:NonEmptyFSList xmi:id="6159" head="1479" tail="6162"/><cas:NonEmptyFSList xmi:id="6156" head="1467" tail="6159"/><cas:NonEmptyFSList xmi:id="6153" head="1455" tail="6156"/><cas:NonEmptyFSList xmi:id="6150" head="1443" tail="6153"/><cas:NonEmptyFSList xmi:id="6147" head="1431" tail="6150"/><cas:NonEmptyFSList xmi:id="6144" head="1419" tail="6147"/><cas:NonEmptyFSList xmi:id="6141" head="1407" tail="6144"/><cas:NonEmptyFSList xmi:id="6138" head="1395" tail="6141"/><cas:NonEmptyFSList xmi:id="6135" head="1383" tail="6138"/><cas:NonEmptyFSList xmi:id="6132" head="1371" tail="6135"/><cas:NonEmptyFSList xmi:id="6129" head="1359" tail="6132"/><cas:NonEmptyFSList xmi:id="6126" head="1347" tail="6129"/><cas:NonEmptyFSList xmi:id="6123" head="1335" tail="6126"/><cas:NonEmptyFSList xmi:id="6120" head="1323" tail="6123"/><cas:NonEmptyFSList xmi:id="6117" head="1311" tail="6120"/><cas:NonEmptyFSList xmi:id="6114" head="1299" tail="6117"/><cas:NonEmptyFSList xmi:id="6111" head="1287" tail="6114"/><cas:NonEmptyFSList xmi:id="6108" head="1275" tail="6111"/><cas:NonEmptyFSList xmi:id="6105" head="1263" tail="6108"/><cas:NonEmptyFSList xmi:id="6102" head="1251" tail="6105"/><cas:NonEmptyFSList xmi:id="6099" head="1239" tail="6102"/><cas:NonEmptyFSList xmi:id="6096" head="1227" tail="6099"/><cas:NonEmptyFSList xmi:id="6093" head="1215" tail="6096"/><cas:NonEmptyFSList xmi:id="6090" head="1203" tail="6093"/><cas:NonEmptyFSList xmi:id="6087" head="1191" tail="6090"/><cas:NonEmptyFSList xmi:id="6084" head="1179" tail="6087"/><cas:NonEmptyFSList xmi:id="6081" head="1167" tail="6084"/><cas:NonEmptyFSList xmi:id="6078" head="1155" tail="6081"/><types:NER xmi:id="29833" sofa="12" begin="0" end="0" text="presenilin 1 transgenes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29824" sofa="12" begin="0" end="0" text="mutant amyloid precursor protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29801" sofa="12" begin="0" end="0" text="APP mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29792" sofa="12" begin="0" end="0" text="presenilin 1 and 2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29783" sofa="12" begin="0" end="0" text="amyloid beta-protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29774" sofa="12" begin="0" end="0" text="Eckman C" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29760" sofa="12" begin="0" end="0" text="beta amyloid protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29740" sofa="12" begin="0" end="0" text="amyloid-beta" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29731" sofa="12" begin="0" end="0" text="Abeta42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29722" sofa="12" begin="0" end="0" text="Abeta40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29705" sofa="12" begin="0" end="0" text="A4 / beta" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29696" sofa="12" begin="0" end="0" text="Soreghan B" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29671" sofa="12" begin="0" end="0" text="mutant presenilin 1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29662" sofa="12" begin="0" end="0" text="amyloid-beta42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29653" sofa="12" begin="0" end="0" text="Yu X" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29644" sofa="12" begin="0" end="0" text="Eckman C" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29624" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29615" sofa="12" begin="0" end="0" text="Pen-2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29606" sofa="12" begin="0" end="0" text="active gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29592" sofa="12" begin="0" end="0" text="Alzheimer 's disease gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29572" sofa="12" begin="0" end="0" text="gamma } -secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29563" sofa="12" begin="0" end="0" text="presenilin-1 mutation" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29554" sofa="12" begin="0" end="0" text="Xia W" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29534" sofa="12" begin="0" end="0" text="presenilin 1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29525" sofa="12" begin="0" end="0" text="Lei T , Bentahir M" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29516" sofa="12" begin="0" end="0" text="Tu H" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29499" sofa="12" begin="0" end="0" text="presenilin 1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29490" sofa="12" begin="0" end="0" text="Lee MK" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29473" sofa="12" begin="0" end="0" text="Nicastrin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29464" sofa="12" begin="0" end="0" text="Pen-2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29447" sofa="12" begin="0" end="0" text="nicastrin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29438" sofa="12" begin="0" end="0" text="gamma-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29421" sofa="12" begin="0" end="0" text="presenilin 1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29412" sofa="12" begin="0" end="0" text="Presenilin 2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29398" sofa="12" begin="0" end="0" text="purified gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29384" sofa="12" begin="0" end="0" text="active gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29370" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29356" sofa="12" begin="0" end="0" text="human gamma-secretase complex" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29342" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29325" sofa="12" begin="0" end="0" text="Aph1 subunit" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29316" sofa="12" begin="0" end="0" text="gamma-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29302" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29282" sofa="12" begin="0" end="0" text="Pro117S" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29273" sofa="12" begin="0" end="0" text="Pro117L" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29264" sofa="12" begin="0" end="0" text="Pro117S" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29250" sofa="12" begin="0" end="0" text="amyloid beta-protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29237" sofa="12" begin="0" end="0" text="U S A 99" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29221" sofa="12" begin="0" end="0" text="Notch" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29212" sofa="12" begin="0" end="0" text="Xia X" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29192" sofa="12" begin="0" end="0" text="Presenilin-1 P264L" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29183" sofa="12" begin="0" end="0" text="Lin YG" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29174" sofa="12" begin="0" end="0" text="Trusko S" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29160" sofa="12" begin="0" end="0" text="Sun X" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29140" sofa="12" begin="0" end="0" text="presenilin 1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29131" sofa="12" begin="0" end="0" text="Abeta42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29122" sofa="12" begin="0" end="0" text="Eckman C" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29108" sofa="12" begin="0" end="0" text="Champain D" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29088" sofa="12" begin="0" end="0" text="amyloid beta-protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29079" sofa="12" begin="0" end="0" text="Xia W" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29070" sofa="12" begin="0" end="0" text="Westaway D" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29053" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29044" sofa="12" begin="0" end="0" text="Presenilins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29027" sofa="12" begin="0" end="0" text="Gamma-secretase activating protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="29018" sofa="12" begin="0" end="0" text="Luo W" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28998" sofa="12" begin="0" end="0" text="epsilon-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28989" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28980" sofa="12" begin="0" end="0" text="TMP21" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28957" sofa="12" begin="0" end="0" text="lipoprotein receptor LRP1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28948" sofa="12" begin="0" end="0" text="Amyloid precursor protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28939" sofa="12" begin="0" end="0" text="Hoe HS" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28930" sofa="12" begin="0" end="0" text="Liu Q , Zerbinatti CV" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28913" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28904" sofa="12" begin="0" end="0" text="amyloid beta protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28885" sofa="12" begin="0" end="0" text="alpha } - and { gamma } -secretases" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28876" sofa="12" begin="0" end="0" text="Schweizer C" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28862" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28842" sofa="12" begin="0" end="0" text="amyloid beta-protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28833" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28824" sofa="12" begin="0" end="0" text="Xia W" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28807" sofa="12" begin="0" end="0" text="presenilin endoproteolysis and gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28798" sofa="12" begin="0" end="0" text="Xia W" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28784" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28770" sofa="12" begin="0" end="0" text="Martoglio B ( 2003 ) Intramembrane-cleaving proteases" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28752" sofa="12" begin="0" end="0" text="MC LA JH PCF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28738" sofa="12" begin="0" end="0" text="MC LA JH PCF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28704" sofa="12" begin="0" end="0" text="Flag-PEN2 cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28695" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28686" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28677" sofa="12" begin="0" end="0" text="PS1 D385A cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28668" sofa="12" begin="0" end="0" text="PS1 D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28659" sofa="12" begin="0" end="0" text="PS1 ��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28650" sofa="12" begin="0" end="0" text="WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28637" sofa="12" begin="0" end="0" text="APH1 isoforms" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28622" sofa="12" begin="0" end="0" text="APH1 isoform" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28609" sofa="12" begin="0" end="0" text="Qiagen RNAeasy kit )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28596" sofa="12" begin="0" end="0" text="APH1 isoforms" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28583" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28561" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28552" sofa="12" begin="0" end="0" text="human APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28543" sofa="12" begin="0" end="0" text="MEF PS1/2 ��� / ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28534" sofa="12" begin="0" end="0" text="WT MEF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28515" sofa="12" begin="0" end="0" text="SPA4CT construct" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28506" sofa="12" begin="0" end="0" text="MEF PS1/2 ��� / ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28497" sofa="12" begin="0" end="0" text="WT MEF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28482" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28469" sofa="12" begin="0" end="0" text="anti-PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28455" sofa="12" begin="0" end="0" text="��-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28441" sofa="12" begin="0" end="0" text="-Actin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28410" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28401" sofa="12" begin="0" end="0" text="UD1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28392" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28383" sofa="12" begin="0" end="0" text="MAB1563" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28374" sofa="12" begin="0" end="0" text="hPS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28365" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28356" sofa="12" begin="0" end="0" text="endogenous ��-secretase core components" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28343" sofa="12" begin="0" end="0" text="per PS1 variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28330" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28317" sofa="12" begin="0" end="0" text="human FAD-linked PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28304" sofa="12" begin="0" end="0" text="Information Top Figure S1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28285" sofa="12" begin="0" end="0" text="Invitrogen KHB3544" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28276" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28267" sofa="12" begin="0" end="0" text="Invitrogen KHB3481 )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28251" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28242" sofa="12" begin="0" end="0" text="A�� peptidesA��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28228" sofa="12" begin="0" end="0" text="Anti-mouse / rabbit / rat IgG" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28176" sofa="12" begin="0" end="0" text="��-actin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28167" sofa="12" begin="0" end="0" text="A2066" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28158" sofa="12" begin="0" end="0" text="APP CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28149" sofa="12" begin="0" end="0" text="C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28140" sofa="12" begin="0" end="0" text="Flag-PEN-2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28131" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28122" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28113" sofa="12" begin="0" end="0" text="PS1 CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28104" sofa="12" begin="0" end="0" text="MAB5232" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28095" sofa="12" begin="0" end="0" text="PS1 NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28086" sofa="12" begin="0" end="0" text="ab10281" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28077" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28068" sofa="12" begin="0" end="0" text="anti-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28059" sofa="12" begin="0" end="0" text="anti-Nicastrin NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28045" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28026" sofa="12" begin="0" end="0" text="antibodiesTotal" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28017" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="28008" sofa="12" begin="0" end="0" text="-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27988" sofa="12" begin="0" end="0" text="His tag sequence" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27979" sofa="12" begin="0" end="0" text="pET21 -C100 -His" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27970" sofa="12" begin="0" end="0" text="pET21 -C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27954" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27945" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27932" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27915" sofa="12" begin="0" end="0" text="anti-Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27906" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27891" sofa="12" begin="0" end="0" text="HA peptides" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27876" sofa="12" begin="0" end="0" text="���V5 pooled 1.6 mL fractions���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27863" sofa="12" begin="0" end="0" text="V5 peptides" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27850" sofa="12" begin="0" end="0" text="anti-V5 affinity resin beads" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27831" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27822" sofa="12" begin="0" end="0" text="solubilised ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27809" sofa="12" begin="0" end="0" text="Anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27796" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27783" sofa="12" begin="0" end="0" text="���solubilised ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27768" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27750" sofa="12" begin="0" end="0" text="Avestin Inc" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27722" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27713" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27704" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27695" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27686" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27677" sofa="12" begin="0" end="0" text="MEF PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27661" sofa="12" begin="0" end="0" text="FAD-linked PS1 variants1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27652" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27633" sofa="12" begin="0" end="0" text="BCA protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27624" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27615" sofa="12" begin="0" end="0" text="Protein extractionTotal protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27595" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27586" sofa="12" begin="0" end="0" text="human SPA4CT -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27577" sofa="12" begin="0" end="0" text="SPA4CT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27564" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27530" sofa="12" begin="0" end="0" text="PS1 -DDAA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27521" sofa="12" begin="0" end="0" text="PS1 -D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27512" sofa="12" begin="0" end="0" text="PS1 -D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27503" sofa="12" begin="0" end="0" text="PS1 -P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27494" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27485" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27476" sofa="12" begin="0" end="0" text="human PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27467" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27448" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27439" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27430" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27414" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27405" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27389" sofa="12" begin="0" end="0" text="P / S )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27380" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27367" sofa="12" begin="0" end="0" text="p24 ELISA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27352" sofa="12" begin="0" end="0" text="pMD2G" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27334" sofa="12" begin="0" end="0" text="pET21 -C100 -His" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27325" sofa="12" begin="0" end="0" text="pET21 -C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27296" sofa="12" begin="0" end="0" text="AAT TCT GCA TCT GCA TCC GCC CGA GCC GTC CAG GCG GCC AGC AGG AGC AGT GCC AAA CCG GGC AGC ATA 3 ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27287" sofa="12" begin="0" end="0" text="AGC TTA TGC TGC CCG GTT TG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT CGG GCG GAT GCA GAT GCA G 3" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27278" sofa="12" begin="0" end="0" text="pcDNA3 -APP695 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27269" sofa="12" begin="0" end="0" text="HindIII / EcoRI fragment" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27260" sofa="12" begin="0" end="0" text="APP-C99 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27251" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27232" sofa="12" begin="0" end="0" text="PS1 D385A into pcDNA3.1 -PS1 D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27223" sofa="12" begin="0" end="0" text="DraI / XhoI digested fragment" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27214" sofa="12" begin="0" end="0" text="PS1 D257A / D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27198" sofa="12" begin="0" end="0" text="HindIII / XhoI" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27189" sofa="12" begin="0" end="0" text="BamHI / HindIII" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27145" sofa="12" begin="0" end="0" text="tTG CCA GCT CTT CAA ATC TCC 3 ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27136" sofa="12" begin="0" end="0" text="TCG AGT TTA Gaa" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27127" sofa="12" begin="0" end="0" text="tTC TTG AAA ATG GCA AGG AG 3 ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27118" sofa="12" begin="0" end="0" text="TCG AGT TTA Gaa" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27109" sofa="12" begin="0" end="0" text="ttA TTG TTG CTG 3 ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27100" sofa="12" begin="0" end="0" text="CTT ATT ATA TCa" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27091" sofa="12" begin="0" end="0" text="tGA TAT AAT AGG 3 ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27082" sofa="12" begin="0" end="0" text="CAG CAA CAA Taa" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27073" sofa="12" begin="0" end="0" text="BGH primers" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27064" sofa="12" begin="0" end="0" text="L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27055" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27039" sofa="12" begin="0" end="0" text="PS1 D385A cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27030" sofa="12" begin="0" end="0" text="PS1 D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="27017" sofa="12" begin="0" end="0" text="PS1 ��E9 cDNA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26992" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26983" sofa="12" begin="0" end="0" text="wild-type PS1 human cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26974" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26965" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26956" sofa="12" begin="0" end="0" text="mutagenesisNCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26922" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26913" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26904" sofa="12" begin="0" end="0" text="epsilon versus gamma-cleavage sites" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26895" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26886" sofa="12" begin="0" end="0" text="how FAD mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26877" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26868" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26859" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26846" sofa="12" begin="0" end="0" text="FAD-linked PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26830" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26821" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26808" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26795" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26782" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26768" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26746" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26737" sofa="12" begin="0" end="0" text="endogenous PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26728" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26719" sofa="12" begin="0" end="0" text="Notch" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26706" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26690" sofa="12" begin="0" end="0" text="LRP1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26681" sofa="12" begin="0" end="0" text="lipoprotein receptor" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26665" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26656" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26639" sofa="12" begin="0" end="0" text="��-secretase activating protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26630" sofa="12" begin="0" end="0" text="TMP21" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26617" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26589" sofa="12" begin="0" end="0" text="PS1 -WT complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26580" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26571" sofa="12" begin="0" end="0" text="AHP1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26562" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26553" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26544" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26525" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26516" sofa="12" begin="0" end="0" text="APH1 aS" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26507" sofa="12" begin="0" end="0" text="��-secretase complexes carrying APH1 b" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26491" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26482" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26468" sofa="12" begin="0" end="0" text="FAD-linked PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26452" sofa="12" begin="0" end="0" text="FAD-linked PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26443" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26421" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26412" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26403" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26394" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26377" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26368" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26352" sofa="12" begin="0" end="0" text="semi-purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26343" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26318" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26309" sofa="12" begin="0" end="0" text="PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26300" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26291" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26282" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26260" sofa="12" begin="0" end="0" text="PS1 -CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26251" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26242" sofa="12" begin="0" end="0" text="full-length PS1 -P436Q protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26233" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26217" sofa="12" begin="0" end="0" text="PS1 -P436Q mutant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26208" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26177" sofa="12" begin="0" end="0" text="wild-type PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26168" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26159" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26150" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26141" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26132" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26123" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26101" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26092" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26083" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26074" sofa="12" begin="0" end="0" text="PS1 -��E9 mutant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26061" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26047" sofa="12" begin="0" end="0" text="APP Swedish mutation" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26033" sofa="12" begin="0" end="0" text="K670M / N671L" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26020" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="26003" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25994" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25978" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25969" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25944" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25935" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25926" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25917" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25908" sofa="12" begin="0" end="0" text="PS1 -L166P variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25895" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25876" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25867" sofa="12" begin="0" end="0" text="dominant-negative PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25858" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25827" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25818" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25809" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25800" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25791" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25782" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25773" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25751" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25742" sofa="12" begin="0" end="0" text="P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25733" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25724" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25699" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25690" sofa="12" begin="0" end="0" text="MEF PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25681" sofa="12" begin="0" end="0" text="APP-CTFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25672" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25663" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25650" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25631" sofa="12" begin="0" end="0" text="APH1 genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25622" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25613" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25600" sofa="12" begin="0" end="0" text="APH1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25587" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25553" sofa="12" begin="0" end="0" text="PSEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25544" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25535" sofa="12" begin="0" end="0" text="presenilin genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25526" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25517" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25508" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25499" sofa="12" begin="0" end="0" text="human APH1 genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25490" sofa="12" begin="0" end="0" text="Indeed , ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25468" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25459" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25450" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25441" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25425" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25416" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25403" sofa="12" begin="0" end="0" text="PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25387" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25378" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25365" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25352" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25330" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25321" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25312" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25303" sofa="12" begin="0" end="0" text="g005 Discussion Top" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25285" sofa="12" begin="0" end="0" text="FAD-linked ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25266" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25257" sofa="12" begin="0" end="0" text="C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25248" sofa="12" begin="0" end="0" text="anti-Flag antibody" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25235" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25219" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25210" sofa="12" begin="0" end="0" text="highly purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25197" sofa="12" begin="0" end="0" text="g004 thumbnailFigure 5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25168" sofa="12" begin="0" end="0" text="anti-PS1 -CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25159" sofa="12" begin="0" end="0" text="anti-PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25150" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25141" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25132" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25108" sofa="12" begin="0" end="0" text="ab10281" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25099" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25090" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25081" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25063" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25054" sofa="12" begin="0" end="0" text="Presenilin double-knockout MEFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25035" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25026" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25017" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="25000" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24991" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24975" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24966" sofa="12" begin="0" end="0" text="PS1 -WT ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24950" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24941" sofa="12" begin="0" end="0" text="A�� species by ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24925" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24916" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24899" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24890" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24877" sofa="12" begin="0" end="0" text="PS1 affect ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24849" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24840" sofa="12" begin="0" end="0" text="PS1 -P436Q variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24831" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24822" sofa="12" begin="0" end="0" text="purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24813" sofa="12" begin="0" end="0" text="PS1 -FL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24804" sofa="12" begin="0" end="0" text="PS1 -NTF / CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24782" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24773" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24764" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24755" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24742" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24726" sofa="12" begin="0" end="0" text="PS1 ( Figure 4 B" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24717" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24704" sofa="12" begin="0" end="0" text="molecular weight ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24680" sofa="12" begin="0" end="0" text="homogeneity ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24671" sofa="12" begin="0" end="0" text="how PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24662" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24653" sofa="12" begin="0" end="0" text="Highly purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24639" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24626" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24613" sofa="12" begin="0" end="0" text="WT ��-MEFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24588" sofa="12" begin="0" end="0" text="PS1 -WT-containing complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24579" sofa="12" begin="0" end="0" text="PS1 -P436Q ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24570" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24561" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24552" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24530" sofa="12" begin="0" end="0" text="PS1 -WT ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24521" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24512" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24503" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24487" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24478" sofa="12" begin="0" end="0" text="FAD-linked mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24450" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24441" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24432" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24423" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24414" sofa="12" begin="0" end="0" text="anti-HA resins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24405" sofa="12" begin="0" end="0" text="anti-Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24383" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24374" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24365" sofa="12" begin="0" end="0" text="anti-HA 3 F10" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24356" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24340" sofa="12" begin="0" end="0" text="C100 -His" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24331" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24318" sofa="12" begin="0" end="0" text="g003" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24301" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24288" sofa="12" begin="0" end="0" text="IgG light chains" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24272" sofa="12" begin="0" end="0" text="anti-APP-CTF antibody" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24263" sofa="12" begin="0" end="0" text="AICD-His cleavage products" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24235" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24226" sofa="12" begin="0" end="0" text="UD1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24217" sofa="12" begin="0" end="0" text="PS1 -NTF )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24208" sofa="12" begin="0" end="0" text="MAB1563" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24199" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24190" sofa="12" begin="0" end="0" text="for ��-secretase subunits" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24171" sofa="12" begin="0" end="0" text="anti-HA affinity resins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24162" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24153" sofa="12" begin="0" end="0" text="microsomal proteins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24140" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24127" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24114" sofa="12" begin="0" end="0" text="anti-PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24094" sofa="12" begin="0" end="0" text="��-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24085" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24076" sofa="12" begin="0" end="0" text="partially purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24059" sofa="12" begin="0" end="0" text="human ��-secretase components" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24050" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24037" sofa="12" begin="0" end="0" text="PS1 -P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24018" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24009" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="24000" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23987" sofa="12" begin="0" end="0" text="AICD-Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23968" sofa="12" begin="0" end="0" text="C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23959" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23950" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23928" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23919" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23910" sofa="12" begin="0" end="0" text="semi-purified ��-secretase complexesWe" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23901" sofa="12" begin="0" end="0" text="g002 FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23882" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23873" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23860" sofa="12" begin="0" end="0" text="APP ( A8717 )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23841" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23832" sofa="12" begin="0" end="0" text="human APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23823" sofa="12" begin="0" end="0" text="WT MEF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23810" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23793" sofa="12" begin="0" end="0" text="Figure 2 D )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23784" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23771" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23758" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23739" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23730" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23721" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23702" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23693" sofa="12" begin="0" end="0" text="PS1 aspartate mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23684" sofa="12" begin="0" end="0" text="SPA4CT -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23664" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23655" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23646" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23633" sofa="12" begin="0" end="0" text="SPA4CT -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23614" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23605" sofa="12" begin="0" end="0" text="APP-CTFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23596" sofa="12" begin="0" end="0" text="above-described ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23583" sofa="12" begin="0" end="0" text="APP-based ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23570" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23548" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23539" sofa="12" begin="0" end="0" text="APP-CTFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23530" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23521" sofa="12" begin="0" end="0" text="FAD mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23499" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23490" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23481" sofa="12" begin="0" end="0" text="Flag-hPEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23472" sofa="12" begin="0" end="0" text="hAPH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23450" sofa="12" begin="0" end="0" text="PS1 -P436Q mutation" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23441" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23432" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23423" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23410" sofa="12" begin="0" end="0" text="APP-CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23388" sofa="12" begin="0" end="0" text="PS1 -P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23379" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23370" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23361" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23342" sofa="12" begin="0" end="0" text="PS1 ( Figure 1 B )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23333" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23324" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23308" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23299" sofa="12" begin="0" end="0" text="g001" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23282" sofa="12" begin="0" end="0" text="-Actin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23257" sofa="12" begin="0" end="0" text="Flag-PEN2 ( M2 )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23248" sofa="12" begin="0" end="0" text="APH1 aL-HA ( 3 F10" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23239" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23230" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23221" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23208" sofa="12" begin="0" end="0" text="per ��-secretase variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23192" sofa="12" begin="0" end="0" text="MEF PS1/2 ��� / ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23183" sofa="12" begin="0" end="0" text="WT MEF )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23170" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23157" sofa="12" begin="0" end="0" text="hAPH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23144" sofa="12" begin="0" end="0" text="all human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23118" sofa="12" begin="0" end="0" text="PS1 -CTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23109" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23100" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23091" sofa="12" begin="0" end="0" text="CTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23082" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23057" sofa="12" begin="0" end="0" text="PS1 -NTF+ PS1 -FL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23048" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23039" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23030" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="23021" sofa="12" begin="0" end="0" text="NTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22993" sofa="12" begin="0" end="0" text="PS1 -FL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22984" sofa="12" begin="0" end="0" text="full-length PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22975" sofa="12" begin="0" end="0" text="PS1 -CTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22966" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22957" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22948" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22935" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22922" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22900" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22891" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22882" sofa="12" begin="0" end="0" text="WT PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22873" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22854" sofa="12" begin="0" end="0" text="PS1 clones" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22845" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22836" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22823" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22804" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22795" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22786" sofa="12" begin="0" end="0" text="PS" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22769" sofa="12" begin="0" end="0" text="recombinant proteins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22760" sofa="12" begin="0" end="0" text="PS1 variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22732" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22723" sofa="12" begin="0" end="0" text="D257A / D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22714" sofa="12" begin="0" end="0" text="D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22705" sofa="12" begin="0" end="0" text="D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22696" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22687" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22664" sofa="12" begin="0" end="0" text="human Flag-PEN2 ( Flag-hPEN2 )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22655" sofa="12" begin="0" end="0" text="hAPH1 aL-HA )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22646" sofa="12" begin="0" end="0" text="human APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22637" sofa="12" begin="0" end="0" text="human NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22624" sofa="12" begin="0" end="0" text="mouse ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22599" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22590" sofa="12" begin="0" end="0" text="human PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22581" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22572" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22563" sofa="12" begin="0" end="0" text="human ��-secretase subunits NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22541" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22532" sofa="12" begin="0" end="0" text="homogenous human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22523" sofa="12" begin="0" end="0" text="PS1 mutantsIn" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22514" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22498" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22489" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22473" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22464" sofa="12" begin="0" end="0" text="homogenous human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22451" sofa="12" begin="0" end="0" text="wild-type PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22429" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22420" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22411" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22402" sofa="12" begin="0" end="0" text="proteolytically active ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22389" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22367" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22358" sofa="12" begin="0" end="0" text="APH1 isoforms" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22349" sofa="12" begin="0" end="0" text="PS genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22340" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22321" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22312" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22303" sofa="12" begin="0" end="0" text="FAD-linked PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22284" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22275" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22256" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22247" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22225" sofa="12" begin="0" end="0" text="brain ApoE" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22216" sofa="12" begin="0" end="0" text="APP intracellular domain" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22207" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22198" sofa="12" begin="0" end="0" text="APP C-terminal fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22170" sofa="12" begin="0" end="0" text="generating amyloid-beta peptides" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22161" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22152" sofa="12" begin="0" end="0" text="BACE1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22143" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22134" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22125" sofa="12" begin="0" end="0" text="amyloid precursor protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22106" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22097" sofa="12" begin="0" end="0" text="ERBB4" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22088" sofa="12" begin="0" end="0" text="NOTCH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22075" sofa="12" begin="0" end="0" text="type-I membrane proteins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22056" sofa="12" begin="0" end="0" text="��-secretase complex" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22047" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22038" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22022" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="22013" sofa="12" begin="0" end="0" text="transition-state analogue ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21985" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21976" sofa="12" begin="0" end="0" text="presenilin enhancer 2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21967" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21958" sofa="12" begin="0" end="0" text="nicastrin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21949" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21940" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21915" sofa="12" begin="0" end="0" text="Proteases" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21906" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21897" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21888" sofa="12" begin="0" end="0" text="PSEN2 encode transmembrane proteins PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21879" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21863" sofa="12" begin="0" end="0" text="PSEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21854" sofa="12" begin="0" end="0" text="presenilin genes PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21832" sofa="12" begin="0" end="0" text="Purified ��-Secretase Complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21823" sofa="12" begin="0" end="0" text="Presenilin-1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21807" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21798" sofa="12" begin="0" end="0" text="PS1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21776" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21767" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21758" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21749" sofa="12" begin="0" end="0" text="PS1 FAD-linked" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21736" sofa="12" begin="0" end="0" text="highly purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21714" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21705" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21696" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21687" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21665" sofa="12" begin="0" end="0" text="PS1 mutants L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21656" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21647" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21638" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21625" sofa="12" begin="0" end="0" text="how PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21606" sofa="12" begin="0" end="0" text="APP intracellular domain" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21597" sofa="12" begin="0" end="0" text="A��1���42 / A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21588" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21557" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21548" sofa="12" begin="0" end="0" text="amyloid precursor protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21539" sofa="12" begin="0" end="0" text="��-secretase complex" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21530" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21521" sofa="12" begin="0" end="0" text="presenilin enhancer 2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21512" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21503" sofa="12" begin="0" end="0" text="nicastrin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21469" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21460" sofa="12" begin="0" end="0" text="gene encoding presenilin-1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21451" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21442" sofa="12" begin="0" end="0" text="SwitzerlandAbstract Top" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21433" sofa="12" begin="0" end="0" text="Purified ��-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21424" sofa="12" begin="0" end="0" text="Presenilin-1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21415" sofa="12" begin="0" end="0" text="Purified ��-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="21406" sofa="12" begin="0" end="0" text="Presenilin-1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15008" sofa="12" begin="0" end="0" text="beta amyloid protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14992" sofa="12" begin="0" end="0" text="gamma-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14983" sofa="12" begin="0" end="0" text="Presenilins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14949" sofa="12" begin="0" end="0" text="Flag-PEN2 cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14940" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14931" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14922" sofa="12" begin="0" end="0" text="PS1 D385A cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14913" sofa="12" begin="0" end="0" text="PS1 D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14904" sofa="12" begin="0" end="0" text="PS1 ��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14895" sofa="12" begin="0" end="0" text="WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14882" sofa="12" begin="0" end="0" text="APH1 isoforms" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14868" sofa="12" begin="0" end="0" text="APH1 isoform" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14855" sofa="12" begin="0" end="0" text="Qiagen RNAeasy kit )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14842" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14820" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14811" sofa="12" begin="0" end="0" text="human APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14802" sofa="12" begin="0" end="0" text="MEF PS1/2 ��� / ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14793" sofa="12" begin="0" end="0" text="WT MEF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14774" sofa="12" begin="0" end="0" text="SPA4CT construct" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14765" sofa="12" begin="0" end="0" text="MEF PS1/2 ��� / ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14756" sofa="12" begin="0" end="0" text="WT MEF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14742" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14729" sofa="12" begin="0" end="0" text="anti-PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14715" sofa="12" begin="0" end="0" text="��-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14701" sofa="12" begin="0" end="0" text="-Actin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14670" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14661" sofa="12" begin="0" end="0" text="UD1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14652" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14643" sofa="12" begin="0" end="0" text="MAB1563" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14634" sofa="12" begin="0" end="0" text="hPS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14625" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14616" sofa="12" begin="0" end="0" text="endogenous ��-secretase core components" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14603" sofa="12" begin="0" end="0" text="per PS1 variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14590" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14577" sofa="12" begin="0" end="0" text="human FAD-linked PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14564" sofa="12" begin="0" end="0" text="Information Top Figure S1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14548" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14539" sofa="12" begin="0" end="0" text="A�� peptidesA��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14525" sofa="12" begin="0" end="0" text="Anti-mouse / rabbit / rat IgG" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14473" sofa="12" begin="0" end="0" text="��-actin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14464" sofa="12" begin="0" end="0" text="A2066" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14455" sofa="12" begin="0" end="0" text="APP CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14446" sofa="12" begin="0" end="0" text="C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14437" sofa="12" begin="0" end="0" text="Flag-PEN-2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14428" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14419" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14410" sofa="12" begin="0" end="0" text="PS1 CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14401" sofa="12" begin="0" end="0" text="MAB5232" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14392" sofa="12" begin="0" end="0" text="PS1 NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14383" sofa="12" begin="0" end="0" text="ab10281" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14374" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14365" sofa="12" begin="0" end="0" text="anti-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14356" sofa="12" begin="0" end="0" text="anti-Nicastrin NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14342" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14323" sofa="12" begin="0" end="0" text="antibodiesTotal" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14314" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14305" sofa="12" begin="0" end="0" text="-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14286" sofa="12" begin="0" end="0" text="His tag sequence" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14277" sofa="12" begin="0" end="0" text="pET21 -C100 -His" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14268" sofa="12" begin="0" end="0" text="pET21 -C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14252" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14243" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14230" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14213" sofa="12" begin="0" end="0" text="anti-Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14204" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14189" sofa="12" begin="0" end="0" text="HA peptides" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14175" sofa="12" begin="0" end="0" text="���V5 pooled 1.6 mL fractions���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14162" sofa="12" begin="0" end="0" text="V5 peptides" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14149" sofa="12" begin="0" end="0" text="anti-V5 affinity resin beads" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14130" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14121" sofa="12" begin="0" end="0" text="solubilised ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14108" sofa="12" begin="0" end="0" text="Anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14095" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14082" sofa="12" begin="0" end="0" text="���solubilised ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14067" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14050" sofa="12" begin="0" end="0" text="Avestin Inc" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14022" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14013" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="14004" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13995" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13986" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13977" sofa="12" begin="0" end="0" text="MEF PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13961" sofa="12" begin="0" end="0" text="FAD-linked PS1 variants1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13952" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13933" sofa="12" begin="0" end="0" text="BCA protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13924" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13915" sofa="12" begin="0" end="0" text="Protein extractionTotal protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13895" sofa="12" begin="0" end="0" text="protease" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13886" sofa="12" begin="0" end="0" text="human SPA4CT -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13877" sofa="12" begin="0" end="0" text="SPA4CT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13864" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13830" sofa="12" begin="0" end="0" text="PS1 -DDAA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13821" sofa="12" begin="0" end="0" text="PS1 -D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13812" sofa="12" begin="0" end="0" text="PS1 -D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13803" sofa="12" begin="0" end="0" text="PS1 -P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13794" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13785" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13776" sofa="12" begin="0" end="0" text="human PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13767" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13748" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13739" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13730" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13714" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13705" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13689" sofa="12" begin="0" end="0" text="P / S )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13680" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13667" sofa="12" begin="0" end="0" text="p24 ELISA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13652" sofa="12" begin="0" end="0" text="pMD2G" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13634" sofa="12" begin="0" end="0" text="pET21 -C100 -His" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13625" sofa="12" begin="0" end="0" text="pET21 -C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13605" sofa="12" begin="0" end="0" text="PS1 D385A into pcDNA3.1 -PS1 D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13596" sofa="12" begin="0" end="0" text="DraI / XhoI digested fragment" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13587" sofa="12" begin="0" end="0" text="PS1 D257A / D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13571" sofa="12" begin="0" end="0" text="HindIII / XhoI" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13562" sofa="12" begin="0" end="0" text="BamHI / HindIII" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13545" sofa="12" begin="0" end="0" text="PS1 D385A cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13536" sofa="12" begin="0" end="0" text="PS1 D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13523" sofa="12" begin="0" end="0" text="PS1 ��E9 cDNA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13498" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13489" sofa="12" begin="0" end="0" text="wild-type PS1 human cDNAs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13480" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13471" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13462" sofa="12" begin="0" end="0" text="mutagenesisNCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13428" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13419" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13410" sofa="12" begin="0" end="0" text="epsilon versus gamma-cleavage sites" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13401" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13392" sofa="12" begin="0" end="0" text="how FAD mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13383" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13374" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13365" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13352" sofa="12" begin="0" end="0" text="FAD-linked PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13336" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13327" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13314" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13301" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13288" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13274" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13252" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13243" sofa="12" begin="0" end="0" text="endogenous PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13234" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13225" sofa="12" begin="0" end="0" text="Notch" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13212" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13196" sofa="12" begin="0" end="0" text="LRP1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13187" sofa="12" begin="0" end="0" text="lipoprotein receptor" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13171" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13162" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13145" sofa="12" begin="0" end="0" text="��-secretase activating protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13136" sofa="12" begin="0" end="0" text="TMP21" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13123" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13095" sofa="12" begin="0" end="0" text="PS1 -WT complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13086" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13077" sofa="12" begin="0" end="0" text="AHP1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13068" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13059" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13050" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13031" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13022" sofa="12" begin="0" end="0" text="APH1 aS" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="13013" sofa="12" begin="0" end="0" text="��-secretase complexes carrying APH1 b" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12997" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12988" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12974" sofa="12" begin="0" end="0" text="FAD-linked PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12958" sofa="12" begin="0" end="0" text="FAD-linked PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12949" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12927" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12918" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12909" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12900" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12883" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12874" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12858" sofa="12" begin="0" end="0" text="semi-purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12849" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12824" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12815" sofa="12" begin="0" end="0" text="PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12806" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12797" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12788" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12766" sofa="12" begin="0" end="0" text="PS1 -CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12757" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12748" sofa="12" begin="0" end="0" text="full-length PS1 -P436Q protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12739" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12723" sofa="12" begin="0" end="0" text="PS1 -P436Q mutant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12714" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12683" sofa="12" begin="0" end="0" text="wild-type PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12674" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12665" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12656" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12647" sofa="12" begin="0" end="0" text="AICD" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12638" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12629" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12607" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12598" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12589" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12580" sofa="12" begin="0" end="0" text="PS1 -��E9 mutant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12567" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12553" sofa="12" begin="0" end="0" text="APP Swedish mutation" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12539" sofa="12" begin="0" end="0" text="K670M / N671L" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12526" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12509" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12500" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12484" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12475" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12450" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12441" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12432" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12423" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12414" sofa="12" begin="0" end="0" text="PS1 -L166P variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12401" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12382" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12373" sofa="12" begin="0" end="0" text="dominant-negative PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12364" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12333" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12324" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12315" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12306" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12297" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12288" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12279" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12257" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12248" sofa="12" begin="0" end="0" text="P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12239" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12230" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12205" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12196" sofa="12" begin="0" end="0" text="MEF PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12187" sofa="12" begin="0" end="0" text="APP-CTFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12178" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12169" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12156" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12137" sofa="12" begin="0" end="0" text="APH1 genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12128" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12119" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12106" sofa="12" begin="0" end="0" text="APH1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12093" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12059" sofa="12" begin="0" end="0" text="PSEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12050" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12041" sofa="12" begin="0" end="0" text="presenilin genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12032" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12023" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12014" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="12005" sofa="12" begin="0" end="0" text="human APH1 genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11996" sofa="12" begin="0" end="0" text="Indeed , ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11974" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11965" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11956" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11947" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11931" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11922" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11909" sofa="12" begin="0" end="0" text="PS1 / PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11893" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11884" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11871" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11858" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11836" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11827" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11818" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11809" sofa="12" begin="0" end="0" text="g005 Discussion Top" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11793" sofa="12" begin="0" end="0" text="FAD-linked ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11774" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11765" sofa="12" begin="0" end="0" text="C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11756" sofa="12" begin="0" end="0" text="anti-Flag antibody" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11743" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11727" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11718" sofa="12" begin="0" end="0" text="highly purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11691" sofa="12" begin="0" end="0" text="anti-PS1 -CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11682" sofa="12" begin="0" end="0" text="anti-PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11673" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11664" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11655" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11631" sofa="12" begin="0" end="0" text="ab10281" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11622" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11613" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11604" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11586" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11577" sofa="12" begin="0" end="0" text="Presenilin double-knockout MEFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11558" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11549" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11540" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11524" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11515" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11499" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11490" sofa="12" begin="0" end="0" text="PS1 -WT ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11474" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11465" sofa="12" begin="0" end="0" text="A�� species by ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11449" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11440" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11423" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11414" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11401" sofa="12" begin="0" end="0" text="PS1 affect ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11373" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11364" sofa="12" begin="0" end="0" text="PS1 -P436Q variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11355" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11346" sofa="12" begin="0" end="0" text="purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11337" sofa="12" begin="0" end="0" text="PS1 -FL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11328" sofa="12" begin="0" end="0" text="PS1 -NTF / CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11306" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11297" sofa="12" begin="0" end="0" text="Flag-PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11288" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11279" sofa="12" begin="0" end="0" text="NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11266" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11250" sofa="12" begin="0" end="0" text="PS1 ( Figure 4 B" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11241" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11228" sofa="12" begin="0" end="0" text="molecular weight ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11204" sofa="12" begin="0" end="0" text="homogeneity ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11195" sofa="12" begin="0" end="0" text="how PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11186" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11177" sofa="12" begin="0" end="0" text="Highly purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11163" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11150" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11137" sofa="12" begin="0" end="0" text="WT ��-MEFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11112" sofa="12" begin="0" end="0" text="PS1 -WT-containing complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11103" sofa="12" begin="0" end="0" text="PS1 -P436Q ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11094" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11085" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11076" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11054" sofa="12" begin="0" end="0" text="PS1 -WT ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11045" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11036" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11027" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11011" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="11002" sofa="12" begin="0" end="0" text="FAD-linked mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10974" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10965" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10956" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10947" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10938" sofa="12" begin="0" end="0" text="anti-HA resins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10929" sofa="12" begin="0" end="0" text="anti-Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10907" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10898" sofa="12" begin="0" end="0" text="APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10889" sofa="12" begin="0" end="0" text="anti-HA 3 F10" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10880" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10864" sofa="12" begin="0" end="0" text="C100 -His" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10855" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10842" sofa="12" begin="0" end="0" text="g003" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10828" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10815" sofa="12" begin="0" end="0" text="IgG light chains" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10799" sofa="12" begin="0" end="0" text="anti-APP-CTF antibody" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10790" sofa="12" begin="0" end="0" text="AICD-His cleavage products" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10762" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10753" sofa="12" begin="0" end="0" text="UD1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10744" sofa="12" begin="0" end="0" text="PS1 -NTF )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10735" sofa="12" begin="0" end="0" text="MAB1563" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10726" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10717" sofa="12" begin="0" end="0" text="for ��-secretase subunits" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10698" sofa="12" begin="0" end="0" text="anti-HA affinity resins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10689" sofa="12" begin="0" end="0" text="anti-Flag M2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10680" sofa="12" begin="0" end="0" text="microsomal proteins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10667" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10654" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10641" sofa="12" begin="0" end="0" text="anti-PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10621" sofa="12" begin="0" end="0" text="��-Secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10612" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10603" sofa="12" begin="0" end="0" text="partially purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10587" sofa="12" begin="0" end="0" text="human ��-secretase components" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10578" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10565" sofa="12" begin="0" end="0" text="PS1 -P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10546" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10537" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10528" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10515" sofa="12" begin="0" end="0" text="AICD-Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10496" sofa="12" begin="0" end="0" text="C100 -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10487" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10478" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10456" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10447" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10438" sofa="12" begin="0" end="0" text="semi-purified ��-secretase complexesWe" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10429" sofa="12" begin="0" end="0" text="g002 FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10415" sofa="12" begin="0" end="0" text="APP ( A8717 )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10396" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10387" sofa="12" begin="0" end="0" text="human APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10378" sofa="12" begin="0" end="0" text="WT MEF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10365" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10352" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10333" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10324" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10315" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10296" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10287" sofa="12" begin="0" end="0" text="PS1 aspartate mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10278" sofa="12" begin="0" end="0" text="SPA4CT -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10259" sofa="12" begin="0" end="0" text="human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10250" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10241" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10228" sofa="12" begin="0" end="0" text="SPA4CT -Flag" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10209" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10200" sofa="12" begin="0" end="0" text="APP-CTFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10191" sofa="12" begin="0" end="0" text="above-described ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10178" sofa="12" begin="0" end="0" text="APP-based ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10165" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10143" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10134" sofa="12" begin="0" end="0" text="APP-CTFs" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10125" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10116" sofa="12" begin="0" end="0" text="FAD mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10094" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10085" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10076" sofa="12" begin="0" end="0" text="Flag-hPEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10067" sofa="12" begin="0" end="0" text="hAPH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10045" sofa="12" begin="0" end="0" text="PS1 -P436Q mutation" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10036" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10027" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10018" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="10005" sofa="12" begin="0" end="0" text="APP-CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9983" sofa="12" begin="0" end="0" text="PS1 -P436Q" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9974" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9965" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9956" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9937" sofa="12" begin="0" end="0" text="PS1 ( Figure 1 B )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9928" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9919" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9903" sofa="12" begin="0" end="0" text="PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9894" sofa="12" begin="0" end="0" text="g001" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9880" sofa="12" begin="0" end="0" text="-Actin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9855" sofa="12" begin="0" end="0" text="Flag-PEN2 ( M2 )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9846" sofa="12" begin="0" end="0" text="APH1 aL-HA ( 3 F10" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9837" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9828" sofa="12" begin="0" end="0" text="NCT164" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9819" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9806" sofa="12" begin="0" end="0" text="per ��-secretase variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9790" sofa="12" begin="0" end="0" text="MEF PS1/2 ��� / ���" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9781" sofa="12" begin="0" end="0" text="WT MEF )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9768" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9755" sofa="12" begin="0" end="0" text="hAPH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9742" sofa="12" begin="0" end="0" text="all human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9717" sofa="12" begin="0" end="0" text="PS1 -CTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9708" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9699" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9690" sofa="12" begin="0" end="0" text="CTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9681" sofa="12" begin="0" end="0" text="PS1 -��E9" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9656" sofa="12" begin="0" end="0" text="PS1 -NTF+ PS1 -FL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9647" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9638" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9629" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9620" sofa="12" begin="0" end="0" text="NTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9592" sofa="12" begin="0" end="0" text="PS1 -FL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9583" sofa="12" begin="0" end="0" text="full-length PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9574" sofa="12" begin="0" end="0" text="PS1 -CTF fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9565" sofa="12" begin="0" end="0" text="PS1 -NTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9556" sofa="12" begin="0" end="0" text="PS1 -L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9547" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9534" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9521" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9499" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9490" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9481" sofa="12" begin="0" end="0" text="WT PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9472" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9453" sofa="12" begin="0" end="0" text="PS1 clones" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9444" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9435" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9422" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9403" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9394" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9385" sofa="12" begin="0" end="0" text="PS" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9368" sofa="12" begin="0" end="0" text="recombinant proteins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9359" sofa="12" begin="0" end="0" text="PS1 variant" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9331" sofa="12" begin="0" end="0" text="FAD-linked PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9322" sofa="12" begin="0" end="0" text="D257A / D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9313" sofa="12" begin="0" end="0" text="D385A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9304" sofa="12" begin="0" end="0" text="D257A" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9295" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9286" sofa="12" begin="0" end="0" text="PS1 -WT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9263" sofa="12" begin="0" end="0" text="human Flag-PEN2 ( Flag-hPEN2 )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9254" sofa="12" begin="0" end="0" text="hAPH1 aL-HA )" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9245" sofa="12" begin="0" end="0" text="human APH1 aL-HA" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9236" sofa="12" begin="0" end="0" text="human NCT-V5" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9223" sofa="12" begin="0" end="0" text="mouse ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9198" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9189" sofa="12" begin="0" end="0" text="human PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9180" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9171" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9162" sofa="12" begin="0" end="0" text="human ��-secretase subunits NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9140" sofa="12" begin="0" end="0" text="PS1 variants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9131" sofa="12" begin="0" end="0" text="homogenous human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9122" sofa="12" begin="0" end="0" text="PS1 mutantsIn" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9113" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9097" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9088" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9072" sofa="12" begin="0" end="0" text="PS1 mutants" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9063" sofa="12" begin="0" end="0" text="homogenous human ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9050" sofa="12" begin="0" end="0" text="wild-type PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9028" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9019" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9010" sofa="12" begin="0" end="0" text="NCT" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="9001" sofa="12" begin="0" end="0" text="proteolytically active ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8988" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8966" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8957" sofa="12" begin="0" end="0" text="APH1 isoforms" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8948" sofa="12" begin="0" end="0" text="PS genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8939" sofa="12" begin="0" end="0" text="��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8920" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8911" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8902" sofa="12" begin="0" end="0" text="FAD-linked PSEN1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8883" sofa="12" begin="0" end="0" text="A��40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8874" sofa="12" begin="0" end="0" text="A��42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8855" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8846" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8824" sofa="12" begin="0" end="0" text="brain ApoE" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8815" sofa="12" begin="0" end="0" text="APP intracellular domain" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8806" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8797" sofa="12" begin="0" end="0" text="APP C-terminal fragments" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8769" sofa="12" begin="0" end="0" text="generating amyloid-beta peptides" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8760" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8751" sofa="12" begin="0" end="0" text="BACE1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8742" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8733" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8724" sofa="12" begin="0" end="0" text="amyloid precursor protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8705" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8696" sofa="12" begin="0" end="0" text="ERBB4" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8687" sofa="12" begin="0" end="0" text="NOTCH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8674" sofa="12" begin="0" end="0" text="type-I membrane proteins" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8655" sofa="12" begin="0" end="0" text="��-secretase complex" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8646" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8637" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8621" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8612" sofa="12" begin="0" end="0" text="transition-state analogue ��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8584" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8575" sofa="12" begin="0" end="0" text="presenilin enhancer 2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8566" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8557" sofa="12" begin="0" end="0" text="nicastrin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8548" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8539" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8514" sofa="12" begin="0" end="0" text="Proteases" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8505" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8496" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8487" sofa="12" begin="0" end="0" text="PSEN2 encode transmembrane proteins PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8478" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8462" sofa="12" begin="0" end="0" text="PSEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8453" sofa="12" begin="0" end="0" text="presenilin genes PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8433" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8424" sofa="12" begin="0" end="0" text="PS1 mutations" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8402" sofa="12" begin="0" end="0" text="A��1���42" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8393" sofa="12" begin="0" end="0" text="A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8384" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8375" sofa="12" begin="0" end="0" text="PS1 FAD-linked" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8362" sofa="12" begin="0" end="0" text="highly purified ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8340" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8331" sofa="12" begin="0" end="0" text="human ��-secretase complexes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8322" sofa="12" begin="0" end="0" text="PS2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8313" sofa="12" begin="0" end="0" text="PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8291" sofa="12" begin="0" end="0" text="PS1 mutants L166P" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8282" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8273" sofa="12" begin="0" end="0" text="APH1 aL" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8264" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8251" sofa="12" begin="0" end="0" text="how PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8232" sofa="12" begin="0" end="0" text="APP intracellular domain" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8223" sofa="12" begin="0" end="0" text="A��1���42 / A��1���40" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8214" sofa="12" begin="0" end="0" text="FAD-linked PS1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8183" sofa="12" begin="0" end="0" text="APP" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8174" sofa="12" begin="0" end="0" text="amyloid precursor protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8165" sofa="12" begin="0" end="0" text="��-secretase complex" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8156" sofa="12" begin="0" end="0" text="PEN2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8147" sofa="12" begin="0" end="0" text="presenilin enhancer 2" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8138" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="8129" sofa="12" begin="0" end="0" text="nicastrin" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15243" sofa="12" begin="0" end="0" text="C100" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15190" sofa="12" begin="0" end="0" text="APH1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15176" sofa="12" begin="0" end="0" text="PSEN1" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15163" sofa="12" begin="0" end="0" text="APP-CTF" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15150" sofa="12" begin="0" end="0" text="PSEN1 gene" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15134" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15125" sofa="12" begin="0" end="0" text="PS1 protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15112" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15099" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15086" sofa="12" begin="0" end="0" text="PS1 protein" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15073" sofa="12" begin="0" end="0" text="ApoE gene" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15060" sofa="12" begin="0" end="0" text="��-secretase complex" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15043" sofa="12" begin="0" end="0" text="A��" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15034" sofa="12" begin="0" end="0" text="APH1 genes" tag="B-PROTEIN" weight="0.0"/><types:NER xmi:id="15021" sofa="12" begin="0" end="0" text="��-secretase" tag="B-PROTEIN" weight="0.0"/><cas:View sofa="12" members="1 19 127 235 343 451 559 667 775 883 991 29 44 59 74 89 137 152 167 182 197 245 260 275 290 305 353 368 383 398 413 461 476 491 506 521 569 584 599 614 629 677 692 707 722 737 785 800 815 830 845 893 908 923 938 953 1001 1016 1031 1046 1061 120 228 336 444 552 660 768 876 984 1092 1130 1135 1143 1155 1167 1179 1191 1203 1215 1227 1239 1251 1263 1275 1287 1299 1311 1323 1335 1347 1359 1371 1383 1395 1407 1419 1431 1443 1455 1467 1479 1491 1503 1515 1527 1539 1551 1563 1575 1587 1599 1611 1623 1635 1647 1659 1671 1683 1695 1707 1719 1731 1743 1755 1767 1779 1791 1803 1815 1827 1839 1851 1863 1875 1887 1899 1911 1923 1935 1947 1959 1971 1983 1995 2007 2019 2031 2043 2055 2067 2079 2091 2103 2115 2127 2139 2151 2163 2175 2187 2199 2211 2223 2235 2247 2259 2271 2283 2295 2307 2319 2331 2343 2355 2379 2391 2403 2415 2427 2439 2451 2463 2475 2487 2499 2511 2523 2535 2547 2559 2571 2583 2595 2607 2619 2631 2643 2655 2667 2679 2691 2703 2715 2727 2739 2751 2763 2775 2787 2799 2811 2823 2835 2847 2859 2883 2895 2907 2919 2931 2943 2955 2967 2979 2991 3003 3015 3027 3039 3051 3063 3075 3087 3099 3111 3123 3135 3147 3159 3171 3183 3195 3207 3219 3231 3243 3255 3267 3279 3291 3303 3315 3327 3339 3351 3363 3375 3387 3399 3411 3423 3435 3447 3459 3471 3483 3495 3507 3519 3531 3543 3555 3567 3579 3591 3603 3615 3627 3639 3651 3663 3675 3687 3699 3711 3723 3735 3747 3759 3771 3783 3795 3807 3819 3831 3843 3855 3867 3879 3891 3903 3915 3927 3939 3951 3963 3975 3987 3999 4011 4023 4035 4047 4059 4071 4083 4095 4107 4119 4131 4143 4155 4167 4179 4191 4203 4215 4227 4239 4251 4263 4275 4287 4299 4311 4323 4335 4347 4359 4371 4383 4395 4407 4419 4431 4443 4455 4467 4479 4491 4503 4515 4527 4539 4551 4563 4575 4587 4599 4611 4623 4635 4647 4659 4671 4683 4695 4707 4719 4731 4755 4767 4779 4803 4815 4827 4839 4851 4875 4887 4911 4923 4935 4947 4959 4971 4983 4995 5007 5019 5031 5043 5055 5067 5079 5091 5103 5115 5127 5139 5151 5163 5175 5187 5199 5211 5223 5235 5247 5259 5271 5283 5295 5307 5319 5331 5343 5355 5367 5379 5391 5403 5415 5427 5439 5451 5463 5475 5487 5499 5511 5523 5535 5547 5559 5571 5583 5595 5607 5619 5631 5643 5655 5667 5679 5691 5703 5715 5727 5739 5751 5763 5775 5787 5799 5811 5823 5835 5847 5859 5871 5883 5895 5907 5919 5931 5943 5955 5967 5979 5991 6003 6015 6027 6039 6051 15261 15273 15285 15297 15309 15321 15333 15345 15357 15369 15381 15393 15405 15417 15429 15441 15453 15465 15477 15489 15501 15513 15525 15537 15549 15561 15573 15585 15597 15609 15621 15633 15645 15657 15669 15681 15693 15705 15717 15729 15741 15753 15765 15777 15789 15801 15813 15825 15837 15849 15861 15873 15885 15897 15909 15921 15933 15945 15957 15969 15981 15993 16005 16017 16029 16041 16053 16065 16077 16089 16101 16113 16125 16137 16149 16161 16173 16185 16197 16209 16221 16233 16245 16257 16269 16281 16293 16305 16317 16329 16341 16353 16365 16377 16389 16401 16413 16425 16437 16449 16461 16473 16497 16509 16521 16533 16545 16557 16569 16581 16593 16605 16617 16629 16641 16653 16665 16677 16689 16701 16713 16725 16737 16749 16761 16773 16785 16797 16809 16821 16833 16845 16857 16869 16881 16893 16905 16917 16929 16941 16953 16965 16977 17001 17013 17025 17037 17049 17061 17073 17085 17097 17109 17121 17133 17145 17157 17169 17181 17193 17205 17217 17229 17241 17253 17265 17277 17289 17301 17313 17325 17337 17349 17361 17373 17385 17397 17409 17421 17433 17445 17457 17469 17481 17493 17505 17517 17529 17541 17553 17565 17577 17589 17601 17613 17625 17637 17649 17661 17673 17685 17697 17709 17721 17733 17745 17757 17769 17781 17793 17805 17817 17829 17841 17853 17865 17877 17889 17901 17913 17925 17937 17949 17961 17973 17985 17997 18009 18021 18033 18045 18057 18069 18081 18093 18105 18117 18129 18141 18153 18165 18177 18189 18201 18213 18225 18237 18249 18261 18273 18285 18297 18309 18321 18333 18345 18357 18369 18381 18393 18405 18417 18429 18441 18453 18465 18477 18489 18501 18513 18525 18537 18549 18561 18573 18585 18597 18609 18621 18633 18645 18657 18669 18681 18693 18705 18717 18729 18741 18753 18765 18777 18789 18801 18813 18825 18837 18849 18873 18885 18897 18921 18933 18945 18957 18969 18993 19005 19029 19041 19053 19065 19077 19089 19101 19113 19125 19137 19149 19161 19173 19185 19197 19209 19221 19233 19245 19257 19269 19281 19293 19305 19317 19329 19341 19353 19365 19377 19389 19401 19413 19425 19437 19449 19461 19473 19485 19497 19509 19521 19533 19545 19557 19569 19581 19593 19605 19617 19629 19641 19653 19665 19677 19689 19701 19713 19725 19737 19749 19761 19773 19785 19797 19809 19821 19833 19845 19857 19869 19881 19893 19905 19917 19929 19941 19953 19965 19977 19989 20001 20013 20025 20037 20049 20061 20073 20085 20097 20109 20121 20133 20145 20157 20169 6075 20193"/></xmi:XMI>